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ABSTRACT 
Superiority clinical trials are often designed with a planned interim analysis 
for the purpose of sample size re-estimation (SSR) when limited information is 
available at the start of the trial to estimate the required sample size. Typically 
these trials are designed with a two-arm internal pilot where subjects are enrolled 
to both treatment arms prior to the interim analysis. Circumstances may 
sometimes call for a trial with a single-arm internal pilot (enroll only in the control 
group). For a dichotomous outcome, Herson and Wittes proposed a SSR method 
(HW-SSR) that can be applied to single-arm internal pilot trials using an 
unblinded estimate of the control group outcome rate. Previous evaluations of the 
HW-SSR method reported conflicting results regarding the impact of the method 
on the two-sided Type I error rate and power of the final hypothesis test. 
 vii 
In this research we evaluate the HW-SSR method under the null and 
alternative hypothesis in various scenarios to investigate the one-sided Type I 
error rate and power of trials with a two-arm internal pilot. We find that the one-
sided Type I error rate is sometimes inflated and that the power is sometimes 
reduced. We propose a new method, the Critical Value and Power Adjusted 
Sample Size Re-estimation (CVPA-SSR) algorithm to adjust the critical value 
cutoff used in the final Z-test and the power critical value used in the interim SSR 
formula to preserve the nominal Type I error rate and the desired power. We 
conduct simulations for trials with single-arm and two-arm internal pilots to 
confirm that the CVPA-SSR algorithm does preserve the nominal Type I error 
rate and the desired power. We investigate the robustness of the CVPA-SSR 
algorithm for trials with single-arm and two-arm internal pilots when the 
assumptions used in designing the trial are incorrect. No Type I error inflation is 
observed but significant over- or under-powering of the trial occurs when the 
treatment effect used to design the trial is misspecified. 
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CHAPTER 1  
Introduction 
In superiority clinical trials, an experimental product may be compared to a 
control product such as a placebo or standard of care to determine if the 
experimental product performs better than the alternative treatment. In many 
such trials a binomial endpoint such as death, myocardial infarction, disease 
response, or successful vaccination is used as it can be easily measured and 
interpreted. The null      and alternative hypotheses      for a one-sided 
superiority clinical trial with a binary endpoint are: 
Negative Outcome Positive Outcome 
                      
                      
where    is the event rate for those subjects who receive the experimental 
product (denoted "experimental group") and    is the event rate for those 
subjects who receive the control product or standard of care (denoted "control 
group"). Superiority clinical trials can be designed with a fixed sample size in 
each group to evaluate the null hypothesis of no treatment effect. A test statistic 
often used at the conclusion of the trial is the binary two-sample uncorrected Z-
test, using the normal approximation to the binomial distribution. If    and    are 
the observed percentages of subjects who experience the event in the 
experimental group and the control group, respectively, and   is the number of 
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subjects randomized into each group with equal allocation then the test statistic Z 
is given by:  
Equation 1.1 
  
        
 
       
  
  
where    
      
 
. This value is compared to the critical value    (for a negative 
outcome) or      (for a positive outcome) where    and      are the     α
   
and        α    percentiles of the standard normal distribution, respectively. 
The sample size for a superiority trial with a binomial endpoint is 
calculated at a desired Type I error rate  α , power    β , and ratio of subjects 
assigned to each treatment group and under assumptions regarding the true 
(population) event rate when treated with the control product and for a 
hypothesized treatment effect (1). Such calculations require reasonably precise 
assumptions of the true event rate in the control product and of the hypothesized 
treatment effect. If limited information is available on either of these parameters, 
they may be misspecified and the calculated sample size may be either too small 
or too large, resulting in a trial that is either underpowered (sample size too 
small) or overpowered (sample size too large) (1). These assumptions are often 
based on prior clinical trials or epidemiologic studies and the accuracy of these 
assumptions may vary with the amount of available knowledge regarding the 
products. In circumstances where there is limited information contributing to the 
hypothesized values, it may be appropriate to consider an adaptive clinical trial 
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design where a mid-trial sample size re-estimation (SSR) is performed using data 
accrued in-trial to enhance the precision of parameter assumptions used in the 
final sample size calculation (2). 
The initial sample size for an adaptive clinical trial design with a mid-trial 
SSR is computed in the trial’s design stage, prior to enrolling any subjects, using 
prior information to formulate assumptions about the parameters. A prospectively 
planned interim analysis then occurs after a pre-specified number of subjects per 
group have their outcome assessed. The interim data is used to revise the 
parameter assumptions and re-estimate the final number of subjects required to 
attain the desired power. At the end of the trial the computation of the final test 
statistic includes all subjects, including those used in the interim to recalculate 
the sample size. The interim data is similar to a pilot study, with the major 
exception that the interim data is included in calculating the test statistic at the 
end of the trial. Wittes and Brittain have termed the part of the trial up to and 
including the interim analysis as the "internal pilot" (3). 
While many adaptive clinical trials with SSR have an internal pilot stage 
for both experimental and control arms, circumstances may sometimes call for 
the study to be designed with only a single-arm (control arm) internal pilot.  
1.1 Motivating Example 
Suppose a Sponsor wants to design a superiority clinical trial with a 
binomial outcome to compare an experimental product to a current standard of 
care (control product) in a previously un-researched population. If there is limited 
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information available on the standard of care in the targeted study population but 
the treatment effect is well known, the Sponsor may want to begin the clinical trial 
with a single-arm internal pilot in order to obtain a more precise estimate of the 
control group outcome rate. After a pre-specified number of subjects complete 
the single-arm internal pilot portion of the trial, the observed control group 
outcome rate would be used to compute the final sample size required to achieve 
the desired power for a two-arm superiority clinical trial. The Sponsor would like 
to include the internal-pilot subjects in the calculation of the final test statistic. 
This type of clinical trial can be viewed as an adaptive clinical trial design 
that involves SSR based on a single-arm internal pilot in the control group. To 
date, no research has been undertaken to develop a method that can be applied 
to re-estimate the sample size to achieve desired power while simultaneously 
controlling the Type I error rate of such a trial. Such a method must be developed 
to make this study design a feasible option in clinical trials.  
1.2 Objectives 
In this research we develop a method that can be used to adequately 
control the Type I error rate at the nominal level while achieving the desired 
power for studies designed with a single-arm internal pilot in the control group for 
the purpose of estimating the sample size required for a randomized, non-
concurrent, two-arm superiority clinical trial with a binomial outcome based on 
the observed control group event rate. 
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In Chapter 2 we present SSR methods for trials with two-arm internal 
pilots and a binomial outcome. These methods are widely available in the 
literature and can be classified into two categories: methods based on a blinded 
review of the interim data and methods based on an unblinded review of the 
interim data (4). To better understand the statistical issues involved in SSR we 
explore methods available for studies with two-arm internal pilot studies to 
determine if such methods can be applied to a trial designed with a single-arm 
internal pilot in the control group. 
In Chapter 3 we consider a method first proposed by Herson and Wittes 
(1993) that can be applied in trials with a single-arm internal pilot in the control 
group to re-estimate the sample size at the interim analysis (5). Previous 
evaluations of this method explored its application to trials designed with two-arm 
internal pilots and reported conflicting results regarding the impact of the method 
on the two-sided Type I error rate and power of the final hypothesis test (4-7). 
While the final goal is to apply the Herson and Wittes SSR (HW-SSR) method to 
a trial designed with a single-arm internal pilot, the impact of the HW-SSR 
method on the Type I error rates and power of the final hypothesis test in two-
arm internal pilots must first be better understood. We investigate the application 
of the HW-SSR method to trials with a two-arm internal pilot to determine the 
Type I error rate and resulting power. 
In Chapter 4 we develop a new method, the Critical Value and Power 
Adjusted Sample Size Re-estimation (CVPA-SSR) algorithm, to correct the 
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deficiencies that occur in some scenarios when the HW-SSR method is used for 
trials with a two-arm internal pilot. Specifically, the CVPA-SSR algorithm will 
adjust the critical value cutoff used in the final Z-test and the critical value for 
power used in the SSR formula at the interim to preserve the nominal Type I 
error rate and desired power. We investigate the Type I error rates and power of 
the CVPA-SSR algorithm in a variety of simulation scenarios. 
In Chapter 5 we apply the CVPA-SSR algorithm when the HW-SSR 
method is used for trials designed with a single-arm internal pilot in the control 
group. We investigate the Type I error rates and power of the CVPA-SSR 
algorithm in a variety of scenarios. 
In Chapter 6 we summarize the main conclusions, examine the 





CHAPTER 2  
Literature Review 
In this research we seek to identify a method that can be used to 
adequately control the Type I error rate at the nominal level while achieving the 
desired power for studies designed with a single-arm internal pilot in the control 
group for the purpose of estimating the sample size required for a randomized, 
non-concurrent, two-arm superiority clinical trial with a binomial outcome based 
on the observed control group event rate. To date, no research has been 
undertaken to develop such a method. SSR methods for trials with two-arm 
internal pilots, however, are widely available in the literature. These methods can 
be classified into two categories: methods based on a blinded review of the 
interim data and methods based on an unblinded review of the interim data (4). 
To better understand the statistical issues involved in SSR we first explore the 
methods available for studies with two-arm internal pilot studies with a binomial 
outcome. 
2.1 Blinded Sample Size Re-estimation 
Blinded SSR involves re-estimating the final sample size during a trial 
using an updated assumption of a nuisance parameter from accrued data without 
unblinding the treatment groups (2). One commonly used method for blinded 
SSR with a binomial outcome and two treatment groups was introduced by Gould 




In his 1992 manuscript, Gould detailed a method for blinded SSR with a 
binomial outcome and a final hypothesis test evaluated using the normal 
approximation to the binomial distribution two-sample uncorrected Z-test (Z-test). 
The Z statistic calculated for the Z-test is given by:  
Equation 2.1 
  
        
 
       
  
  
where    and    are the observed percentages of subjects who experience the 
event in the experimental group and the control group, respectively,    is the 
number of subjects randomized into each group with equal allocation, and    
      
 
. This value is compared to the    (for a negative outcome) or      (for a 
positive outcome) critical value to evaluate the null hypothesis where    and      
are the     α   and        α    percentiles of the standard normal 
distribution, respectively. The initial (protocol-specified) sample size required for 
a study with equal allocation of subjects to two treatment groups can be 
calculated using:  
Equation 2.2 
    
                      
 
            
        
 
where    (for a negative outcome),      (for a positive outcome), and      are the 
    α  ,        α   , and            percentiles of the standard normal 
distribution, respectively,    and    are the hypothesized event rates under the 
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alternative hypothesis, and    
      
 
. This calculation occurs in the design 
stage, prior to initial subject enrollment. After a predetermined number of 
subjects are enrolled and their outcomes observed, the trial can have a blinded 
interim analysis where the observed interim data is used to recalculate the final 
sample size by replacing   with the estimated overall sample event rate obtained 
from the interim data (  ), in Equation 2.2. Through simulations Gould showed 
that his proposed blinded SSR method did not materially affect the Type I error 
rate which was well preserved at the nominal alpha level, i.e., the Type I error 
rate was no larger than would have been observed using a non-adaptive design 
(8). 
In a 2004 manuscript, Friede and Kieser developed a solution for 
calculating the exact Type I error rate of Gould’s blinded SSR method (9). For 
their derivations Friede and Kieser used the uncorrected    test statistic, 
equivalent to the square of the Z statistic from the Z-test. The authors first noted 
that for a fixed non-adaptive trial design the exact Type I error rate is given by:  
Equation 2.3 
    
      
  










                                  
   
where    and    are the sample sizes in each treatment arm,    and    are the 
number events in each treatment arm,   is the assumed overall event rate under 
the null hypothesis and       
  denotes the        α   percentile of the 
  distribution with one degree of freedom. Note that this formula sums over all 
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possible    and    so it does not use any observed data and as such, the exact 
Type I error rate can be calculated during the design stage based on study 
design assumptions. 
Friede and Kieser expanded Equation 2.3 to account for Gould's blinded 
SSR method and noted that the exact Type I error rate of this trial design is given 
by:  
Equation 2.4 
    
         
   
     
   
   
     
  
   
   
 
   
     
 
   
   
 
   
     
 
   
   
  
   
   
                      
   
where     and     are the sample sizes in each treatment arm before the interim 
analysis and     and     are the sample sizes in each treatment arm after the 
interim analysis.    ,    ,    , and     are the numbers of events in each 
treatment arm before and after the interim analysis, π is the assumed overall 
event rate under the null hypothesis,   is the total number of events,   is the total 
sample size of the trial, and       
  denotes the        α   percentile of the 
  distribution with one degree of freedom. Again note that that this formula sums 
over all possible    ,    ,    , and     so it does not use any observed data and 
as such, the exact Type I error rate can be calculated during the design stage 
based on study design assumptions. 
Using Equation 2.4 to calculate the exact Type I error rate, Friede and 
Kieser confirmed that there is no impact on the Type I error rate of a trial with a 
final uncorrected    hypothesis test after implementing Gould’s SSR method 
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when compared to a non-adaptive design; however this does not guarantee that 
the nominal alpha level is preserved. In fact, Friede and Kieser noted that 
sometimes the Type I error rate of the uncorrected    test after a trial with a fixed 
sample size is greater than nominal Type I error rate. If strict control of the Type I 
error rate is required, the authors suggested that Equation 2.4 be used to adjust 
the critical values so that the exact Type I error rate of a trial implementing 
Gould’s blinded SSR procedure is no greater than the nominal Type I error rate 
(9). 
SSR methods that do not unblind the data minimize non-statistical 
operational biases making such methods generally well accepted by regulators 
(2). In the Adaptive Design Clinical Trials for Drugs and Biologics Food and Drug 
Administration (FDA) Guidance released in 2010, the FDA confirmed that a 
blinded analysis does not introduce statistical bias and that, when applied, no 
statistical adjustments are necessary to control the Type I error at the nominal 
level (10). As a result, consideration of blinded SSR methods is encouraged for 
most studies when a sample size adjustment is planned (10); however there are 
instances where blinded SSR may not be the best approach. Blinded SSR can 
only remove uncertainty in the nuisance parameter of the overall sample. If there 
is a large amount of uncertainty in not only an overall sample nuisance 
parameter but also in the magnitude of treatment effect, unblinded SSR methods 
may provide a better alternative as treatment group specific information is 
available (2).  
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2.2 Unblinded Sample Size Re-estimation 
Unblinded SSR involves re-estimating the final sample size during a trial 
using interim estimates of treatment-group specific information from accrued 
data. Compared to blinded SSR, unblinded SSR is considered more 
controversial. In the Adaptive Design Clinical Trials for Drugs and Biologics FDA 
Guidance released in 2010, the FDA stated that SSR based on an unblinded 
treatment effect is less well understood than other adaptive design methods and 
that unblinded methods should only be used when better understood methods 
are unable to meet the primary objectives of the trial (10). Despite the FDA’s 
concerns, there are some instances where unblinded SSR methods may be 
required to meet the primary objectives of the trial. Unblinded SSR methods that 
control Type I error are statistically valid and the FDA’s concerns are due to 
operational biases that may occur due to changes in the conduct of the trial if 
investigators are privy to unblinded data results (11) highlighting the importance 
of appropriate limitations to the availability of unblinded results when such 
methods are used in clinical trials. 
Unblinded SSR can be classified into two categories: re-estimation based 
on an updated estimate of the treatment effect and re-estimation based on an 
updated estimate of a nuisance parameter (4). 
2.2.1 Unblinded Re-estimation Based on the Treatment Effect 
A widely researched unblinded SSR technique based on the treatment 
effect relies on the calculation of conditional power at an interim analysis. 
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Conditional power is the probability that the test statistic computed at the end of 
the trial will exceed the critical value, given the treatment effect size and 
variability observed in the interim analysis (4). Specifically: 
                                            
where    is the conditional power,   is the final test statistic,   is the critical 
value, and the unblinded observed interim data refers to the treatment effect size 
and variability from the interim data. In practice, the conditional power is 
calculated during the interim analysis and the final sample size may be increased 
such that either the conditional power exceeds some pre-specified minimum level 
or to a predetermined maximum sample size. The study then continues to enroll 
subjects until the final sample size is attained. Denne (2001) noted that the 
interim test statistic is not independent of the final revised sample size when a 
SSR is performed using conditional power (12). Without accounting for the 
dependence of the two values, the Type I error rate may be inflated as much as 
twice the nominal level (13).  
A number of methods have been proposed to account for inflation of the 
Type I error when SSR is based on conditional power. Bauher and Kohne (1994) 
used Fisher’s product criterion to combine p-values from hypothesis test statistics 
calculated before and after the preplanned SSR into a single global test statistic 
that controls the overall Type I error rate at the nominal level (14). Proschan and 
Hunsberger (1995) introduced a conditional error function, proposed a priori, that 
can be used to derive an adjusted critical value for the final hypothesis test based 
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on the conditional power observed from the interim analysis, thereby controlling 
the overall Type I error rate (13). Li et al. (2002) extended the work of Proschan 
and Hunsberger by modifying the procedure to make the critical value of the final 
test hypothesis test independent of the interim test statistic (15). Denne (2001) 
derived a method for controlling the Type I error rate by choosing a new critical 
value during the interim analysis such that the conditional probability of a Type I 
error after the interim SSR is no more than the conditional probability of a Type I 
error rate were there no SSR (12). Muller and Schafer (2001) introduced a 
method for controlling the overall Type I error by viewing the trial as two separate 
studies, defined as before and after the interim analysis, and changing the alpha 
spending function and the future timing of the interim analyses (16). Fisher 
(1998) introduced the “variance spending sequential method” by noting that if 
conditionally independent observations are added after an interim analysis the 
distribution under the null hypothesis will remain unchanged as long as the new 
observations are normalized to have the variance that would be obtained under 
the original study design (17). Lehmacher and Wassmer (1999) introduced a 
method based on an inverse normal combination of independent tests to control 
the overall Type I error rate (18). Cui, Hung, and Wang showed that if the Wald 
test statistic for a binomial outcome is calculated using the originally planned 
number of subjects after the interim analysis as the sample size instead of the 
recalculated number of subjects after the interim analysis, the Type I error rate is 
controlled at the nominal level (19). 
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Chen and Demets (2004) took a novel approach to account for Type I 
error inflation in studies with unblinded SSR at an interim analysis. Instead of 
providing an adjustment so that the Type I error rate is controlled across all 
possible SSR, they instead derived the scenarios where no adjustment would be 
needed. They determined that if the conditional power at the interim analysis is at 
least 50% or the required sample size increase does not exceed a pre-specified 
upper bound then the nominal alpha level will be maintained. They noted that the 
sample size should only be increased and the trial continued if the interim 
analysis results are considered “promising”. Otherwise, the trial should be 
continued as planned or stopped early for futility (20). Gao (2008) extended Chen 
and Demets’ method to include scenarios where the conditional power at the 
interim analysis was less than 50% (21). Mehta and Pocock (2010) explicitly 
calculated cutoff values for a “promising zone” for the minimum allowable level of 
conditional power that Gao referenced (11). 
When SSR is based on the observed interim treatment effect, the Type I 
error rate may be increased if the dependence of the interim test statistic and 
final sample size is not accounted for in the end of trial hypothesis test, as 
discussed above. In some instances, however, the treatment effect may not be 
available for SSR (i.e., when only the control group results are observed at the 
interim) and the unblinded SSR methods based on conditional power are 
inappropriate. In such studies unblinded SSR based on a nuisance parameter 
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provides an alternative method for updating the final sample size midway through 
the trial. 
2.2.2 Unblinded Re-estimation Based on a Nuisance Parameter 
Herson and Wittes (1993) proposed a SSR method for a binary outcome 
where the treatment groups be unblinded at a preplanned interim analysis but 
that the number of events in the experimental group and the treatment effect at 
the interim analysis remain unobserved and not be used in the SSR (5). In this 
method, the only unblinded value used is the observed event rate in the control 
group and the final sample size is updated based on the revised estimate of the 
control group rate to have a pre-specified level of power for a final Z-test 
(Equation 2.1). 
In their manuscript, Herson and Wittes investigated a single alternative 
hypothesis:                 where γ is the proportional reduction of the control 
group rate that will be observed in the experimental treatment arm. They used a 
minimum allowable sample size for the remainder of the trial of either the original 
proctocol-specified sample size or 10% more than the interim sample size. The 
maximum allowable sample size was set at a pre-specified “practical limit” of 2.5 
times the original protocol-specified sample size. They stated that the overall 
two-sided Type I error rate was controlled at the nominal level and that the power 
was increased in scenarios where it was needed, i.e., when the true control 
group event rate was smaller than the control group event rate that was used to 
compute the initial sample size (5). It is important to note that in the Herson and 
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Wittes SSR (HW-SSR) method, despite unblinding only the control group at the 
interim analysis, subjects are concurrently randomized into both the control and 
experimental groups before and after the interim analysis. 
Jennison and Turnbull (200) investigated the Herson and Wittes method 
under two alternative hypotheses:       
   
ρ
 where ρ>0 is the relative treatment 
effect, allowing both decreases and increases in the treatment effect, and 
             Δ where Δ>0 is the treatment difference effect. They showed 
that the two-sided Type I error rates from simulations performed on both 
alternative hypotheses could be as high as 0.06 with a nominal level of 0.05 
using the HW-SSR method (6). They stated that the observed powers from 
simulation results were close to the nominal pre-specified values for both 
alternative hypotheses; however, in some scenarios, the observed power did not 
attain the pre-specified value of 0.90. 
Gould (2001) investigated the HW-SSR method under the alternative 
hypothesis        Δ where Δ>0 is the treatment difference. Gould states that 
two-sided Type I error rate and power of the hypothesis test are “reasonably 
preserved” as the conclusion of his simulation scenarios; however, Gould’s 
simulation results showed inflation of the two-sided Type I error to as much as 
0.056, above the nominal level of 0.05, and he observed powers as low as 0.831 
when the desired level was 0.90 (4).  
Proschan (2005) noted that even though there is a possibility of a Type I 
error inflation, the HW-SSR method is asymptotically valid and he was unable to 
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produce substantial Type I error inflation in simulation studies, though exact 
simulation results were not reported (7). 
2.3 Summary 
In this Chapter we explored SSR methods for trials designed with a two-
arm internal pilot with a binary outcome. These methods are classified into two 
categories: methods based on a blinded review of the interim data and methods 
based on an unblinded review of the interim data (4). Blinded SSR requires no 
statistical adjustments to control the Type I error at the nominal level (10). 
Unblinded SSR could lead to Type I error inflation when the SSR is based on 
conditional power so methods have been introduced to control the Type I error at 
the nominal level. When the unblinded SSR is based on the updated control 
group rate at the interim analysis, as in the HW-SSR method, conflicting results 
are reported in the literature on the resulting statistical operational characteristics 
of the final hypothesis test (4-7).  
The HW-SSR method is promising as it could be applied to trials with a 
single-arm internal pilot in the control group; however we must first better 
understand the resulting Type I error rate and power when it is applied to trials 




CHAPTER 3  
Investigation of the HW-SSR Method in Trials Designed with a 
Two-arm Internal Pilot 
In Chapter 2, a literature review of SSR methods for trials with a binary 
outcome and a two-arm internal pilot were presented. These methods were 
summarized into two categories: blinded SSR and unblinded SSR. Unblinded 
SSR was further classified into methods using an unblinded SSR based on a 
treatment effect and methods using an unblinded SSR based on a nuisance 
parameter. Of particular interest is the HW-SSR method, an unblinded SSR 
method based on a nuisance parameter, as its application could be expanded to 
trials with a single-arm internal pilot in the control group. The HW-SSR method 
has been investigated by a few authors who have provided conflicting reports of 
its control over the Type I error and power in a trial with a two-arm internal pilot 
(4-7). While the final goal of this research is to apply the HW-SSR method to 
trials designed with a single-arm internal pilot in the control group, we must first 
better understand its impact on the Type I error rate and power when applied to 
trials with a two-arm internal pilot  
In the following sections, the HW-SSR method will be presented. As an 
example of a conflicting result presented in the literature, results obtained by 
Jennison and Turnbull (2000) in their review of the HW-SSR method will be 
discussed. Results from our independent simulation study will further explore the 
statistical operating characteristics of the HW-SSR method when used in a trial 
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with a two-arm internal pilot. Finally, the distribution of the final test statistic in 
trials with a two-arm internal pilot after the HW-SSR method is applied will be 
derived under the null and alternative hypotheses. 
3.1 Herson and Wittes (1993) Sample Size Re-estimation Method 
The HW-SSR method is performed by updating the control group event 
rate in the SSR formula at the interim analysis based on the interim observed 
control group event rate. At the design stage (prior to the start of the trial), an 
initial (protocol-specified) sample size per group is calculated to provide some 
pre-specified power to reject the null hypothesis in favor of the alternative 
hypothesis  
           
                
where γ is the proportional reduction of the control group rate that will be 
observed in the experimental treatment arm. At the interim analysis the data is 
unblinded, the observed event rate in the control group       is calculated, and 
the sample size is updated using the power formula (Equation 3.1) based on the 
arcsine transformation, a Z-test (Equation 2.1) for the end of study hypothesis 
test, and the hypothesized protocol-specified effect size as the assumed 
treatment effect. 
Equation 3.1 
    
         
 




where    (for negative outcome) and      are the     α
   and             
percentiles of the standard normal distribution, respectively. For the purpose of 
the interim SSR calculation,             . The recalculated sample size is 
restricted to fall between a minimum and maximum allowable value. The two 
suggested minimum allowable values used in the Herson and Wittes manuscript 
were at least 10% more than the interim sample size or the original protocol-
specified sample size. Herson and Wittes suggested using a "practical" 
maximum allowable sample size of 2.5 times the original protocol-specified 
sample size. At the end of the trial the Z-test would be used to evaluate the null 
hypothesis (5). 
Herson and Wittes investigated the performance characteristics of their 
approach by using an example two-arm superiority clinical trial designed to test 
the hypothesis of whether an experimental treatment reduces the infection rate of 
febrile neutropenia in patients receiving chemotherapy for breast cancer. The 
study was powered at 0.80 for a two-sided test with 0.05 alpha level and the 
hypothesized event rates at the initial study design stage in the control group and 
experimental group were 0.40 and 0.20, respectively (note that 0.20 = (1-
0.5)*0.40, hence   = 0.5). The initial sample size estimate for this study was 80 
subjects per group. A single interim analysis for the purpose of SSR was planned 
to occur after a pre-specified number of events occurred and at the interim 
analysis the sample size would be re-estimated using the unblinded control 
group infection rate (5). 
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Herson and Wittes performed simulations to investigate the Type I error 
rate and power levels for this study design. Two sets of simulations were 
conducted: one with a minimum allowable sample size of 10% more than the 
interim analysis (Appendix Table A.1) and the other with a minimum allowable 
sample size of the original protocol-specified sample size (Appendix Table A.2). 
The maximum allowable sample size was 200 subjects per arm (2.5 times the 
original protocol-specified sample size). A single interim analysis was 
prospectively planned to occur after 25%, 50%, or 75% of the subject outcomes 
were measured. Scenarios in which no interim analyses were performed (where 
“Interim Analysis Location” is “100%” in Appendix Table A.1 and Appendix Table 
A.2) are presented for comparison. Herson and Wittes performed 30,000 
simulations for each of the Type I error scenarios and 1,500 simulations for each 
of the power scenarios (5). 
Herson and Wittes concluded that their simulation results illustrated that 
the method had little effect on the Type I error rate. In addition, they concluded 
that the power was increased for scenarios where it was needed, i.e., when the 
true control group event rate was smaller than the control group event rate used 
to compute the sample size during the design phase (5).  
3.2 Jennison and Turnbull (2000) Evaluations of the HW-SSR Method 
Jennison and Turnbull investigated the HW-SSR method under two 
alternative hypotheses:       
   
 
 where  >0 is the relative treatment effect, 
allowing both decreases and increases in the treatment effect, and          
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      where Δ>0 is the risk difference treatment effect. Note that in the case of 
a relative treatment reduction, the relationship between Jennison and Turnbull’s 
notation and the Herson and Wittes’ treatment notation is   
 
   
. At the design 
stage (prior to the start of the trial) the initial (protocol-specified) sample size is 
calculated to provide some pre-specified power to reject the null hypothesis in 
favor of the alternative hypothesis using: 
Equation 3.2 
    
                      
 
                    
        
 
where    (for a negative outcome),      (for a positive outcome), and      are the 
    α  ,        α   , and            percentiles of the standard normal 
distribution, respectively, and    and    are the hypothesized event rates under 
the alternative hypothesis. At the pre-specified interim analysis, Jennison and 
Turnbull used the observed result in the control group       to re-estimate the 
sample size using the following formula: 
Equation 3.3 
    
                      
 
                        
          
 
where    (for a negative outcome),      (for a positive outcome), and      are the 
    α  ,        α   , and             percentiles of the standard normal 
distribution, respectively, and     is 
   
 
 or       depending on the alternative 
hypothesis of interest. In their simulations, Jennison and Turnbull used the 
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internal pilot sample size as the minimum allowable sample size. They set the 
maximum allowable sample size to be the internal pilot sample size + 1,000 
subjects per treatment arm. Jennison and Turnbull conducted a single interim 
analysis after a pre-specified number of subject outcomes were measured. They 
performed 1,000,000 replicates for all simulations (6). 
Appendix Table A.3 presents results from the Jennison and Turnbull 
manuscript including simulations for the alternative hypothesis        
   
 
. For 
extreme simulation scenarios, Jennison and Turnbull used the following 
simulation rules:  
1. If there were no events in the control group at the interim analysis then     
was set to 
    
  
 (   is the sample size at the interim analysis) to ensure that 
the sample size recalculation could still be performed, and  
2. If     and       then     was truncated to   so that 
    
 
 does not 
exceed 1.  
The maximum observed Type I error rate from the simulation scenarios for the 
alternative hypothesis        
   
 
 was 0.054, found to be higher than the nominal 
level of 0.05 as the lower limit of the 95% confidence interval (CI) for the 
simulated two-sided Type I error rate fell above 0.05 (6). 
Appendix Table A.4 presents results from the Jennison and Turnbull 
manuscript including simulations for the alternative hypothesis             . 
For the purpose of extreme simulation scenarios, Jennison and Turnbull 
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restricted     to be a maximum of 1 so that     was truncated to    . The 
maximum observed Type I error rate from the simulations scenarios for the 
alternative hypothesis              was 0.061, found to be higher than the 
nominal level of 0.05 as the lower limit of the 95% CI for the simulated two-sided 
Type I error rate fell above 0.05 (6). 
Based on these simulation scenarios, Jennison and Turnbull concluded 
that the Type I error rate may be slightly perturbed from the nominal level for the 
HW-SSR method. Jennison and Turnbull also stated that the observed powers 
from simulation results were close to the nominal pre-specified values for both 
alternative hypotheses; however in some scenarios the simulated power did not 
attain the pre-specified value of 0.90 with observed values as low as 0.823 (6). 
3.3 Further Independent Simulation Investigations 
Herson and Wittes and Jennison and Turnbull presented conflicting 
reports of the impact of the HW-SSR method on the Type I error rate and power 
of the final hypothesis test in a randomized trial with a two-arm internal pilot. To 
better understand when the Type I error rate might not be adequately controlled 
at the nominal level and when the power might not achieve the desired level we 
conducted an independent simulation investigation. 
3.3.1 Simulation Methods 
We simulated data to determine if the application of the HW-SSR method 
to a clinical trial with a two-arm internal pilot affects the Type I error rate and 
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power of the trial when the SSR is based only on the interim estimate of the 
control group event rate and the protocol-specified effect size. Four sets of 
simulation scenarios were generated, one for each set of hypotheses where the 
outcome was a negative event:  
Relative treatment effect                                          , 
Risk difference treatment effect                              , 
and one for each set of hypotheses where the outcome was a positive event: 
 Relative treatment effect                                          , 
Risk difference treatment effect                               
For each simulation scenario, at the design stage (prior to the start of the trial) 
the initial (protocol-specified) sample size for a randomized clinical trial with 
equal allocation to two treatment groups was calculated using the Equation 3.2, 
assuming the final hypothesis test is the Z-test (Equation 2.1). The Type I error 
rate and power used for the two-sided Z-test were 0.05 and 0.80, respectively. A 
single interim analysis was prospectively planned to occur after 25%, 50%, or 
75% of the subject outcomes were measured. At the interim analysis the re-
estimated sample size was calculated using Equation 3.3 where     was 
estimated from the simulated data and     was calculated as either         , 
    –  ,          or     +   to match the alternative hypothesis of the simulation 
scenario. Additionally, a scenario with no SSR (fixed design) was presented for 
comparison. The maximum allowable sample size had two possible values: twice 
the original protocol-specified sample size or no maximum sample size. Note that 
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for the purposes of calculations presented later in this Chapter, the no maximum 
sample size scenarios were implemented with a maximum sample size of 5,000 
times the original protocol-specified sample size. The minimum allowable sample 
size had three possible values: the sample size at the interim analysis, 10% more 
than the sample size at the interim analysis, or the original protocol-specified 
sample size. The event rates in the control group were 0.10, 0.20, 0.30, and 0.40 
when the outcome was negative and 0.60, 0.70, 0.80, and 0.90 when the 
outcome was positive. The effect sizes for the risk difference treatment effect 
alternative hypothesis were 0.025 for event rates of 0.10 and 0.90, 0.05 and 0.10 
for event rates of 0.20 and 0.80, 0.075 and 0.15 for event rates of 0.30 and 0.70, 
and 0.10 and 0.20 for event rates of 0.40 and 0.60. For comparability, the effect 
sizes for the relative treatment effect alternative hypothesis match the 
corresponding risk difference treatment effect scenarios (i.e., for the negative 
outcome scenario where the control group event rate equaled 0.20 and the risk 
difference treatment effect equaled 0.10, the relative treatment effect equaled 
0.50). For extreme simulation scenarios the following rules were used: 
1. For a negative outcome and a hypothesized relative treatment effect, if 
there are no events in the control group at the interim analysis then     is 
set to 
    
  
 (   is the sample size at the interim analysis) to ensure that the 
SSR calculation can still be performed. 
    
  
 is a value that is very close, 
but not equal to 0, 
28 
 
2. For a negative outcome and a hypothesized risk difference treatment 
effect,    cannot be less than 0;    is truncated at    
    
  
 so that 
            will equal 
    
  
, a value that is very close but not equal to 0, 
3. For a positive outcome and a hypothesized relative treatment effect,    
cannot be greater than 1;     is truncated to 
 
   
 
    
  
 so that     
         will equal        
    
  
, a value that is very close but not equal 
to 1, and  
4. For a positive outcome and a hypothesized risk difference treatment 
effect,    cannot be greater than 1;    is truncated to       
    
  
  so that 
            will equal   
    
  
, a value that is very close but not equal to 
1. 
For all scenarios, 100,000 replications were performed. 
Note that data were simulated under the protocol-specified assumptions. 
For example, for a given set of simulations, the study was designed and powered 
in the protocol with certain assumptions of   ,    and the corresponding   
(relative treatment effect) or Δ (risk difference treatment effect) for the null and 




3.3.2 Simulation Results 
For each simulation scenario the full set of results are presented in 
Appendix Table A.5 – Appendix Table A.52, including: 
 Simulated overall two-sided Type I error rate 
 Simulated lower one-sided Type I error rate 
 Simulated upper one-sided Type I error rate 
 Simulated power 
 Average sample size per treatment group 
 Number of simulations that required an extreme 
simulation rule to be used 
Lower and upper sides of the Type I error rate are presented in addition to the 
overall two-sided Type I error rate as superiority tests are essentially one-sided 
hypothesis tests. The lower side of the Type I error rate is of interest when the 
outcome is negative since we are designing the clinical trial assuming    is less 
than     The upper side of the Type I error rate is of interest when the outcome is 
positive since we are designing the clinical trial assuming    is greater than     
A subset of simulation results are presented in the sections below, 
containing the simulated one-sided Type I error rate of interest, the simulated 
power, and the average sample size per treatment group.  
Negative Outcome – Relative Treatment Effect 
Simulations performed for a negative outcome and a hypothesized relative 
treatment effect when a) the sample size at the interim analysis is the minimum 
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allowable sample size and b) the maximum allowable sample size is twice the 
original protocol-specified sample size are presented in Appendix Table A.5 and 
Appendix Table A.6. Results of the simulations show that the two-sided Type I 
error rate is inflated in some scenarios with an interim analysis as the lower limit 
of the 95% CI surrounding the simulated two-sided Type I error rate is above the 
nominal level of 0.05 in five of 21 (23.8%) scenarios. For the one-sided lower 
Type I error rate, the simulated values are larger than the nominal level of 0.025 
in all scenarios with an interim analysis as the lower limit of the 95% CI fell 
entirely above the nominal level. Conversely, in all scenarios without an interim 
analysis, the lower limit of the 95% CI for the simulated one-sided lower Type I 
error is at or below the nominal value of 0.025, so the increased one-sided lower 
Type I error rate in scenarios with an interim analysis is not due entirely to 
simulation variance or asymptotic issues. 
In these simulations, the simulated power is greater than the nominal level 
of 0.80 for scenarios with an interim analysis as the simulated power values are 
between 0.8273 and 0.8659. For scenarios without an interim analysis, the 
simulated power is near the nominal level of 0.80. Across all scenarios, the mean 
sample size is largest when the interim analysis is performed after 25% of the 
subject outcomes are measured and smallest when there is no interim analysis. 
Note that for scenarios where the Type I error is inflated, the interpretation of 
power needs to be interpreted with caution. Selected simulation results are 
presented in Table 3.1 in the Minimum Allowable SS = “Interim” row. 
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Simulations performed for a negative outcome and a hypothesized relative 
treatment effect when a) 10% more the sample size at the interim analysis is the 
minimum allowable sample size and b) the maximum allowable sample size is 
twice the original protocol-specified sample size are presented in Appendix Table 
A.9 and Appendix Table A.10. Results of the simulations show that the two-sided 
Type I error rate is inflated in some scenarios with an interim analysis as lower 
limit of the 95% CI surrounding the simulated two-sided Type I error rate is above 
the nominal level of 0.05 in four of 21 (19.0%) scenarios. For the one-sided lower 
Type I error rate, the simulated values are larger than the nominal level of 0.025 
in most scenarios with an interim analysis as the lower limit of the 95% CI fell 
entirely above the nominal level in 18 of 21 (85.7%) scenarios. Conversely, in all 
scenarios without an interim analysis, the lower limit of the 95% CI for the 
simulated one-sided lower Type I error is at or below the nominal value of 0.025, 
so again the increased one-sided lower Type I error rate in scenarios with an 
interim analysis is not due entirely to simulation variance or asymptotic issues. 
In these simulations, the simulated power is greater than the nominal level 
of 0.80 for scenarios with an interim analysis as the simulated power values are 
between 0.8281 and 0.8655. For scenarios without an interim analysis, the 
simulated power is near the nominal level of 0.80. Across all scenarios, the mean 
sample size is largest when the interim analysis is performed after 25% of the 
subject outcomes are measured and smallest when there is no interim analysis. 
Note that for scenarios where the Type I error is inflated, the interpretation of 
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power needs to be interpreted with caution. Selected simulation results are 
presented in Table 3.1 in the Minimum Allowable SS = “10% more than the 
Interim” row. 
Simulations performed for a negative outcome and a hypothesized relative 
treatment effect when a) the original protocol-specified sample size is the 
minimum allowable sample size and b) the maximum allowable sample size is 
twice the original protocol-specified sample size are presented in Appendix Table 
A.13 and Appendix Table A.14. Results of the simulations show that the two-
sided Type I error rate fell at or below the nominal level of 0.05 in nearly all 
simulation scenarios as only one scenario without an interim analysis had a lower 
limit of the 95% CI for the simulated two-sided Type I error above the nominal 
level. For the one-sided lower Type I error rate, the simulated values are larger 
than the nominal level of 0.025 some scenarios with an interim analysis as the 
lower limit of the 95% CI fell entirely above the nominal level in four of 21 (19.0%) 
scenarios. Conversely, in all scenarios without an interim analysis, the lower limit 
of the 95% CI for the simulated one-sided lower Type I error is at or below the 
nominal value of 0.025 
In these simulations, the simulated power is greater than the nominal level 
of 0.80 for scenarios with an interim analysis as the simulated power values are 
between 0.8302 and 0.8779. For scenarios without an interim analysis, the 
simulated power is near the nominal level of 0.80. Across all scenarios, the mean 
sample size is largest when the interim analysis is performed after 25% of the 
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subject outcomes are measured and smallest when there is no interim analysis. 
Note that for scenarios where the Type I error is inflated, power needs to be 
interpreted with caution. Selected simulation results are presented in Table 3.1 in 
the Minimum Allowable SS = “Original Protocol-Specified” row. 
 
Table 3.1: A Subset of Results from Simulations where the Maximum Allowable 
Sample Size is Twice the Original Protocol-Specified Sample Size for the HW-
SSR Method for the Alternative Hypothesis Ha: pe = (1 – γ)pc when the Outcome 







Per Group  IAL 
Simulated Lower Type I 






Interim 903 25% 0.0269 (0.0259-0.0279) 0.8282 (0.8257-0.8307) 923 
50% 0.0278 (0.0268-0.0288) 0.8303 (0.8278-0.8328) 913 
75% 0.0274 (0.0264-0.0284) 0.8273 (0.8248-0.8298) 910 




903 25% 0.0257 (0.0247-0.0267) 0.8281 (0.8256-0.8306) 924 
50% 0.0278 (0.0268-0.0288) 0.8283 (0.8258-0.8308) 913 
75% 0.0272 (0.0262-0.0282) 0.8278 (0.8253-0.8303) 910 




903 25% 0.0251 (0.0241-0.0261) 0.8395 (0.8370-0.8420) 974 
50% 0.0253 (0.0243-0.0263) 0.8326 (0.8301-0.8351) 951 
75% 0.0253 (0.0243-0.0263) 0.8302 (0.8277-0.8327) 940 
100% 0.0250 (0.0240-0.0260) 0.8000 (0.7975-0.8025) 903 
Note:  
1. SS = sample size, IAL = interim analysis location. 
2. Interim analysis location refers to the percent of subjects out of the original protocol-
specified sample size who have been assessed for the outcome at the interim analysis. 
100% refers to the situation where no sample size re-estimation is planned. 
 
Simulations performed for a negative outcome and a hypothesized relative 
treatment effect when there is no maximum allowable sample size are presented 
in Appendix Table A.7 and Appendix Table A.8 for the scenarios where the 
sample size at the interim analysis is the minimum allowable sample size, 
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Appendix Table A.11 and Appendix Table A.12 for the scenarios where 10% 
more than the sample size at the interim analysis is the minimum allowable 
sample size, and Appendix Table A.15 and Appendix Table A.16 for the 
scenarios where original protocol-specified sample size is the minimum allowable 
sample size. The results were similar to those scenarios where the maximum 
allowable sample size is twice the original protocol-specified sample size. 
Selected simulation results are presented in Table 3.2.  
 
Table 3.2: Results from Simulations where there is No Maximum Allowable 
Sample Size for the HW-SSR Method for the Alternative Hypothesis Ha: pe = (1 – 







Per Group  IAL 
Simulated Lower Type I 






Interim 903 25% 0.0265 (0.0255-0.0275) 0.8260 (0.8235-0.8285) 922 
50% 0.0268 (0.0258-0.0278) 0.8300 (0.8275-0.8325) 913 
75% 0.0265 (0.0255-0.0275) 0.8307 (0.8282-0.8332) 910 




903 25% 0.0276 (0.0266-0.0286) 0.8267 (0.8242-0.8292) 924 
50% 0.0262 (0.0252-0.0272) 0.8287 (0.8262-0.8312) 913 
75% 0.0273 (0.0263-0.0283) 0.8291 (0.8266-0.8316) 910 




903 25% 0.0251 (0.0241-0.0261) 0.8401 (0.8376-0.8426) 973 
50% 0.0250 (0.0240-0.0260) 0.8336 (0.8311-0.8361) 950 
75% 0.0259 (0.0249-0.0269) 0.8291 (0.8266-0.8316) 940 
100% 0.0247 (0.0237-0.0257) 0.8004 (0.7979-0.8029) 903 
Note:  
1. SS = sample size, IAL = interim analysis location. 
2. Interim analysis location refers to the percent of subjects out of the original protocol-
specified sample size who have been assessed for the outcome at the interim analysis. 




Negative Outcome – Risk Difference Treatment Effect 
Simulations performed for a negative outcome and a hypothesized risk 
difference treatment effect when a) the sample size at the interim analysis is the 
minimum allowable sample size and b) the maximum allowable sample size is 
twice the original protocol-specified sample size are presented in Appendix Table 
A.17 and Appendix Table A.18. Results of the simulations show that the two-
sided Type I error rate is inflated in some scenarios with an interim analysis as 
the lower limit of the 95% CI surrounding the simulated two-sided Type I error 
rate is above the nominal level of 0.05 in nine of 21 (42.9%) scenarios, occurring 
most often when the interim analysis location is 25% or 50% and when the effect 
of the experimental treatment is 50% of the effect of the control treatment. For 
the one-sided lower Type I error rate, the simulated values are not inflated as the 
lower limit of the 95% CIs fall at or below the nominal level of 0.025 in all 
scenarios. 
In these simulations, the simulated power is lower than the nominal level 
of 0.80 in all scenarios with an interim analysis as the upper limit of the 95% CI 
for the simulated power is entirely below the nominal value. When the interim 
analysis is performed earlier in the trial and when the effect of the experimental 
treatment is 50% of the effect of the control treatment, the reduction in power is 
the most extreme. For scenarios without an interim analysis, the simulated power 
is near the nominal level of 0.80. Across all scenarios, the mean sample size is 
smallest when the interim analysis is performed after 25% of the subject 
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outcomes are measured. Selected simulation result are presented in Table 3.3 in 
the Minimum Allowable SS = “Interim” row. 
Simulations performed for a negative outcome and a hypothesized risk 
difference treatment effect when a) 10% more than the sample size at the interim 
analysis is the minimum allowable sample size and b) the maximum allowable 
sample size is twice the original protocol-specified sample size are presented in 
Appendix Table A.21 and Appendix Table A.22. Results of the simulations show 
that the two-sided Type I error rate is inflated in some scenarios with an interim 
analysis as the lower limit of the 95% CI surrounding the simulated two-sided 
Type I error rate is above the nominal level of 0.05 in 12 of 21 (57.1%) scenarios, 
occurring most often when the interim analysis location is 25% or 50% and when 
the effect of the experimental treatment is 50% of the effect of the control 
treatment. For the one-sided lower Type I error rate, the simulated values are not 
inflated as the lower limit of the 95% CIs fall at or below the nominal level of 
0.025 in all scenarios except one with no interim analysis. 
In these simulations, the simulated power is lower than the nominal level 
of 0.80 in all scenarios with an interim analysis as the upper limit of the 95% CI 
for the simulated power is entirely below the nominal value. When the interim 
analysis is performed earlier in the trial and when the effect of the experimental 
treatment is 50% of the effect of the control treatment, the reduction in power is 
the most extreme. For scenarios without an interim analysis, the simulated power 
is near the nominal level of 0.80. Across all scenarios, the mean sample size is 
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smallest when the interim analysis is performed after 25% of the subject 
outcomes are measured. Selected simulation results are presented in Table 3.3 
in the Minimum Allowable SS = “10% more than the Interim” row. 
Simulations performed for a negative outcome and a hypothesized risk 
difference treatment effect when a) the original protocol-specified sample size is 
the minimum allowable sample size and b) the maximum allowable sample size 
is twice the original protocol-specified sample size are presented in Appendix 
Table A.25 and Appendix Table A.26. Results of the simulations show that the 
two-sided Type I error rate is near the nominal level of 0.05 as the lower limit of 
the 95% CI surrounding the simulated two-sided Type I error rate is above the 
nominal level in only one scenario with no interim analysis. For the one-sided 
lower Type I error rate, the simulated values are not inflated as the lower limit of 
the 95% CIs fall at or below the nominal level of 0.025 in all scenarios.  
In these simulations, the simulated power attains the nominal level of 0.80 
in all scenarios with an interim analysis as the upper limit of the 95% CI for the 
simulated power is at or above the nominal value. For scenarios without an 
interim analysis, the simulated power is near the nominal level of 0.80. Across all 
scenarios, the mean sample size is largest when the interim analysis is 
performed after 25% of the subject outcomes are measured. Selected simulation 
results are presented in Table 3.3 in the Minimum Allowable SS = “Original 
Protocol-Specified” row.  
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Table 3.3: Results from Simulations where the Maximum Allowable Sample Size 
is Twice the Original Protocol-Specified Sample Size for the HW-SSR Method for 
the Alternative Hypothesis Ha: pe = pc – Δ when the Outcome is Negative and pc = 







Per Group  IAL 
Simulated Lower Type I 






Interim 903 25% 0.0240 (0.0230-0.0250) 0.7746 (0.7721-0.7771) 899 
50% 0.0234 (0.0224-0.0244) 0.7778 (0.7753-0.7803) 901 
75% 0.0242 (0.0232-0.0252) 0.7799 (0.7774-0.7824) 902 




903 25% 0.0245 (0.0235-0.0255) 0.7744 (0.7719-0.7769) 899 
50% 0.0250 (0.0240-0.0260) 0.7760 (0.7735-0.7785) 901 
75% 0.0247 (0.0237-0.0257) 0.7779 (0.7754-0.7804) 902 




903 25% 0.0242 (0.0232-0.0252) 0.8083 (0.8058-0.8108) 944 
50% 0.0249 (0.0239-0.0259) 0.8038 (0.8013-0.8063) 933 
75% 0.0253 (0.0243-0.0263) 0.8030 (0.8005-0.8055) 927 
100% 0.0244 (0.0234-0.0254) 0.8014 (0.7989-0.8039) 903 
Note:  
1. SS = sample size, IAL = interim analysis location. 
2. Interim analysis location refers to the percent of subjects out of the original protocol-
specified sample size who have been assessed for the outcome at the interim analysis. 
100% refers to the situation where no sample size re-estimation is planned. 
 
Simulations performed for a negative outcome and a hypothesized risk 
difference treatment effect when there is no maximum allowable sample size are 
presented in Appendix Table A.19 and Appendix Table A.20 for the scenarios 
where the sample size at the interim analysis is the minimum allowable sample 
size, Appendix Table A.23 and Appendix Table A.24 for the scenarios where 
10% more than the sample size at the interim analysis is the minimum allowable 
sample size, and Appendix Table A.27 and Appendix Table A.28 for the 
scenarios where original protocol-specified sample size is the minimum allowable 
sample size. The results were similar to those scenarios where the maximum 
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allowable sample size is twice the original protocol-specified sample size. 
Selected simulation results are presented in Table 3.4.  
 
Table 3.4: Results from Simulations where there is No Maximum Allowable 
Sample Size for the HW-SSR Method for the Alternative Hypothesis Ha: pe = pc – 







Per Group  IAL 
Simulated Lower Type I 






Interim 903 25% 0.0250 (0.0240-0.0260) 0.7765 (0.7740-0.7790) 900 
50% 0.0242 (0.0232-0.0252) 0.7775 (0.7750-0.7800) 901 
75% 0.0246 (0.0236-0.0256) 0.7785 (0.7760-0.7810) 902 




903 25% 0.0242 (0.0232-0.0252) 0.7736 (0.7711-0.7761) 899 
50% 0.0237 (0.0227-0.0247) 0.7781 (0.7756-0.7806) 901 
75% 0.0246 (0.0236-0.0256) 0.7785 (0.7760-0.7810) 902 




903 25% 0.0238 (0.0228-0.0248) 0.8091 (0.8066-0.8116) 944 
50% 0.0249 (0.0239-0.0259) 0.8038 (0.8013-0.8063) 933 
75% 0.0244 (0.0234-0.0254) 0.8009 (0.7984-0.8034) 927 
100% 0.0250 (0.0240-0.0260) 0.7995 (0.7970-0.8020) 903 
Note:  
1. SS = sample size, IAL = interim analysis location. 
2. Interim analysis location refers to the percent of subjects out of the original protocol-
specified sample size who have been assessed for the outcome at the interim analysis. 
100% refers to the situation where no sample size re-estimation is planned. 
 
Positive Outcome – Relative Treatment Effect 
Simulations performed for a positive outcome and a hypothesized relative 
treatment effect when a) the sample size at the interim analysis is the minimum 
allowable sample size and b) the maximum allowable sample size is twice the 
original protocol-specified sample size are presented in Appendix Table A.29 and 
Appendix Table A.30. Results of the simulations show that two-sided Type I error 
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rate is inflated in some scenarios with an interim analysis as the lower limit of the 
95% CI surrounding the simulated two-sided Type I error rate is above the 
nominal level of 0.05 in 14 of 21 (66.7%) scenarios, occurring most often when 
the interim analysis location is 25% or 50%. For the one-sided upper Type I error 
rate, the simulated values are not inflated as the lower limit of the 95% CIs fall at 
or below the nominal one-sided level of 0.025 in all scenarios.  
In these simulations, the simulated power is lower than the nominal level 
of 0.80 in all scenarios with an interim analysis as the upper limit of the 95% CI 
for the simulated power is entirely below the nominal value. When the interim 
analysis is performed earlier in the trial and when the effect of the experimental 
treatment is 50% of the effect of the control treatment, the reduction in power is 
the most extreme. For scenarios without an interim analysis, the simulated power 
is near the nominal level of 0.80. Across all scenarios, the mean sample size was 
smallest when no interim analysis was performed. Selected simulation results are 
presented in Table 3.5 in the Minimum Allowable SS = “Interim” row. 
Simulations performed for a positive outcome and a hypothesized relative 
treatment effect when a) 10% more than the sample size at the interim analysis 
is the minimum allowable sample size and b) the maximum allowable sample 
size is twice the original protocol-specified sample size are presented in 
Appendix Table A.33 and Appendix Table A.34. Results of the simulations show 
that the two-sided Type I error rate is inflated in some scenarios with an interim 
analysis as the lower limit of the 95% CI surrounding the simulated two-sided 
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Type I error rate is above the nominal level of 0.05 in 12 of 21 (57.1%) scenarios, 
occurring most often when the interim analysis location is 25% or 50%. For the 
one-sided upper Type I error rate, the simulated values are not inflated as the 
lower limit of the 95% CIs fall at or below the nominal one-sided level of 0.025 in 
all scenarios except two with no interim analysis. 
In these simulations, the simulated power is lower than the nominal level 
of 0.80 in all scenarios with an interim analysis as the upper limit of the 95% CI 
for the simulated power is entirely below the nominal value. When the interim 
analysis is performed earlier in the trial and when the effect of the experimental 
treatment is 50% of the effect of the control treatment, the reduction in power is 
the most extreme. For scenarios without an interim analysis, the simulated power 
is near the nominal level of 0.80. Across all scenarios, the mean sample size is 
smallest when no interim analysis is performed. Selected simulation results are 
presented in Table 3.5 in the Minimum Allowable SS = “10% more than the 
Interim” row. 
Simulations performed for a positive outcome and a hypothesized relative 
treatment effect when a) the original protocol-specified sample size is the 
minimum allowable sample size and b) the maximum allowable sample size is 
twice the original protocol-specified sample size are presented in Appendix Table 
A.37 and Appendix Table A.38. Results of the simulations show that the two-
sided Type I error rate is near the nominal level of 0.05 as the lower limit of the 
95% CI surrounding the simulated two-sided Type I error rate is above the 
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nominal level in only one scenario with no interim analysis. For the one-sided 
upper Type I error rate, the simulated values are not inflated as the lower limit of 
the 95% CIs fall at or below the nominal one-sided level of 0.025 in all scenarios 
except one with no interim analysis. 
In these simulations, the simulated power attains the nominal level of 0.80 
in all scenarios with an interim analysis as the upper limit of the 95% CI for the 
simulated power is at or above the nominal value. For scenarios without an 
interim analysis, the simulated power is near the nominal level of 0.80. Across all 
scenarios, the mean sample size is largest when the interim analysis is 
performed after 25% of the subject outcomes are measured. Selected simulation 
results are presented in Table 3.5 in the Minimum Allowable SS = “Original 
Protocol-Specified” row.  
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Table 3.5: Results from Simulations where the Maximum Allowable Sample Size 
is Twice the Original Protocol-Specified Sample Size for the HW-SSR Method for 
the Alternative Hypothesis Ha: pe = (1 + γ)pc when the Outcome is Positive and pc 







Per Group  IAL 
Simulated Upper Type I 






Interim 903 25% 0.0236 (0.0226-0.0246) 0.7666 (0.7641-0.7691) 910 
50% 0.0240 (0.0230-0.0250) 0.7677 (0.7652-0.7702) 906 
75% 0.0235 (0.0225-0.0245) 0.7683 (0.7658-0.7708) 905 




903 25% 0.0230 (0.0220-0.0240) 0.7623 (0.7598-0.7648) 909 
50% 0.0228 (0.0218-0.0238) 0.7678 (0.7653-0.7703) 906 
75% 0.0231 (0.0221-0.0241) 0.7678 (0.7653-0.7703) 907 




903 25% 0.0247 (0.0237-0.0257) 0.8145 (0.8120-0.8170) 975 
50% 0.0238 (0.0228-0.0248) 0.8054 (0.8029-0.8079) 953 
75% 0.0233 (0.0223-0.0243) 0.8023 (0.7998-0.8048) 944 
100% 0.0244 (0.0234-0.0254) 0.7989 (0.7964-0.8014) 903 
Note:  
1. SS = sample size, IAL = interim analysis location. 
2. Interim analysis location refers to the percent of subjects out of the original protocol-
specified sample size who have been assessed for the outcome at the interim analysis. 
100% refers to the situation where no sample size re-estimation is planned. 
 
Simulations performed for a positive outcome and a hypothesized relative 
treatment effect when there is no maximum allowable sample size are presented 
in Appendix Table A.31 and Appendix Table A.32 for the scenarios where the 
sample size at the interim analysis is the minimum allowable sample size, 
Appendix Table A.35 and Appendix Table A.36 for the scenarios where 10% 
more than the sample size at the interim analysis is the minimum allowable 
sample size, and Appendix Table A.39 and Appendix Table A.40 for the 
scenarios where original protocol-specified sample size is the minimum allowable 
sample size. The results were similar to those scenarios where the maximum 
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allowable sample size is twice the original protocol-specified sample size. 
Selected simulation results are presented in Table 3.6. 
 
Table 3.6: Results from Simulations where there is No Maximum Allowable 
Sample Size for the HW-SSR Method for the Alternative Hypothesis Ha: pe = (1 + 







Per Group  IAL 
Simulated Upper Type I 






Interim 903 25% 0.0236 (0.0226-0.0246) 0.7632 (0.7607-0.7657) 909 
50% 0.0239 (0.0229-0.0249) 0.7660 (0.7635-0.7685) 906 
75% 0.0233 (0.0223-0.0243) 0.7649 (0.7624-0.7674) 905 




903 25% 0.0236 (0.0226-0.0246) 0.7586 (0.7561-0.7611) 908 
50% 0.0244 (0.0234-0.0254) 0.7667 (0.7642-0.7692) 907 
75% 0.0236 (0.0226-0.0246) 0.7692 (0.7667-0.7717) 907 




903 25% 0.0239 (0.0229-0.0249) 0.8097 (0.8072-0.8122) 975 
50% 0.0239 (0.0229-0.0249) 0.8053 (0.8028-0.8078) 953 
75% 0.0235 (0.0225-0.0245) 0.8024 (0.7999-0.8049) 944 
100% 0.0257 (0.0247-0.0267) 0.8005 (0.7980-0.8030) 903 
Note:  
1. SS = sample size, IAL = interim analysis location. 
2. Interim analysis location refers to the percent of subjects out of the original protocol-
specified sample size who have been assessed for the outcome at the interim analysis. 
100% refers to the situation where no sample size re-estimation is planned. 
 
Positive Outcome – Risk Difference Treatment Effect 
Simulations performed for a positive outcome and a hypothesized risk 
difference treatment effect when a) the sample size at the interim analysis is the 
minimum allowable sample size and b) the maximum allowable sample size is 
twice the original protocol-specified sample size are presented in Appendix Table 
A.41 and Appendix Table A.42. Results of the simulations show that the two-
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sided Type I error rate is inflated in some scenarios with an interim analysis as 
the lower limit of the 95% CI surrounding the simulated two-sided Type I error 
rate is above the nominal level of 0.05 in 12 of 21 (57.1%) scenarios, occurring 
most often when the interim analysis location is 25% or 50%. For the one-sided 
upper Type I error rate, the simulated values are not inflated as the lower limit of 
the 95% CIs fall at or below the nominal level of 0.025 in all scenarios. 
In these simulations, the simulated power is lower than the nominal level 
of 0.80 in all scenarios with an interim analysis as the upper limit of the 95% CI 
for the simulated power is entirely below the nominal value. When the interim 
analysis is performed earlier in the trial and when the effect of the experimental 
treatment is 50% of the effect of the control treatment, the reduction in power is 
the most extreme. For scenarios without an interim analysis, the simulated power 
is near the nominal level of 0.80. Across all scenarios, the mean sample size is 
smallest when the interim analysis is performed after 25% of the subject 
outcomes are measured. Selected simulation results are presented in Table 3.7 
in the Minimum Allowable SS = “Interim” row. 
Simulations performed for a positive outcome and a hypothesized risk 
difference treatment effect when a) 10% more than the sample size at the interim 
analysis is the minimum allowable sample size and b) the maximum allowable 
sample size is twice the original protocol-specified sample size are presented in 
Appendix Table A.45 and Appendix Table A.46. Results of the simulations show 
that the two-sided Type I error rate is inflated in some scenarios with an interim 
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analysis as the lower limit of the 95% CI surrounding the simulated two-sided 
Type I error rate is above the nominal level of 0.05 in 10 of 21 (47.6%) scenarios, 
occurring most often when the interim analysis location is 25% or 50%. For the 
one-sided upper Type I error rate, the simulated values are not inflated as the 
lower limit of the 95% CIs fall at or below the nominal level of 0.025 in all 
scenarios. 
In these simulations, the simulated power is lower than the nominal level 
of 0.80 in all scenarios with an interim analysis as the upper limit of the 95% CI 
for the simulated power is entirely below the nominal value. When the interim 
analysis is performed earlier in the trial and when the effect of the experimental 
treatment is 50% of the effect of the control treatment, the reduction in power is 
the most extreme. For scenarios without an interim analysis, the simulated power 
is near the nominal level of 0.80. Across all scenarios, the mean sample size is 
smallest when the interim analysis is performed after 25% of the subject 
outcomes are measured. Selected simulation results are presented in Table 3.7 
in the Minimum Allowable SS = “10% more than the Interim” row. 
Simulations performed for a positive outcome and a hypothesized risk 
difference treatment effect when a) the original protocol-specified sample size is 
the minimum allowable sample size and b) the maximum allowable sample size 
is twice the original protocol-specified sample size are presented in Appendix 
Table A.49 and Appendix Table A.50. Results of the simulations show that the 
two-sided Type I error rate is near the nominal level of 0.05 as the lower limit of 
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the 95% CI surrounding the simulated two-sided Type I error rate is above the 
nominal level of 0.05 in only one scenario with an interim analysis and three 
scenarios with no interim analysis. For the one-sided upper Type I error rate, the 
simulated values are near the nominal level as the 95% CI fell at or below the 
nominal level of 0.025 in all scenarios except two with no interim analysis.  
In these simulations, the simulated power attains the nominal level of 0.80 
in all scenarios with an interim analysis except for one as the upper limit of the 
95% CI for the simulated power is at or above the nominal value. For scenarios 
without an interim analysis, the simulated power is near the nominal level of 0.80. 
Across all scenarios, the mean sample size is largest when the interim analysis is 
performed after 25% of the subject outcomes are measured. Selected simulation 
results are presented in Table 3.7 in the Minimum Allowable SS = “Original 
Protocol-Specified” row.  
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Table 3.7: Results from Simulations where the Maximum Allowable Sample Size 
is Twice the Original Protocol-Specified Sample Size for the HW-SSR Method for 
the Alternative Hypothesis Ha: pe = pc + Δ when the Outcome is Positive and pc = 







Per Group  IAL 
Simulated Upper Type I 






Interim 903 25% 0.0237 (0.0227-0.0247) 0.7745 (0.7720-0.7770) 898 
50% 0.0247 (0.0237-0.0257) 0.7754 (0.7729-0.7779) 901 
75% 0.0234 (0.0224-0.0244) 0.7772 (0.7747-0.7797) 901 




903 25% 0.0241 (0.0231-0.0251) 0.7773 (0.7748-0.7798) 899 
50% 0.0237 (0.0227-0.0247) 0.7782 (0.7757-0.7807) 901 
75% 0.0242 (0.0232-0.0252) 0.7789 (0.7764-0.7814) 902 




903 25% 0.0236 (0.0226-0.0246) 0.8060 (0.8035-0.8085) 944 
50% 0.0242 (0.0232-0.0252) 0.8026 (0.8001-0.8051) 933 
75% 0.0250 (0.0240-0.0260) 0.8030 (0.8005-0.8055) 927 
100% 0.0245 (0.0235-0.0255) 0.8010 (0.7985-0.8035) 903 
Note:  
1. SS = sample size, IAL = interim analysis location. 
2. Interim analysis location refers to the percent of subjects out of the original protocol-
specified sample size who have been assessed for the outcome at the interim analysis. 
100% refers to the situation where no sample size re-estimation is planned. 
 
Simulations performed for a positive outcome and a hypothesized risk 
difference treatment effect when there is no maximum allowable sample size are 
presented in Appendix Table A.43 and Appendix Table A.44 for the scenarios 
where the sample size at the interim analysis is the minimum allowable sample 
size, Appendix Table A.47 and Appendix Table A.48 for the scenarios where 
10% more than the sample size at the interim analysis is the minimum allowable 
sample size, and Appendix Table A.51 and Appendix Table A.52 for the 
scenarios where original protocol-specified sample size is the minimum allowable 
sample size. The results were similar to those scenarios where the maximum 
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allowable sample size is twice the original protocol-specified sample size. 
Selected simulation results are presented in Table 3.8. 
 
Table 3.8: Results from Simulations where there is No Maximum Allowable 
Sample Size for the HW-SSR Method for the Alternative Hypothesis Ha: pe = pc + 







Per Group  IAL 
Simulated Upper Type I 






Interim 903 25% 0.0241 (0.0231-0.0251) 0.7748 (0.7723-0.7773) 899 
50% 0.0242 (0.0232-0.0252) 0.7785 (0.7760-0.7810) 901 
75% 0.0236 (0.0226-0.0246) 0.7802 (0.7777-0.7827) 901 




903 25% 0.0240 (0.0230-0.0250) 0.7736 (0.7711-0.7761) 898 
50% 0.0245 (0.0235-0.0255) 0.7782 (0.7757-0.7807) 901 
75% 0.0233 (0.0223-0.0243) 0.7791 (0.7766-0.7816) 902 




903 25% 0.0238 (0.0228-0.0248) 0.8065 (0.8040-0.8090) 944 
50% 0.0242 (0.0232-0.0252) 0.8012 (0.7987-0.8037) 933 
75% 0.0246 (0.0236-0.0256) 0.8007 (0.7982-0.8032) 927 
100% 0.0255 (0.0245-0.0265) 0.7991 (0.7966-0.8016) 903 
Note:  
1. SS = sample size, IAL = interim analysis location. 
2. Interim analysis location refers to the percent of subjects out of the original protocol-
specified sample size who have been assessed for the outcome at the interim analysis. 
100% refers to the situation where no sample size re-estimation is planned. 
 
3.3.3 Discussion of Simulation Results 
Applying the HW-SSR method to a randomized, concurrent, two-arm 
superiority clinical trial with a two-arm internal pilot and a binomial outcome to 
conduct SSR based solely on the interim observed control group event rate and 
the protocol-specified effect size affected both the Type I error rate and the 
power of the trial. Though there are instances of inflation in the two-sided Type I 
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error rate, we will focus this discussion on the inflation of the one-sided Type I 
error rate of interest and the reduction of power. 
For a negative outcome and a hypothesized relative treatment effect, the 
one-sided lower Type I error rate was inflated in nearly all scenarios with an 
interim analysis when the minimum allowable sample size was less than the 
original protocol-specified sample size, regardless of the maximum allowable 
sample size. When the minimum allowable sample size was the original protocol-
specified sample size, the inflation was mitigated as there were few instances of 
inflation in the one-sided lower Type I error rate. Event when the one-sided Type 
I error rate was inflated, the power obtained from these simulation scenarios, 
regardless of minimum and maximum allowable sample sizes, was at least 0.80. 
For a hypothesized risk difference treatment effect (for both negative and 
positive outcomes) and a hypothesized relative treatment effect for a positive 
outcome, the one-sided Type I error rate of interest was approximately at or 
below the nominal level in all scenarios with an interim analysis. The same 
cannot be said for the power results as when the minimum allowable sample size 
was less than the original protocol-specified sample size, regardless of the 
maximum allowable sample size, the simulated power did not attain 0.80 in any 
scenarios with an interim analysis. When the minimum allowable sample size 




In general, when the HW-SSR method was applied to a randomized, 
concurrent, two-arm superiority clinical trial with a two-arm internal pilot and a 
binomial outcome to conduct SSR based on the interim observed control group 
event rate and the protocol-specified effect size the statistical operational 
characteristics were generally not maintained. The impact of the HW-SSR 
method on the Type I error and power depended on whether the hypothesized 
treatment effect was a relative treatment effect or a risk difference treatment 
effect and whether the outcome was negative or positive. Inflation of the one-
sided Type I error rate and reduction of power occurred when the minimum 
allowable sample size was less than the original protocol-specified sample size, 
though there were still some scenarios where the one-sided Type I error rate was 
inflated when the minimum allowable sample size was the original protocol-
specified sample size. The maximum allowable sample size did not affect the 
one-sided Type I error rate or power. Finally, a review of the results comparing 
scenarios where there were no extreme simulations that required simulation rules 
versus those scenarios where there were extreme simulations that required 
simulation rules showed that the overall conclusions remained the same. 
3.4 Distribution of the Final Test Statistic 
In the following sections we derive the distribution of the final test statistic 
after the HW-SSR method is applied and illustrate that its deviation from the 
assumed standard normal distribution results in the inflated Type I error rate and 
reduced power described previously. 
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3.4.1 Derivation of Mean and Standard Error 
In the derivations below the following notation is used in addition to what 
has already been defined: 
   = Interim control group event rate 
   = Sample size accrued at the interim analysis in each treatment group 
   = Sample size accrued after the interim analysis in each treatment 
group 
   =        
Note that the following derivations assume equal allocation to the two treatment 
groups. According to the central limit theorem given X1, X2, ..., Xn independent and 
identically distributed random variables with a mean and finite variance, the 
following is true: 
         
      
         
Under the central limit theorem the following holds true for         
                   
           
         
In the current investigation, the final sample size is recalculated based on     and 
    is also included in the final test statistic. As a result    depends on the 
random outcome of    . To find           , we must condition on     as follows: 
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If    were independent of     then the expectation in the final line would reduce 
to 0 and                  , an assumption in the Z-test; however,    
depends on     and as such the expectation in the final line needs to be solved 
by numerical integration. If the expectation in the final line results in a non-zero 
term then                   and the final Z-statistic calculated in the Z-test 
would not follow a standard normal. 
The calculation of             also requires conditioning on    . The 
standard error of the difference between the event rate in the experimental and 
control groups can be derived as: 
                                                     
The covariance of the two estimates is zero as the groups are composed of 
independent subjects. Only the variances of the two estimates need to be 
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calculated. The variance of the event rate in the experimental group can be 
derived as follows by conditioning on    : 
                                        
   
        
  
          
   
        
  
  
The variance of the event rate in the control group can be derived as follows by 
conditioning on    : 
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If    was independent of     then the above would reduce to: 
           
        
  
 
        
  
 
This would be the standard error that is used for the Z-test; however,    depends 




3.4.2 Comparison of Expected, Simulated, and Derived Mean and Standard 
Error Results for the Final Test Statistic 
The mean of       and standard error of       after applying the HW-
SSR method (derived in Section 3.4.1) was computed under the null and 
alternative hypotheses for the scenarios in Section 3.3 via numerical integration 
using the trapezoidal rule. Note that for scenarios with no maximum allowable 
sample size a maximum sample size of 5,000 times the original protocol-
specified sample size was used in the numerical integration to allow computation. 
These results were compared to a) the expected mean of       and standard 
error of       if the Z-statistic calculated for the Z-test followed a standard 
normal distribution and b) the average simulated mean of       and average 
simulated standard error of      .  
Results from the simulation scenarios and calculations under the null 
hypothesis are presented in the odd numbered tables between Appendix Table 
A.53 and Appendix Table A.100. Results from the simulation scenarios and 
calculations under the alternative hypothesis are presented in the even 
numbered tables between Appendix Table A.53 and Appendix Table A.100. 
Negative Outcome – Relative Treatment Effect 
Results for scenarios with a negative outcome and hypothesized relative 
treatment effect are presented in Appendix Table A.53 – Appendix Table A.64. 
Under the null hypothesis the expected mean of       if the Z-statistic 
calculated for the Z-test followed a standard normal distribution is zero but the 
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derived mean of       for those scenarios that involved an interim analysis are 
less than zero. For those scenarios that did not involve an interim analysis 
(labeled as Interim analysis location of “100%”) the derived mean of       is 
close to zero. The results for the average simulated mean of       are similar 
to the derived mean of      . 
The results for the standard error under the null hypothesis showed that 
the derived standard error of       is larger than the expected standard error of 
      if the Z-statistic calculated for the Z-test followed a standard normal 
distribution when the minimum allowable sample size is less than the original 
protocol-specified sample size. When the minimum allowable sample size is the 
original protocol-specified sample size, the derived standard error of       is 
generally smaller than the expected standard error of       if the Z-statistic 
calculated for the Z-test followed a standard normal distribution. The results for 
the average simulated standard error of       are similar to the derived 
standard error of      . 
The results under the alternative hypothesis are similar to the results 
under the null hypothesis for both the mean and the standard error. Note that the 
expected mean under the null hypothesis is zero but under the alternative 
hypothesis the expected mean depends on the magnitude of the treatment effect. 
Selected simulation results under the null hypothesis are presented in Table 3.9 
and under the alternative hypothesis are presented in Table 3.10 where the 
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maximum allowable sample size is twice the original protocol-specified sample 
size. 
 
Table 3.9: Mean and Standard Error Results under the Null Hypothesis Ho: pe = 
pc from Simulations and Formulas where the Maximum Allowable Sample Size is 
Twice the Original Protocol-Specified Sample Size for the HW-SSR Method for 
the Alternative Hypothesis Ha: pe = (1 – γ)pc when the Outcome is Negative and 





      
Mean 
Expected 








      
SE 
Derived 
      
Mean 
Derived 
      
SE 
Interim 25% 0 0.01880 -0.00109 0.0189399 -0.001080 0.0189214 
50% 0 0.01882 -0.00115 0.0189477 -0.001079 0.0188987 
75% 0 0.01881 -0.00104 0.0189117 -0.001078 0.0188897 




25% 0 0.01880 -0.00106 0.0189107 -0.00108 0.0189214 
50% 0 0.01882 -0.00113 0.0189627 -0.001079 0.0188987 
75% 0 0.01882 -0.00108 0.0188795 -0.001061 0.0188533 




25% 0 0.01820 -0.00052 0.0181013 -0.000515 0.0181020 
50% 0 0.01838 -0.00050 0.0182071 -0.000523 0.0182113 
75% 0 0.01847 -0.00057 0.0182198 -0.000526 0.0182397 
100% 0 0.01882 0.00011 0.0188415 5.23E-18 0.0188248 
Note:  
1. IAL = interim analysis location. 
2. Interim analysis location refers to the percent of subjects out of the original protocol-
specified sample size who have been assessed for the outcome at the interim analysis. 
100% refers to the situation where no sample size re-estimation is planned. 






Table 3.10: Mean and Standard Error Results under the Alternative Hypothesis 
Ha: pe = (1 – γ)pc from Simulations and Formulas where the Maximum Allowable 
Sample Size is Twice the Original Protocol-Specified Sample Size for the HW-
SSR Method for the Alternative Hypothesis Ha: pe = (1 – γ)pc when the Outcome 





      
Mean 
Expected 








      
SE 
Derived 
      
Mean 
Derived 
      
SE 
Interim 25% -0.050 0.01782 -0.05111 0.0179778 -0.051080 0.0179406 
50% -0.050 0.01784 -0.05119 0.0179306 -0.051079 0.0179190 
75% -0.050 0.01783 -0.05101 0.0179019 -0.051078 0.0179103 




25% -0.050 0.01782 -0.05107 0.0179937 -0.051080 0.0179406 
50% -0.050 0.01784 -0.05107 0.0178285 -0.051079 0.0179190 
75% -0.050 0.01783 -0.05104 0.0178908 -0.051061 0.0178724 




25% -0.050 0.01726 -0.05049 0.0171970 -0.050515 0.0171446 
50% -0.050 0.01743 -0.05044 0.0172604 -0.050523 0.0172414 
75% -0.050 0.01751 -0.05050 0.0173192 -0.050526 0.0172630 
100% -0.050 0.01784 -0.04997 0.0178296 -0.050000 0.0178433 
Note:  
1. IAL = interim analysis location. 
2. Interim analysis location refers to the percent of subjects out of the original protocol-
specified sample size who have been assessed for the outcome at the interim analysis. 
100% refers to the situation where no sample size re-estimation is planned. 
3. Theoretically derived results refer to the results from the formulas derived in Section 
3.4.1. 
 
Negative Outcome – Risk Difference Treatment Effect 
Results for scenarios with a negative outcome and hypothesized risk 
difference treatment effect are presented in Appendix Table A.65 – Appendix 
Table A.76. Under the null hypothesis the expected mean of       if the Z-
statistic calculated for the Z-test followed a standard normal distribution is zero 
but the derived mean of       for those scenarios that involved an interim 
analysis are greater than zero. For those scenarios that did not involve an interim 
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analysis (labeled as Interim analysis location of “100%”) the derived mean of 
      is close to zero. The results for the average simulated mean of       
are similar to the derived mean of      . 
The results for the standard error under the null hypothesis showed that 
the derived standard error of       is larger than the expected standard error of 
      if the Z-statistic calculated for the Z-test followed a standard normal 
distribution when the minimum allowable sample size is less than the original 
protocol-specified sample size. When the minimum allowable sample size is the 
original protocol-specified sample size, the derived standard error of       is 
generally smaller than the expected standard error of       if the Z-statistic 
calculated for the Z-test followed a standard normal distribution. The results for 
the average simulated standard error of       are similar to the derived 
standard error of      . 
The results under the alternative hypothesis are similar to the results 
under the null hypothesis for both the mean and the standard error. Note that the 
expected mean under the null hypothesis is zero but under the alternative 
hypothesis the expected mean depended on the magnitude of the treatment 
effect. Selected simulations results under the null hypothesis are presented in 
Table 3.11 and under the alternative hypothesis are presented in Table 3.12 





Table 3.11: Mean and Standard Error Results under the Null Hypothesis Ho: pe = 
pc from Simulations and Formulas where the Maximum Allowable Sample Size is 
Twice the Original Protocol-Specified Sample Size for the HW-SSR Method for 
the Alternative Hypothesis Ha: pe = pc – Δ when the Outcome is Negative and pc = 





      
Mean 
Expected 








      
SE 
Derived 
      
Mean 
Derived 
      
SE 
Interim 25% 0 0.01898 0.00082 0.0190620 0.0008673 0.0191601 
50% 0 0.01890 0.00084 0.0190079 0.0008317 0.0190398 
75% 0 0.01887 0.00079 0.0189867 0.0008202 0.0190002 




25% 0 0.01897 0.00080 0.0191102 0.0008673 0.0191601 
50% 0 0.01890 0.00083 0.0190976 0.0008317 0.0190398 
75% 0 0.01887 0.00081 0.0189542 0.0008085 0.0189737 




25% 0 0.01844 0.00038 0.0183573 0.0003199 0.0183680 
50% 0 0.01854 0.00029 0.0184829 0.0003399 0.0184239 
75% 0 0.01859 0.00032 0.0184647 0.0003497 0.0184366 
100% 0 0.01882 0.00002 0.0187653 5.23E-18 0.0188248 
Note:  
1. IAL = interim analysis location. 
2. Interim analysis location refers to the percent of subjects out of the original protocol-
specified sample size who have been assessed for the outcome at the interim analysis. 
100% refers to the situation where no sample size re-estimation is planned. 






Table 3.12: Mean and Standard Error Results under the Alternative Hypothesis 
Ha: pe = pc – Δ from Simulations and Formulas where the Maximum Allowable 
Sample Size is Twice the Original Protocol-Specified Sample Size for the HW-
SSR Method for the Alternative Hypothesis Ha: pe = pc – Δ when the Outcome is 





      
Mean 
Expected 








      
SE 
Derived 
      
Mean 
Derived 
      
SE 
Interim 25% -0.050 0.01799 -0.04919 0.0181355 -0.049133 0.0181761 
50% -0.050 0.01791 -0.04915 0.0180826 -0.049168 0.0180601 
75% -0.050 0.01789 -0.04926 0.0179896 -0.049180 0.0180217 




25% -0.050 0.01798 -0.04916 0.0181084 -0.049133 0.0181761 
50% -0.050 0.01791 -0.04914 0.0180903 -0.049168 0.0180600 
75% -0.050 0.01788 -0.04924 0.0179779 -0.049192 0.0179941 




25% -0.050 0.01748 -0.04973 0.0173707 -0.049680 0.0174023 
50% -0.050 0.01757 -0.04972 0.0175061 -0.049660 0.0174506 
75% -0.050 0.01762 -0.04969 0.0174688 -0.049650 0.0174589 
100% -0.050 0.01784 -0.05007 0.0178334 -0.050000 0.0178433 
Note:  
1. IAL = interim analysis location. 
2. Interim analysis location refers to the percent of subjects out of the original protocol-
specified sample size who have been assessed for the outcome at the interim analysis. 
100% refers to the situation where no sample size re-estimation is planned. 
3. Theoretically derived results refer to the results from the formulas derived in Section 
3.4.1. 
 
Positive Outcome – Relative Treatment Effect 
Results for scenarios with a positive outcome and hypothesized relative 
treatment effect are presented in Appendix Table A.77 – Appendix Table A.88. 
Under the null hypothesis the expected mean of       if the Z-statistic 
calculated for the Z-test followed a standard normal distribution is zero but the 
derived mean of       for those scenarios that involved an interim analysis are 
less than zero. For those scenarios that did not involve an interim analysis 
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(labeled as Interim analysis location of “100%”) the derived mean of       is 
close to zero. The results for the average simulated mean of       are similar 
to the derived mean of      . 
The results for the standard error under the null hypothesis showed that 
the derived standard error of       is larger than the expected standard error of 
      if the Z-statistic calculated for the Z-test followed a standard normal 
distribution when the minimum allowable sample size is less than the original 
protocol-specified sample size. When the minimum allowable sample size is the 
original protocol-specified sample size, the derived standard error of       is 
generally smaller than the expected standard error of       if the Z-statistic 
calculated for the Z-test followed a standard normal distribution. The results for 
the average simulated standard error of       are similar to the derived 
standard error of      . 
The results under the alternative hypothesis are similar to the results 
under the null hypothesis for both the mean and the standard error. Note that the 
expected mean under the null hypothesis is zero but under the alternative 
hypothesis the expected mean depended on the magnitude of the treatment 
effect. Selected simulations results under the null hypothesis are presented in 
Table 3.13 and under the alternative hypothesis are presented in Table 3.14 





Table 3.13: Mean and Standard Error Results under the Null Hypothesis Ho: pe = 
pc from Simulations and Formulas where the Maximum Allowable Sample Size is 
Twice the Original Protocol-Specified Sample Size for the HW-SSR Method for 
the Alternative Hypothesis Ha: pe = (1 + γ)pc when the Outcome is Positive and pc 





      
Mean 
Expected 








      
SE 
Derived 
      
Mean 
Derived 
      
SE 
Interim 25% 0 0.01902 -0.00132 0.0193082 -0.001379 0.0193814 
50% 0 0.01892 -0.00139 0.0191733 -0.001321 0.0191820 
75% 0 0.01889 -0.00130 0.0190254 -0.001283 0.0190710 




25% 0 0.01903 -0.00147 0.0192820 -0.001379 0.0193810 
50% 0 0.01892 -0.00135 0.0192479 -0.001320 0.0191802 
75% 0 0.01886 -0.00130 0.0189218 -0.001203 0.0189313 




25% 0 0.01819 -0.00038 0.0180969 -0.000511 0.0180958 
50% 0 0.01836 -0.00063 0.0181371 -0.000542 0.0181888 
75% 0 0.01844 -0.00065 0.0182619 -0.000557 0.0182105 
100% 0 0.01882 -0.00005 0.0188023 2.91E-18 0.0188248 
Note:  
1. IAL = interim analysis location. 
2. Interim analysis location refers to the percent of subjects out of the original protocol-
specified sample size who have been assessed for the outcome at the interim analysis. 
100% refers to the situation where no sample size re-estimation is planned. 





Table 3.14: Mean and Standard Error Results under the Alternative Hypothesis 
Ha: pe = (1 + γ)pc from Simulations and Formulas where the Maximum Allowable 
Sample Size is Twice the Original Protocol-Specified Sample Size for the HW-
SSR Method for the Alternative Hypothesis Ha: pe = (1 + γ)pc when the Outcome 





      
Mean 
Expected 








      
SE 
Derived 
      
Mean 
Derived 
      
SE 
Interim 25% 0.050 0.01803 0.04875 0.0181925 0.0486209 0.0183977 
50% 0.050 0.01794 0.04863 0.0181582 0.0486794 0.0182044 
75% 0.050 0.01790 0.04876 0.0180505 0.0487170 0.0180933 




25% 0.050 0.01804 0.04864 0.0183133 0.0486209 0.0183974 
50% 0.050 0.01794 0.04877 0.0182797 0.0486799 0.0182025 
75% 0.050 0.01788 0.04875 0.0179573 0.0487966 0.0179490 




25% 0.050 0.01724 0.04959 0.0170804 0.0494885 0.0171398 
50% 0.050 0.01740 0.04941 0.0172531 0.0494581 0.0172206 
75% 0.050 0.01748 0.04939 0.0172685 0.0494432 0.0172353 
100% 0.050 0.01784 0.04988 0.0177813 0.0500000 0.0178433 
Note:  
1. IAL = interim analysis location. 
2. Interim analysis location refers to the percent of subjects out of the original protocol-
specified sample size who have been assessed for the outcome at the interim analysis. 
100% refers to the situation where no sample size re-estimation is planned. 
3. Theoretically derived results refer to the results from the formulas derived in Section 
3.4.1. 
 
Positive Outcome – Risk Difference Treatment Effect 
Results for scenarios with a positive outcome and hypothesized risk 
difference treatment effect are presented in Appendix Table A.89 – Appendix 
Table A.100. Under the null hypothesis the expected mean of       if the Z-
statistic calculated for the Z-test followed a standard normal distribution is zero 
but the derived mean of       for those scenarios that involved an interim 
analysis are less than zero. For those scenarios that did not involve an interim 
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analysis (labeled as Interim analysis location of “100%”) the derived mean of 
      is close to zero. The results for the average simulated mean of       
are similar to the derived mean of      . 
The results for the standard error under the null hypothesis showed that 
the derived standard error of       is larger than the expected standard error of 
      if the Z-statistic calculated for the Z-test followed a standard normal 
distribution when the minimum allowable sample size is less than the original 
protocol-specified sample size. When the minimum allowable sample size is the 
original protocol-specified sample size, the derived standard error of       is 
generally smaller than the expected standard error of       if the Z-statistic 
calculated for the Z-test followed a standard normal distribution. The results for 
the average simulated standard error of       are similar to the derived 
standard error of      . 
The results under the alternative hypothesis are similar to the results 
under the null hypothesis for both the mean and the standard error. Note that the 
expected mean under the null hypothesis is zero but under the alternative 
hypothesis the expected mean depended on the magnitude of the treatment 
effect. Selected simulations results under the null hypothesis are presented in 
Table 3.15 and under the alternative hypothesis are presented in Table 3.16 





Table 3.15: Mean and Standard Error Results under the Null Hypothesis Ho: pe = 
pc from Simulations and Formulas where the Maximum Allowable Sample Size is 
Twice the Original Protocol-Specified Sample Size for the HW-SSR Method for 
the Alternative Hypothesis Ha: pe = pc + Δ when the Outcome is Positive and pc = 


























      
SE 
Interim 25% 0 0.01898 -0.00096 0.0191294 -0.000867 0.0191601 
50% 0 0.01890 -0.00086 0.0190722 -0.000832 0.0190398 
75% 0 0.01888 -0.00090 0.0189721 -0.000820 0.0190002 




25% 0 0.01897 -0.00077 0.0190510 -0.000867 0.0191601 
50% 0 0.01890 -0.00084 0.0190199 -0.000832 0.0190398 
75% 0 0.01887 -0.00094 0.0190094 -0.000808 0.0189737 




25% 0 0.01844 -0.00037 0.0183482 -0.000320 0.0183680 
50% 0 0.01854 -0.00036 0.0184854 -0.000340 0.0184239 
75% 0 0.01858 -0.00029 0.0184928 -0.000350 0.0184366 
100% 0 0.01882 0.00004 0.0187943 2.91E-18 0.0188248 
Note:  
1. IAL = interim analysis location. 
2. Interim analysis location refers to the percent of subjects out of the original protocol-
specified sample size who have been assessed for the outcome at the interim analysis. 
100% refers to the situation where no sample size re-estimation is planned. 





Table 3.16: Mean and Standard Error Results under the Alternative Hypothesis 
Ha: pe = pc + Δ from Simulations and Formulas where the Maximum Allowable 
Sample Size is Twice the Original Protocol-Specified Sample Size for the HW-
SSR Method for the Alternative Hypothesis Ha: pe = pc + Δ when the Outcome is 





      
Mean 
Expected 








      
SE 
Derived 
      
Mean 
Derived 
      
SE 
Interim 25% 0.050 0.01799 0.04914 0.0181290 0.0491327 0.0181761 
50% 0.050 0.01792 0.04910 0.0181282 0.0491683 0.0180601 
75% 0.050 0.01789 0.04914 0.0180584 0.0491798 0.0180217 




25% 0.050 0.01799 0.04925 0.0180691 0.0491327 0.0181761 
50% 0.050 0.01792 0.04918 0.0180649 0.0491683 0.0180600 
75% 0.050 0.01789 0.04910 0.0179841 0.0491915 0.0179941 




25% 0.050 0.01747 0.04968 0.0173915 0.0496801 0.0174023 
50% 0.050 0.01757 0.04970 0.0175030 0.0496601 0.0174506 
75% 0.050 0.01762 0.04966 0.0174064 0.0496503 0.0174589 
100% 0.050 0.01784 0.05006 0.0178160 0.0500000 0.0178433 
Note:  
1. IAL = interim analysis location. 
2. Interim analysis location refers to the percent of subjects out of the original protocol-
specified sample size who have been assessed for the outcome at the interim analysis. 
100% refers to the situation where no sample size re-estimation is planned. 
3. Theoretically derived results refer to the results from the formulas derived in Section 
3.4.1. 
 
3.4.3 Discussion of the Final Test Statistic Results 
The results for the simulations and calculations of the mean and standard 
error of       from the derived formulas under the null and alternative 
hypotheses indicate that for all scenarios that did not involve a SSR the mean 
and standard error were near what we would expect if the Z-statistic calculated 
for the Z-test followed a standard normal distribution. For scenarios with SSR at 
an interim analysis the results show that the average simulated mean of       
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and the derived mean of       did not equal the expected mean of       (0 
under the null and       under the alternative). For a negative outcome and a 
hypothesized relative treatment effect and positive outcome for both treatment 
effects there was a consistent trend in the simulations and the derived values for 
the mean to be less than the expected mean (0 under the null and       under 
the alternative). For a negative outcome and a hypothesized risk difference 
treatment effect there was a consistent trend in the simulations and the derived 
values for the mean to be greater than the expected mean (0 under the null and 
      under the alternative). Additionally, the standard error of the simulations 
and the derived values was different from the expected standard error. In all 
scenarios, the simulated mean and standard error clearly aligned with the results 
from the derived formulas rather than the expected mean and standard error if 
the Z-statistic calculated for the Z-test followed a standard normal distribution. 
The actual distribution of the final Z statistic calculated for the Z-test is not       . 
3.5 Discussion of Counterintuitive Results 
One seemingly counterintuitive result from the simulations presented in 
Section 3.3 is that the lower one-sided Type I error rate is inflated for the 
scenarios when the outcome is negative for a hypothesized relative treatment 
effect but not when outcome is negative for a hypothesized risk difference 
treatment effect (in the latter scenario, there is a reduction in power). This is 
counterintuitive as the assumptions prior to the trial are the same. For instance, 
when the control group event rate is 0.30 and the relative reduction is 50%, the 
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corresponding risk difference effect is 0.15 and the event rate is assumed to be 
0.15 at the design stage for both treatment effect designs, yielding the same 
initial sample size in the protocol. Appendix Table A.53 – Appendix Table A.76 
showed that the mean       for the relative treatment effect was smaller than 
expected and for the risk difference treatment effect approach was larger than 
expected if the Z-statistic calculated for the Z-test followed a standard normal 
distribution. 
When conducting the test of the null hypothesis at the end of the trial, if 
the mean difference is assumed to be 0 but, in truth, is less than 0 (as it was for 
the relative treatment effect), then the null hypothesis is more likely to be rejected 
on the lower side than would be expected. Conversely, if the mean difference is 
greater than 0 (as it was for the risk difference treatment effect), then the null 
hypothesis is less likely to be rejected on the lower side than would be expected. 
This leads to the lower-side of the Type I error being inflated for the relative 
treatment effect whereas the lower side of the Type I error is not inflated for the 
risk difference treatment effect.  
When computing the required sample size under the alternative 
hypothesis, if the mean difference is assumed to be       (a negative number) 
but, in truth, is less than       (an absolute larger number), the power is greater 
than expected because it is more likely to reject the null hypothesis than 
expected. Conversely, if the mean difference is greater than       (an absolute 
smaller number) the power is lower than expected because it is less likely to 
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reject the null hypothesis than expected. This leads to higher power for the 
relative treatment effect and lower power the risk difference treatment effect.  
From the simulation results presented in Section 3.3 when the outcome is 
negative the Type I error inflation and reduced power was most prevalent when 
the minimum allowable sample size was less than the original protocol-specified 
sample size. It can therefore be assumed that the issues with the increased one-
sided lower Type I error rate for the relative treatment effect and the reduced 
power for the risk difference treatment effect happen when the re-estimated 
sample size is smaller than the original protocol-specified sample size.  
In the scenarios with the relative treatment effect, when the observed 
control group rate is greater than true control group rate at the interim analysis a 
re-estimated sample size that is smaller than the original protocol-specified 
sample size is required. As a result, this observed control group rate has less of 
a chance to “regress to the mean” value of the true control group event rate. If, 
on average, the control group event rate is larger than the true event rate, the 
difference between the observed event rates in the experimental arm and the 
control arm is smaller than       on average (i.e the difference is an absolute 
larger number). An absolute larger difference between the experimental arm and 
the control arm on average yields an increased chance of rejecting the null 
hypothesis on the lower side of the critical region than expected and results in an 
increase of the lower one-sided Type I error as well as an increase in power. 
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In the scenarios with the risk difference treatment effect the opposite 
occurred. When the observed control group rate is smaller than the true control 
group rate at the interim analysis a re-estimated sample size that is smaller than 
the original protocol-specified sample size is required. As a result, this observed 
control group rate has less of a chance to “regress to the mean” value of the true 
control group event rate. If, on average, the control group event rate is smaller 
than the true event rate, the difference between the observed event rates in the 
experimental arm and the control arm is larger than       on average (i.e. the 
difference is an absolute smaller number). An absolute smaller difference 
between the experimental arm and the control arm than on average yields an 
decreased chance of rejecting the null hypothesis on the lower side of the critical 
region than expected and results in an decrease of the lower one-sided Type I 
error as well as a decrease in power. 
This seemingly counterintuitive result, when investigated more closely, is 
explained by the relationship between the control group event rate at the interim 
analysis, the hypothesized treatment effect, and the resulting re-estimated 
sample size. 
3.6 Conclusion 
In this Chapter we reviewed the results of the HW-SSR method when it 
was applied to a randomized, concurrent, two-arm superiority clinical trial with a 
two-arm internal pilot and a binomial outcome to conduct SSR based solely on 
the interim observed control group event rate and the protocol-specified effect 
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size as presented in the Herson and Wittes (1993) manuscript and the Jennison 
and Turnbull (2000) text. As the reported results were inconsistent with one 
another we investigated the statistical operational characteristics of the HW-SSR 
method when applied to this trial design. Our investigation showed that the one-
sided lower Type I error rate is sometimes inflated for a hypothesized relative 
treatment effect with a negative outcome. In addition, the power is sometimes 
reduced for a hypothesized risk difference treatment effect (for both negative and 
positive outcomes) and for a hypothesized relative treatment effect with a 
positive outcome. While the final goal is to apply the HW-SSR method to a study 
designed with a single-arm internal pilot, the HW-SSR method must be 
implemented such that the Type I error rate is controlled and adequate power is 




CHAPTER 4  
Development of the CVPA-SSR Algorithm in Trials Designed with a Two-arm 
Internal Pilot 
As illustrated through simulation results in Chapter 3, simulations using 
the HW-SSR method in a randomized, concurrent, two-arm superiority clinical 
trial with a two-arm internal pilot and a binomial outcome may result in an inflated 
lower one-sided Type I error rate for a hypothesized relative treatment effect with 
a negative outcome. In addition, the power did not always reach the desired level 
when the minimum allowable recalculated sample size was less than the original 
protocol-specified sample size for a hypothesized relative treatment effect with a 
positive outcome or for a risk difference treatment effect with both positive and 
negative outcomes. Prior to extending the HW-SSR methodology to a trial with 
single-arm internal pilot, the Type I error rate must first be controlled at the 
nominal level and the desired power should be attained for a two-arm internal 
pilot study. 
The following sections describe a method to calculate the exact Type I 
error rate of the HW-SSR method. The calculation will be used as part of an 
algorithm to adjust the critical value cutoff used in the final Z-test following the 
application of the HW-SSR method in order to maintain the one-sided Type I 
error rate of interest at the nominal level. After confirmation that the adjusted 
critical value will preserve the nominal one-sided Type I error rate, a second 
portion of the algorithm will be defined to update the critical value for power in the 
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interim SSR formula to ensure the desired power is attained. Finally, the one-
sided Type I error rate of interest and the power of the study will be investigated 
when the protocol-specified parameter values are different from the true 
parameter values for the population (i.e. those used to simulate the data). 
4.1 Adjusting Critical Value for Type I Error Inflation 
For the purpose of the all investigations in this Chapter, the hypotheses to 
be considered are: 
Negative Outcome Positive Outcome 
                      
                      
where    and    are the outcome event rates for the experimental and control 
groups, respectively. As such, the lower-side of the Type I error is of interest 
when the outcome is negative and the upper-side of the Type I error is of interest 
when the outcome is positive. 
4.1.1 mFKα Formula 
In Chapter 2, a formula (Equation 2.4) developed by Friede and Kieser 
was introduced to calculate the exact Type I error rate for Gould’s blinded SSR 
method. This formula is repeated here for reference: 
Equation 4.1 
    
         
   
     
   
   
     
  
   
   
 
   
     
 
   
   
 
   
     
 
   
   
  
   
   
                      
   
76 
 
where     and     are the sample sizes in each treatment arm before the interim 
analysis and     and     are the sample sizes in each treatment arm after the 
interim analysis.    ,    ,    , and     are the numbers of events in each 
treatment arm before and after the interim analysis, π is the assumed overall 
event rate under the null hypothesis,   is the total number of events,   is the total 
sample size of the trial, and       
  denotes the        α   percentile of the 
  distribution with 1 degree of freedom. 
Equation 4.1 can be adapted to calculate the exact Type I error for a two-
arm internal pilot study that uses the HW-SSR method by replacing the    test 
statistic with either a lower or upper one-sided Z statistic resulting in:  
Equation 4.2 
           
        
  
   
     
   
   
     
  
   
   
 
   
     
 
   
   
 
   
     
 
   
   
  
   
   
                   
           
        
  
   
     
   
   
     
  
   
   
 
   
     
 
   
   
 
   
     
 
   
   
  
   
   
                     
where  α (for a negative outcome) and    α (for a positive outcome) are the 
    α   and        α    percentiles of the standard normal distribution, 
respectively. This will be referred to as the modified Friede and Kieser Exact 
Type I Error (mFKα) formula for determining either the lower or upper one-sided 
exact Type I error rate. 
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4.1.1.1 Calculations using the mFKα Formula versus Simulation 
Results from Chapter 3 
The mFKα was computed for 12 simulation scenarios (six for positive and 
six for negative outcomes) presented in Chapter 3 where the maximum allowable 
sample size was twice the original protocol-specified sample size to compare the 
mFKα one-sided Type I error rate versus the simulated one-sided Type I error 
rate. The minimum allowable sample size was the sample size at the interim 
analysis, 10% more than the sample size at the interim analysis, or the original 
protocol-specified sample size. The hypothesized treatment could be a relative 
effect or a risk difference effect. Table 4.1 presents selected results for a 
negative outcome and a hypothesized relative treatment effect, Table 4.2 
presents selected results for a negative outcome and a hypothesized risk 
difference treatment effect, Table 4.3 presents selected results for a positive 
outcome and a hypothesized relative treatment effect, and Table 4.4 presents 
selected results for a positive outcome and a hypothesized risk difference 
treatment effect. The full set of simulation and calculation results are available in 
Appendix Table A.101– Table A.112.  
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Table 4.1: Comparisons between the Simulated and mFKα Calculated Lower-
Type I Error Rates for the Alternative Hypothesis Ha: pe = (1 – γ)pc when the 
Outcome is Negative. 
Minimum 
 Allowable SS     γ  IAL 
Simulated Lower Type I 
Error (95% CI)* 
mFKα Calculated 
 Lower Type I Error 
Interim 0.20 0.25 25% 0.0269 (0.0259-0.0279) 0.0267 
  50% 0.0278 (0.0268-0.0288) 0.0268 
  75% 0.0274 (0.0264-0.0284) 0.0268 
  100% 0.0250 (0.0240-0.0260) N/A 
10% more 
 than the  
Interim 
0.20 0.25 25% 0.0257 (0.0247-0.0267) 0.0267 
  50% 0.0278 (0.0268-0.0288) 0.0268 
  75% 0.0272 (0.0262-0.0282) 0.0265 




0.20 0.25 25% 0.0251 (0.0241-0.0261) 0.0254 
  50% 0.0253 (0.0243-0.0263) 0.0252 
  75% 0.0253 (0.0243-0.0263) 0.0251 
  100% 0.0250 (0.0240-0.0260) N/A 
*Results are presented from the corresponding scenarios in Chapter 3. 
Note:  
1. SS = sample size,    = control group rate, γ = relative treatment effect, IAL = interim 
analysis location. 
2. Interim analysis location refers to the percent of subjects out of the original protocol-
specified sample size who have been assessed for the outcome at the interim analysis. 




Table 4.2: Comparisons between the Simulated and mFKα Calculated Lower-
Type I Error Rates for the Alternative Hypothesis Ha: pe = pc – Δ when the 
Outcome is Negative. 
Minimum 
 Allowable SS      IAL 
Simulated Lower Type I 
Error (95% CI)* 
mFKα Calculated 
 Lower Type I Error 
Interim 0.20 0.05 25% 0.0240 (0.0230-0.0250) 0.0240 
  50% 0.0234 (0.0224-0.0244) 0.0240 
  75% 0.0242 (0.0232-0.0252) 0.0240 
  100% 0.0252 (0.0242-0.0262) N/A 
10% more 
 than the  
Interim 
0.20 0.05 25% 0.0245 (0.0235-0.0255) 0.0234 
  50% 0.0250 (0.0240-0.0260) 0.0240 
  75% 0.0247 (0.0237-0.0257) 0.0240 




0.20 0.05 25% 0.0239 (0.0229-0.0249) 0.0238 
  50% 0.0238 (0.0228-0.0248) 0.0234 
  75% 0.0239 (0.0229-0.0249) 0.0232 
  100% 0.0248 (0.0238-0.0258) N/A 
*Results are presented from the corresponding scenarios in Chapter 3. 
Note:  
1. SS = sample size,    = control group rate, Δ = risk difference treatment effect, IAL = 
interim analysis location. 
2. Interim analysis location refers to the percent of subjects out of the original protocol-
specified sample size who have been assessed for the outcome at the interim analysis. 




Table 4.3: Comparisons between the Simulated and mFKα Calculated Upper-
Type I Error Rates for the Alternative Hypothesis Ha: pe = (1 + γ)pc when the 
Outcome is Positive. 
Minimum 
 Allowable SS     γ  IAL 
Simulated Upper Type I 
Error (95% CI)* 
mFKα Calculated 
 Upper Type I Error 
Interim 0.80 0.0625 25% 0.0236 (0.0226-0.0246) 0.0234 
  50% 0.0240 (0.0230-0.0250) 0.0234 
  75% 0.0235 (0.0225-0.0245) 0.0234 
  100% 0.0247 (0.0237-0.0257) N/A 
10% more 
 than the  
Interim 
0.80 0.0625 25% 0.0230 (0.0220-0.0240) 0.0234 
  50% 0.0228 (0.0218-0.0238) 0.0234 
  75% 0.0231 (0.0221-0.0241) 0.0234 




0.80 0.0625 25% 0.0247 (0.0237-0.0257) 0.0238 
  50% 0.0238 (0.0228-0.0248) 0.0236 
  75% 0.0233 (0.0223-0.0243) 0.0235 
  100% 0.0244 (0.0234-0.0254) N/A 
*Results are presented from the corresponding scenarios in Chapter 3. 
Note:  
1. SS = sample size,    = control group rate, γ = relative treatment effect, IAL = interim 
analysis location. 
2. Interim analysis location refers to the percent of subjects out of the original protocol-
specified sample size who have been assessed for the outcome at the interim analysis. 




Table 4.4: Comparisons between the Simulated and mFKα Calculated Upper-
Type I Error Rates for the Alternative Hypothesis Ha: pe = pc + Δ when the 
Outcome is Positive. 
Minimum 
 Allowable SS      IAL 
Simulated Upper Type I 
Error (95% CI)* 
mFKα Calculated 
 Upper Type I Error 
Interim 0.80 0.05 25% 0.0237 (0.0227-0.0247) 0.0240 
  50% 0.0247 (0.0237-0.0257) 0.0240 
  75% 0.0234 (0.0224-0.0244) 0.0240 
  100% 0.0253 (0.0243-0.0263) N/A 
10% more 
 than the  
Interim 
0.80 0.05 25% 0.0241 (0.0231-0.0251) 0.0240 
  50% 0.0237 (0.0227-0.0247) 0.0240 
  75% 0.0242 (0.0232-0.0252) 0.0240 




0.80 0.05 25% 0.0236 (0.0226-0.0246) 0.0243 
  50% 0.0242 (0.0232-0.0252) 0.0242 
  75% 0.0250 (0.0240-0.0260) 0.0241 
  100% 0.0245 (0.0235-0.0255) N/A 
*Results are presented from the corresponding scenarios in Chapter 3. 
Note:  
1. SS = sample size,    = control group rate, Δ = risk difference treatment effect, IAL = 
interim analysis location. 
2. Interim analysis location refers to the percent of subjects out of the original protocol-
specified sample size who have been assessed for the outcome at the interim analysis. 
100% refers to the situation where no sample size re-estimation is planned. 
 
Results of the calculations show that the mFKα calculated Type I error rate 
of interest aligns with the observed simulation. In most cases, the 95% CI for the 
simulated Type I error rate contained the Type I error rate calculated using the 
mFKα formula. Only 11 out of 252 (4.4%) scenarios have calculated results falling 
outside of the 95% CI. Note that when the simulated Type I error is inflated, the 
exact Type I error rate is also inflated, again confirming the need to adjust the 




4.1.2 Proposed Algorithm for Type I Error Rate Adjustment 
The following algorithm using the mFKα formula is proposed to adjust the 
critical value cutoff used in the final Z-test in order to maintain control of the one-
sided Type I error rate at the nominal level. The Critical Value Adjusted Sample 
Size Re-estimation (CVA-SSR) algorithm is implemented at the beginning of the 
trial, before any subjects have enrolled. For the following discussion, without the 
loss of generality, the algorithm assumes that the final hypothesis test is either a 
lower or an upper one-sided Z-test, with a one-sided Type I error rate of 0.025, a 
desired power of 0.80, and a 1:1 allocation of subjects into each treatment group. 
(Note that the CVA-SSR algorithm can be applied to other one-sided Type I error 
rates, powers, and allocation of subjects. Here a single value of each is used for 
illustration.) 
Critical Value Adjusted Sample Size Re-estimation (CVA-SSR) Algorithm: 
1. Compute the sample size per group,   , necessary to attain 0.80 power 
with a one-sided Type I error rate of 0.025 and assumed values of control 
group rate, the treatment effect magnitude, and the type of treatment 
effect in the following fixed study design formula 
    
                      
 
                    
        
 
2. Determine the timing of the interim analysis based on    (e.g., when 50% 
of the    subjects have the outcome). This will be the value for     and     
in Step 3. 
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3. Calculate the exact Type I error of the trial under the null hypothesis given 
the SSR rule at the interim analysis using the mFKα equation:  
              
  
   
     
   
   
     
  
   
   
 
   
     
 
   
   
 
   
     
 
   
   
  
   
   
                   
              
  
   
     
   
   
     
  
   
   
 
   
     
 
   
   
 
   
     
 
   
   
  
   
   
                     
and the SSR formula is given by  
           
                      
 
                        
          
 
where      
   
   
 and              ,          Δ,               or 
          Δ to match the alternative hypothesis of the simulation 
scenario. Note that the SSR is also subject to the minimum and maximum 
allowable sample sizes and that     +     =     +     =         . 
4. If         then Stop.    (for a negative outcome) or      (for a positive 
outcome) is the critical value to be used as the cutoff in the final Z-test and 
in the SSR formula at the interim. If         then determine the critical 
value   
  (for a negative outcome) or     
  (for a positive outcome) that if 
substituted into         or           for    or      respectively in Step 3 
will lead to         . 
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5. Update    (for a negative outcome) to   
  or      (for a positive outcome) to 
    
  in Step 3 in both the SSR formula and the indicator function in the 
mFKα formula. 
6. Repeat Steps 3 – 6 until the condition         in Step 4 is met. 
Note that in this algorithm, the critical value is not allowed to be less extreme 
than    (for a negative outcome) or      (for a positive outcome). That is, if    = -
1.96 then the critical value cannot be larger than -1.96. If      = 1.96, the critical 
value cannot be smaller than 1.96.  
This algorithm will be used to derive the critical value required to maintain 
the Type I error rate at the nominal level when re-estimating the sample size at 
the interim analysis using the observed control group information in a trial 
designed with a two-arm internal pilot.  
4.1.3 Simulations where Assumptions Used in the Design Stage are 
Correct 
In Section 4.1.2, the CVA-SSR algorithm was proposed to adjust the 
critical value cutoff in the final Z-test to maintain control of the Type I error rate 
when using HW-SSR method in a trial designed with a two-arm internal pilot. To 
investigate the statistical operational characteristics after application of the HW-
SSR method and the CVA-SSR algorithm, we conducted a simulation study. 
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4.1.3.1 Simulation Methods 
Data were simulated to demonstrate the application of the CVA-SSR 
algorithm to control the Type I error rate at the nominal level and examine the 
corresponding power estimates. Four sets of simulation scenarios were 
generated, one for each set of hypotheses where the outcome was a negative 
event: 
Relative treatment effect                                          , 
Risk difference treatment effect                             Δ, 
and one for each set of hypotheses where the outcome was a positive event: 
Relative treatment effect                                          , 
Risk difference treatment effect                             Δ 
For each simulation scenario, the CVA-SSR algorithm was implemented at the 
design stage (prior to the start of the trial). All trials were designed to be 
evaluated using a lower or an upper one-sided Z statistic with a nominal Type I 
error rate of 0.025, a desired power of 0.80, and a 1:1 allocation of subjects into 
each treatment group. The SSR formula in Step 3 of the CVA-SSR algorithm was 
used to calculate the re-estimated sample size at the interim analysis. The 
maximum allowable sample size was twice the original protocol-specified sample 
size. The minimum allowable sample size had three possible values: the sample 
size at the interim analysis, 10% more than the sample size at the interim 
analysis, or the original protocol-specified sample size. A single interim analysis 
was prospectively planned to occur after 25%, 50%, or 75% of the subject 
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outcomes were measured. Additionally, a scenario with no SSR (fixed design) 
was presented for comparison where no adjustment to the critical value was 
made. The event rates in the control group were 0.10, 0.20, 0.30, and 0.40 when 
the outcome was negative and 0.60, 0.70, 0.80, and 0.90 when the outcome was 
positive. The effect sizes for the risk difference treatment effect alternative 
hypothesis were 0.025 for event rates of 0.10 and 0.90, 0.05 and 0.10 for event 
rates of 0.20 and 0.80, 0.075 and 0.15 for event rates of 0.30 and 0.70, and 0.10 
and 0.20 for event rates of 0.40 and 0.60. For comparability, the effect sizes for 
the relative treatment effect alternative hypothesis match the corresponding risk 
difference treatment effect scenarios (i.e., for the negative outcome scenario 
where the control group event rate equaled 0.20 and the risk difference treatment 
effect equaled 0.10, the relative treatment effect equaled 0.50). For the purpose 
of extreme simulation scenarios the rules described in Section 3.3.1 were used. 
For all simulation scenarios, 100,000 replications were performed.  
Note that data were simulated under the protocol-specified assumptions. 
For example, for a given set of simulations, the study was designed and powered 
in the protocol with certain assumptions of   ,    and the corresponding   
(relative treatment effect) or Δ (risk difference treatment effect) for the null and 




4.1.3.2 Simulation Results 
Complete results from all simulations are presented in Appendix Table 
A.113 – Table A.136. 
Negative Outcome – Relative Treatment Effect 
Results for simulation scenarios with a negative outcome and a 
hypothesized relative treatment effect show that critical value adjustments are 
required when the minimum allowable sample size is the sample size at the 
interim or is 10% more than the sample size at the interim. When the minimum 
allowable sample size is the original protocol-specified sample size, adjustments 
to the critical value are still required but are less extreme. When the interim 
analysis is conducted earlier in the trial (i.e., after a lesser percentage of subjects 
have recorded outcomes), a more extreme critical value adjustment is required 
than when the interim analysis is performed later in the trial.  
When comparing across all scenarios with an interim analysis the 
simulated one-sided lower Type I error rate is near the nominal level of 0.025 and 
the lower limit of the 95% CI of the one-sided lower Type I error rate is at or 
below the nominal level in all scenarios performed with an interim analysis except 
one where the control group event rate is 0.20, the relative treatment effect is 
0.25, the interim analysis location is after 25% of subject outcomes are 
measured, and the minimum sample size is 10% more than the sample size at 
the interim (Type I error rate 0.0261; 95% CI 0.0251 – 0.0271). The simulated 
power in all of the scenarios is at least 0.80. Table 4.5 presents selected 
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simulation results where the control group event rate is 0.20 and the treatment 
effect is a 25% relative reduction in the control group event rate. 
 
Table 4.5: Results from Simulations for the CVA-SSR Algorithm for the 
Alternative Hypothesis Ha: pe = (1 – γ)pc when the Outcome is Negative and pc = 
0.20 and γ = 0.25. 
Minimum 
 Allowable 
 SS IAL 
Simulated Lower Type I 
 Error (95% CI) 
Simulated Power 







Interim 25% 0.0249 (0.0239-0.0259) 0.8269 (0.8244-0.8294) 944 -1.99 
50% 0.0251 (0.0241-0.0261) 0.8282 (0.8257-0.8307) 933 -1.99 
75% 0.0246 (0.0236-0.0256) 0.8291 (0.8266-0.8316) 929 -1.99 




25% 0.0261 (0.0251-0.0271) 0.8290 (0.8265-0.8315) 942 -1.99 
50% 0.0249 (0.0239-0.0259) 0.8263 (0.8238-0.8288) 934 -1.99 
75% 0.0254 (0.0244-0.0264) 0.8302 (0.8277-0.8327) 929 -1.99 




25% 0.0245 (0.0235-0.0255) 0.8402 (0.8377-0.8427) 977 -1.97 
50% 0.0244 (0.0234-0.0254) 0.8321 (0.8296-0.8346) 954 -1.97 
75% 0.0253 (0.0243-0.0263) 0.8296 (0.8271-0.8321) 944 -1.97 
100% 0.0248 (0.0238-0.0258) 0.7992 (0.7967-0.8017) 903 -1.96 
Note:  
1. SS = sample size, IAL = interim analysis location. 
2. Interim analysis location refers to the percent of subjects out of the original protocol-
specified sample size who have been assessed for the outcome at the interim analysis. 
100% refers to the situation where no sample size re-estimation is planned. 
3. Original protocol-specified sample size per group is 903 for these scenarios. 
 
Negative Outcome – Risk Difference Treatment Effect 
Results for simulation scenarios with a negative outcome and a 
hypothesized risk difference treatment effect illustrate that no adjustments to the 
critical values are needed to maintain the one-sided lower Type I error rate. 
When comparing all scenarios with an interim analysis, the lower limit of the 95% 
CI of the one-sided lower Type I error rate is at or below the nominal level of 
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0.025. The simulated power results, however, do not always attain 0.80. The 
minimum simulated power values in the scenarios with an interim analysis are 
0.718 when the minimum allowable sample size is the sample size at the interim, 
0.721 when the minimum allowable sample size is 10% more than the sample 
size at the interim, and 0.796 when the minimum allowable sample size is the 
original protocol-specified sample size. Table 4.6 presents selected simulation 
results where the control group event rate is 0.20 and the risk difference 
treatment effect is 0.05. 
 
Table 4.6: Results from Simulations for the CVA-SSR Algorithm for the 
Alternative Hypothesis Ha: pe = pc – Δ when the Outcome is Negative and pc = 
0.20 and Δ = 0.05. 
Minimum 
 Allowable 
 SS IAL 
Simulated Lower Type I 
 Error (95% CI) 
Simulated Power 







Interim 25% 0.0240 (0.0230-0.0250) 0.7760 (0.7735-0.7785) 899 -1.96 
50% 0.0239 (0.0229-0.0249) 0.7779 (0.7754-0.7804) 901 -1.96 
75% 0.0238 (0.0228-0.0248) 0.7772 (0.7747-0.7797) 902 -1.96 




25% 0.0246 (0.0236-0.0256) 0.7744 (0.7719-0.7769) 899 -1.96 
50% 0.0242 (0.0232-0.0252) 0.7771 (0.7746-0.7796) 901 -1.96 
75% 0.0237 (0.0227-0.0247) 0.7802 (0.7777-0.7827) 902 -1.96 




25% 0.0240 (0.0230-0.0250) 0.8070 (0.8045-0.8095) 944 -1.96 
50% 0.0243 (0.0233-0.0253) 0.8028 (0.8003-0.8053) 933 -1.96 
75% 0.0239 (0.0229-0.0249) 0.8035 (0.8010-0.8060) 927 -1.96 
100% 0.0250 (0.0240-0.0260) 0.8010 (0.7985-0.8035) 903 -1.96 
Note:  
1. SS = sample size, IAL = interim analysis location. 
2. Interim analysis location refers to the percent of subjects out of the original protocol-
specified sample size who have been assessed for the outcome at the interim analysis. 
100% refers to the situation where no sample size re-estimation is planned. 




Positive Outcome – Relative Treatment Effect 
Results for simulation scenarios with a positive outcome and a 
hypothesized relative treatment effect illustrate that no adjustments are needed 
to the critical value to maintain the one-sided upper Type I error rate. When 
comparing all scenarios with an interim analysis, the lower limit of the 95% CI of 
the one-sided upper Type I error rate is at or below the nominal level of 0.025. 
The simulated power results, however, do not always attain 0.80. The minimum 
simulated power values in the scenarios with an interim analysis are 0.675 when 
the minimum allowable sample size is the sample size at the interim, 0.676 when 
the minimum allowable sample size is 10% more than the sample size at the 
interim, and 0.801 when the minimum allowable sample size is the original 
protocol-specified sample size. Table 4.7 presents selected simulation results 
where the control group event rate is 0.80 and the treatment effect is a 6.25% 
relative increase in the control event rate.  
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Table 4.7: Results from Simulations for the CVA-SSR Algorithm for the 
Alternative Hypothesis Ha: pe = (1 + γ)pc when the Outcome is Positive and pc = 
0.80 and γ = 0.0625. 
Minimum 
 Allowable 
 SS IAL 
Simulated Upper Type I 
 Error (95% CI) 
Simulated Power 







Interim 25% 0.0233 (0.0223-0.0243) 0.7619 (0.7594-0.7644) 909 1.96 
50% 0.0234 (0.0224-0.0244) 0.7673 (0.7648-0.7698) 906 1.96 
75% 0.0239 (0.0229-0.0249) 0.7679 (0.7654-0.7704) 905 1.96 




25% 0.0233 (0.0223-0.0243) 0.7661 (0.7636-0.7686) 909 1.96 
50% 0.0230 (0.0220-0.0240) 0.7662 (0.7637-0.7687) 906 1.96 
75% 0.0243 (0.0233-0.0253) 0.7681 (0.7656-0.7706) 908 1.96 




25% 0.0242 (0.0232-0.0252) 0.8141 (0.8116-0.8166) 975 1.96 
50% 0.0236 (0.0226-0.0246) 0.8059 (0.8034-0.8084) 953 1.96 
75% 0.0239 (0.0229-0.0249) 0.8022 (0.7997-0.8047) 944 1.96 
100% 0.0256 (0.0246-0.0266) 0.7994 (0.7969-0.8019) 903 1.96 
Note:  
1. SS = sample size, IAL = interim analysis location. 
2. Interim analysis location refers to the percent of subjects out of the original protocol-
specified sample size who have been assessed for the outcome at the interim analysis. 
100% refers to the situation where no sample size re-estimation is planned. 
3. Original protocol-specified sample size per group is 903 for these scenarios. 
 
Positive Outcome – Risk Difference Treatment Effect 
Results for simulation scenarios with a positive outcome and a 
hypothesized risk difference treatment effect illustrate that no adjustments are 
needed to the critical value to maintain the one-sided upper Type I error rate. 
When comparing all scenarios with an interim analysis, the lower limit of the 95% 
CI of the one-sided upper Type I error rate is at or below the nominal level of 
0.025. The simulated power results, however, do not always attain 0.80. The 
minimum simulated power values in the scenarios with an interim analysis are 
0.720 when the minimum allowable sample size is the sample size at the interim, 
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0.716 when the minimum allowable sample size is 10% more than the sample 
size at the interim, and 0.800 when the minimum allowable sample size is the 
original protocol-specified sample size. Table 4.8 presents selected simulation 
results where the control group event rate is 0.80 and the risk difference 
treatment effect is 0.05. 
 
Table 4.8: Results from Simulations for the CVA-SSR Algorithm for the 
Alternative Hypothesis Ha: pe = pc + Δ when the Outcome is Positive and pc = 
0.80 and Δ = 0.05. 
Minimum 
 Allowable 
 SS IAL 
Simulated Upper Type I 
 Error (95% CI) 
Simulated Power 







Interim 25% 0.0240 (0.0230-0.0250) 0.7761 (0.7736-0.7786) 899 1.96 
50% 0.0238 (0.0228-0.0248) 0.7775 (0.7750-0.7800) 901 1.96 
75% 0.0238 (0.0228-0.0248) 0.7788 (0.7763-0.7813) 902 1.96 




25% 0.0239 (0.0229-0.0249) 0.7765 (0.7740-0.7790) 899 1.96 
50% 0.0249 (0.0239-0.0259) 0.7784 (0.7759-0.7809) 901 1.96 
75% 0.0239 (0.0229-0.0249) 0.7790 (0.7765-0.7815) 902 1.96 




25% 0.0250 (0.0240-0.0260) 0.8082 (0.8057-0.8107) 944 1.96 
50% 0.0248 (0.0238-0.0258) 0.8056 (0.8031-0.8081) 933 1.96 
75% 0.0234 (0.0224-0.0244) 0.8030 (0.8005-0.8055) 927 1.96 
100% 0.0244 (0.0234-0.0254) 0.8001 (0.7976-0.8026) 903 1.96 
Note:  
1. SS = sample size, IAL = interim analysis location. 
2. Interim analysis location refers to the percent of subjects out of the original protocol-
specified sample size who have been assessed for the outcome at the interim analysis. 
100% refers to the situation where no sample size re-estimation is planned. 
3. Original protocol-specified sample size per group is 903 for these scenarios. 
 
4.1.3.3 Discussion of Simulation Results 
The Type I error rate of a randomized, concurrent, two-arm superiority 
clinical trial with a two-arm internal pilot and a binomial outcome that uses the 
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HW-SSR method was controlled at the nominal level when the CVA-SSR 
algorithm was used to adjust the critical value cutoff used in the final Z-test. In all 
simulation scenarios except for one, the simulated one-sided Type I error rates 
were maintained at the nominal level of 0.025 as the lower limit of the 95% CIs 
for the simulated one-sided Type I error rate contained the nominal value. For a 
negative outcome and a hypothesized relative treatment effect, an adjustment to 
the critical value was required, with the largest adjustments for a minimum 
allowable sample size less than the original protocol-specified sample size and 
an interim analysis conducted after 25% of subject outcomes were measured. 
For a positive outcome and a hypothesized relative treatment effect, no 
adjustments to the critical value were required to maintain the nominal one-sided 
Type I error rate. For a hypothesized risk difference treatment effect, neither the 
negative nor the positive outcome required a critical value adjustment to maintain 
the nominal Type I error rate.  
A review of the results comparing scenarios where there were no extreme 
simulations that required simulation rules versus those scenarios where there 
were extreme simulations that required simulation rules showed that the overall 
conclusions remained the same. 
Despite the controlled Type I error rate, the simulated power fell below the 
desired level in many of the simulation scenarios. 
While the CVA-SSR algorithm sufficiently controls the Type I error rate, it 
does not also control the power of the study. In the next section, we will 
94 
 
investigate modifications to the CVA-SSR algorithm that will allow for both Type I 
error and power control when the algorithm is applied with the HW-SSR method 
in a trial with a two-arm internal pilot. 
4.2 Adjusting Critical Value for Type I Error Inflation and Reduced Power 
4.2.1 mFKβ Formula 
The mFKα formula, used to calculate the exact Type I error rate of a trial 
that uses the HW-SSR method, was derived under the null hypothesis that the 
experimental group event rate is equal to the control group event rate. In a 
similar manner, a modified Friede and Kieser Power (mFKβ) formula can be 
derived under the alternative hypothesis to calculate the expected power of a trial 
with a two-arm internal pilot that uses the HW-SSR method. Substituting the 
experimental and control group event rates under the alternative hypothesis into 
Equation 4.2 yields: 
Equation 4.3 
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where     and     are the sample sizes in each treatment arm before the interim 
analysis and     and     are the sample sizes in each treatment arm after the 
interim analysis.    ,    ,    , and     are the numbers of events in each 
treatment arm before and after the interim analysis,    and   , are the assumed 
event rates in the two treatment groups under the alternative hypothesis,       
is the stage of the trial, and    (for a negative outcome) and      (for a positive 
outcome) are the     α   and        α    percentiles of the standard normal 
distribution. 
4.2.2 Proposed Algorithm for Type I Error Rate and Power Adjustment 
The CVA-SSR algorithm requires modification to maintain control of the 
one-sided Type I error rate of interest while also achieving the desired power. 
This can be accomplished by expanding the algorithm to use both the mFKα and 
mFKβ formulas in an iterative process. The Critical Value and Power Adjusted 
Sample Size Re-estimation (CVPA-SSR) algorithm is proposed to adjust the 
critical value cutoff used in the final Z-test and also adjust the critical value used 
for power in the interim SSR formula. This algorithm is implemented at the 
beginning of the trial, before any subjects have enrolled. For the following 
discussion, the algorithm assumes, without loss of generality, that the final 
hypothesis test is either a lower or an upper one-sided Z test (for negative and 
positive outcomes, respectively) with a one-sided Type I error rate of 0.025, a 
desired power of 0.80, and a 1:1 allocation of subjects into each treatment group. 
(Note that the CVPA-SSR algorithm can be applied to other one-sided Type I 
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error rates, powers, and allocations of subjects. Here a single value of each is 
used for illustration.) 
Critical Value and Power Adjusted Sample Size Re-estimation (CVPA-SSR) 
Algorithm: 
1. Compute the sample size per group necessary to attain 0.80 power with a 
one-sided Type I error rate of 0.025 and assumed values of the control 
group rate, the treatment effect magnitude, and the type of treatment 
effect in the following fixed study design formula: 
    
                      
 
                    
        
 
2. Determine the timing of the interim analysis based on    (e.g., when 50% 
of the    subjects have the outcome). This will be the value for     and     
in Step 3 and Step 7. 
3. Calculate the power of the trial under the alternative hypothesis given the 
SSR rule at the interim analysis using the mFKβ equation: 
                   
   
     
   
   
     
  
   
   
 
   
     
 
   
   
 
   
     
 
   
   
  
   
   
   
  
          
           
          
                
                   
   
     
   
   
     
  
   
   
 
   
     
 
   
   
 
   
     
 
   
   
  
   
   
   
  
          
           
          
                  
and the SSR formula is given by 
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where      
   
   
 and              ,          Δ,               or 
         Δ to match the alternative hypothesis of the simulation 
scenario. Note that the SSR is also subject to the minimum and maximum 
allowable sample sizes and that     +     =     +     =         . 
4. If                 then skip to Step 7,      is the critical value to be 
used in the SSR formula at the interim. If                 then derive 
a new critical value     
  by increasing the power used in the interim 
analysis SSR calculation by 0.001 (e.g, update 0.80 to 0.801). 
5. Update      in the SSR formula in Step 3 with     
  
6. Repeat Steps 3 – 6 until the condition                 in Step 3 is 
met. 
7. Calculate the exact Type I error of the trial under the null hypothesis given 
the SSR rule at the interim analysis using the mFKα equation:  
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where      
   
   
 and              ,          Δ,               or 
         Δ to match the alternative hypothesis of the simulation 
scenario. Note that the SSR is also subject to the minimum and maximum 
allowable sample sizes and that     +     =     +     =         . 
8. If         then stop.    (for a negative outcome) or      (for a positive 
outcome) is the critical value cutoff to be used in the final Z-test and in the 
SSR formula at the interim. If         then determine the critical value   
  
(for a negative outcome) or     
  (for a positive outcome) that if substituted 
into         or           for    or      respectively in Step 7 would 
have lead to         . 
9. Update    (for a negative outcome) to   
  or      (for a positive outcome) to 
    
  in Step 3 in both the SSR formula and the indicator function in the 
mFKβ equation. 
10. Repeat Steps 3 – 10 until the conditions                 and         
in Steps 4 and 8 are met. 
Note that in this algorithm, the critical value is not allowed to be less extreme 
than    (for a negative outcome) or      (for a positive outcome). That is, if    = -
1.96 then the critical value cannot be larger than -1.96. If      = 1.96, the critical 
value cannot be smaller than 1.96.  
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Note that though the critical values for both the Type I error and power can 
be adjusted with the CVPA-SSR algorithm, for the purpose of all presentations, 
the critical value cutoff used in the final Z-test will be presented as is. Values for 
power will reported as a proportion rather than a critical value to avoid any 
confusion (e.g., power value of 0.886 instead of critical value for power of 1.21). 
This algorithm will be used to derive the critical value required to maintain 
the Type I error rate at the nominal level and the required power value to achieve 
the desired power when re-estimating the sample size at the interim analysis 
using the observed control group information in a trial designed with a two-arm 
internal pilot. 
4.2.3 Simulations where Assumptions Used in the Design Stage are 
Correct 
In Section 4.2.2, the CVPA-SSR algorithm was proposed to adjust the 
critical value cutoff used in the final Z-test in order to maintain control of the Type 
I error rate while attaining the desired power when using the HW-SSR method in 
a trial designed with a two-arm internal pilot. The following simulation study was 
performed to demonstrate that the statistical operational characteristics of this 
trial design are sound. 
4.2.3.1 Simulation Methods 
Data were simulated under the same scenarios (with different seeds) as 
were explored in Section 4.1.3.  
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4.2.3.2 Simulation Results 
Complete results from all simulations are presented in Appendix Table 
A.137 - Table A.160. 
Negative Outcome – Relative Treatment Effect 
As was observed when the CVA-SSR algorithm was applied to simulation 
scenarios with a negative outcome and a hypothesized relative treatment effect, 
critical value adjustments are required to control the Type I error at the nominal 
level of 0.025; however the power of the study attains the desired level of 0.80 so 
no adjustment to the power values are required. The results after the CVPA-SSR 
algorithm is applied mimic those observed after the application of the CVA-SSR 
algorithm. Table 4.9 presents selected simulation results where the control group 
event rate is 0.20 and the treatment effect is a 25% relative reduction in the 
control event rate.  
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Table 4.9: Results from Simulations for the CVPA-SSR Algorithm for the 
Alternative Hypothesis Ha: pe = (1 – γ)pc when the Outcome is Negative and pc = 
0.20 and γ = 0.25. 
Minimum 
 Allowable 
 SS IAL 
Simulated Lower  












Interim 25% 0.0249 (0.0239-0.0259) 0.8257 (0.8232-0.8282) 944 -1.99 0.800 
50% 0.0246 (0.0236-0.0256) 0.8281 (0.8256-0.8306) 933 -1.99 0.800 
75% 0.0256 (0.0246-0.0266) 0.8299 (0.8274-0.8324) 929 -1.99 0.800 




25% 0.0249 (0.0239-0.0259) 0.8261 (0.8236-0.8286) 943 -1.99 0.800 
50% 0.0250 (0.0240-0.0260) 0.8308 (0.8283-0.8333) 933 -1.99 0.800 
75% 0.0246 (0.0236-0.0256) 0.8290 (0.8265-0.8315) 929 -1.99 0.800 




25% 0.0246 (0.0236-0.0256) 0.8395 (0.8370-0.8420) 977 -1.97 0.800 
50% 0.0240 (0.0230-0.0250) 0.8335 (0.8310-0.8360) 954 -1.97 0.800 
75% 0.0252 (0.0242-0.0262) 0.8322 (0.8297-0.8347) 944 -1.97 0.800 
100% 0.0245 (0.0235-0.0255) 0.7966 (0.7941-0.7991) 903 -1.96 0.800 
Note:  
1. SS = sample size, IAL = interim analysis location. 
2. Interim analysis location refers to the percent of subjects out of the original protocol-
specified sample size who have been assessed for the outcome at the interim analysis. 
100% refers to the situation where no sample size re-estimation is planned. 
3. Original protocol-specified sample size per group is 903 for these scenarios. 
 
Negative Outcome – Risk Difference Treatment Effect 
As was observed after application of CVA-SSR algorithm, results for the 
simulation scenarios with a negative outcome and a hypothesized risk difference 
treatment effect show that no adjustments to the critical value cutoff used in the 
final Z-test are needed to maintain the one-sided lower Type I error rate at the 
nominal level when applying the CVPA-SSR algorithm. 
Adjustments to the power value used in the SSR formula at the interim 
analysis are required in some scenarios. When the minimum allowable sample 
size is the sample size at the interim or 10% more than the sample size at the 
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interim a more extreme power value than the nominal value of 0.80 is required. 
When the minimum allowable sample size is the original protocol-specified 
sample size, most scenarios do not require an adjustment to the power value, 
with the exception of one where the control group rate is 0.40, the risk difference 
treatment effect is 0.20, and the interim analysis location is after 75% of subject 
outcomes are measured. In general, a more extreme adjustment is required 
when the interim analysis is conducted earlier in the trial compared to when the 
interim analysis is done later in the trial. After applying the CVPA-SSR algorithm 
across all scenarios with an interim analysis, the simulated power attains the 
desired level of 0.80 as the upper limit of the 95% CI for the simulated power is at 
or above the nominal value of 0.80. Table 4.10 presents selected simulation 
results when the control group event rate is 0.20 and the risk difference treatment 
effect is 0.05.  
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Table 4.10: Results from Simulations for the CVPA-SSR Algorithm for the 
Alternative Hypothesis Ha: pe = pc – Δ when the Outcome is Negative and pc = 
0.20 and Δ = 0.05. 
Minimum 
 Allowable 
 SS IAL 
Simulated Lower  












Interim 25% 0.0232 (0.0222-0.0242) 0.8001 (0.7976-0.8026) 962 -1.96 0.826 
50% 0.0250 (0.0240-0.0260) 0.8008 (0.7983-0.8033) 956 -1.96 0.823 
75% 0.0241 (0.0231-0.0251) 0.7999 (0.7974-0.8024) 955 -1.96 0.822 




25% 0.0230 (0.0220-0.0240) 0.7991 (0.7966-0.8016) 961 -1.96 0.826 
50% 0.0241 (0.0231-0.0251) 0.7992 (0.7967-0.8017) 956 -1.96 0.823 
75% 0.0251 (0.0241-0.0261) 0.7999 (0.7974-0.8024) 955 -1.96 0.822 




25% 0.0251 (0.0241-0.0261) 0.8076 (0.8051-0.8101) 944 -1.96 0.800 
50% 0.0245 (0.0235-0.0255) 0.8050 (0.8025-0.8075) 933 -1.96 0.800 
75% 0.0254 (0.0244-0.0264) 0.8045 (0.8020-0.8070) 927 -1.96 0.800 
100% 0.0258 (0.0248-0.0268) 0.8005 (0.7980-0.8030) 903 -1.96 0.800 
Note:  
1. SS = sample size, IAL = interim analysis location. 
2. Interim analysis location refers to the percent of subjects out of the original protocol-
specified sample size who have been assessed for the outcome at the interim analysis. 
100% refers to the situation where no sample size re-estimation is planned. 
3. Original protocol-specified sample size per group is 903 for these scenarios. 
 
Positive Outcome – Relative Treatment Effect 
As was observed after application of CVA-SSR algorithm, results for the 
simulation scenarios with a positive outcome and a hypothesized relative 
treatment effect show that no adjustments to the critical value cutoff used in the 
final Z-test are needed to maintain the one-sided lower Type I error rate at the 
nominal level when applying the CVPA-SSR algorithm. 
Adjustments to the power value used in the SSR formula at the interim 
analysis are required in some scenarios. When the minimum allowable sample 
size is the sample size at the interim or 10% more than the sample size at the 
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interim a more extreme power value than the nominal value of 0.80 is required. 
When the minimum allowable sample size is the original protocol-specified 
sample size, no adjustment to the power value is necessary. In general, a more 
extreme adjustment is required when the interim analysis is conducted earlier in 
the trial compared to when the interim analysis is done later in the trial. After 
applying the CVPA-SSR algorithm across all scenarios with an interim analysis, 
the simulated power attains the desired level of 0.80 as the upper limit of the 
95% CI for the simulated power is at or above the nominal value of 0.80. Table 
4.11 presents selected simulation results when the control group event rate is 




Table 4.11: Results from Simulations for the CVPA-SSR Algorithm for the 
Alternative Hypothesis Ha: pe = (1 + γ)pc when the Outcome is Positive and pc = 
0.80 and γ = 0.0625. 
Minimum 
 Allowable 
 SS IAL 
Simulated Upper  












Interim 25% 0.0231 (0.0221-0.0241) 0.8002 (0.7977-0.8027) 1008 1.96 0.839 
50% 0.0235 (0.0225-0.0245) 0.7998 (0.7973-0.8023) 991 1.96 0.834 
75% 0.0247 (0.0237-0.0257) 0.7990 (0.7965-0.8015) 987 1.96 0.833 




25% 0.0242 (0.0232-0.0252) 0.7985 (0.7960-0.8010) 1008 1.96 0.839 
50% 0.0240 (0.0230-0.0250) 0.8012 (0.7987-0.8037) 991 1.96 0.834 
75% 0.0234 (0.0224-0.0244) 0.8016 (0.7991-0.8041) 988 1.96 0.833 




25% 0.0234 (0.0224-0.0244) 0.8111 (0.8086-0.8136) 974 1.96 0.800 
50% 0.0241 (0.0231-0.0251) 0.8062 (0.8037-0.8087) 953 1.96 0.800 
75% 0.0234 (0.0224-0.0244) 0.7998 (0.7973-0.8023) 944 1.96 0.800 
100% 0.0255 (0.0245-0.0265) 0.8000 (0.7975-0.8025) 903 1.96 0.800 
Note:  
1. SS = sample size, IAL = interim analysis location. 
2. Interim analysis location refers to the percent of subjects out of the original protocol-
specified sample size who have been assessed for the outcome at the interim analysis. 
100% refers to the situation where no sample size re-estimation is planned. 
3. Original protocol-specified sample size per group is 903 for these scenarios. 
 
Positive Outcome – Risk Difference Treatment Effect 
As was observed after application of CVA-SSR algorithm, results for the 
simulation scenarios with a positive outcome and a risk difference treatment 
effect show that no adjustments to the critical value used as the cutoff in the final 
Z-test are needed to maintain the one-sided lower Type I error rate at the 
nominal level when applying the CVPA-SSR algorithm. 
Adjustments to the power value used in the SSR formula at the interim 
analysis are required in some scenarios. When the minimum allowable sample 
size is the sample size at the interim or 10% more than the sample size at the 
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interim a more extreme power value than the nominal value of 0.80 is required. 
When the minimum allowable sample size is the original protocol-specified 
sample size, most scenarios do not require an adjustment to the power value, 
with the exception of one where the control group rate is 0.60, the risk difference 
treatment effect is 0.20, and the interim analysis location is after 75% of subject 
outcomes are measured. In general, a more extreme adjustment is required 
when the interim analysis is conducted earlier in the trial compared to when the 
interim analysis is done later in the trial. After applying the CVPA-SSR algorithm 
across all scenarios with an interim analysis, the simulated power attains the 
desired level of 0.80 as the upper limit of the 95% CI for the simulated power is at 
or above the nominal value of 0.80 with the exception of one scenario where the 
simulated power is 0.7974 (95% CI: 0.7949 – 0.7999) for a control group rate of 
0.90, a risk difference treatment effect of 0.05 and a minimum allowable sample 
size of the sample size at the interim. Table 4.12 presents selected simulation 
results when the control group event rate is 0.80 and the risk difference treatment 
effect is 0.05.  
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Table 4.12: Results from Simulations for the CVPA-SSR Algorithm for the 
Alternative Hypothesis Ha: pe = pc + Δ when the Outcome is Positive and pc = 
0.80 and Δ = 0.05. 
Minimum 
 Allowable 
 SS IAL 
Simulated Upper  












Interim 25% 0.0242 (0.0232-0.0252) 0.7986 (0.7961-0.8011) 962 1.96 0.826 
50% 0.0249 (0.0239-0.0259) 0.8000 (0.7975-0.8025) 956 1.96 0.823 
75% 0.0249 (0.0239-0.0259) 0.8012 (0.7987-0.8037) 955 1.96 0.822 




25% 0.0238 (0.0228-0.0248) 0.8004 (0.7979-0.8029) 961 1.96 0.826 
50% 0.0244 (0.0234-0.0254) 0.7997 (0.7972-0.8022) 956 1.96 0.823 
75% 0.0243 (0.0233-0.0253) 0.8005 (0.7980-0.8030) 955 1.96 0.822 




25% 0.0245 (0.0235-0.0255) 0.8086 (0.8061-0.8111) 944 1.96 0.800 
50% 0.0241 (0.0231-0.0251) 0.8055 (0.8030-0.8080) 933 1.96 0.800 
75% 0.0246 (0.0236-0.0256) 0.8018 (0.7993-0.8043) 928 1.96 0.800 
100% 0.0255 (0.0245-0.0265) 0.7992 (0.7967-0.8017) 903 1.96 0.800 
Note:  
1. SS = sample size, IAL = interim analysis location. 
2. Interim analysis location refers to the percent of subjects out of the original protocol-
specified sample size who have been assessed for the outcome at the interim analysis. 
100% refers to the situation where no sample size re-estimation is planned. 
3. Original protocol-specified sample size per group is 903 for these scenarios. 
 
4.2.3.3 Comparison between Adjusted and Unadjusted Simulation 
Results from Chapter 3 
Results from the simulations investigating the application of the CVPA-
SSR algorithm when the HW-SSR method is used in a trial with a two-arm 
internal pilot can be compared to the similar scenarios investigated in Chapter 3 
when no adjustment is used with the HW-SSR method. Table 4.13 and Table 
4.14 shows selected simulation results when the HW-SSR method is used with 
the CVPA-SSR algorithm (adjusted results) and when the HW-SSR method is 
used alone (unadjusted results).   
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Table 4.13: A Comparison of Results from Simulations for the HW-SSR Method 
(Unadjusted) vs. the HW-SSR Method + CVPA-SSR Algorithm (Adjusted) for 













  = 0.25 
 
Interim 25% 0.0269 0.8282 0.0249 0.8257 
50% 0.0278 0.8303 0.0246 0.8281 




25% 0.0257 0.8281 0.0249 0.8261 
50% 0.0278 0.8283 0.0250 0.8308 




25% 0.0251 0.8395 0.0246 0.8395 
50% 0.0253 0.8326  0.0240 0.8335 




  = 0.05 
 
Interim 25% 0.0240 0.7746 0.0232 0.8001 
50% 0.0234 0.7778 0.0250 0.8008 




25% 0.0245 0.7744 0.0230 0.7991 
50% 0.0250 0.7760 0.0241 0.7992 




25% 0.0242 0.8083 0.0251 0.8076 
50% 0.0249 0.8038 0.0245 0.8050 
75% 0.0253 0.8030 0.0254 0.8045 
Note:  
1. SS = sample size, IAL = interim analysis location. 
2. Interim analysis location refers to the percent of subjects out of the original protocol-
specified sample size who have been assessed for the outcome at the interim analysis. 
100% refers to the situation where no sample size re-estimation is planned. 




Table 4.14: A Comparison of Results from Simulations for the HW-SSR Method 
(Unadjusted) vs. the HW-SSR Method + CVPA-SSR Algorithm (Adjusted) for 













  = 0.0625 
 
Interim 25% 0.0236 0.7666 0.0231 0.8002 
50% 0.0240 0.7677 0.0235 0.7998 




25% 0.0230 0.7623 0.0242 0.7985 
50% 0.0228 0.7678 0.0240 0.8012 




25% 0.0247 0.8145 0.0234 0.8111 
50% 0.0238 0.8054 0.0241 0.8062 




  = 0.05 
 
Interim 25% 0.0237 0.7745 0.0242 0.7986 
50% 0.0247 0.7754 0.0249 0.8000 




25% 0.0241 0.7773 0.0238 0.8004 
50% 0.0237 0.7782 0.0244 0.7997 




25% 0.0236 0.8060 0.0245 0.8086 
50% 0.0242 0.8026 0.0241 0.8055 
75% 0.0250 0.8030 0.0246 0.8018 
Note:  
1. SS = sample size, IAL = interim analysis location. 
2. Interim analysis location refers to the percent of subjects out of the original protocol-
specified sample size who have been assessed for the outcome at the interim analysis. 
100% refers to the situation where no sample size re-estimation is planned. 
3. 95% CI for Type I error ± 0.0010, for Power ± 0.0025 
 
Comparisons show that when the HW-SSR method is not used in 
conjunction with the CVPA-SSR algorithm, Type I error inflation and reduced 
power may occur when the minimum allowable sample size is less than the 
original protocol-specified sample size. When the CVPA-SSR algorithm is used, 




4.2.3.4 Discussion of Simulation Results 
The CVPA-SSR algorithm was applied to a randomized, concurrent, two-
arm superiority clinical trial with a two-arm internal pilot and a binomial outcome 
that uses the HW-SSR method to allow critical value and power value adjustment 
to control the Type I error and power at the nominal levels when the final test is a 
Z-test. The one-sided Type I error rate was maintained at the nominal level in all 
simulation scenarios except for two as the lower bound of the 95% CI for the 
simulated Type I error rate contained the nominal value of 0.025 and the power 
achieved the desired level in all simulation scenarios except for one as the upper 
bound of the 95% CI for the simulated power contained the nominal value of 
0.80. Even in these scenarios the simulated Type I error rate and power were 
close to the nominal levels. 
For a negative outcome and a hypothesized relative treatment effect, 
adjustment to the critical value cutoff used in the final Z-test was required but no 
adjustment to the power value was required. Larger adjustments to the critical 
value cutoff in the final Z-test were observed when the minimum allowable 
sample size was smaller than the original protocol-specified sample size and 
when the SSR was conducted earlier in the trial. Of particular interest was that 
the critical value cutoff used in the final Z-test required adjustment even when the 
minimum allowable sample size was the originally planned sample size, although 
the adjustments were minor. 
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For a hypothesized risk difference treatment effect (for both negative and 
positive outcomes) and a hypothesized relative treatment effect for a positive 
outcome, adjustments to the critical value cutoff used in the final Z-test were not 
required in the scenarios investigated; however adjustments to the power value 
in the SSR formula were required in some scenarios. Adjustments to the power 
value in the SSR formula were required in all scenarios when the minimum 
allowable sample size was smaller than the original protocol-specified sample 
size and the adjustments were larger when the SSR was conducted earlier in the 
trial. Adjustment to the power value was required in one scenario where the 
minimum allowable sample size was the original protocol-specified sample size 
for both positive and negative outcomes for a hypothesized risk difference 
treatment effect. This was most likely due to asymptotic issues as the average 
sample size is small after the interim analysis (24 in each arm on average) and 
the simulations results without an interim analysis did not attain 0.80 power 
either. No adjustment to the power value in the SSR formula was required for a 
positive outcome and a hypothesized relative treatment effect. 
A review of the results comparing scenarios where there were no extreme 
simulations that required simulation rules versus those scenarios where there 
were extreme simulations that required simulation rules showed that the overall 
conclusions remained the same. 
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4.2.4 Simulations where Assumptions Used in the Design Stage are 
Incorrect (Misspecified) 
In the simulations described in Section 4.2.3, data were simulated under 
the protocol-specified assumptions. For example, for a given set of simulations, 
the study was designed and powered in the protocol with certain assumptions of 
  ,    and the corresponding   (relative treatment effect) or Δ (risk difference 
treatment effect) for the null and alternative hypothesis. The simulated datasets 
were generated under these assumptions. We now generate simulations to 
investigate the application of the CVPA-SSR algorithm to scenarios where the 
study is designed using assumed parameter values (  ,   , and the 
corresponding   [relative treatment effect] or Δ [risk difference treatment effect]) 
that are incorrect or, i.e., do not equal the true and unknown parameter values in 
the population.  
4.2.4.1 Simulation Methods 
Data were simulated for scenarios where the minimum allowable sample 
size is the sample size at the interim analysis, the hypothesized treatment effect 
was either a relative treatment effect or risk difference treatment effect, and for 
both negative and positive outcomes. A single interim analysis was prospectively 
planned to occur after 25%, 50%, or 75% of subject outcomes were measured. A 
scenario with no SSR (fixed design) is also presented though no adjustments 
were made to the critical value cutoff used in the final Z-test or the power value. 
Protocol-specified assumed control group event rates include values of 0.20 and 
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0.30 when the outcome was negative and 0.70 and 0.80 when the outcome was 
positive. For a hypothesized risk difference treatment effect, the protocol-
specified assumed risk difference treatment effect used was 0.05 for a control 
group event rate of 0.20 or 0.80 and was 0.075 for a control group event rate of 
0.30 or 0.70. For a hypothesized relative treatment effect, the protocol-specified 
assumed relative treatment effect was 0.25 for a control group event rate of 0.20 
or 0.30, 0.0625 for a control group event rate of 0.80, and 0.1071 for a control 
group event rate of 0.70. 
Misspecifications of both the control group event rate and the treatment effect 
were simulated. In general, the misspecification of each of these parameters was 
captured in one of five settings: 
 Large underestimation of the true parameter value at the design stage 
 Small underestimation of the true parameter value at the design stage 
 Design stage assumption of the parameter value is correct 
 Small overestimation of the true parameter value at the design stage 
 Large overestimation of the true parameter value at the design stage 
There are 25 scenarios investigated (i.e., (1) large underestimation of both 
control group event rate and treatment effect; (2) large underestimation of the 
control group event rate and small underestimation of the treatment effect; (3) 
large underestimation of the control group event rate and the correct assumption 
of the treatment effect; etc.).  
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For these simulations, a large misspecification in the control group event 
rate is defined as a 25% difference between the assumed value at the design 
stage and the true parameter value in the population for a negative outcome. A 
large misspecification in the treatment effect is defined as a 25% difference 
between the assumed value at the design stage and the true parameter value in 
the population. A small misspecification in the control group event rate is defined 
as a 5% difference between the assumed value at the design stage and the true 
parameter value in the population for a negative outcome. A small 
misspecification in the treatment effect is defined as a 5% difference between the 
assumed value at the design stage and the true parameter value in the 
population. For example, when the design assumption for the control group rate 
is 0.20, then a "large overestimation" at the design corresponds to a true control 
group rate in the population of 0.15 (i.e., 0.20 – 0.20*0.25 = 0.15). For positive 
outcomes, the misspecification is computed for the complement of the event rate 
      . For example, if the design assumption for the control group is 0.80, then 
a “large overestimation” at the design corresponds to a true control group rate in 
the population of 0.75 (i.e., 0.80 – (1-0.80)*0.25 = 0.75). Similarly for the 
treatment effect, when the design assumption for the treatment effect is 0.05 for 
a risk difference treatment effect, then a “small underestimation” at the design 
corresponds to a true risk difference treatment effect of 0.0525 (i.e., 0.05 + 
0.05*0.05 = 0.0525). When the design assumption for the treatment effect is 0.25 
for a relative treatment effect, then a “small underestimation” at the design 
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corresponds to a true relative treatment effect of 0.2625 (i.e., 0.25 + 0.25*0.05 = 
0.2625). 
Note that misspecification of either the control group event rate or the 
treatment effect also corresponds to a misspecification of the experimental group 
event rate in the study design. For example, if the assumed control group is 0.20 
and the assumed relative treatment effect is 0.25, a “large overestimation” at the 
design for both the control group rate and the treatment effect corresponds to a 
true control group event rate of 0.15, a true relative treatment effect of 0.1875 
(i.e., 0.25*(1-0.25) = 0.1875), and a true experimental group event rate of 0.122 
(i.e., (1-0.1875)*0.15 = 0.122). For the same setting with an assumed risk 
difference treatment effect of 0.05, a “large overestimation” corresponds to a true 
control group event rate of 0.15, a true risk difference treatment effect of 0.0375 
(i.e., 0.05*(1-0.25) = 0.0375) and a true event rate in the experimental group of 
0.113 (i.e., 0.15 – 0.0375 = 0.113). While many of the assumptions are shared 
between the relative and risk difference treatment effects, the true experimental 
group event rates differed. As a result, comparing anything more than the 
general patterns of required adjustments in the Type I error and power between 
different simulation scenarios must be done with caution. 
For all scenarios, the original protocol-specified sample sizes were 
calculated using the protocol-specified assumed parameter values. The CVPA-
SSR algorithm was applied to calculate the adjusted critical value cutoff used in 
the final Z-test and the adjusted power value used in the interim SSR formula 
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using the protocol-specified assumed parameter values. The sample sizes were 
re-estimated based on the observed control group event rate at the interim and 
the protocol-specified assumed treatment effect.  
4.2.4.2 Simulation Results 
Simulations were conducted for the five types of misspecification of the 
control group event rate and the treatment effect for a total of 25 scenarios for 
each outcome and treatment effect. The following discussions consider only 
those scenarios with an interim analysis. All results from simulations are 
presented in Appendix Table A.161 – Table A.200.  
Negative Outcome – Relative Treatment Effect 
Results for simulation scenarios with a negative outcome and a 
hypothesized relative treatment effect show that across all types of 
misspecifications, the simulated one-sided lower Type I error rate is near the 
nominal level of 0.025 as the lower limit of the 95% CI for the one-sided lower 
Type I error rate is at or below the nominal value with the exception of one 
scenario where the control group rate is 0.20, the relative treatment effect is 0.25, 
a large underestimation of the control group rate and a small underestimation for 
the treatment effect are the misspecifications, and the interim analysis is 
conducted after 75% subject outcomes are measured (Type I error = 0.0263; 
95% CI: 0.0253 – 0.0273).  
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When there is a misspecification of the control group event rate only, the 
simulated power attains the desired level of 0.80 as the lower limit of the 95% CI 
around the simulated power is at or above the nominal value of 0.80. 
When there is misspecification in the treatment effect only, for an 
overestimation, the simulated power does not attain 0.80 even after adjustment 
by the CVPA-SSR algorithm. When there is an underestimation in the treatment 
effect, however, the simulated power is at least 0.80 in all scenarios. 
When there is misspecification in the control group event rate and in the 
treatment effect, regardless of whether the control group was overestimated or 
underestimated, if the treatment effect is overestimated, the simulated power 
does not attain 0.80 even after adjustment by the CVPA-SSR algorithm; 
however, if the treatment effect is underestimated, the simulated power is at least 
0.80 for all scenarios.  
Table 4.15 presents selected simulation results where the design stage 
assumptions are 0.20 for the control group event rate and a 25% relative 
reduction for the relative treatment effect for the scenarios with a large 
misspecification and for the scenarios where the design stage assumptions are 
correct. Simulations are presented for either the scenario with no interim analysis 















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Negative Outcome – Risk Difference Treatment Effect 
Results for simulation scenarios with a negative outcome and a 
hypothesized risk difference treatment effect show that across all types of 
misspecifications, the simulated one-sided lower Type I error rate is near the 
nominal level of 0.025 as the lower limit of the 95% CI for the one-sided lower 
Type I error is at or below the nominal value. 
When there is a misspecification of the control group event rate only, for 
an underestimation, the simulated power attains 0.80 power. When there is an 
overestimation of the control group event rate, the simulated power is close to 
0.80 though 0.80 power is not always attained. 
When there is misspecification in the treatment effect only, for an 
overestimation, the simulated power does not attain 0.80 even after adjustment 
by the CVPA-SSR algorithm. When there is an underestimation in the treatment 
effect, however, the simulated power is at least 0.80 in all scenarios. 
When there is misspecification in the control group event rate and in the 
treatment effect, results indicate that regardless of whether the control group was 
overestimated or underestimated, if the treatment effect is overestimated, the 
simulated power does not attain 0.80 even after adjustment by the CVPA-SSR 
algorithm; however, if the treatment effect is underestimated, the simulated 
power is at least 0.80 for all scenarios.  
Table 4.16 presents selected simulation results where the design 
assumptions are 0.20 for the control group event rate and 0.05 for the risk 
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difference treatment effect for the scenarios with a large misspecification and for 
the scenarios where the design stage assumptions are correct. Simulations are 
presented for either the scenario with no interim analysis or the scenario with an 

















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Positive Outcome – Relative Treatment Effect 
Results for simulation scenarios with a positive outcome and a 
hypothesized relative treatment effect show that across all types of 
misspecifications, the simulated one-sided upper Type I error rate is near the 
nominal level of 0.025 as the lower limit of the 95% CI for the one-sided upper 
Type I error is at or below the nominal value. 
When there is a misspecification of the control group event rate only, for 
an overestimation, the simulated power attains 0.80 power. When there is an 
underestimation of the control group event rate, the simulated power is close to 
0.80 though 0.80 power is not always attained. 
When there is misspecification in the treatment effect only, for an 
overestimation, the simulated power does not attain 0.80 even after adjustment 
by the CVPA-SSR algorithm. When there is an underestimation in the treatment 
effect, however, the simulated power is at least 0.80 in all scenarios. 
When there is misspecification in the control group event rate and the 
treatment effect, results indicate than regardless of whether the control group 
was overestimated or underestimated, if the treatment effect is overestimated, 
simulated power does not attain 0.80 even after adjustment by the CVPA-SSR 
algorithm; however, if the treatment effect is underestimated, the simulated 
power is at least 0.80 for all scenarios. 
Table 4.17 presents selected simulation results where the design stage 
assumptions are 0.20 for the control group event rate and a 6.25% relative 
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increase for the relative treatment effect for the scenarios with a large 
misspecification and for the scenarios where the design stage assumptions are 
correct. Simulations are presented for either the scenario with no interim analysis 






















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Positive Outcome – Risk Difference Treatment Effect 
Results for the simulation scenarios with a positive outcome and a 
hypothesized risk difference treatment effect show that across all types of 
misspecifications, the simulated one-sided upper Type I error rate is near the 
nominal level of 0.025 as the lower limit of the 95% CI for the one-sided upper 
Type I error is at or below the nominal value. 
When there is a misspecification of the control group event rate only, for 
an overestimation, the simulated power attains 0.80 power. When there is an 
underestimation of the control group event rate, the simulated power is close to 
0.80 though 0.80 power is not always attained. 
When there is misspecification in the treatment effect only, for an 
overestimation, the simulated power does not attain 0.80 even after adjustment 
by the CVPA-SSR algorithm. When there is an underestimation in the treatment 
effect, however, the simulated power is at least 0.80 in all scenarios. 
When there is misspecification in the control group event rate and the 
treatment effect, results indicate than regardless of whether the control group 
was overestimated or underestimated, if the treatment effect is overestimated, 
simulated power does not attain 0.80 even after adjustment by the CVPA-SSR 
algorithm; however, if the treatment effect is underestimated, the simulated 
power is at least 0.80 for all scenarios.  
Table 4.18 presents selected simulation results where the design 
assumptions are 0.80 for the control group event rate and 0.05 for the risk 
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difference treatment for the scenarios with a large misspecification and for the 
scenarios where the design stage assumptions are correct. Simulations are 
presented for either the scenario with no interim analysis or the scenario with an 
















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































4.2.4.3 Discussion of Simulation Results 
When the design stage assumptions of the true control group event rate 
and/or the true treatment effect are incorrect, the CVPA-SSR algorithm still 
appears to control the Type I error rate as the simulated one-sided Type I error 
rate is near the nominal level of 0.025. In the simulations performed, only one 
scenario out of 600 had a lower limit of the 95% CI that was above the nominal 
value of 0.025. It cannot, however, be definitively declared that the CVPA-SSR 
algorithm controls the Type I error rate universally. When parameter values are 
misspecified in the design stage, the CVPA-SSR algorithm computes the 
required critical value cutoff to be used in the final Z-test for the misspecified 
parameter values which do not accurately reflect the true population parameters 
and, as a result, there may be situations where the Type I error rate may not be 
necessarily controlled.  
In the simulation results, in most cases where only the control group event 
rate was misspecificed, the simulated power using the CVPA-SSR algorithm 
method attained 0.80 regardless of the type of misspecification. There were a 
few scenarios where the simulated power was close, but did not attain the 
desired value. All such scenarios were for positive outcomes when the control 
group rate was underestimated and for negative outcomes when the control 
group rate was overestimated for a hypothesized risk difference treatment effect. 
SSR based on an updated control group event rate is most appropriate for 
studies that have an accurate assumption of the treatment effect but not 
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necessarily an accurate assumption of the control group rate at the protocol 
design stage. When the treatment effect is misspecified, a SSR method that is 
blinded to the interim treatment effect cannot account for this as the treatment 
effect at the interim analysis is not available for use in the SSR. As a result, a trial 
could be severely over- or underpowered depending on the type and magnitude 
of misspecification. The simulations presented in this Chapter with misspecified 
treatment effect demonstrated both over- and underpowered results, highlighting 
the importance of using SSR methods that are blinded to the interim treatment 
effect, such as the HW-SSR method, only when precise assumptions of the 
treatment effect are available. 
Finally, a review of the results comparing scenarios where there were no 
extreme simulations that required simulation rules versus those scenarios where 
there were extreme simulations that required simulation rules showed that the 
overall conclusions remained the same. 
4.3 Summary and Conclusions 
In this Chapter a method for calculating the exact Type I error rate and 
power of a randomized, concurrent, two-arm superiority clinical trial with a two-
arm internal pilot and a binomial outcome that uses the HW-SSR method was 
derived and, through simulation, was shown to control the nominal Type I error 
rate while achieving the desired power when the protocol-specified assumed 
parameter estimates used in the design stage were accurately specified. When 
the parameters used in the design stage were incorrect, no Type I error rate 
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inflation trend was observed in the scenarios investigated; however significant 
over- and underpowering of the trial occurred when the treatment effect used at 
the design stage was not the true population value. This is important as it 
highlights a limitation of partially unblinded SSR methods and indicates that such 
methods should be used with considerable caution when a precise estimate of 
the treatment effect is not available. When the control group event rate used at 
the design stage was not the true population value, most scenarios were 
appropriately powered. 
In Chapter 5 the CVPA-SSR algorithm will be applied to trials designed 
with a single-arm internal pilot to re-estimate the sample size needed based on 




CHAPTER 5  
Application of the CVPA-SSR Algorithm to Trials Designed with a Single-arm 
Internal Pilot in the Control Group 
In Chapter 4 we derived the CVPA-SSR algorithm, a method that adjusts 
the critical value cutoff used in the final Z-test and the power value used in the 
SSR formula in order to maintain the nominal Type I error and attain the desired 
power in trials where the HW-SSR method is used. In the explorations so far, we 
considered a randomized, concurrent, two-arm superiority clinical trial with a two-
arm internal pilot and a binomial outcome. In this Chapter we investigate the 
impact of applying the CVPA-SSR algorithm to a trial designed with a single-arm 
internal pilot in the control group for the purpose of estimating the sample size 
required for a randomized, non-concurrent, two-arm superiority clinical trial with a 
binomial outcome based on the observed control group event rate.  
The following sections introduce the single-arm internal pilot study design 
and review the required modifications to the CVPA-SSR algorithm in order to 
implement it for this study design. The effect of using the HW-SSR method in a 
trial with a single-arm internal pilot both with and without applying the CVPA-SSR 
algorithm will be investigated and compared. Finally, the one-sided Type I error 
rate of interest and the power of the trial will be investigated for when the CVPA-




5.1 Single-Arm Internal Pilot Study Design 
Suppose a Sponsor wants to design a superiority clinical trial with a 
binomial outcome to compare an experimental product to a current standard of 
care (control) in a previously un-researched population. If there is limited 
information available on the standard of care in the targeted study population but 
the treatment effect is well-known, the Sponsor may want to begin the clinical 
trial with a single-arm internal pilot in order to obtain a more precise estimate of 
the control group outcome rate. After a pre-specified number of subjects 
complete the single-arm internal pilot portion of the trial, the observed control 
group outcome rate would be used to compute the final sample size required to 
achieve desired power for a two-arm superiority clinical trial. The Sponsor would 
like to include the internal-pilot subjects in the calculation of the final test statistic 
This is a study designed with a single-arm internal pilot in the control 
group for the purpose of estimating the sample size required for a randomized, 
non-concurrent, two-arm superiority clinical trial with a binomial outcome based 
on the observed control group event rate. For the purpose of discussion in this 
Chapter, we will refer to this type of study design as a trial with a single-arm 
internal pilot. The study design examined in Chapter 3 and Chapter 4, with a 
randomized, concurrent, two-arm superiority clinical trial with a two-arm internal 




The hypotheses examined for studies with a single-arm internal pilot are 
identical to those used for studies with a two-arm internal pilot:  
Negative Outcome Positive Outcome 
                      
                      
where    and    are the event rates for those subjects in the experimental and 
control groups, respectively. As such, the lower-side of the Type I error is of 
interest when the outcome is negative and the upper-side of the Type I error is of 
interest when the outcome is positive. 
5.1.1 HW-SSR for Single-Arm Internal Pilot Studies 
A single-arm internal pilot study begins with the enrollment of a pre-
specified number of subjects       in the control group. After the outcomes of the 
    subjects have been observed and     is calculated, the sample size required 
for the desired Type I error, power, and 1:1 overall allocation of subjects into 
each treatment group (non-concurrent) is calculated at the interim analysis using: 
Equation 5.1 
        
                      
 
                        
          
 
where              ,           ,               or            to 
match the alternative hypothesis for the relative treatment and risk difference 
treatment effects when the outcomes are negative or positive, respectively, and   
and   are the hypothesized treatment effects. Subsequently,       -    subjects 
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in the control group and       in the experimental group are enrolled and followed 
until the outcomes have been observed. The final Z-test (Equation 5.2) includes 
information from all subjects enrolled in the trial.  
Equation 5.2 
  
        
 
       
     
  
where    and    are the observed percentages of subjects who experience the 
event in the experimental group and the control group, respectively,       is the 
number of subjects in each group with equal allocation, and    
      
 
. This value 
is compared to the    (for a negative outcomes) or      (for a positive outcomes) 
critical value. 
Note that though the required sample size for the trial is estimated partway 
through the trial, we will refer to this as the re-estimated sample size to be 
consistent with the terminology used for two-arm internal pilot studies. In 
addition, though specification of     is critical for a single-arm internal pilot study 
design, the method for calculating this value is not investigated. We assume that 
a     has been pre-specified. 
5.1.1.1 HW-SSR for Single-Arm Internal Pilot Studies: Example 
Suppose that two devices will be compared (X the standard of care 
[control group], and Y a newer device [experimental group]) on a binomial 
outcome that is a negative event using a single-arm internal pilot study design. It 
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has been shown in previous trials that Device Y reduces the incidence of the 
outcome by 50%. The Sponsor decides that a sample size of 150 subjects for the 
internal pilot is sufficient to obtain an estimate of the control group event rate. 
The trial starts and, of the 150 subjects in the internal pilot, 30 subjects (20%) 
experience the event. The HW-SSR method is used to estimate the sample size 
and based on an observed event rate of 20% in the Device X group, a one-sided 
Type I error rate of 0.025, a desired power of 0.80, and an overall 1:1 allocation 
of subjects, 197 subjects per treatment group are required. The trial continues, 
enrolling 47 subjects in the Device X group and 197 subjects in the Device Y 
group. At the end of the trial the final Z-test (Equation 5.2) is computed based on 
the outcomes of the 197 subjects in the Device X group and the outcomes of the 
197 subjects in the Device Y group. 
5.2 Proposed Algorithm for Type I Error Rate and Power Adjustment 
In Chapter 4 it was shown that the CVPA-SSR algorithm maintains control 
of the one-sided Type I error rate of interest while also achieving the desired 
power when a study is designed with a two-arm internal pilot. The CVPA-SSR 
algorithm requires a few modifications to be applied to the single-arm internal 
pilot study design.  
As there is no sample size estimation at the beginning of the trial (Step 1) and 
timing of the interim analysis is not derived from the original protocol-specified 
sample size (Step 2) for the single-arm internal pilot study design, Step 1 and 
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Step 2 in the CVPA-SSR algorithm presented in Section 4.2.2 are no longer 
applicable. Instead these two steps will be replaced with a single step. 
1. Determine the number of subjects       necessary for the single-arm 
internal pilot. 
As no subjects are enrolled in the experimental group prior to the interim 
analysis, modifications to the notation of the CVPA-SSR algorithm are required to 
reflect this. Though there have been modifications to the algorithm because of 
the change of study design, we will still refer to it as the CVPA-SSR algorithm as 
the method has not changed. 
The CVPA-SSR algorithm below describes the procedure for adjusting the 
critical value cutoff used in the final Z-test and the critical value used for 
computing power in the interim SSR formula when the study is designed with a 
single-arm internal pilot. For the following discussion, the CVPA-SSR algorithm 
assumes, without loss of generality, that the final hypothesis test is either a lower 
or an upper one-sided Z-test (for negative and positive outcomes, respectively) 
with a one-sided Type I error rate of 0.025, a desired power of 0.80, and a overall 
1:1 allocation of subjects into each treatment group. (Note that CVPA-SSR 
algorithm can be applied to other one-sided Type I error rates, powers, and 
allocations of subjects. Here a single value of each is used for illustration.) 




1. Determine the number of subjects       necessary for the single-arm 
internal pilot. 
2. Calculate the power of the trial under the alternative hypothesis given the 
SSR rule at the interim analysis using the mFKβ equation: 
                   
   
     
   
   
   
 
     
    
 
   
   
 
   
     
 
     
  
   
  
          
           
        
                
                   
   
     
   
   
   
 
     
    
 
   
   
 
   
     
 
     
  
   
  
          
           
        
                  
and the SSR formula is given by 
        
                      
 
                        
          
 
where      
   
   
 and              ,           ,               or 
           to match the alternative hypothesis of the simulation 
scenario. Note that the SSR is also subject to the minimum and maximum 
allowable sample sizes and that     +     =     . 
3. If                 then skip to Step 6,      is the critical value to be 
used in the SSR formula at the interim. If                 then derive 
a new critical value     
  by increasing the power used in the interim 
analysis SSR calculation by 0.001 (e.g, update 0.80 to 0.801). 
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4. Update      in SSR formula in Step 2 with     
  
5. Repeat Steps 2 – 5 until the condition                 in Step 3 is 
met. 
6. Calculate the exact Type I error of the trial under the null hypothesis given 
the SSR rule at the interim analysis using the mFKα equation:  
               
   
     
   
   
   
 
     
    
 
   
   
 
   
     
 
     
  
                   
               
   
     
   
   
   
 
     
    
 
   
   
 
   
     
 
     
  
                     
 and the SSR formula is given by  
        
                              
   
 
                        
          
 
where      
   
   
 and              ,          Δ,               or 
         Δ to match the alternative hypothesis of the simulation 
scenario. Note that the SSR is also subject to the minimum and maximum 
allowable sample sizes and that     +     =     ,   is the total number of 
events (both groups), and   is the total sample size (e.g.,         of the 
trial. 
7. If         then stop.    (for a negative outcome) or      (for a positive 
outcome) is the critical value cutoff used in the final Z-test and in the SSR 
formula at the interim. If         then determine the critical value   
  (for a 
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negative outcome) or     
  (for a positive outcome) that if substituted into 
        or           for    or      respectively in Step 6 will lead to 
        . 
8. Update    (for a negative outcome) to   
  or      (for a positive outcome) to 
    
  in Step 2 in both the SSR formula and the indicator function in the 
mFKα formula. 
9. Repeat Steps 2 – 9 until the conditions                 and         
in Steps 3 and 7 are met. 
Note that in this algorithm, the critical value is not allowed to be less extreme 
than    (for a negative outcome) or      (for a positive outcome). That is, if    = -
1.96 then the critical value cannot be larger than -1.96. If      = 1.96, the critical 
value cannot be smaller than 1.96.  
Note that though the critical values for both the Type I error and power can 
be adjusted with the CVPA-SSR algorithm, for the purpose of all presentations, 
the critical value cutoff used in the final Z-test will be presented as is. Values for 
power will reported as a proportion rather than a critical value to avoid any 
confusion (e.g., power value of 0.886 instead of critical value for power of 1.21). 
5.3 Simulations where Assumptions Used in CVPA-SSR Algorithm are 
Correct 
In Section 5.2, the CVPA-SSR algorithm was proposed to adjust the 
critical value cutoff used in the final Z-test in order to maintain control of the Type 
I error rate while attaining the desired power when using the HW-SSR method in 
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a trial designed with a single-arm internal pilot. The following simulation study 
was performed to demonstrate that the statistical operational characteristics of 
this trial design are sound. 
5.3.1 Simulation Methods 
Data were simulated to demonstrate the application of the CVPA-SSR 
algorithm to both control the Type I error rate at the nominal level and attain the 
desired power. For comparison, data were also simulated (with different seeds) 
where the CVPA-SSR algorithm is not applied. Those scenarios that do not apply 
the CVPA-SSR algorithm are referred to as the “unadjusted scenarios” and those 
that do apply the CVPA-SSR algorithm are referred to as the “adjusted 
scenarios”. 
Four sets of simulation scenarios were generated, one for each set of 
hypotheses where the outcome was a negative event: 
Relative treatment effect                                          , 
Risk difference treatment effect                             Δ, 
and one for each set of hypotheses where the outcome was a positive event: 
Relative treatment effect                                          , 
Risk difference treatment effect                             Δ 
For adjusted scenarios, the CVPA-SSR algorithm was implemented at the design 
stage, prior to the start of the trial. All trials were designed to be evaluated using 
a lower or an upper one-sided Z-test statistic with a nominal Type I error rate of 
0.025 a desired power of 0.80, and a 1:1 overall allocation of subjects into each 
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treatment group. The SSR formula in Step 2 of the CVPA-SSR algorithm was 
used to calculate the re-estimated sample size at the interim analysis. The 
maximum allowable sample size was set to 1,500 subjects in each treatment 
group (3,000 total) for all scenarios. The minimum allowable sample size in each 
treatment group was the single-arm internal pilot sample size. A single interim 
analysis was prospectively planned to occur after 150, 200, or 250 subjects in the 
control group had the outcome measured. The event rates in the control group 
were 0.20, 0.30, and 0.40 when the outcome was negative and 0.60, 0.70, and 
0.80 when the outcome was positive. The effect size for all the risk difference 
treatment effect alternative hypothesis scenarios was 0.075. The effect size for 
the relative treatment effect alternative hypothesis scenarios was 0.25 for 
negative outcomes and 0.1071 for positive outcomes. For the purpose of 
extreme simulation scenarios the rules described in Section 3.3.1 were used. For 
all simulation scenarios, 100,000 replications were performed.  
Note that data were simulated assuming the control group rate and 
treatment effect used in the CVPA-SSR algorithm were correct (i.e., control 
group rate and treatment effect used in the CVPA-SSR algorithm are the true 
population values). For example, for a given set of simulations, the CVPA 
algorithm was implemented with certain assumptions of   ,    and the 
corresponding   (relative treatment effect) or   (risk difference treatment effect) 
for the null and alternative hypothesis. The simulated datasets were generated 
under these assumptions. 
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5.3.2 Unadjusted Simulation Results 
Results for simulation scenarios when the HW-SSR method is used with 
no adjustment have similar findings to those observed in Section 3.3.2 when the 
HW-SSR method was used without applying the CVPA-SSR algorithm for trials 
designed with a two-arm internal pilot. For a hypothesized relative treatment 
effect and a negative outcome the simulated one-sided lower Type I error rate is 
inflated as the lower limit of the 95% CI for the one-sided lower Type I error rate 
is above the nominal level of 0.025 for all scenarios. For these scenarios, the 
simulated power is at least 0.80 though when the Type I error is inflated, power 
needs to be interpreted with caution. 
For a hypothesized risk difference treatment effect (for both negative and 
positive outcomes) and a hypothesized relative treatment effect for a positive 
outcome, the simulated one-sided Type I error is maintained at the nominal level 
of 0.025 as the 95% CI for the one-sided Type I error rate of interest is at or 
below the nominal level in all scenarios. The simulated power results do not 
always attain at least 0.80 for these scenarios. The minimum simulated power 
values are 0.755 for a risk difference treatment effect and a negative outcome, 
0.758 for a risk difference treatment effect and a positive outcome, and 0.731 for 
a relative treatment effect and a positive outcome. Table 5.1 and Table 5.2 
present the results for the unadjusted relative and risk difference treatment effect 
scenarios when the outcome is negative and Table 5.3 and Table 5.4 present 
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results for the unadjusted relative and risk difference treatment effect scenarios 
when the outcome is positive. 
 
Table 5.1: Results from Simulations for the HW-SSR Method (Unadjusted) with a 
Single-Arm Internal Pilot in the Control Group for the Alternative Hypothesis Ha: 
pe = (1 – γ)pc when the Outcome is Negative and γ = 0.25. 
Control Group 










150 0.0266 (0.0256-0.0276) 0.8248 (0.8223-0.8273) 933 
200 0.0277 (0.0267-0.0287) 0.8288 (0.8263-0.8313) 925 
250 0.0271 (0.0261-0.0281) 0.8276 (0.8251-0.8301) 921 
0.30 
150 0.0272 (0.0262-0.0282) 0.8276 (0.8251-0.8301) 549 
200 0.0273 (0.0263-0.0283) 0.8312 (0.8287-0.8337) 545 
250 0.0273 (0.0263-0.0283) 0.8299 (0.8274-0.8324) 544 
0.40 
150 0.0281 (0.0271-0.0291) 0.8324 (0.8299-0.8349) 359 
200 0.0270 (0.0260-0.0280) 0.8317 (0.8292-0.8342) 358 
250 0.0273 (0.0263-0.0283) 0.8328 (0.8303-0.8353) 357 
Note:  
1. SS = sample size, IP = internal pilot. 
 
 
Table 5.2: Results from Simulations for the HW-SSR Method with a Single-Arm 
Internal Pilot in the Control Group for the Alternative Hypothesis Ha: pe = pc – Δ 
when the Outcome is Negative and Δ = 0.075. 
Control Group 










150 0.0244 (0.0234-0.0254) 0.7552 (0.7527-0.7577) 373 
200 0.0243 (0.0233-0.0253) 0.7596 (0.7571-0.7621) 374 
250 0.0251 (0.0241-0.0261) 0.7638 (0.7613-0.7663) 375 
0.30 
150 0.0243 (0.0233-0.0253) 0.7782 (0.7757-0.7807) 533 
200 0.0244 (0.0234-0.0254) 0.7783 (0.7758-0.7808) 534 
250 0.0253 (0.0243-0.0263) 0.7788 (0.7763-0.7813) 534 
0.40 
150 0.0246 (0.0236-0.0256) 0.7857 (0.7832-0.7882) 637 
200 0.0239 (0.0229-0.0249) 0.7877 (0.7852-0.7902) 638 
250 0.0248 (0.0238-0.0258) 0.7884 (0.7859-0.7909) 639 
Note:  




Table 5.3: Results from Simulations for the HW-SSR Method (Unadjusted) with a 
Single-Arm Internal Pilot in the Control Group for the Alternative Hypothesis Ha: 
pe = (1 + γ)pc when the Outcome is Positive and γ = 0.1071. 
Control Group 
Rate (  ) 
Single- 
Arm IP SS 
Simulated Upper 






150 0.0226 (0.0216-0.0236) 0.7312 (0.7287-0.7337) 283 
200 0.0230 (0.0220-0.0240) 0.7399 (0.7374-0.7424) 284 
250 0.0224 (0.0214-0.0234) 0.7700 (0.7675-0.7725) 292 
0.70 
150 0.0233 (0.0223-0.0243) 0.7590 (0.7565-0.7615) 543 
200 0.0236 (0.0226-0.0246) 0.7593 (0.7568-0.7618) 542 
250 0.0243 (0.0233-0.0253) 0.7615 (0.7590-0.7640) 541 
0.60 
150 0.0242 (0.0232-0.0252) 0.7708 (0.7683-0.7733) 892 
200 0.0243 (0.0233-0.0253) 0.7707 (0.7682-0.7732) 888 
250 0.0232 (0.0222-0.0242) 0.7719 (0.7694-0.7744) 887 
Note:  
1. SS = sample size, IP = internal pilot. 
 
 
Table 5.4: Results from Simulations for the HW-SSR Method (Unadjusted) with a 
Single-Arm Internal Pilot in the Control Group for the Alternative Hypothesis Ha: 
pe = pc + Δ when the Outcome is Positive and Δ = 0.075. 
Control Group 
Rate (  ) 
Single- 
Arm IP SS 
Simulated Upper 






150 0.0252 (0.0242-0.0262) 0.7582 (0.7557-0.7607) 374 
200 0.0243 (0.0233-0.0253) 0.7591 (0.7566-0.7616) 374 
250 0.0238 (0.0228-0.0248) 0.7631 (0.7606-0.7656) 375 
0.70 
150 0.0248 (0.0238-0.0258) 0.7767 (0.7742-0.7792) 533 
200 0.0250 (0.0240-0.0260) 0.7801 (0.7776-0.7826) 534 
250 0.0248 (0.0238-0.0258) 0.7803 (0.7778-0.7828) 535 
0.60 
150 0.0242 (0.0232-0.0252) 0.7873 (0.7848-0.7898) 637 
200 0.0250 (0.0240-0.0260) 0.7901 (0.7876-0.7926) 638 
250 0.0245 (0.0235-0.0255) 0.7892 (0.7867-0.7917) 639 
Note:  
1. SS = sample size, IP = internal pilot. 
 
5.3.3 Adjusted Simulation Results 
Results for simulation scenarios when the HW-SSR method is used and 
the CVPA-SSR algorithm is applied indicate similar findings to those observed in 
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Section 4.2.3.2 when the HW-SSR method was used and the CVPA-SSR 
algorithm was applied for trials designed with a two-arm internal pilot. The one-
sided Type I error rate is maintained at the nominal level in all scenarios as the 
lower bound of the 95% CI for the simulated Type I error rate contained the 
nominal value of 0.025. In addition, the simulated power attains the desired level 
as the upper bound of the 95% CI for the simulated power contains the nominal 
value of 0.80 in all scenarios with the exception of one scenario where the 
simulated power is 0.7971 (95% CI: 0.7946 – 0.7996) for a positive outcome 
where the control group rate is 0.80, the internal pilot sample size is 150, and the 
risk difference treatment effect is 0.075. 
For a negative outcome and a hypothesized relative treatment effect, 
adjustment to the critical value cutoff used in the final Z-test is required but no 
adjustment to the power value is required. Larger adjustments to the critical value 
cutoff in the final Z-test are required as the control group event rate increases.  
For a hypothesized risk difference treatment effect (for both negative and 
positive outcomes) and a hypothesized relative treatment effect for a positive 
outcome, adjustments to the critical value cutoff used in the final Z-test are not 
required in the scenarios investigated; however adjustments to the power value 
in the SSR formula are required. For the risk difference treatment effect, 
adjustments to the power value in the SSR formula are larger as the control 
group event rate decreases (negative outcomes) or increases (positive 
outcomes). For the relative treatment effect for a positive outcome, adjustments 
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to the power value in the SSR formula are larger as the control event rate 
increases. In addition, larger adjustments to the power value in the SSR formula 
are required when the single-arm internal pilot in the control group is smaller 
across all scenarios. Table 5.5 and Table 5.6 present the results for the adjusted 
relative and risk difference treatment effect scenarios when the outcome is 
negative and Table 5.7 and Table 5.8 present results for the adjusted relative 
and risk difference treatment effect scenarios when the outcome is positive. 
 
Table 5.5: Results from Simulations for the CVPA-SSR Algorithm (Adjusted) with 
a Single-Arm Internal Pilot in the Control Group for the Alternative Hypothesis Ha: 
pe = (1 – γ)pc when the Outcome is Negative and γ = 0.25. 
Control 
Group 





 Type I Error 













150 0.0256 (0.0246-0.0266) 0.8268 (0.8243-0.8293) 953 -1.99 0.800 
200 0.0253 (0.0243-0.0263) 0.8297 (0.8272-0.8322) 945 -1.99 0.800 
250 0.0256 (0.0246-0.0266) 0.8266 (0.8241-0.8291) 941 -1.99 0.800 
0.30 
150 0.0246 (0.0236-0.0256) 0.8267 (0.8242-0.8292) 564 -2.00 0.800 
200 0.0248 (0.0238-0.0258) 0.8296 (0.8271-0.8321) 562 -2.00 0.800 
250 0.0245 (0.0235-0.0255) 0.8333 (0.8308-0.8358) 559 -2.00 0.800 
0.40 
150 0.0244 (0.0234-0.0254) 0.8305 (0.8280-0.8330) 370 -2.00 0.800 
200 0.0255 (0.0245-0.0265) 0.8327 (0.8302-0.8352) 368 -2.00 0.800 
250 0.0252 (0.0242-0.0262) 0.8325 (0.8300-0.8350) 367 -2.00 0.800 
Note:  




Table 5.6: Results from Simulations for the CVPA-SSR Algorithm (Adjusted) with 
a Single-Arm Internal Pilot in the Control Group for the Alternative Hypothesis Ha: 
pe = pc – Δ when the Outcome is Negative and Δ = 0.075. 
Control 
Group 





 Type I Error 













150 0.0239 (0.0229-0.0249) 0.7994 (0.7969-0.8019) 419 -1.96 0.843 
200 0.0242 (0.0232-0.0252) 0.7997 (0.7972-0.8022) 416 -1.96 0.840 
250 0.0240 (0.0230-0.0250) 0.7984 (0.7959-0.8009) 415 -1.96 0.839 
0.30 
150 0.0246 (0.0236-0.0256) 0.8006 (0.7981-0.8031) 566 -1.96 0.823 
200 0.0249 (0.0239-0.0259) 0.8019 (0.7994-0.8044) 564 -1.96 0.821 
250 0.0249 (0.0239-0.0259) 0.7986 (0.7961-0.8011) 563 -1.96 0.820 
0.40 
150 0.0250 (0.0240-0.0260) 0.7998 (0.7973-0.8023) 659 -1.96 0.813 
200 0.0239 (0.0229-0.0249) 0.8001 (0.7976-0.8026) 658 -1.96 0.812 
250 0.0251 (0.0241-0.0261) 0.7995 (0.7970-0.8020) 657 -1.96 0.811 
Note:  
1. SS = sample size, IP = internal pilot. 
 
 
Table 5.7: Results from Simulations for the CVPA-SSR Algorithm (Adjusted) with 
a Single-Arm Internal Pilot in the Control Group for the Alternative Hypothesis Ha: 
pe = (1 + γ)pc when the Outcome is Positive and γ = 0.1071. 
Control 
Group 





 Type I Error 













150 0.0231 (0.0221-0.0241) 0.8009 (0.7984-0.8034) 344 1.96 0.871 
200 0.0236 (0.0226-0.0246) 0.8009 (0.7984-0.8034) 339 1.96 0.866 
250 0.0234 (0.0224-0.0244) 0.8030 (0.8005-0.8055) 330 1.96 0.855 
0.70 
150 0.0226 (0.0216-0.0236) 0.8004 (0.7979-0.8029) 609 1.96 0.843 
200 0.0234 (0.0224-0.0244) 0.8009 (0.7984-0.8034) 604 1.96 0.841 
250 0.0228 (0.0218-0.0238) 0.8014 (0.7989-0.8039) 599 1.96 0.839 
0.60 
150 0.0241 (0.0231-0.0251) 0.7993 (0.7968-0.8018) 964 1.96 0.830 
200 0.0241 (0.0231-0.0251) 0.7991 (0.7966-0.8016) 959 1.96 0.829 
250 0.0240 (0.0230-0.0250) 0.8005 (0.7980-0.8030) 955 1.96 0.828 
Note:  





Table 5.8: Results from Simulations for the CVPA-SSR Algorithm (Adjusted) with 
a Single-Arm Internal Pilot in the Control Group for the Alternative Hypothesis Ha: 
pe = pc + Δ when the Outcome is Positive and Δ = 0.075. 
Control 
Group 





 Type I Error 













150 0.0241 (0.0231-0.0251) 0.7971 (0.7946-0.7996) 418 1.96 0.843 
200 0.0243 (0.0233-0.0253) 0.7984 (0.7959-0.8009) 416 1.96 0.840 
250 0.0240 (0.0230-0.0250) 0.8023 (0.7998-0.8048) 416 1.96 0.839 
0.70 
150 0.0240 (0.0230-0.0250) 0.7990 (0.7965-0.8015) 566 1.96 0.823 
200 0.0238 (0.0228-0.0248) 0.8002 (0.7977-0.8027) 564 1.96 0.821 
250 0.0244 (0.0234-0.0254) 0.7997 (0.7972-0.8022) 563 1.96 0.820 
0.60 
150 0.0251 (0.0241-0.0261) 0.8034 (0.8009-0.8059) 659 1.96 0.813 
200 0.0256 (0.0246-0.0266) 0.7994 (0.7969-0.8019) 658 1.96 0.812 
250 0.0251 (0.0241-0.0261) 0.8001 (0.7976-0.8026) 657 1.96 0.811 
Note:  
1. SS = sample size, IP = internal pilot. 
 
5.3.4 Discussion of Simulation Results 
Data were simulated to investigate the effect of using the HW-SSR method 
alone (unadjusted results) versus using the HW-SSR method when applying the 
CVPA-SSR algorithm (adjusted results) when the studies were designed with a 
single-arm internal pilot. Table 5.9 and Table 5.10 show the simulated Type I 





Table 5.9: A Comparison of Results from Simulations for the HW-SSR Method 
(Unadjusted) vs. the CVPA-SSR Algorithm (Adjusted) with a Single-Arm Internal 














Type I Error Power 
Lower 




  = 0.25 
 
0.20 
150 0.0266 0.8248 0.0256 0.8268 
200 0.0277 0.8288 0.0253 0.8297 
250 0.0271 0.8276 0.0256 0.8266 
0.30 
150 0.0272 0.8276 0.0246 0.8267 
200 0.0273 0.8312 0.0248 0.8296 
250 0.0273 0.8299 0.0245 0.8333 
0.40 
150 0.0281 0.8324 0.0244 0.8305 
200 0.0270 0.8317 0.0255 0.8327 




  = 0.075 
 
0.20 
150 0.0244 0.7552 0.0239 0.7994 
200 0.0243 0.7596 0.0242 0.7997 
250 0.0251 0.7638 0.0240 0.7984 
0.30 
150 0.0243 0.7782 0.0246 0.8006 
200 0.0244 0.7783 0.0249 0.8019 
250 0.0253 0.7788 0.0249 0.7986 
0.40 
150 0.0246 0.7857 0.0250 0.7998 
200 0.0239 0.7877 0.0239 0.8001 
250 0.0248 0.7884 0.0251 0.7995 
Note:  
1. SS = sample size, IP = internal pilot. 




Table 5.10: A Comparison of Results from Simulations for the HW-SSR Method 
(Unadjusted) vs. the CVPA-SSR Algorithm (Adjusted) with a Single-Arm Internal 














Type I Error Power 
Upper 




  = 0.1071 
 
0.80 
150 0.0226 0.7312 0.0231 0.8009 
200 0.0230 0.7399 0.0236 0.8009 
250 0.0224 0.7700 0.0234 0.8030 
0.70 
150 0.0233 0.7590 0.0226 0.8004 
200 0.0236 0.7593 0.0234 0.8009 
250 0.0243 0.7615 0.0228 0.8014 
0.60 
150 0.0242 0.7708 0.0241 0.7993 
200 0.0243 0.7707 0.0241 0.7991 




  = 0.075 
0.80 
150 0.0252 0.7582 0.0241 0.7971 
200 0.0243 0.7591 0.0243 0.7984 
250 0.0238 0.7631 0.0240 0.8023 
0.70 
150 0.0248 0.7767 0.0240 0.7990 
200 0.0250 0.7801 0.0238 0.8002 
250 0.0248 0.7803 0.0244 0.7997 
0.60 
150 0.0242 0.7873 0.0251 0.8034 
200 0.0250 0.7901 0.0256 0.7994 
250 0.0245 0.7892 0.0251 0.8001 
Note:  
1. SS = sample size, IP = internal pilot. 
2. 95% CI for Type I error ± 0.0010, for Power ± 0.0025 
 
The results were similar to Chapter 4 simulation results when the CVPA-SSR 
algorithm was applied to studies designed with a two-arm internal pilot. When the 
HW-SSR method was used without applying the CVPA-SSR algorithm, Type I 
error inflation occurred for the scenarios with a negative outcome and a 
hypothesized relative treatment effect and reduced power occurred for a 
hypothesized risk difference treatment effect (for both negative and positive 
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outcomes) and a hypothesized relative treatment effect for a positive outcome. 
When the HW-SSR method was used when applying the CVPA-SSR algorithm, 
the Type I error inflation and reduced power issues were corrected as the critical 
value cutoff in the final Z-test and power value in the interim SSR formula were 
adjusted. 
A review of the results comparing scenarios where there were no extreme 
simulations that required simulation rules versus those scenarios where there 
were extreme simulations that required simulation rules showed that the overall 
conclusions remained the same. 
5.4 Simulations where Assumptions Used in CVPA-SSR Algorithm are 
Incorrect (Misspecified) 
In the simulations described in Section 5.3, data were simulated assuming 
the control group rate and treatment effect used in the CVPA-SSR algorithm 
were correct (i.e., control group rate and treatment effect used in the CVPA-SSR 
algorithm are the true population values). For example, for a given set of 
simulations, the CVPA algorithm was implemented with certain assumptions of 
  ,    and the corresponding   (relative treatment effect) or   (risk difference 
treatment effect) for the null and alternative hypothesis. The simulated datasets 
were generated under these assumptions. We now generate simulations to 
investigate the application of the CVPA-SSR algorithm to scenarios where the 
CVPA-SSR algorithm is calculated using assumed parameter values (  ,   , and 
the corresponding   [relative treatment effect] or   [risk difference treatment 
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effect]) that are incorrect or, i.e., do not equal the true and unknown parameter 
values in the population.  
5.4.1 Simulation Methods 
Data were simulated for scenarios that included single-arm internal pilot 
sample sizes of 150, 200, 250; the hypothesized treatment effect was either a 
relative treatment effect or risk difference treatment effect; and for both negative 
and positive outcomes. Assumed control group event rates included a value of 
0.30 when the outcome was negative and a value of 0.70 when the outcome was 
positive. For a hypothesized risk difference treatment effect, the assumed risk 
difference treatment effect used in the CVPA-SSR algorithm was 0.075 for both 
negative and positive outcomes. For a hypothesized relative treatment effect, the 
assumed relative treatment effect was 0.25 for a negative outcome and 0.1071 
for a positive outcome. 
Similar to Section 4.2.4.1, misspecifications of both the control group event 
rate and the treatment effect were simulated. In general, the misspecification for 
both of these parameters was captured in one of five settings: 
 Large underestimation of the true parameter value in the CVPA-SSR 
algorithm 
 Small underestimation of the true parameter value in the CVPA-SSR 
algorithm 




 Small overestimation of the true parameter value in the CVPA-SSR 
algorithm 
 Large overestimation of the true parameter value in the CVPA-SSR 
algorithm 
There are 25 scenarios investigated (e.g., (1) large underestimation of both 
control group event rate and treatment effect; (2) large underestimation of the 
control group event rate and small underestimation of the treatment effect; (3) 
large underestimation of the control group event rate and the correct assumption 
of the treatment effect; etc.). 
For these simulations, a large misspecification in the control group event 
rate is defined as a 25% difference between the assumed value used in the 
CVPA-SSR algorithm and the true parameter value in the population for a 
negative outcome. A large misspecification in the treatment effect is defined as a 
25% difference between the assumed value used in the CVPA-SSR algorithm 
and the true parameter value in the population. A small misspecification in the 
control group event rate is defined as a 5% difference between the assumed 
value used in the CVPA-SSR algorithm and the true parameter value in the 
population for a negative outcome. A small misspecification in the treatment 
effect is defined as a 5% difference between the assumed value used in the 
CVPA-SSR algorithm and the true parameter value in the population. 
Misspecification of either the control group event rate or the treatment effect also 
corresponds to a misspecification of the experimental group event rate. Further 
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description and examples can be found in Section 4.2.4.1. While many of the 
assumptions were shared between the relative and risk difference treatment 
effects, the true experimental group event rates differed. As a result, comparing 
anything more than the general patterns of required adjustments in the Type I 
error and power between different simulation scenarios must be done with 
caution. 
For all scenarios, the CVPA-SSR algorithm was applied to calculate the 
adjusted critical value cutoff used in the final Z-test and the power value used in 
the interim SSR formula using assumed parameter values. The sample sizes 
were re-estimated based on the observed control group event rate at the interim 
and the protocol-specified assumed treatment effect.  
5.4.2 Simulation Results 
Simulations were conducted for the five types of misspecifications of the 
control group event rate and the treatment effect for a total of 25 scenarios for 
each outcome and treatment effect. All results from simulations are presented in 
Appendix Table A.201 – Table A.220.  
Results for simulation scenarios where the CVPA-SSR algorithm is 
applied to a single-arm internal pilot design using assumed parameter values 
indicate similar findings that were seen in the Chapter 4 misspecification 
scenarios. The simulated one-sided Type I error rate is maintained at the nominal 
level as the lower bound of the 95% CI for the simulated one-sided Type I error 
rate contained the nominal value of 0.025 in all simulation scenarios. 
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When there is a misspecification of the control group event rate only, the 
lower limit of the 95% CI around the simulated power is at or above the nominal 
value of 0.80 for the scenarios for a hypothesized relative treatment effect and a 
negative outcome. For a hypothesized risk difference treatment effect for a 
negative outcome, the simulated power attains the nominal level of 0.80 for the 
underestimation scenarios as the lower limit of the 95% CI around the simulated 
power is at or above the nominal level. For the overestimation scenarios, the 
simulated power is close to 0.80 though 0.80 power is not always attained. For a 
positive outcome for both hypothesized relative and risk difference treatment 
effects, the simulated power attains the nominal level of 0.80 for the 
overestimation scenarios as the lower limit of the 95% CI around the simulated 
power is at or above the nominal level. For the underestimation scenarios, the 
simulated power is close to 0.80 though 0.80 power is not always attained. 
When there is misspecification in the treatment effect only or when there is 
misspecification in the control group event rate and in the treatment effect over- 
and under-powering of the study occurs regardless of whether the control group 
was overestimated or underestimated. If the treatment effect is overestimated, 
the simulated power does not attain 0.80 even after adjustment by the CVPA-
SSR algorithm. If the treatment effect is underestimated, however, the simulated 
power is at least 0.80 for all scenarios.  
Selected simulation results are presented in Table 5.11, Table 5.12, Table 
5.13, and Table 5.14. Simulations scenarios presented are those with 150 or 250 
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subjects in the single arm internal pilot and those scenarios with either a large 
misspecification or the scenarios where the assumptions used in the CVPA-SSR 
algorithm are correct. Table 5.11 and Table 5.12 present the results for the 
relative and risk difference treatment effect scenarios when the outcome is 
negative and Table 5.13 and Table 5.14 present results for the relative and risk 

















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































5.4.3 Discussion of Simulation Results 
Simulation results investigating the misspecification scenarios for the 
single-arm internal pilot design were similar to the misspecification scenarios 
presented in Chapter 4 for the two-arm internal pilot design. When the 
assumptions used in the CVPA-SSR algorithm were incorrect, the CVPA-SSR 
algorithm still appeared to control the Type I error rate as the simulated one-
sided Type I error was maintained at the nominal level of 0.025. In all simulation 
scenarios the lower bound of the 95% CI for the simulated one-sided Type I error 
rate contained the nominal value of 0.025. It cannot, however, be definitively 
declared that the CVPA-SSR algorithm controls the Type I error rate universally. 
When parameter values are misspecified in the CVPA-SSR algorithm, the CVPA-
SSR algorithm computes the required critical value cutoff used in the final Z-test 
for the misspecified parameter values which do not accurately reflect the true 
population parameters and, as a result, the Type I error rate is not necessarily 
controlled.  
In the simulation results, in most cases where only the control group event 
rate was misspecificed, the simulated power attained 0.80 regardless of the type 
of misspecification. There were a few scenarios where the simulated power was 
close, but did not attain the desired value. All such scenarios were for positive 
outcomes when the control group rate was underestimated and for negative 
outcomes when the control group rate was overestimated for a hypothesized risk 
difference treatment effect. 
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SSR based on an updated control group event rate is most appropriate for 
studies that have an accurate assumption of the treatment effect but not aan 
accurate assumption of the control group rate. When the treatment effect is 
misspecified, a SSR method that is blinded to the interim treatment effect cannot 
account for this as the treatment effect at the interim analysis is not available for 
use in the SSR. As a result, a trial could be severely over- or underpowered 
depending on the type and magnitude of misspecification. The simulations 
presented in this Chapter with misspecified treatment effect demonstrated both 
over- and underpowered results, highlighting the importance of using SSR 
methods that are blinded to the interim treatment effect, such as the HW-SSR 
method, only when precise assumptions of the treatment effect are available.  
Finally, a review of the results comparing scenarios where there were no 
extreme simulations that required simulation rules versus those scenarios where 
there were extreme simulations that required simulation rules showed that the 
overall conclusions remained the same.  
5.5 Summary and Conclusions 
In this Chapter, the CVPA-SSR algorithm was applied to a study designed 
with a single-arm internal pilot in the control group for the purpose of estimating 
the sample size required for a randomized, non-concurrent, two-arm superiority 
clinical trial with a binomial outcome based on the observed control group event 
rate, and was shown to control the nominal Type I error rate while achieving the 
desired power when the assumed parameter estimates used in the CVPA-SSR 
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algorithm were accurately specified. When the parameters used in the CVPA-
SSR algorithm were incorrect, no Type I error rate inflation trend was observed in 
the scenarios investigated; however significant over- and underpowering of the 
trial occurred when the treatment effect used in the CVPA-SSR algorithm was 
misspecified. This is important as it highlights a limitation of partially unblinded 
SSR methods and reinforces that such methods should be used with 
considerable caution when a precise estimate of the treatment effect is not 
available. When the control group event rate used in the CVPA-SSR algorithm 
was not the true population value, most scenarios were appropriately powered. 
The overall conclusions about the CVPA-SSR algorithm are the same 
when it is used for trials with a single-arm internal pilot as when it is used for 
trials with a two-arm internal pilot. This is unsurprising as when the HW-SSR 
method is used when applying the CVPA-SSR algorithm, only the control group 
is unblinded and examined at the interim analysis. Since the experimental group 
is only unblinded at the end of the trial, it is irrelevant whether the experimental 
group was enrolled before the interim analysis or not. As a result, the CVPA-SSR 
algorithm is expected to perform similarly regardless of whether the internal pilot 




CHAPTER 6  
Conclusion 
In this research we sought to identify a method that can be used to 
adequately control the Type I error rate at the nominal level while achieving the 
desired power for studies designed with a single-arm internal pilot in the control 
group for the purpose of estimating the sample size required for a randomized, 
non-concurrent, two-arm superiority clinical trial with a binomial outcome based 
on the observed control group event rate. To date, no research had been 
undertaken for a method that can be applied to re-estimate the sample size to 
achieve desired power while simultaneously controlling the Type I error rate of 
such a trial.  
SSR methods for trials with two-arm internal pilots are widely available in 
the literature. A review of available methods revealed that the HW-SSR method 
could be applied in trials with a single-arm internal pilot in the control group. 
Previous evaluations of the HW-SSR method reported conflicting results 
regarding the impact of the method on the two-sided Type I error rate and power 
of the final hypothesis test for two-arm internal pilot studies (4-7). While the final 
goal of this research was to apply the HW-SSR method to trials designed with a 
single-arm internal pilot, we first examined the impact of this method on the one-
sided Type I error rate of interest and power of the final hypothesis test in trials 
with a two-arm internal pilot through simulation studies.  
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We generated a variety of simulation scenarios including negative and 
positive outcomes, hypothesized relative and risk difference treatment effects, 
and varied minimum and maximum allowable sample sizes, interim analysis 
locations, control group event rates, and treatment effect sizes. In general, when 
the HW-SSR method was applied to trials with a two-arm internal pilot the 
statistical operational characteristics were not always maintained. We sometimes 
observed inflation of the one-sided Type I error of interest in scenarios with a 
negative outcome and a relative treatment effect. Additionally, we sometimes 
observed reduced power in scenarios with a hypothesized risk difference 
treatment effect (for both negative and positive outcomes) and a hypothesized 
relative treatment effect for a positive outcome. The inflation of the Type I error 
rate and reduction of the power occurred when the minimum allowable sample 
size was less than the original protocol-specified sample size though there were 
a handful of scenarios where Type I error inflation and reduced power occurred 
when the minimum allowable sample size was the original protocol-specified 
sample size. The maximum allowable sample size did not affect the Type I error 
rate or power.  
Before extending the HW-SSR method to a single-arm internal pilot study, 
we set out to develop an adjusted version of the HW-SSR method where the 
Type I error rate would be controlled at the nominal level and the desired power 
would be attained in two-arm internal pilot studies. To achieve this, we proposed 
a new method, the CVPA-SSR algorithm, to calculate the exact Type I error rate 
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and power for a study designed with a two-arm internal pilot that uses the HW-
SSR method to re-estimate the sample size. These calculations are then used to 
adjust the critical value cutoff used in the final Z-test and the power value used in 
the interim SSR formula to preserve the nominal Type I error rate and attain the 
desired power. We applied the CVPA-SSR algorithm in conjunction with the HW-
SSR method to the same simulation scenarios that were used to evaluate the 
HW-SSR method only, with the exception of the scenarios with no maximum 
allowable sample size, to evaluate whether the CVPA-SSR algorithm can be 
shown to adequately control the Type I error rate and preserve the desired 
power. We found that the CVPA-SSR algorithm controlled the nominal Type I 
error rate while achieving the desired power when the parameter estimates for 
the control group rate and treatment effect used in the design stage accurately 
reflected the true values in trials with a two-arm internal pilot. 
We conducted an additional simulation study to investigate whether the 
CVPA-SSR algorithm controls the nominal Type I error rate while achieving the 
desired power when the parameter estimates for the control group rate and 
treatment effect used in the design stage were not accurately specified. We 
observed no Type I error rate inflation trend in the scenarios investigated; 
however we observed significant over- and underpowering of the trial occurred 
when the treatment effect used at the design stage was not the true population 
value. We also found that when the control group event rate used at the design 
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stage was not the true population value, most scenarios were appropriately 
powered. 
We then modified the CVPA-SSR algorithm so that it can be used for trials 
with a single-arm internal pilot. We conducted a simulation study to investigate 
whether the CVPA-SSR algorithm modified for trials with a single-arm internal 
pilot controls the nominal Type I error rate while achieving the desired power 
when the parameter estimates for the control group rate and treatment effect 
used in the CVPA-SSR algorithm were accurately specified. As was observed for 
two-arm internal pilot studies, the CVPA-SSR algorithm modified for trials with a 
single-arm internal pilot was shown to control the nominal type I error rate while 
achieving the desired power when the parameter estimates for the control group 
rate and treatment effect used in the CVPA-SSR algorithm were accurately 
specified. 
We conducted a final simulation study to investigate whether the CVPA-
SSR algorithm modified for trials with a single-arm internal pilot controls the 
nominal Type I error rate while achieving the desired power when the parameter 
estimates for the control group rate and treatment effect used in the CVPA-SSR 
algorithm were not accurately specified. As we observed for the two-arm internal 
pilot studies, no Type I error rate inflation trend and significant over- and 
underpowering of the trial occurred when the treatment effect used in the CVPA-
SSR algorithm was not the true population value. We also found that when the 
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control group event rate used in the CVPA-SSR algorithm was not the true 
population value, most scenarios were appropriately powered. 
6.1 Implications 
When SSR is performed it is generally done in either a blinded fashion, 
where treatment group specific information is not available, or an unblinded 
fashion, where treatment group specific information is available. When unblinded 
SSR is performed, it typically uses the treatment effect in SSR. Much less 
common is unblinded SSR based on information from only one of the treatment 
groups such as the HW-SSR method. Though less common, the HW-SSR 
method can be used to re-estimate the sample size in trials with single-arm 
internal pilots in the control group whereas other methods cannot. Previous 
literature reported conflicting results regarding the impact of the HW-SSR method 
on the two-sided Type I error rate and power of the final hypothesis test (4-7). 
We demonstrated that there is sometimes inflation of the one-sided Type I error 
rate of interest and there is also sometimes reduced power in some scenarios 
when using the HW-SSR method. As a result, we recommend that the HW-SSR 
method not be used for SSR unless it can be demonstrated that the particular 
scenario of interest is one that does not have Type I error inflation or reduced 
power or the HW-SSR method is used in conjunction with some other method to 
correct its deficiencies. 
In this research we proposed the CVPA-SSR algorithm which can be used 
in studies with both single- and two-arm internal pilots to correct the deficiencies 
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of the HW-SSR method. The overall conclusions regarding the CVPA-SSR 
algorithm are the same when it is used for trials with a single-arm internal pilot as 
when it is used for trials with a two-arm internal pilot. This is unsurprising as 
when the HW-SSR method is used when applying the CVPA-SSR algorithm, only 
the control group is unblinded and examined at the interim analysis. Since the 
experimental group is only unblinded at the end of the trial, it is irrelevant whether 
the experimental group is enrolled before the interim analysis. As a result, the 
CVPA-SSR algorithm is expected to perform similarly regardless of whether the 
internal pilot follows a one- or two-arm design.  
We demonstrated that the Type I error is controlled and the desired power 
is maintained when the parameter estimates for the control group rate and 
treatment effect used in the design stage are accurately specified. In settings 
where the true treatment effect is different than what was used to design the trial, 
we observed no Type I error rate inflation trend; however we observed significant 
over- and underpowering of the trial. In settings where the true control group rate 
is different than what was used to design the trial, there may be a small reduction 
of power. As a result, the HW-SSR method should be used with caution when the 
treatment effect is not known with a relatively high degree of accuracy. Despite 
this, the proposal of the CVPA-SSR algorithm extends the use of HW-SSR 
method and makes the application of studies with internal pilots and partially 




In this research, we focused on study designs with a single interim 
analysis for the purpose of SSR and 1:1 overall subject allocations in each 
treatment group. In practice, there may be more than one interim analysis for 
SSR and other subject allocations which may require additional modifications to 
the CVPA-SSR algorithm.  
We did not perform exhaustive simulation scenarios across all possible 
control group event rates and treatment effects and defined rules to address 
extreme scenarios that occurred during the simulations such as control group 
event rates of zero at the interim analysis (see Section 3.3.1 for the full list of 
simulation rules). While the conclusions did not change when comparing 
between situations that had extreme scenarios and those that did not have any 
extreme scenarios, other extreme scenario rules could be used instead and 
could possibly impact the results.  
At the single-interim analysis, we required that the study continue with a 
sample size between the minimum allowable sample size and the maximum 
allowable sample size. Additional trial adaptations could be specified, such as 
adding a futility boundary to stop a trial if the observed event rate in the control 
group from the internal pilot is too small or large. Another possibility is for the 
SSR to be done for a different power if the required sample size is larger than the 
maximum allowable sample size. We did not explore any additional adaptations 
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which, if implemented, could influence the effectiveness of the CVPA-SSR 
algorithm. 
In the CVPA-SSR algorithm we only allowed the critical values to be more 
extreme than the nominal values. In some settings this may lead to deflation of 
the Type I error or an increase in power above the desired level. While 
adjustments may be made, we elected to implement this rule rather than allow 
the claiming of significance with a Z-statistic < 1.96 for a positive outcome with a 
0.025 Type I error rate. 
We sought to determine how to implement a single-arm internal pilot study 
design with appropriate Type I error and power. This is not the only statistical 
issue that needs to be researched for this study design. Further research is 
required to better understand items such as whether this study design leads to 
balanced treatment groups, whether any operational biases are introduced due 
to non-concurrent enrollment, and the implications of the SSR always leading to 
a sample size that requires no more subjects to be enrolled in the control group 
after the interim analysis. Further research is needed to ensure that strengths 
and weaknesses of this study design are well-known before we would advocate 
for the general use of this study design. 
6.3 Future Research 
In this research, if the required sample size calculated at the interim was 
greater than the maximum sample size allowed, we set the sample size for that 
scenario to the maximum sample size allowed. In practice, if the observed control 
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group event rate from the internal pilot leads to a required sample size that is 
very large, the trial may be stopped. As such a futility boundary for the observed 
control group event rate from the internal pilot may be set a priori and this may 
affect the Type I error and power results. We leave these investigations to future 
research. 
We only explored the properties of these study designs with a 1:1 overall 
subject allocation in the treatment groups. In practice, there are many different 
subject allocations. In addition, for single-arm internal pilot trials, there are many 
different types of allocations based on the objective of the study. We leave these 
investigations to future research. 
For the single-arm internal pilot design, we investigated scenarios in which 
there were subjects that were required to be enrolled in the control group after 
the interim analysis. Of interest is what would happen if the sample size in the 
single-arm control group is large enough that the SSR always leads to a sample 
size that requires no more subjects to be enrolled in the control group after the 
interim analysis. In essence, the study design would be like a historical control 
study design. A next step in this course of research is to investigate whether the 
Type I error rate and the power are maintained in this type of study design or if 
the CVPA-SSR algorithm is required to be calculated to maintain control or Type 
I error and achieve desired power. 
We explored a study design where there was a single-arm internal pilot in 
the control group. A natural extension is for the single-arm internal pilot to be in 
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the experimental group. This type of study could happen when the efficacy of a 
type of treatment is well known, but the safety is not and a small pilot study first 
demonstrates that the treatment is reasonable safe before expanding into a large 
comparative trial to demonstrate efficacy. We leave the exploration of the Type I 
error rate and power properties of a single-arm internal pilot in the experimental 
group to future research. 
Finally, we evaluated the Type I error and power of the HW-SSR method 
and developed the CVPA-SSR algorithm for a superiority clinical trial. Another 
common trial design is the non-inferiority trial, where the null hypothesis is that 
the experimental treatment is worse than the control treatment versus the 
alternative where the experimental treatment is not worse than a clinically 
acceptable difference. The Type I error and power of a single-arm internal pilot in 
the control group for a non-inferiority trial and whether the CVPA-SSR algorithm 
in required for Type I error and power control is left for future research. 
6.4 Summary 
We introduced the CVPA-SSR algorithm to correct the deficiencies that 
occur in certain scenarios when the HW-SSR method is used for trials with a two-
arm internal pilot while still using the easily interpretable Z-test as the final 
hypothesis test. We showed that the CVPA-SSR algorithm maintains the nominal 
Type I error rate while achieving desired power when using the HW-SSR method 
when the parameter estimates for the control group rate and treatment effect 
used in the design stage were accurately specified. The CVPA-SSR algorithm 
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was extended to trials with a single-arm internal pilot in the control group when 
the HW-SSR method is used and was also shown to maintain the nominal Type I 
error rate while achieving desired power when the parameter estimates for the 
control group rate and treatment effect used in the design stage were accurately 
specified. When planning to use the HW-SSR method, the CVPA-SSR algorithm 
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Table A.1: Results from Simulations where the Minimum Allowable Sample Size is 10% more 
than the Interim Analysis Sample Size and the Maximum Allowable Sample Size is 200 Subjects 
per Treatment Group Performed by Herson and Wittes (1993) for the Alternative Hypothesis Ha: 





Rate (  ) 
Simulated Two- 





25% 0.20 0.0506 171.2 0.747 
0.30 0.0508 128.2 - 
0.40 0.0516 88.8 0.844 
0.50 0.0516 61.8 - 
0.60 0.0488 44.3 0.868 
50% 0.20 0.0524 176.1 0.771 
0.30 0.0508 125.2 - 
0.40 0.0494 84.2 0.867 
0.50 0.0466 60.0 - 
0.60 0.0434 47.6 0.892 
75% 0.20 0.0528 179.0 0.777 
0.30 0.0511 123.2 - 
0.40 0.0457 84.3 0.874 
0.50 0.0444 68.4 - 
0.60 0.0495 66.1 0.939 
100% 0.20 0.0530 80.0 0.431 
0.30 0.0502 80.0 - 
0.40 0.0467 80.0 0.789 
0.50 0.0484 80.0 - 
0.60 0.0467 80.0 0.966 
Note:  
1. Interim analysis location refers to the percent of subjects out of the original protocol-
specified sample size who have been assessed for the outcome at the interim analysis. 
100% refers to the situation where no sample size re-estimation is planned. 
2. Original protocol-specified sample size in all scenarios was 80 per treatment group 
obtained from the following assumptions: control group event rate = 0.40, relative 
treatment effect = 0.50 reduction, two-sided Type I error rate = 0.05, power = 0.80. 
3. 30,000 simulations produced for the Type I error results, 95% CI is ± 0.0025 for Type I 
error 




Table A.2: Results from Simulations where the Minimum Allowable Sample Size is the Original 
Protocol-Specified Sample Size and the Maximum Allowable Sample Size is 200 Subjects per 
Treatment Group Performed by Herson and Wittes (1993) for the Alternative Hypothesis Ha: pe = 





Rate (  ) 
Simulated Two- 





25% 0.20 0.0526 171.6 0.754 
0.30 0.0503 129.7 - 
0.40 0.0498 98.1 0.872 
0.50 0.0465 84.2 - 
0.60 0.0457 80.6 0.971 
50% 0.20 0.0524 176.1 0.771 
0.30 0.0495 125.9 - 
0.40 0.0439 91.5 0.882 
0.50 0.0480 81.3 - 
0.60 0.0448 80.0 0.975 
75% 0.20 0.0528 179.0 0.777 
0.30 0.0505 123.5 - 
0.40 0.0466 89.1 0.883 
0.50 0.0471 80.6 - 
0.60 0.0485 80.0 0.969 
100% 0.20 0.0530 80.0 0.431 
0.30 0.0502 80.0 - 
0.40 0.0467 80.0 0.789 
0.50 0.0484 80.0 - 
0.60 0.0467 80.0 0.966 
Note:  
1. Interim analysis location refers to the percent of subjects out of the original protocol-
specified sample size who have been assessed for the outcome at the interim analysis. 
100% refers to the situation where no sample size re-estimation is planned. 
2. Original sample size in all scenarios was 80 per treatment group obtained from the 
following assumptions: control group event rate = 0.40, relative treatment effect = 0.50 
reduction, two-sided Type I error rate = 0.05, power = 0.80. 
3. 30,000 simulations produced for the Type I error results, 95% CI is ± 0.0025 for Type I 
error 




Table A.3: Results from Simulations where the Minimum Allowable Sample Size is the Internal 
Pilot Sample Size and the Maximum Allowable Sample Size is the Internal Pilot Sample Size + 
1000 Subjects per Treatment Group Performed by Jennison and Turnbull (2000) for the 
Alternative Hypothesis Ha: pe = pc / ρ.  
Relative 
Treatment 
Effect  ρ  
Control 
Group 













1.50 0.75 20 74 0.054 77.8 0.917 
1.25 0.75 80 200 0.052 202.8 0.927 
0.50 0.20 80 106 0.048 116.9 0.834 
0.25 0.10 30 39 0.051 71.4 0.832 
Note:  
1. SS = sample size  
2. Original protocol-specified sample size in all scenarios was obtained from the following 
assumptions: control group event rate     , relative treatment effect  ρ , two-sided Type I 
error rate = 0.05, power = 0.90. 
3. 1,000,000 simulations were produced, standard errors are 0.0002 for Type I errors, 




Table A.4: Results from Simulations where the Minimum Allowable Sample Size is the Internal 
Pilot Sample Size and the Maximum Allowable Sample Size is the Internal Pilot Sample Size + 
1000 Subjects per Treatment Group Performed by Jennison and Turnbull (2000) for the 




Effect  Δ  
Control 
Group 













0.3 0.1 10 39 0.059 36.8 0.897 
0.1 20 39 0.061 38.0 0.919 
0.2 20 48 0.056 46.3 0.898 
0.2 30 48 0.055 47.1 0.903 
0.3 30 53 0.053 51.4 0.879 
0.3 40 53 0.053 51.6 0.880 
0.4 30 53 0.054 51.2 0.859 
0.2 0.1 30 79 0.056 77.6 0.921 
0.1 50 79 0.053 78.3 0.931 
0.2 50 106 0.053 103.9 0.910 
0.2 70 106 0.052 104.4 0.914 
0.3 60 121 0.052 119.4 0.898 
0.3 90 121 0.051 120.1 0.900 
0.4 60 127 0.050 124.3 0.886 
Note:  
1. SS = sample size  
2. Original protocol-specified sample size in all scenarios was obtained from the following 
assumptions: control group event rate     , risk difference treatment effect  Δ , two-sided 
Type I error rate = 0.05, power = 0.90. 
3. 1,000,000 simulations were produced, standard errors are 0.0002 for Type I errors, 




Table A.5: Results from Simulations where the Minimum Allowable Sample Size is the Interim 
Analysis Sample Size and the Maximum Allowable Sample Size is Twice the Original Protocol-
Specified Sample Size for the HW-SSR Method for the Alternative Hypothesis Ha: pe = (1 - γ)pc 
when the Outcome is Negative (Part 1). 
Control 
Group 
Rate (  ) 
Relative 
Treatment 






Type I Error (95% CI) 
Simulated Power 
(95% CI) 
0.10 0.50 432 25% 0.0506 (0.0492-0.0520) 0.8554 (0.8529-0.8579) 
50% 0.0524 (0.0510-0.0538) 0.8623 (0.8598-0.8648) 
75% 0.0501 (0.0487-0.0515) 0.8659 (0.8634-0.8684) 
100% 0.0522 (0.0508-0.0536) 0.8068 (0.8043-0.8093) 
0.20 0.50 197 25% 0.0506 (0.0492-0.0520) 0.8530 (0.8505-0.8555) 
50% 0.0510 (0.0496-0.0524) 0.8618 (0.8593-0.8643) 
75% 0.0511 (0.0497-0.0525) 0.8632 (0.8607-0.8657) 
100% 0.0507 (0.0493-0.0521) 0.8053 (0.8028-0.8078) 
0.20 0.25 903 25% 0.0501 (0.0487-0.0515) 0.8282 (0.8257-0.8307) 
50% 0.0508 (0.0494-0.0522) 0.8303 (0.8278-0.8328) 
75% 0.0503 (0.0489-0.0517) 0.8273 (0.8248-0.8298) 
100% 0.0503 (0.0489-0.0517) 0.7992 (0.7967-0.8017) 
0.30 0.50 118 25% 0.0526 (0.0512-0.0540) 0.8477 (0.8452-0.8502) 
50% 0.0525 (0.0511-0.0539) 0.8566 (0.8541-0.8591) 
75% 0.0480 (0.0466-0.0494) 0.8632 (0.8607-0.8657) 
100% 0.0509 (0.0495-0.0523) 0.7993 (0.7968-0.8018) 
0.30 0.25 537 25% 0.0499 (0.0485-0.0513) 0.8279 (0.8254-0.8304) 
50% 0.0505 (0.0491-0.0519) 0.8315 (0.8290-0.8340) 
75% 0.0503 (0.0489-0.0517) 0.8308 (0.8283-0.8333) 
100% 0.0497 (0.0483-0.0511) 0.7992 (0.7967-0.8017) 
0.40 0.50 79 25% 0.0517 (0.0503-0.0531) 0.8429 (0.8404-0.8454) 
50% 0.0522 (0.0508-0.0536) 0.8572 (0.8547-0.8597) 
75% 0.0513 (0.0499-0.0527) 0.8649 (0.8624-0.8674) 
100% 0.0492 (0.0478-0.0506) 0.7947 (0.7922-0.7972) 
0.40 0.25 354 25% 0.0509 (0.0495-0.0523) 0.8282 (0.8257-0.8307) 
50% 0.0502 (0.0488-0.0516) 0.8319 (0.8294-0.8344) 
75% 0.0512 (0.0498-0.0526) 0.8304 (0.8279-0.8329) 
100% 0.0508 (0.0494-0.0522) 0.7999 (0.7974-0.8024) 
Note:  
1. SS = sample size, IAL = interim analysis location. 
2. Interim analysis location refers to the percent of subjects out of the original protocol-
specified sample size who have been assessed for the outcome at the interim analysis. 




Table A.6: Results from Simulations where the Minimum Allowable Sample Size is the Interim 
Analysis Sample Size and the Maximum Allowable Sample Size is Twice the Original Protocol-
Specified Sample Size for the HW-SSR Method for the Alternative Hypothesis Ha: pe = (1 - γ)pc 
when the Outcome is Negative (Part 2). 
Control 
Group 
Rate (  ) 
Relative 
Treatment 
Effect ( ) IAL 
Simulated Lower Type I 
Error (95% CI) 
Simulated Upper Type I 






0.10 0.50 25% 0.0288 (0.0278-0.0298) 0.0219 (0.0209-0.0229) 471 1 
50% 0.0297 (0.0287-0.0307) 0.0227 (0.0217-0.0237) 453 0 
75% 0.0275 (0.0265-0.0285) 0.0226 (0.0216-0.0236) 447 0 
100% 0.0260 (0.0250-0.0270) 0.0262 (0.0252-0.0272) 432 0 
0.20 0.50 25% 0.0285 (0.0275-0.0295) 0.0221 (0.0211-0.0231) 215 5 
50% 0.0290 (0.0280-0.0300) 0.0220 (0.0210-0.0230) 207 0 
75% 0.0288 (0.0278-0.0298) 0.0224 (0.0214-0.0234) 204 0 
100% 0.0251 (0.0241-0.0261) 0.0256 (0.0246-0.0266) 197 0 
0.20 0.25 25% 0.0269 (0.0259-0.0279) 0.0232 (0.0222-0.0242) 923 0 
50% 0.0278 (0.0268-0.0288) 0.0231 (0.0221-0.0241) 913 0 
75% 0.0274 (0.0264-0.0284) 0.0229 (0.0219-0.0239) 910 0 
100% 0.0250 (0.0240-0.0260) 0.0253 (0.0243-0.0263) 903 0 
0.30 0.50 25% 0.0299 (0.0289-0.0309) 0.0227 (0.0217-0.0237) 130 2 
50% 0.0299 (0.0289-0.0309) 0.0226 (0.0216-0.0236) 125 0 
75% 0.0263 (0.0253-0.0273) 0.0217 (0.0207-0.0227) 123 0 
100% 0.0253 (0.0243-0.0263) 0.0256 (0.0246-0.0266) 118 0 
0.30 0.25 25% 0.0274 (0.0264-0.0284) 0.0226 (0.0216-0.0236) 550 0 
50% 0.0268 (0.0258-0.0278) 0.0237 (0.0227-0.0247) 543 0 
75% 0.0274 (0.0264-0.0284) 0.0230 (0.0220-0.0240) 541 0 
100% 0.0251 (0.0241-0.0261) 0.0246 (0.0236-0.0256) 537 0 
0.40 0.50 25% 0.0304 (0.0294-0.0314) 0.0213 (0.0203-0.0223) 86 3 
50% 0.0302 (0.0292-0.0312) 0.0221 (0.0211-0.0231) 84 0 
75% 0.0292 (0.0282-0.0302) 0.0221 (0.0211-0.0231) 83 0 
100% 0.0244 (0.0234-0.0254) 0.0247 (0.0237-0.0257) 79 0 
0.40 0.25 25% 0.0272 (0.0262-0.0282) 0.0237 (0.0227-0.0247) 364 0 
50% 0.0274 (0.0264-0.0284) 0.0229 (0.0219-0.0239) 359 0 
75% 0.0267 (0.0257-0.0277) 0.0245 (0.0235-0.0255) 357 0 
100% 0.0258 (0.0248-0.0268) 0.0250 (0.0240-0.0260) 354 0 
Note:  
1. IAL = interim analysis location. 
2. Interim analysis location refers to the percent of subjects out of the original protocol-
specified sample size who have been assessed for the outcome at the interim analysis. 
100% refers to the situation where no sample size re-estimation is planned. 





Table A.7: Results from Simulations where the Minimum Allowable Sample Size is the Interim 
Analysis Sample Size and where there is No Maximum Allowable Sample Size for the HW-SSR 
Method for the Alternative Hypothesis Ha: pe = (1 - γ)pc when the Outcome is Negative (Part 1). 
Control 
Group 









Type I Error (95% CI) 
Simulated Power 
(95% CI) 
0.10 0.50 432 25% 0.0515 (0.0501-0.0529) 0.8556 (0.8531-0.8581) 
50% 0.0507 (0.0493-0.0521) 0.8626 (0.8601-0.8651) 
75% 0.0494 (0.0480-0.0508) 0.8647 (0.8622-0.8672) 
100% 0.0526 (0.0512-0.0540) 0.8062 (0.8037-0.8087) 
0.20 0.50 197 25% 0.0505 (0.0491-0.0519) 0.8553 (0.8528-0.8578) 
50% 0.0521 (0.0507-0.0535) 0.8610 (0.8585-0.8635) 
75% 0.0498 (0.0484-0.0512) 0.8642 (0.8617-0.8667) 
100% 0.0506 (0.0492-0.0520) 0.8051 (0.8026-0.8076) 
0.20 0.25 903 25% 0.0504 (0.0490-0.0518) 0.8260 (0.8235-0.8285) 
50% 0.0510 (0.0496-0.0524) 0.8300 (0.8275-0.8325) 
75% 0.0500 (0.0486-0.0514) 0.8307 (0.8282-0.8332) 
100% 0.0498 (0.0484-0.0512) 0.8019 (0.7994-0.8044) 
0.30 0.50 118 25% 0.0511 (0.0497-0.0525) 0.8513 (0.8488-0.8538) 
50% 0.0503 (0.0489-0.0517) 0.8601 (0.8576-0.8626) 
75% 0.0484 (0.0470-0.0498) 0.8616 (0.8591-0.8641) 
100% 0.0503 (0.0489-0.0517) 0.7972 (0.7947-0.7997) 
0.30 0.25 537 25% 0.0503 (0.0489-0.0517) 0.8273 (0.8248-0.8298) 
50% 0.0511 (0.0497-0.0525) 0.8315 (0.8290-0.8340) 
75% 0.0503 (0.0489-0.0517) 0.8307 (0.8282-0.8332) 
100% 0.0498 (0.0484-0.0512) 0.7998 (0.7973-0.8023) 
0.40 0.50 79 25% 0.0510 (0.0496-0.0524) 0.8461 (0.8436-0.8486) 
50% 0.0526 (0.0512-0.0540) 0.8604 (0.8579-0.8629) 
75% 0.0503 (0.0489-0.0517) 0.8647 (0.8622-0.8672) 
100% 0.0489 (0.0475-0.0503) 0.7959 (0.7934-0.7984) 
0.40 0.25 354 25% 0.0501 (0.0487-0.0515) 0.8284 (0.8259-0.8309) 
50% 0.0499 (0.0485-0.0513) 0.8318 (0.8293-0.8343) 
75% 0.0515 (0.0501-0.0529) 0.8324 (0.8299-0.8349) 
100% 0.0507 (0.0493-0.0521) 0.7997 (0.7972-0.8022) 
Note:  
1. SS = sample size, IAL = interim analysis location. 
2. Interim analysis location refers to the percent of subjects out of the original protocol-
specified sample size who have been assessed for the outcome at the interim analysis. 




Table A.8: Results from Simulations where the Minimum Allowable Sample Size is the Interim 
Analysis Sample Size and where there is No Maximum Allowable Sample Size for the HW-SSR 
Method for the Alternative Hypothesis Ha: pe = (1 - γ)pc when the Outcome is Negative (Part 2). 
Control 
Group 
Rate (  ) 
Relative 
Treatment 
Effect ( ) IAL 
Simulated Lower Type I 
Error (95% CI) 
Simulated Upper Type I 






0.10 0.50 25% 0.0292 (0.0282-0.0302) 0.0223 (0.0213-0.0233) 482 1 
50% 0.0278 (0.0268-0.0288) 0.0229 (0.0219-0.0239) 454 0 
75% 0.0273 (0.0263-0.0283) 0.0221 (0.0211-0.0231) 447 0 
100% 0.0260 (0.0250-0.0270) 0.0266 (0.0256-0.0276) 432 0 
0.20 0.50 25% 0.0292 (0.0282-0.0302) 0.0213 (0.0203-0.0223) 221 2 
50% 0.0304 (0.0294-0.0314) 0.0217 (0.0207-0.0227) 207 0 
75% 0.0282 (0.0272-0.0292) 0.0217 (0.0207-0.0227) 204 0 
100% 0.0253 (0.0243-0.0263) 0.0253 (0.0243-0.0263) 197 0 
0.20 0.25 25% 0.0265 (0.0255-0.0275) 0.0240 (0.0230-0.0250) 922 0 
50% 0.0268 (0.0258-0.0278) 0.0242 (0.0232-0.0252) 913 0 
75% 0.0265 (0.0255-0.0275) 0.0234 (0.0224-0.0244) 910 0 
100% 0.0249 (0.0239-0.0259) 0.0250 (0.0240-0.0260) 903 0 
0.30 0.50 25% 0.0299 (0.0289-0.0309) 0.0212 (0.0202-0.0222) 134 1 
50% 0.0290 (0.0280-0.0300) 0.0213 (0.0203-0.0223) 125 0 
75% 0.0260 (0.0250-0.0270) 0.0224 (0.0214-0.0234) 123 0 
100% 0.0254 (0.0244-0.0264) 0.0249 (0.0239-0.0259) 118 0 
0.30 0.25 25% 0.0277 (0.0267-0.0287) 0.0226 (0.0216-0.0236) 550 0 
50% 0.0271 (0.0261-0.0281) 0.0239 (0.0229-0.0249) 543 0 
75% 0.0269 (0.0259-0.0279) 0.0234 (0.0224-0.0244) 541 0 
100% 0.0247 (0.0237-0.0257) 0.0251 (0.0241-0.0261) 537 0 
0.40 0.50 25% 0.0298 (0.0288-0.0308) 0.0212 (0.0202-0.0222) 91 4 
50% 0.0305 (0.0295-0.0315) 0.0222 (0.0212-0.0232) 84 0 
75% 0.0286 (0.0276-0.0296) 0.0217 (0.0207-0.0227) 83 0 
100% 0.0250 (0.0240-0.0260) 0.0240 (0.0230-0.0250) 79 0 
0.40 0.25 25% 0.0272 (0.0262-0.0282) 0.0229 (0.0219-0.0239) 364 0 
50% 0.0268 (0.0258-0.0278) 0.0231 (0.0221-0.0241) 359 0 
75% 0.0279 (0.0269-0.0289) 0.0236 (0.0226-0.0246) 357 0 
100% 0.0254 (0.0244-0.0264) 0.0253 (0.0243-0.0263) 354 0 
Note:  
1. IAL = interim analysis location. 
2. Interim analysis location refers to the percent of subjects out of the original protocol-
specified sample size who have been assessed for the outcome at the interim analysis. 
100% refers to the situation where no sample size re-estimation is planned. 





Table A.9: Results from Simulations where the Minimum Allowable Sample Size is 10% more 
than the Interim Analysis Sample Size and the Maximum Allowable Sample Size is Twice the 
Original Protocol-Specified Sample Size for the HW-SSR Method for the Alternative Hypothesis 
Ha: pe = (1 - γ)pc when the Outcome is Negative (Part 1). 
Control 
Group 
Rate (  ) 
Relative 
Treatment 






Type I Error (95% CI) 
Simulated Power 
(95% CI) 
0.10 0.50 432 25% 0.0515 (0.0501-0.0529) 0.8571 (0.8546-0.8596) 
50% 0.0502 (0.0488-0.0516) 0.8617 (0.8592-0.8642) 
75% 0.0490 (0.0476-0.0504) 0.8664 (0.8639-0.8689) 
100% 0.0509 (0.0495-0.0523) 0.8085 (0.8060-0.8110) 
0.20 0.50 197 25% 0.0518 (0.0504-0.0532) 0.8535 (0.8510-0.8560) 
50% 0.0507 (0.0493-0.0521) 0.8622 (0.8597-0.8647) 
75% 0.0478 (0.0464-0.0492) 0.8616 (0.8591-0.8641) 
100% 0.0502 (0.0488-0.0516) 0.8055 (0.8030-0.8080) 
0.20 0.25 903 25% 0.0491 (0.0477-0.0505) 0.8281 (0.8256-0.8306) 
50% 0.0511 (0.0497-0.0525) 0.8283 (0.8258-0.8308) 
75% 0.0503 (0.0489-0.0517) 0.8278 (0.8253-0.8303) 
100% 0.0503 (0.0489-0.0517) 0.8011 (0.7986-0.8036) 
0.30 0.50 118 25% 0.0529 (0.0515-0.0543) 0.8493 (0.8468-0.8518) 
50% 0.0521 (0.0507-0.0535) 0.8582 (0.8557-0.8607) 
75% 0.0498 (0.0484-0.0512) 0.8631 (0.8606-0.8656) 
100% 0.0503 (0.0489-0.0517) 0.7986 (0.7961-0.8011) 
0.30 0.25 537 25% 0.0500 (0.0486-0.0514) 0.8289 (0.8264-0.8314) 
50% 0.0502 (0.0488-0.0516) 0.8294 (0.8269-0.8319) 
75% 0.0503 (0.0489-0.0517) 0.8308 (0.8283-0.8333) 
100% 0.0503 (0.0489-0.0517) 0.7995 (0.7970-0.8020) 
0.40 0.50 79 25% 0.0507 (0.0493-0.0521) 0.8445 (0.8420-0.8470) 
50% 0.0510 (0.0496-0.0524) 0.8606 (0.8581-0.8631) 
75% 0.0467 (0.0453-0.0481) 0.8655 (0.8630-0.8680) 
100% 0.0482 (0.0468-0.0496) 0.7966 (0.7941-0.7991) 
0.40 0.25 354 25% 0.0508 (0.0494-0.0522) 0.8300 (0.8275-0.8325) 
50% 0.0511 (0.0497-0.0525) 0.8312 (0.8287-0.8337) 
75% 0.0490 (0.0476-0.0504) 0.8326 (0.8301-0.8351) 
100% 0.0510 (0.0496-0.0524) 0.7990 (0.7965-0.8015) 
Note:  
1. SS = sample size, IAL = interim analysis location. 
2. Interim analysis location refers to the percent of subjects out of the original protocol-
specified sample size who have been assessed for the outcome at the interim analysis. 




Table A.10: Results from Simulations where the Minimum Allowable Sample Size is 10% more 
than the Interim Analysis Sample Size and the Maximum Allowable Sample Size is Twice the 
Original Protocol-Specified Sample Size for the HW-SSR Method for the Alternative Hypothesis 
Ha: pe = (1 - γ)pc when the Outcome is Negative (Part 2). 
Control 
Group 
Rate (  ) 
Relative 
Treatment 
Effect ( ) IAL 
Simulated Lower Type I 
Error (95% CI) 
Simulated Upper Type I 






0.10 0.50 25% 0.0290 (0.0280-0.0300) 0.0226 (0.0216-0.0236) 471 1 
50% 0.0280 (0.0270-0.0290) 0.0223 (0.0213-0.0233) 454 0 
75% 0.0270 (0.0260-0.0280) 0.0220 (0.0210-0.0230) 450 0 
100% 0.0256 (0.0246-0.0266) 0.0253 (0.0243-0.0263) 432 0 
0.20 0.50 25% 0.0299 (0.0289-0.0309) 0.0218 (0.0208-0.0228) 215 2 
50% 0.0294 (0.0284-0.0304) 0.0213 (0.0203-0.0223) 207 0 
75% 0.0258 (0.0248-0.0268) 0.0220 (0.0210-0.0230) 206 0 
100% 0.0250 (0.0240-0.0260) 0.0252 (0.0242-0.0262) 197 0 
0.20 0.25 25% 0.0257 (0.0247-0.0267) 0.0235 (0.0225-0.0245) 924 0 
50% 0.0278 (0.0268-0.0288) 0.0233 (0.0223-0.0243) 913 0 
75% 0.0272 (0.0262-0.0282) 0.0230 (0.0220-0.0240) 910 0 
100% 0.0257 (0.0247-0.0267) 0.0246 (0.0236-0.0256) 903 0 
0.30 0.50 25% 0.0308 (0.0298-0.0318) 0.0221 (0.0211-0.0231) 129 0 
50% 0.0304 (0.0294-0.0314) 0.0217 (0.0207-0.0227) 125 0 
75% 0.0272 (0.0262-0.0282) 0.0226 (0.0216-0.0236) 124 0 
100% 0.0251 (0.0241-0.0261) 0.0252 (0.0242-0.0262) 118 0 
0.30 0.25 25% 0.0270 (0.0260-0.0280) 0.0230 (0.0220-0.0240) 550 0 
50% 0.0272 (0.0262-0.0282) 0.0230 (0.0220-0.0240) 543 0 
75% 0.0269 (0.0259-0.0279) 0.0233 (0.0223-0.0243) 542 0 
100% 0.0249 (0.0239-0.0259) 0.0254 (0.0244-0.0264) 537 0 
0.40 0.50 25% 0.0289 (0.0279-0.0299) 0.0219 (0.0209-0.0229) 86 6 
50% 0.0299 (0.0289-0.0309) 0.0211 (0.0201-0.0221) 83 0 
75% 0.0246 (0.0236-0.0256) 0.0220 (0.0210-0.0230) 84 0 
100% 0.0239 (0.0229-0.0249) 0.0243 (0.0233-0.0253) 79 0 
0.40 0.25 25% 0.0282 (0.0272-0.0292) 0.0227 (0.0217-0.0237) 363 0 
50% 0.0277 (0.0267-0.0287) 0.0234 (0.0224-0.0244) 358 0 
75% 0.0266 (0.0256-0.0276) 0.0224 (0.0214-0.0234) 358 0 
100% 0.0258 (0.0248-0.0268) 0.0252 (0.0242-0.0262) 354 0 
Note:  
1. IAL = interim analysis location. 
2. Interim analysis location refers to the percent of subjects out of the original protocol-
specified sample size who have been assessed for the outcome at the interim analysis. 
100% refers to the situation where no sample size re-estimation is planned. 





Table A.11: Results from Simulations where the Minimum Allowable Sample Size is 10% more 
than the Interim Analysis Sample Size and where there is No Maximum Allowable Sample Size 
for the HW-SSR Method for the Alternative Hypothesis Ha: pe = (1 - γ)pc when the Outcome is 
Negative (Part 1). 
Control 
Group 
Rate (  ) 
Relative 
Treatment 






Type I Error (95% CI) 
Simulated Power 
(95% CI) 
0.10 0.50 432 25% 0.0499 (0.0485-0.0513) 0.8573 (0.8548-0.8598) 
50% 0.0504 (0.0490-0.0518) 0.8615 (0.8590-0.8640) 
75% 0.0489 (0.0475-0.0503) 0.8653 (0.8628-0.8678) 
100% 0.0527 (0.0513-0.0541) 0.8060 (0.8035-0.8085) 
0.20 0.50 197 25% 0.0511 (0.0497-0.0525) 0.8541 (0.8516-0.8566) 
50% 0.0496 (0.0482-0.0510) 0.8603 (0.8578-0.8628) 
75% 0.0485 (0.0471-0.0499) 0.8619 (0.8594-0.8644) 
100% 0.0500 (0.0486-0.0514) 0.8045 (0.8020-0.8070) 
0.20 0.25 903 25% 0.0504 (0.0490-0.0518) 0.8267 (0.8242-0.8292) 
50% 0.0499 (0.0485-0.0513) 0.8287 (0.8262-0.8312) 
75% 0.0506 (0.0492-0.0520) 0.8291 (0.8266-0.8316) 
100% 0.0497 (0.0483-0.0511) 0.8019 (0.7994-0.8044) 
0.30 0.50 118 25% 0.0509 (0.0495-0.0523) 0.8496 (0.8471-0.8521) 
50% 0.0515 (0.0501-0.0529) 0.8586 (0.8561-0.8611) 
75% 0.0490 (0.0476-0.0504) 0.8642 (0.8617-0.8667) 
100% 0.0504 (0.0490-0.0518) 0.7930 (0.7905-0.7955) 
0.30 0.25 537 25% 0.0500 (0.0486-0.0514) 0.8284 (0.8259-0.8309) 
50% 0.0509 (0.0495-0.0523) 0.8316 (0.8291-0.8341) 
75% 0.0504 (0.0490-0.0518) 0.8306 (0.8281-0.8331) 
100% 0.0507 (0.0493-0.0521) 0.8002 (0.7977-0.8027) 
0.40 0.50 79 25% 0.0521 (0.0507-0.0535) 0.8473 (0.8448-0.8498) 
50% 0.0499 (0.0485-0.0513) 0.8588 (0.8563-0.8613) 
75% 0.0469 (0.0455-0.0483) 0.8668 (0.8643-0.8693) 
100% 0.0484 (0.0470-0.0498) 0.7962 (0.7937-0.7987) 
0.40 0.25 354 25% 0.0506 (0.0492-0.0520) 0.8277 (0.8252-0.8302) 
50% 0.0500 (0.0486-0.0514) 0.8321 (0.8296-0.8346) 
75% 0.0498 (0.0484-0.0512) 0.8315 (0.8290-0.8340) 
100% 0.0497 (0.0483-0.0511) 0.7989 (0.7964-0.8014) 
Note:  
1. SS = sample size, IAL = interim analysis location. 
2. Interim analysis location refers to the percent of subjects out of the original protocol-
specified sample size who have been assessed for the outcome at the interim analysis. 




Table A.12: Results from Simulations where the Minimum Allowable Sample Size is 10% more 
than the Interim Analysis Sample Size and where there is No Maximum Allowable Sample Size 
for the HW-SSR Method for the Alternative Hypothesis Ha: pe = (1 - γ)pc when the Outcome is 
Negative (Part 2). 
Control 
Group 
Rate (  ) 
Relative 
Treatment 
Effect ( ) IAL 
Simulated Lower Type I 
Error (95% CI) 
Simulated Upper Type I 






0.10 0.50 25% 0.0286 (0.0276-0.0296) 0.0213 (0.0203-0.0223) 482 1 
50% 0.0285 (0.0275-0.0295) 0.0219 (0.0209-0.0229) 453 0 
75% 0.0278 (0.0268-0.0288) 0.0212 (0.0202-0.0222) 450 0 
100% 0.0266 (0.0256-0.0276) 0.0261 (0.0251-0.0271) 432 0 
0.20 0.50 25% 0.0292 (0.0282-0.0302) 0.0220 (0.0210-0.0230) 221 1 
50% 0.0281 (0.0271-0.0291) 0.0214 (0.0204-0.0224) 207 0 
75% 0.0267 (0.0257-0.0277) 0.0218 (0.0208-0.0228) 206 0 
100% 0.0249 (0.0239-0.0259) 0.0251 (0.0241-0.0261) 197 0 
0.20 0.25 25% 0.0276 (0.0266-0.0286) 0.0228 (0.0218-0.0238) 924 0 
50% 0.0262 (0.0252-0.0272) 0.0237 (0.0227-0.0247) 913 0 
75% 0.0273 (0.0263-0.0283) 0.0233 (0.0223-0.0243) 910 0 
100% 0.0243 (0.0233-0.0253) 0.0254 (0.0244-0.0264) 903 0 
0.30 0.50 25% 0.0287 (0.0277-0.0297) 0.0223 (0.0213-0.0233) 134 0 
50% 0.0296 (0.0286-0.0306) 0.0218 (0.0208-0.0228) 125 0 
75% 0.0269 (0.0259-0.0279) 0.0221 (0.0211-0.0231) 124 0 
100% 0.0242 (0.0232-0.0252) 0.0262 (0.0252-0.0272) 118 0 
0.30 0.25 25% 0.0271 (0.0261-0.0281) 0.0229 (0.0219-0.0239) 550 0 
50% 0.0269 (0.0259-0.0279) 0.0240 (0.0230-0.0250) 543 0 
75% 0.0265 (0.0255-0.0275) 0.0239 (0.0229-0.0249) 542 0 
100% 0.0253 (0.0243-0.0263) 0.0253 (0.0243-0.0263) 537 0 
0.40 0.50 25% 0.0303 (0.0293-0.0313) 0.0218 (0.0208-0.0228) 91 2 
50% 0.0283 (0.0273-0.0293) 0.0216 (0.0206-0.0226) 84 0 
75% 0.0261 (0.0251-0.0271) 0.0209 (0.0199-0.0219) 84 0 
100% 0.0242 (0.0232-0.0252) 0.0242 (0.0232-0.0252) 79 0 
0.40 0.25 25% 0.0271 (0.0261-0.0281) 0.0235 (0.0225-0.0245) 364 0 
50% 0.0271 (0.0261-0.0281) 0.0229 (0.0219-0.0239) 358 0 
75% 0.0267 (0.0257-0.0277) 0.0231 (0.0221-0.0241) 357 0 
100% 0.0241 (0.0231-0.0251) 0.0256 (0.0246-0.0266) 354 0 
Note:  
1. IAL = interim analysis location. 
2. Interim analysis location refers to the percent of subjects out of the original protocol-
specified sample size who have been assessed for the outcome at the interim analysis. 
100% refers to the situation where no sample size re-estimation is planned. 





Table A.13: Results from Simulations where the Minimum Allowable Sample Size is the Original 
Protocol-Specified Sample Size and the Maximum Allowable Sample Size is Twice the Original 
Protocol-Specified Sample Size for the HW-SSR Method for the Alternative Hypothesis Ha: pe = (1 
- γ)pc when the Outcome is Negative (Part 1). 
Control 
Group 
Rate (  ) 
Relative 
Treatment 






Type I Error (95% CI) 
Simulated Power 
(95% CI) 
0.10 0.50 432 25% 0.0486 (0.0472-0.0500) 0.8779 (0.8754-0.8804) 
50% 0.0478 (0.0464-0.0492) 0.8723 (0.8698-0.8748) 
75% 0.0476 (0.0462-0.0490) 0.8687 (0.8662-0.8712) 
100% 0.0521 (0.0507-0.0535) 0.8073 (0.8048-0.8098) 
0.20 0.50 197 25% 0.0497 (0.0483-0.0511) 0.8767 (0.8742-0.8792) 
50% 0.0474 (0.0460-0.0488) 0.8733 (0.8708-0.8758) 
75% 0.0473 (0.0459-0.0487) 0.8672 (0.8647-0.8697) 
100% 0.0504 (0.0490-0.0518) 0.8024 (0.7999-0.8049) 
0.20 0.25 903 25% 0.0488 (0.0474-0.0502) 0.8395 (0.8370-0.8420) 
50% 0.0488 (0.0474-0.0502) 0.8326 (0.8301-0.8351) 
75% 0.0472 (0.0458-0.0486) 0.8302 (0.8277-0.8327) 
100% 0.0509 (0.0495-0.0523) 0.8000 (0.7975-0.8025) 
0.30 0.50 118 25% 0.0483 (0.0469-0.0497) 0.8754 (0.8729-0.8779) 
50% 0.0490 (0.0476-0.0504) 0.8703 (0.8678-0.8728) 
75% 0.0472 (0.0458-0.0486) 0.8671 (0.8646-0.8696) 
100% 0.0511 (0.0497-0.0525) 0.7980 (0.7955-0.8005) 
0.30 0.25 537 25% 0.0500 (0.0486-0.0514) 0.8439 (0.8414-0.8464) 
50% 0.0487 (0.0473-0.0501) 0.8354 (0.8329-0.8379) 
75% 0.0490 (0.0476-0.0504) 0.8336 (0.8311-0.8361) 
100% 0.0510 (0.0496-0.0524) 0.7971 (0.7946-0.7996) 
0.40 0.50 79 25% 0.0469 (0.0455-0.0483) 0.8744 (0.8719-0.8769) 
50% 0.0467 (0.0453-0.0481) 0.8721 (0.8696-0.8746) 
75% 0.0470 (0.0456-0.0484) 0.8692 (0.8667-0.8717) 
100% 0.0492 (0.0478-0.0506) 0.7939 (0.7914-0.7964) 
0.40 0.25 354 25% 0.0494 (0.0480-0.0508) 0.8459 (0.8434-0.8484) 
50% 0.0496 (0.0482-0.0510) 0.8403 (0.8378-0.8428) 
75% 0.0492 (0.0478-0.0506) 0.8341 (0.8316-0.8366) 
100% 0.0503 (0.0489-0.0517) 0.8002 (0.7977-0.8027) 
Note:  
1. SS = sample size, IAL = interim analysis location. 
2. Interim analysis location refers to the percent of subjects out of the original protocol-
specified sample size who have been assessed for the outcome at the interim analysis. 




Table A.14: Results from Simulations where the Minimum Allowable Sample Size is the Original 
Protocol-Specified Sample Size and the Maximum Allowable Sample Size is Twice the Original 
Protocol-Specified Sample Size for the HW-SSR Method for the Alternative Hypothesis Ha: pe = (1 
- γ)pc when the Outcome is Negative (Part 2). 
Control 
Group 
Rate (  ) 
Relative 
Treatment 
Effect ( ) IAL 
Simulated Lower Type I 
Error (95% CI) 
Simulated Upper Type I 






0.10 0.50 25% 0.0253 (0.0243-0.0263) 0.0233 (0.0223-0.0243) 511 3 
50% 0.0255 (0.0245-0.0265) 0.0223 (0.0213-0.0233) 484 0 
75% 0.0264 (0.0254-0.0274) 0.0213 (0.0203-0.0223) 472 0 
100% 0.0259 (0.0249-0.0269) 0.0262 (0.0252-0.0272) 432 0 
0.20 0.50 25% 0.0265 (0.0255-0.0275) 0.0232 (0.0222-0.0242) 235 3 
50% 0.0258 (0.0248-0.0268) 0.0216 (0.0206-0.0226) 222 0 
75% 0.0251 (0.0241-0.0261) 0.0221 (0.0211-0.0231) 216 0 
100% 0.0255 (0.0245-0.0265) 0.0249 (0.0239-0.0259) 197 0 
0.20 0.25 25% 0.0251 (0.0241-0.0261) 0.0237 (0.0227-0.0247) 974 0 
50% 0.0253 (0.0243-0.0263) 0.0235 (0.0225-0.0245) 951 0 
75% 0.0253 (0.0243-0.0263) 0.0219 (0.0209-0.0229) 940 0 
100% 0.0250 (0.0240-0.0260) 0.0260 (0.0250-0.0270) 903 0 
0.30 0.50 25% 0.0269 (0.0259-0.0279) 0.0214 (0.0204-0.0224) 142 0 
50% 0.0264 (0.0254-0.0274) 0.0226 (0.0216-0.0236) 135 0 
75% 0.0247 (0.0237-0.0257) 0.0225 (0.0215-0.0235) 131 0 
100% 0.0257 (0.0247-0.0267) 0.0255 (0.0245-0.0265) 118 0 
0.30 0.25 25% 0.0256 (0.0246-0.0266) 0.0245 (0.0235-0.0255) 584 0 
50% 0.0256 (0.0246-0.0266) 0.0231 (0.0221-0.0241) 568 0 
75% 0.0251 (0.0241-0.0261) 0.0239 (0.0229-0.0249) 562 0 
100% 0.0256 (0.0246-0.0266) 0.0254 (0.0244-0.0264) 537 0 
0.40 0.50 25% 0.0253 (0.0243-0.0263) 0.0216 (0.0206-0.0226) 96 3 
50% 0.0249 (0.0239-0.0259) 0.0218 (0.0208-0.0228) 91 0 
75% 0.0251 (0.0241-0.0261) 0.0219 (0.0209-0.0229) 88 0 
100% 0.0247 (0.0237-0.0257) 0.0246 (0.0236-0.0256) 79 0 
0.40 0.25 25% 0.0258 (0.0248-0.0268) 0.0236 (0.0226-0.0246) 388 0 
50% 0.0260 (0.0250-0.0270) 0.0235 (0.0225-0.0245) 377 0 
75% 0.0262 (0.0252-0.0272) 0.0231 (0.0221-0.0241) 372 0 
100% 0.0249 (0.0239-0.0259) 0.0254 (0.0244-0.0264) 354 0 
Note:  
1. IAL = interim analysis location. 
2. Interim analysis location refers to the percent of subjects out of the original protocol-
specified sample size who have been assessed for the outcome at the interim analysis. 
100% refers to the situation where no sample size re-estimation is planned. 





Table A.15: Results from Simulations where the Minimum Allowable Sample Size is the Original 
Protocol-Specified Sample Size and where there is No Maximum Allowable Sample Size for the 




Rate (  ) 
Relative 
Treatment 






Type I Error (95% CI) 
Simulated Power 
(95% CI) 
0.10 0.50 432 25% 0.0497 (0.0483-0.0511) 0.8779 (0.8754-0.8804) 
50% 0.0481 (0.0467-0.0495) 0.8705 (0.8680-0.8730) 
75% 0.0482 (0.0468-0.0496) 0.8698 (0.8673-0.8723) 
100% 0.0529 (0.0515-0.0543) 0.8078 (0.8053-0.8103) 
0.20 0.50 197 25% 0.0477 (0.0463-0.0491) 0.8796 (0.8771-0.8821) 
50% 0.0474 (0.0460-0.0488) 0.8722 (0.8697-0.8747) 
75% 0.0478 (0.0464-0.0492) 0.8668 (0.8643-0.8693) 
100% 0.0505 (0.0491-0.0519) 0.8049 (0.8024-0.8074) 
0.20 0.25 903 25% 0.0494 (0.0480-0.0508) 0.8401 (0.8376-0.8426) 
50% 0.0486 (0.0472-0.0500) 0.8336 (0.8311-0.8361) 
75% 0.0496 (0.0482-0.0510) 0.8291 (0.8266-0.8316) 
100% 0.0507 (0.0493-0.0521) 0.8004 (0.7979-0.8029) 
0.30 0.50 118 25% 0.0497 (0.0483-0.0511) 0.8771 (0.8746-0.8796) 
50% 0.0478 (0.0464-0.0492) 0.8710 (0.8685-0.8735) 
75% 0.0477 (0.0463-0.0491) 0.8690 (0.8665-0.8715) 
100% 0.0509 (0.0495-0.0523) 0.7994 (0.7969-0.8019) 
0.30 0.25 537 25% 0.0500 (0.0486-0.0514) 0.8401 (0.8376-0.8426) 
50% 0.0484 (0.0470-0.0498) 0.8360 (0.8335-0.8385) 
75% 0.0488 (0.0474-0.0502) 0.8340 (0.8315-0.8365) 
100% 0.0492 (0.0478-0.0506) 0.7986 (0.7961-0.8011) 
0.40 0.50 79 25% 0.0469 (0.0455-0.0483) 0.8770 (0.8745-0.8795) 
50% 0.0462 (0.0448-0.0476) 0.8744 (0.8719-0.8769) 
75% 0.0480 (0.0466-0.0494) 0.8709 (0.8684-0.8734) 
100% 0.0485 (0.0471-0.0499) 0.7964 (0.7939-0.7989) 
0.40 0.25 354 25% 0.0501 (0.0487-0.0515) 0.8454 (0.8429-0.8479) 
50% 0.0492 (0.0478-0.0506) 0.8368 (0.8343-0.8393) 
75% 0.0491 (0.0477-0.0505) 0.8346 (0.8321-0.8371) 
100% 0.0511 (0.0497-0.0525) 0.8000 (0.7975-0.8025) 
Note:  
1. SS = sample size, IAL = interim analysis location. 
2. Interim analysis location refers to the percent of subjects out of the original protocol-
specified sample size who have been assessed for the outcome at the interim analysis. 




Table A.16: Results from Simulations where the Minimum Allowable Sample Size is the Original 
Protocol-Specified Sample Size and where there is No Maximum Allowable Sample Size for the 




Rate (  ) 
Relative 
Treatment 
Effect ( ) IAL 
Simulated Lower Type I 
Error (95% CI) 
Simulated Upper Type I 






0.10 0.50 25% 0.0268 (0.0258-0.0278) 0.0229 (0.0219-0.0239) 522 1 
50% 0.0259 (0.0249-0.0269) 0.0222 (0.0212-0.0232) 484 0 
75% 0.0260 (0.0250-0.0270) 0.0223 (0.0213-0.0233) 473 0 
100% 0.0258 (0.0248-0.0268) 0.0270 (0.0260-0.0280) 432 0 
0.20 0.50 25% 0.0259 (0.0249-0.0269) 0.0218 (0.0208-0.0228) 241 2 
50% 0.0262 (0.0252-0.0272) 0.0212 (0.0202-0.0222) 223 0 
75% 0.0262 (0.0252-0.0272) 0.0216 (0.0206-0.0226) 217 0 
100% 0.0253 (0.0243-0.0263) 0.0252 (0.0242-0.0262) 197 0 
0.20 0.25 25% 0.0251 (0.0241-0.0261) 0.0243 (0.0233-0.0253) 973 0 
50% 0.0250 (0.0240-0.0260) 0.0236 (0.0226-0.0246) 950 0 
75% 0.0259 (0.0249-0.0269) 0.0238 (0.0228-0.0248) 940 0 
100% 0.0247 (0.0237-0.0257) 0.0260 (0.0250-0.0270) 903 0 
0.30 0.50 25% 0.0268 (0.0258-0.0278) 0.0229 (0.0219-0.0239) 148 5 
50% 0.0258 (0.0248-0.0268) 0.0220 (0.0210-0.0230) 135 0 
75% 0.0260 (0.0250-0.0270) 0.0217 (0.0207-0.0227) 131 0 
100% 0.0256 (0.0246-0.0266) 0.0253 (0.0243-0.0263) 118 0 
0.30 0.25 25% 0.0258 (0.0248-0.0268) 0.0242 (0.0232-0.0252) 583 0 
50% 0.0252 (0.0242-0.0262) 0.0232 (0.0222-0.0242) 568 0 
75% 0.0255 (0.0245-0.0265) 0.0233 (0.0223-0.0243) 562 0 
100% 0.0248 (0.0238-0.0258) 0.0244 (0.0234-0.0254) 537 0 
0.40 0.50 25% 0.0250 (0.0240-0.0260) 0.0218 (0.0208-0.0228) 101 2 
50% 0.0249 (0.0239-0.0259) 0.0214 (0.0204-0.0224) 91 0 
75% 0.0261 (0.0251-0.0271) 0.0218 (0.0208-0.0228) 88 0 
100% 0.0246 (0.0236-0.0256) 0.0239 (0.0229-0.0249) 79 0 
0.40 0.25 25% 0.0262 (0.0252-0.0272) 0.0240 (0.0230-0.0250) 388 0 
50% 0.0249 (0.0239-0.0259) 0.0243 (0.0233-0.0253) 377 0 
75% 0.0252 (0.0242-0.0262) 0.0239 (0.0229-0.0249) 372 0 
100% 0.0256 (0.0246-0.0266) 0.0255 (0.0245-0.0265) 354 0 
Note:  
1. IAL = interim analysis location. 
2. Interim analysis location refers to the percent of subjects out of the original protocol-
specified sample size who have been assessed for the outcome at the interim analysis. 
100% refers to the situation where no sample size re-estimation is planned. 





Table A.17: Results from Simulations where the Minimum Allowable Sample Size is the Interim 
Analysis Sample Size and the Maximum Allowable Sample Size is Twice the Original Protocol-
Specified Sample Size for the HW-SSR Method for the Alternative Hypothesis Ha: pe = pc – Δ 
when the Outcome is Negative (Part 1). 
Control 
Group 










Type I Error (95% CI) 
Simulated Power 
(95% CI) 
0.10 0.05 432 25% 0.0554 (0.0540-0.0568) 0.7190 (0.7165-0.7215) 
50% 0.0537 (0.0523-0.0551) 0.7369 (0.7344-0.7394) 
75% 0.0514 (0.0500-0.0528) 0.7478 (0.7453-0.7503) 
100% 0.0520 (0.0506-0.0534) 0.8090 (0.8065-0.8115) 
0.20 0.10 197 25% 0.0542 (0.0528-0.0556) 0.7205 (0.7180-0.7230) 
50% 0.0545 (0.0531-0.0559) 0.7348 (0.7323-0.7373) 
75% 0.0500 (0.0486-0.0514) 0.7498 (0.7473-0.7523) 
100% 0.0516 (0.0502-0.0530) 0.8043 (0.8018-0.8068) 
0.20 0.05 903 25% 0.0500 (0.0486-0.0514) 0.7746 (0.7721-0.7771) 
50% 0.0492 (0.0478-0.0506) 0.7778 (0.7753-0.7803) 
75% 0.0511 (0.0497-0.0525) 0.7799 (0.7774-0.7824) 
100% 0.0498 (0.0484-0.0512) 0.8002 (0.7977-0.8027) 
0.30 0.15 118 25% 0.0550 (0.0536-0.0564) 0.7237 (0.7212-0.7262) 
50% 0.0538 (0.0524-0.0552) 0.7395 (0.7370-0.7420) 
75% 0.0508 (0.0494-0.0522) 0.7502 (0.7477-0.7527) 
100% 0.0502 (0.0488-0.0516) 0.7972 (0.7947-0.7997) 
0.30 0.075 537 25% 0.0512 (0.0498-0.0526) 0.7779 (0.7754-0.7804) 
50% 0.0509 (0.0495-0.0523) 0.7787 (0.7762-0.7812) 
75% 0.0512 (0.0498-0.0526) 0.7818 (0.7793-0.7843) 
100% 0.0503 (0.0489-0.0517) 0.7968 (0.7943-0.7993) 
0.40 0.20 79 25% 0.0543 (0.0529-0.0557) 0.7271 (0.7246-0.7296) 
50% 0.0556 (0.0542-0.0570) 0.7416 (0.7391-0.7441) 
75% 0.0519 (0.0505-0.0533) 0.7477 (0.7452-0.7502) 
100% 0.0486 (0.0472-0.0500) 0.7934 (0.7909-0.7959) 
0.40 0.10 354 25% 0.0502 (0.0488-0.0516) 0.7799 (0.7774-0.7824) 
50% 0.0507 (0.0493-0.0521) 0.7835 (0.7810-0.7860) 
75% 0.0503 (0.0489-0.0517) 0.7837 (0.7812-0.7862) 
100% 0.0500 (0.0486-0.0514) 0.8009 (0.7984-0.8034) 
Note:  
1. SS = sample size, IAL = interim analysis location. 
2. Interim analysis location refers to the percent of subjects out of the original protocol-
specified sample size who have been assessed for the outcome at the interim analysis. 




Table A.18: Results from Simulations where the Minimum Allowable Sample Size is the Interim 
Analysis Sample Size and the Maximum Allowable Sample Size is Twice the Original Protocol-
Specified Sample Size for the HW-SSR Method for the Alternative Hypothesis Ha: pe = pc – Δ 
when the Outcome is Negative (Part 2). 
Control 
Group 




Effect (Δ) IAL 
Simulated Lower Type I 
Error (95% CI) 
Simulated Upper Type I 






0.10 0.05 25% 0.0227 (0.0217-0.0237) 0.0327 (0.0317-0.0337) 429 3409 
50% 0.0230 (0.0220-0.0240) 0.0308 (0.0298-0.0318) 430 319 
75% 0.0230 (0.0220-0.0240) 0.0284 (0.0274-0.0294) 436 159 
100% 0.0260 (0.0250-0.0270) 0.0260 (0.0250-0.0270) 432 20 
0.20 0.10 25% 0.0230 (0.0220-0.0240) 0.0312 (0.0302-0.0322) 193 4796 
50% 0.0236 (0.0226-0.0246) 0.0309 (0.0299-0.0319) 194 274 
75% 0.0231 (0.0221-0.0241) 0.0269 (0.0259-0.0279) 197 35 
100% 0.0258 (0.0248-0.0268) 0.0258 (0.0248-0.0268) 197 7 
0.20 0.05 25% 0.0240 (0.0230-0.0250) 0.0260 (0.0250-0.0270) 899 0 
50% 0.0234 (0.0224-0.0244) 0.0258 (0.0248-0.0268) 901 0 
75% 0.0242 (0.0232-0.0252) 0.0269 (0.0259-0.0279) 902 0 
100% 0.0252 (0.0242-0.0262) 0.0246 (0.0236-0.0256) 903 0 
0.30 0.15 25% 0.0237 (0.0227-0.0247) 0.0314 (0.0304-0.0324) 114 3059 
50% 0.0229 (0.0219-0.0239) 0.0309 (0.0299-0.0319) 116 282 
75% 0.0232 (0.0222-0.0242) 0.0277 (0.0267-0.0287) 118 67 
100% 0.0251 (0.0241-0.0261) 0.0251 (0.0241-0.0261) 118 12 
0.30 0.075 25% 0.0241 (0.0231-0.0251) 0.0271 (0.0261-0.0281) 532 0 
50% 0.0242 (0.0232-0.0252) 0.0268 (0.0258-0.0278) 535 0 
75% 0.0246 (0.0236-0.0256) 0.0267 (0.0257-0.0277) 535 0 
100% 0.0247 (0.0237-0.0257) 0.0255 (0.0245-0.0265) 537 0 
0.40 0.20 25% 0.0239 (0.0229-0.0249) 0.0304 (0.0294-0.0314) 75 5125 
50% 0.0241 (0.0231-0.0251) 0.0315 (0.0305-0.0325) 77 627 
75% 0.0239 (0.0229-0.0249) 0.0280 (0.0270-0.0290) 78 75 
100% 0.0240 (0.0230-0.0250) 0.0246 (0.0236-0.0256) 79 9 
0.40 0.10 25% 0.0243 (0.0233-0.0253) 0.0260 (0.0250-0.0270) 349 0 
50% 0.0244 (0.0234-0.0254) 0.0263 (0.0253-0.0273) 352 0 
75% 0.0242 (0.0232-0.0252) 0.0261 (0.0251-0.0271) 352 0 
100% 0.0246 (0.0236-0.0256) 0.0254 (0.0244-0.0264) 354 0 
Note:  
1. IAL = interim analysis location. 
2. Interim analysis location refers to the percent of subjects out of the original protocol-
specified sample size who have been assessed for the outcome at the interim analysis. 
100% refers to the situation where no sample size re-estimation is planned. 





Table A.19: Results from Simulations where the Minimum Allowable Sample Size is the Interim 
Analysis Sample Size and where there is No Maximum Allowable Sample Size for the HW-SSR 
Method for the Alternative Hypothesis Ha: pe = pc – Δ when the Outcome is Negative (Part 1). 
Control 
Group 










Type I Error (95% CI) 
Simulated Power 
(95% CI) 
0.10 0.05 432 25% 0.0545 (0.0531-0.0559) 0.7195 (0.7170-0.7220) 
50% 0.0544 (0.0530-0.0558) 0.7357 (0.7332-0.7382) 
75% 0.0503 (0.0489-0.0517) 0.7469 (0.7444-0.7494) 
100% 0.0526 (0.0512-0.0540) 0.8062 (0.8037-0.8087) 
0.20 0.10 197 25% 0.0539 (0.0525-0.0553) 0.7223 (0.7198-0.7248) 
50% 0.0538 (0.0524-0.0552) 0.7352 (0.7327-0.7377) 
75% 0.0485 (0.0471-0.0499) 0.7489 (0.7464-0.7514) 
100% 0.0506 (0.0492-0.0520) 0.8051 (0.8026-0.8076) 
0.20 0.05 903 25% 0.0519 (0.0505-0.0533) 0.7765 (0.7740-0.7790) 
50% 0.0509 (0.0495-0.0523) 0.7775 (0.7750-0.7800) 
75% 0.0507 (0.0493-0.0521) 0.7785 (0.7760-0.7810) 
100% 0.0498 (0.0484-0.0512) 0.8019 (0.7994-0.8044) 
0.30 0.15 118 25% 0.0533 (0.0519-0.0547) 0.7221 (0.7196-0.7246) 
50% 0.0525 (0.0511-0.0539) 0.7398 (0.7373-0.7423) 
75% 0.0517 (0.0503-0.0531) 0.7488 (0.7463-0.7513) 
100% 0.0503 (0.0489-0.0517) 0.7972 (0.7947-0.7997) 
0.30 0.075 537 25% 0.0523 (0.0509-0.0537) 0.7754 (0.7729-0.7779) 
50% 0.0508 (0.0494-0.0522) 0.7817 (0.7792-0.7842) 
75% 0.0495 (0.0481-0.0509) 0.7807 (0.7782-0.7832) 
100% 0.0498 (0.0484-0.0512) 0.7998 (0.7973-0.8023) 
0.40 0.20 79 25% 0.0528 (0.0514-0.0542) 0.7261 (0.7236-0.7286) 
50% 0.0526 (0.0512-0.0540) 0.7435 (0.7410-0.7460) 
75% 0.0515 (0.0501-0.0529) 0.7489 (0.7464-0.7514) 
100% 0.0489 (0.0475-0.0503) 0.7959 (0.7934-0.7984) 
0.40 0.10 354 25% 0.0502 (0.0488-0.0516) 0.7814 (0.7789-0.7839) 
50% 0.0498 (0.0484-0.0512) 0.7839 (0.7814-0.7864) 
75% 0.0507 (0.0493-0.0521) 0.7830 (0.7805-0.7855) 
100% 0.0507 (0.0493-0.0521) 0.7997 (0.7972-0.8022) 
Note:  
1. SS = sample size, IAL = interim analysis location. 
2. Interim analysis location refers to the percent of subjects out of the original protocol-
specified sample size who have been assessed for the outcome at the interim analysis. 




Table A.20: Results from Simulations where the Minimum Allowable Sample Size is the Interim 
Analysis Sample Size and where there is No Maximum Allowable Sample Size for the HW-SSR 
Method for the Alternative Hypothesis Ha: pe = pc – Δ when the Outcome is Negative (Part 2). 
Control 
Group 




Effect (Δ) IAL 
Simulated Lower Type I 
Error (95% CI) 
Simulated Upper Type I 






0.10 0.05 25% 0.0222 (0.0212-0.0232) 0.0324 (0.0314-0.0334) 429 3466 
50% 0.0226 (0.0216-0.0236) 0.0317 (0.0307-0.0327) 430 288 
75% 0.0226 (0.0216-0.0236) 0.0277 (0.0267-0.0287) 436 176 
100% 0.0260 (0.0250-0.0270) 0.0266 (0.0256-0.0276) 432 24 
0.20 0.10 25% 0.0227 (0.0217-0.0237) 0.0313 (0.0303-0.0323) 193 4765 
50% 0.0227 (0.0217-0.0237) 0.0311 (0.0301-0.0321) 195 257 
75% 0.0223 (0.0213-0.0233) 0.0262 (0.0252-0.0272) 197 46 
100% 0.0253 (0.0243-0.0263) 0.0253 (0.0243-0.0263) 197 9 
0.20 0.05 25% 0.0250 (0.0240-0.0260) 0.0269 (0.0259-0.0279) 900 0 
50% 0.0242 (0.0232-0.0252) 0.0267 (0.0257-0.0277) 901 0 
75% 0.0246 (0.0236-0.0256) 0.0261 (0.0251-0.0271) 902 0 
100% 0.0249 (0.0239-0.0259) 0.0250 (0.0240-0.0260) 903 0 
0.30 0.15 25% 0.0234 (0.0224-0.0244) 0.0299 (0.0289-0.0309) 114 3008 
50% 0.0229 (0.0219-0.0239) 0.0296 (0.0286-0.0306) 116 266 
75% 0.0235 (0.0225-0.0245) 0.0282 (0.0272-0.0292) 117 55 
100% 0.0254 (0.0244-0.0264) 0.0249 (0.0239-0.0259) 118 5 
0.30 0.075 25% 0.0249 (0.0239-0.0259) 0.0275 (0.0265-0.0285) 532 0 
50% 0.0244 (0.0234-0.0254) 0.0264 (0.0254-0.0274) 535 0 
75% 0.0238 (0.0228-0.0248) 0.0257 (0.0247-0.0267) 535 0 
100% 0.0247 (0.0237-0.0257) 0.0251 (0.0241-0.0261) 537 0 
0.40 0.20 25% 0.0233 (0.0223-0.0243) 0.0295 (0.0285-0.0305) 75 5043 
50% 0.0233 (0.0223-0.0243) 0.0293 (0.0283-0.0303) 77 559 
75% 0.0233 (0.0223-0.0243) 0.0282 (0.0272-0.0292) 78 92 
100% 0.0250 (0.0240-0.0260) 0.0240 (0.0230-0.0250) 79 6 
0.40 0.10 25% 0.0238 (0.0228-0.0248) 0.0264 (0.0254-0.0274) 349 0 
50% 0.0238 (0.0228-0.0248) 0.0260 (0.0250-0.0270) 352 0 
75% 0.0248 (0.0238-0.0258) 0.0260 (0.0250-0.0270) 352 0 
100% 0.0254 (0.0244-0.0264) 0.0253 (0.0243-0.0263) 354 0 
Note:  
1. IAL = interim analysis location. 
2. Interim analysis location refers to the percent of subjects out of the original protocol-
specified sample size who have been assessed for the outcome at the interim analysis. 
100% refers to the situation where no sample size re-estimation is planned. 





Table A.21: Results from Simulations where the Minimum Allowable Sample Size is 10% more 
than the Interim Analysis Sample Size and the Maximum Allowable Sample Size is Twice the 
Original Protocol-Specified Sample Size for the HW-SSR Method for the Alternative Hypothesis 
Ha: pe = pc – Δ when the Outcome is Negative (Part 1). 
Control 
Group 










Type I Error (95% CI) 
Simulated Power 
(95% CI) 
0.10 0.05 432 25% 0.0549 (0.0535-0.0563) 0.7181 (0.7156-0.7206) 
50% 0.0536 (0.0522-0.0550) 0.7374 (0.7349-0.7399) 
75% 0.0496 (0.0482-0.0510) 0.7593 (0.7568-0.7618) 
100% 0.0518 (0.0504-0.0532) 0.8080 (0.8055-0.8105) 
0.20 0.10 197 25% 0.0544 (0.0530-0.0558) 0.7204 (0.7179-0.7229) 
50% 0.0527 (0.0513-0.0541) 0.7373 (0.7348-0.7398) 
75% 0.0487 (0.0473-0.0501) 0.7612 (0.7587-0.7637) 
100% 0.0508 (0.0494-0.0522) 0.8045 (0.8020-0.8070) 
0.20 0.05 903 25% 0.0511 (0.0497-0.0525) 0.7744 (0.7719-0.7769) 
50% 0.0520 (0.0506-0.0534) 0.7760 (0.7735-0.7785) 
75% 0.0516 (0.0502-0.0530) 0.7779 (0.7754-0.7804) 
100% 0.0494 (0.0480-0.0508) 0.7978 (0.7953-0.8003) 
0.30 0.15 118 25% 0.0544 (0.0530-0.0558) 0.7206 (0.7181-0.7231) 
50% 0.0537 (0.0523-0.0551) 0.7411 (0.7386-0.7436) 
75% 0.0508 (0.0494-0.0522) 0.7585 (0.7560-0.7610) 
100% 0.0521 (0.0507-0.0535) 0.7981 (0.7956-0.8006) 
0.30 0.075 537 25% 0.0519 (0.0505-0.0533) 0.7750 (0.7725-0.7775) 
50% 0.0509 (0.0495-0.0523) 0.7795 (0.7770-0.7820) 
75% 0.0512 (0.0498-0.0526) 0.7819 (0.7794-0.7844) 
100% 0.0505 (0.0491-0.0519) 0.7983 (0.7958-0.8008) 
0.40 0.20 79 25% 0.0529 (0.0515-0.0543) 0.7257 (0.7232-0.7282) 
50% 0.0543 (0.0529-0.0557) 0.7425 (0.7400-0.7450) 
75% 0.0502 (0.0488-0.0516) 0.7553 (0.7528-0.7578) 
100% 0.0486 (0.0472-0.0500) 0.7952 (0.7927-0.7977) 
0.40 0.10 354 25% 0.0511 (0.0497-0.0525) 0.7794 (0.7769-0.7819) 
50% 0.0509 (0.0495-0.0523) 0.7837 (0.7812-0.7862) 
75% 0.0518 (0.0504-0.0532) 0.7836 (0.7811-0.7861) 
100% 0.0510 (0.0496-0.0524) 0.7986 (0.7961-0.8011) 
Note:  
1. SS = sample size, IAL = interim analysis location. 
2. Interim analysis location refers to the percent of subjects out of the original protocol-
specified sample size who have been assessed for the outcome at the interim analysis. 




Table A.22: Results from Simulations where the Minimum Allowable Sample Size is 10% more 
than the Interim Analysis Sample Size and the Maximum Allowable Sample Size is Twice the 
Original Protocol-Specified Sample Size for the HW-SSR Method for the Alternative Hypothesis 
Ha: pe = pc – Δ when the Outcome is Negative (Part 2). 
Control 
Group 




Effect (Δ) IAL 
Simulated Lower Type I 
Error (95% CI) 
Simulated Upper Type I 






0.10 0.05 25% 0.0231 (0.0221-0.0241) 0.0318 (0.0308-0.0328) 429 3501 
50% 0.0232 (0.0222-0.0242) 0.0303 (0.0293-0.0313) 431 309 
75% 0.0233 (0.0223-0.0243) 0.0264 (0.0254-0.0274) 441 173 
100% 0.0254 (0.0244-0.0264) 0.0263 (0.0253-0.0273) 432 19 
0.20 0.10 25% 0.0229 (0.0219-0.0239) 0.0315 (0.0305-0.0325) 193 4705 
50% 0.0224 (0.0214-0.0234) 0.0302 (0.0292-0.0312) 195 245 
75% 0.0226 (0.0216-0.0236) 0.0261 (0.0251-0.0271) 199 39 
100% 0.0256 (0.0246-0.0266) 0.0252 (0.0242-0.0262) 197 8 
0.20 0.05 25% 0.0245 (0.0235-0.0255) 0.0266 (0.0256-0.0276) 899 0 
50% 0.0250 (0.0240-0.0260) 0.0270 (0.0260-0.0280) 901 0 
75% 0.0247 (0.0237-0.0257) 0.0269 (0.0259-0.0279) 902 0 
100% 0.0247 (0.0237-0.0257) 0.0247 (0.0237-0.0257) 903 0 
0.30 0.15 25% 0.0228 (0.0218-0.0238) 0.0316 (0.0306-0.0326) 114 3065 
50% 0.0236 (0.0226-0.0246) 0.0301 (0.0291-0.0311) 116 268 
75% 0.0240 (0.0230-0.0250) 0.0268 (0.0258-0.0278) 119 69 
100% 0.0262 (0.0252-0.0272) 0.0259 (0.0249-0.0269) 118 8 
0.30 0.075 25% 0.0244 (0.0234-0.0254) 0.0275 (0.0265-0.0285) 532 0 
50% 0.0249 (0.0239-0.0259) 0.0260 (0.0250-0.0270) 535 0 
75% 0.0243 (0.0233-0.0253) 0.0269 (0.0259-0.0279) 535 0 
100% 0.0252 (0.0242-0.0262) 0.0252 (0.0242-0.0262) 537 0 
0.40 0.20 25% 0.0228 (0.0218-0.0238) 0.0302 (0.0292-0.0312) 75 5049 
50% 0.0235 (0.0225-0.0245) 0.0308 (0.0298-0.0318) 77 605 
75% 0.0235 (0.0225-0.0245) 0.0267 (0.0257-0.0277) 78 68 
100% 0.0243 (0.0233-0.0253) 0.0244 (0.0234-0.0254) 79 5 
0.40 0.10 25% 0.0242 (0.0232-0.0252) 0.0270 (0.0260-0.0280) 349 0 
50% 0.0250 (0.0240-0.0260) 0.0259 (0.0249-0.0269) 352 0 
75% 0.0246 (0.0236-0.0256) 0.0271 (0.0261-0.0281) 352 0 
100% 0.0259 (0.0249-0.0269) 0.0251 (0.0241-0.0261) 354 0 
Note:  
1. IAL = interim analysis location. 
2. Interim analysis location refers to the percent of subjects out of the original protocol-
specified sample size who have been assessed for the outcome at the interim analysis. 
100% refers to the situation where no sample size re-estimation is planned. 





Table A.23: Results from Simulations where the Minimum Allowable Sample Size is 10% more 
than the Interim Analysis Sample Size and where there is No Maximum Allowable Sample Size 
for the HW-SSR Method for the Alternative Hypothesis Ha: pe = pc – Δ when the Outcome is 
Negative (Part 1). 
Control 
Group 










Type I Error (95% CI) 
Simulated Power 
(95% CI) 
0.10 0.05 432 25% 0.0536 (0.0522-0.0550) 0.7168 (0.7143-0.7193) 
50% 0.0532 (0.0518-0.0546) 0.7359 (0.7334-0.7384) 
75% 0.0504 (0.0490-0.0518) 0.7601 (0.7576-0.7626) 
100% 0.0500 (0.0486-0.0514) 0.8084 (0.8059-0.8109) 
0.20 0.10 197 25% 0.0548 (0.0534-0.0562) 0.7211 (0.7186-0.7236) 
50% 0.0531 (0.0517-0.0545) 0.7364 (0.7339-0.7389) 
75% 0.0497 (0.0483-0.0511) 0.7625 (0.7600-0.7650) 
100% 0.0502 (0.0488-0.0516) 0.8049 (0.8024-0.8074) 
0.20 0.05 903 25% 0.0511 (0.0497-0.0525) 0.7736 (0.7711-0.7761) 
50% 0.0500 (0.0486-0.0514) 0.7781 (0.7756-0.7806) 
75% 0.0509 (0.0495-0.0523) 0.7785 (0.7760-0.7810) 
100% 0.0497 (0.0483-0.0511) 0.8014 (0.7989-0.8039) 
0.30 0.15 118 25% 0.0551 (0.0537-0.0565) 0.7221 (0.7196-0.7246) 
50% 0.0532 (0.0518-0.0546) 0.7399 (0.7374-0.7424) 
75% 0.0501 (0.0487-0.0515) 0.7587 (0.7562-0.7612) 
100% 0.0504 (0.0490-0.0518) 0.7982 (0.7957-0.8007) 
0.30 0.075 537 25% 0.0521 (0.0507-0.0535) 0.7769 (0.7744-0.7794) 
50% 0.0517 (0.0503-0.0531) 0.7801 (0.7776-0.7826) 
75% 0.0504 (0.0490-0.0518) 0.7834 (0.7809-0.7859) 
100% 0.0502 (0.0488-0.0516) 0.7985 (0.7960-0.8010) 
0.40 0.20 79 25% 0.0529 (0.0515-0.0543) 0.7244 (0.7219-0.7269) 
50% 0.0534 (0.0520-0.0548) 0.7425 (0.7400-0.7450) 
75% 0.0513 (0.0499-0.0527) 0.7580 (0.7555-0.7605) 
100% 0.0470 (0.0456-0.0484) 0.7962 (0.7937-0.7987) 
0.40 0.10 354 25% 0.0500 (0.0486-0.0514) 0.7815 (0.7790-0.7840) 
50% 0.0508 (0.0494-0.0522) 0.7828 (0.7803-0.7853) 
75% 0.0516 (0.0502-0.0530) 0.7837 (0.7812-0.7862) 
100% 0.0511 (0.0497-0.0525) 0.8028 (0.8003-0.8053) 
Note:  
1. SS = sample size, IAL = interim analysis location. 
2. Interim analysis location refers to the percent of subjects out of the original protocol-
specified sample size who have been assessed for the outcome at the interim analysis. 




Table A.24: Results from Simulations where the Minimum Allowable Sample Size is 10% more 
than the Interim Analysis Sample Size and where there is No Maximum Allowable Sample Size 
for the HW-SSR Method for the Alternative Hypothesis Ha: pe = pc – Δ when the Outcome is 
Negative (Part 2). 
Control 
Group 




Effect (Δ) IAL 
Simulated Lower Type I 
Error (95% CI) 
Simulated Upper Type I 






0.10 0.05 25% 0.0217 (0.0207-0.0227) 0.0319 (0.0309-0.0329) 428 3530 
50% 0.0230 (0.0220-0.0240) 0.0302 (0.0292-0.0312) 431 296 
75% 0.0226 (0.0216-0.0236) 0.0278 (0.0268-0.0288) 441 166 
100% 0.0254 (0.0244-0.0264) 0.0245 (0.0235-0.0255) 432 25 
0.20 0.10 25% 0.0232 (0.0222-0.0242) 0.0316 (0.0306-0.0326) 192 4870 
50% 0.0228 (0.0218-0.0238) 0.0303 (0.0293-0.0313) 195 261 
75% 0.0232 (0.0222-0.0242) 0.0265 (0.0255-0.0275) 199 45 
100% 0.0250 (0.0240-0.0260) 0.0252 (0.0242-0.0262) 197 6 
0.20 0.05 25% 0.0242 (0.0232-0.0252) 0.0269 (0.0259-0.0279) 899 0 
50% 0.0237 (0.0227-0.0247) 0.0263 (0.0253-0.0273) 901 0 
75% 0.0246 (0.0236-0.0256) 0.0263 (0.0253-0.0273) 902 0 
100% 0.0249 (0.0239-0.0259) 0.0248 (0.0238-0.0258) 903 0 
0.30 0.15 25% 0.0239 (0.0229-0.0249) 0.0312 (0.0302-0.0322) 114 3021 
50% 0.0231 (0.0221-0.0241) 0.0301 (0.0291-0.0311) 116 281 
75% 0.0232 (0.0222-0.0242) 0.0269 (0.0259-0.0279) 119 63 
100% 0.0255 (0.0245-0.0265) 0.0249 (0.0239-0.0259) 118 6 
0.30 0.075 25% 0.0242 (0.0232-0.0252) 0.0279 (0.0269-0.0289) 532 0 
50% 0.0254 (0.0244-0.0264) 0.0264 (0.0254-0.0274) 535 0 
75% 0.0244 (0.0234-0.0254) 0.0260 (0.0250-0.0270) 535 0 
100% 0.0255 (0.0245-0.0265) 0.0248 (0.0238-0.0258) 537 0 
0.40 0.20 25% 0.0228 (0.0218-0.0238) 0.0301 (0.0291-0.0311) 75 5047 
50% 0.0235 (0.0225-0.0245) 0.0300 (0.0290-0.0310) 77 628 
75% 0.0246 (0.0236-0.0256) 0.0266 (0.0256-0.0276) 78 109 
100% 0.0230 (0.0220-0.0240) 0.0241 (0.0231-0.0251) 79 5 
0.40 0.10 25% 0.0239 (0.0229-0.0249) 0.0261 (0.0251-0.0271) 350 0 
50% 0.0247 (0.0237-0.0257) 0.0261 (0.0251-0.0271) 352 0 
75% 0.0249 (0.0239-0.0259) 0.0268 (0.0258-0.0278) 352 0 
100% 0.0260 (0.0250-0.0270) 0.0252 (0.0242-0.0262) 354 0 
Note:  
1. IAL = interim analysis location. 
2. Interim analysis location refers to the percent of subjects out of the original protocol-
specified sample size who have been assessed for the outcome at the interim analysis. 
100% refers to the situation where no sample size re-estimation is planned. 





Table A.25: Results from Simulations where the Minimum Allowable Sample Size is the Original 
Protocol-Specified Sample Size and the Maximum Allowable Sample Size is Twice the Original 
Protocol-Specified Sample Size for the HW-SSR Method for the Alternative Hypothesis Ha: pe = pc 
– Δ when the Outcome is Negative (Part 1). 
Control 
Group 










Type I Error (95% CI) 
Simulated Power 
(95% CI) 
0.10 0.05 432 25% 0.0504 (0.0490-0.0518) 0.8283 (0.8258-0.8308) 
50% 0.0488 (0.0474-0.0502) 0.8148 (0.8123-0.8173) 
75% 0.0492 (0.0478-0.0506) 0.8127 (0.8102-0.8152) 
100% 0.0516 (0.0502-0.0530) 0.8092 (0.8067-0.8117) 
0.20 0.10 197 25% 0.0502 (0.0488-0.0516) 0.8178 (0.8153-0.8203) 
50% 0.0493 (0.0479-0.0507) 0.8100 (0.8075-0.8125) 
75% 0.0489 (0.0475-0.0503) 0.8075 (0.8050-0.8100) 
100% 0.0494 (0.0480-0.0508) 0.8057 (0.8032-0.8082) 
0.20 0.05 903 25% 0.0497 (0.0483-0.0511) 0.8083 (0.8058-0.8108) 
50% 0.0501 (0.0487-0.0515) 0.8038 (0.8013-0.8063) 
75% 0.0503 (0.0489-0.0517) 0.8030 (0.8005-0.8055) 
100% 0.0490 (0.0476-0.0504) 0.8014 (0.7989-0.8039) 
0.30 0.15 118 25% 0.0508 (0.0494-0.0522) 0.8085 (0.8060-0.8110) 
50% 0.0486 (0.0472-0.0500) 0.8041 (0.8016-0.8066) 
75% 0.0494 (0.0480-0.0508) 0.8028 (0.8003-0.8053) 
100% 0.0514 (0.0500-0.0528) 0.7968 (0.7943-0.7993) 
0.30 0.075 537 25% 0.0493 (0.0479-0.0507) 0.8055 (0.8030-0.8080) 
50% 0.0495 (0.0481-0.0509) 0.8001 (0.7976-0.8026) 
75% 0.0498 (0.0484-0.0512) 0.8010 (0.7985-0.8035) 
100% 0.0495 (0.0481-0.0509) 0.7996 (0.7971-0.8021) 
0.40 0.20 79 25% 0.0495 (0.0481-0.0509) 0.8070 (0.8045-0.8095) 
50% 0.0485 (0.0471-0.0499) 0.7978 (0.7953-0.8003) 
75% 0.0495 (0.0481-0.0509) 0.7988 (0.7963-0.8013) 
100% 0.0499 (0.0485-0.0513) 0.7952 (0.7927-0.7977) 
0.40 0.10 354 25% 0.0492 (0.0478-0.0506) 0.8034 (0.8009-0.8059) 
50% 0.0503 (0.0489-0.0517) 0.8011 (0.7986-0.8036) 
75% 0.0500 (0.0486-0.0514) 0.8006 (0.7981-0.8031) 
100% 0.0504 (0.0490-0.0518) 0.7989 (0.7964-0.8014) 
Note:  
1. SS = sample size, IAL = interim analysis location. 
2. Interim analysis location refers to the percent of subjects out of the original protocol-
specified sample size who have been assessed for the outcome at the interim analysis. 




Table A.26: Results from Simulations where the Minimum Allowable Sample Size is the Original 
Protocol-Specified Sample Size and the Maximum Allowable Sample Size is Twice the Original 
Protocol-Specified Sample Size for the HW-SSR Method for the Alternative Hypothesis Ha: pe = pc 
– Δ when the Outcome is Negative (Part 2). 
Control 
Group 




Effect (Δ) IAL 
Simulated Lower Type I 
Error (95% CI) 
Simulated Upper Type I 






0.10 0.05 25% 0.0239 (0.0229-0.0249) 0.0265 (0.0255-0.0275) 491 3533 
50% 0.0229 (0.0219-0.0239) 0.0259 (0.0249-0.0269) 475 285 
75% 0.0238 (0.0228-0.0248) 0.0254 (0.0244-0.0264) 467 148 
100% 0.0258 (0.0248-0.0268) 0.0258 (0.0248-0.0268) 432 25 
0.20 0.10 25% 0.0239 (0.0229-0.0249) 0.0264 (0.0254-0.0274) 219 4817 
50% 0.0238 (0.0228-0.0248) 0.0255 (0.0245-0.0265) 213 269 
75% 0.0239 (0.0229-0.0249) 0.0250 (0.0240-0.0260) 210 37 
100% 0.0248 (0.0238-0.0258) 0.0246 (0.0236-0.0256) 197 10 
0.20 0.05 25% 0.0242 (0.0232-0.0252) 0.0255 (0.0245-0.0265) 944 0 
50% 0.0249 (0.0239-0.0259) 0.0253 (0.0243-0.0263) 933 0 
75% 0.0253 (0.0243-0.0263) 0.0251 (0.0241-0.0261) 927 0 
100% 0.0244 (0.0234-0.0254) 0.0246 (0.0236-0.0256) 903 0 
0.30 0.15 25% 0.0242 (0.0232-0.0252) 0.0266 (0.0256-0.0276) 128 2998 
50% 0.0237 (0.0227-0.0247) 0.0249 (0.0239-0.0259) 126 286 
75% 0.0241 (0.0231-0.0251) 0.0253 (0.0243-0.0263) 125 64 
100% 0.0258 (0.0248-0.0268) 0.0256 (0.0246-0.0266) 118 8 
0.30 0.075 25% 0.0247 (0.0237-0.0257) 0.0247 (0.0237-0.0257) 556 0 
50% 0.0239 (0.0229-0.0249) 0.0255 (0.0245-0.0265) 551 0 
75% 0.0247 (0.0237-0.0257) 0.0251 (0.0241-0.0261) 548 0 
100% 0.0249 (0.0239-0.0259) 0.0247 (0.0237-0.0257) 537 0 
0.40 0.20 25% 0.0250 (0.0240-0.0260) 0.0246 (0.0236-0.0256) 83 5199 
50% 0.0237 (0.0227-0.0247) 0.0248 (0.0238-0.0258) 83 593 
75% 0.0246 (0.0236-0.0256) 0.0249 (0.0239-0.0259) 82 88 
100% 0.0248 (0.0238-0.0258) 0.0251 (0.0241-0.0261) 79 3 
0.40 0.10 25% 0.0243 (0.0233-0.0253) 0.0250 (0.0240-0.0260) 361 0 
50% 0.0245 (0.0235-0.0255) 0.0258 (0.0248-0.0268) 360 0 
75% 0.0242 (0.0232-0.0252) 0.0258 (0.0248-0.0268) 359 0 
100% 0.0255 (0.0245-0.0265) 0.0249 (0.0239-0.0259) 354 0 
Note:  
1. IAL = interim analysis location. 
2. Interim analysis location refers to the percent of subjects out of the original protocol-
specified sample size who have been assessed for the outcome at the interim analysis. 
100% refers to the situation where no sample size re-estimation is planned. 





Table A.27: Results from Simulations where the Minimum Allowable Sample Size is the Original 
Protocol-Specified Sample Size and where there is No Maximum Allowable Sample Size for the 














Type I Error (95% CI) 
Simulated Power 
(95% CI) 
0.10 0.05 432 25% 0.0507 (0.0493-0.0521) 0.8234 (0.8209-0.8259) 
50% 0.0483 (0.0469-0.0497) 0.8176 (0.8151-0.8201) 
75% 0.0494 (0.0480-0.0508) 0.8122 (0.8097-0.8147) 
100% 0.0520 (0.0506-0.0534) 0.8071 (0.8046-0.8096) 
0.20 0.10 197 25% 0.0496 (0.0482-0.0510) 0.8206 (0.8181-0.8231) 
50% 0.0492 (0.0478-0.0506) 0.8113 (0.8088-0.8138) 
75% 0.0488 (0.0474-0.0502) 0.8080 (0.8055-0.8105) 
100% 0.0496 (0.0482-0.0510) 0.8019 (0.7994-0.8044) 
0.20 0.05 903 25% 0.0489 (0.0475-0.0503) 0.8091 (0.8066-0.8116) 
50% 0.0495 (0.0481-0.0509) 0.8038 (0.8013-0.8063) 
75% 0.0494 (0.0480-0.0508) 0.8009 (0.7984-0.8034) 
100% 0.0501 (0.0487-0.0515) 0.7995 (0.7970-0.8020) 
0.30 0.15 118 25% 0.0494 (0.0480-0.0508) 0.8106 (0.8081-0.8131) 
50% 0.0494 (0.0480-0.0508) 0.8050 (0.8025-0.8075) 
75% 0.0486 (0.0472-0.0500) 0.8037 (0.8012-0.8062) 
100% 0.0507 (0.0493-0.0521) 0.7975 (0.7950-0.8000) 
0.30 0.075 537 25% 0.0494 (0.0480-0.0508) 0.8051 (0.8026-0.8076) 
50% 0.0495 (0.0481-0.0509) 0.8020 (0.7995-0.8045) 
75% 0.0504 (0.0490-0.0518) 0.7997 (0.7972-0.8022) 
100% 0.0492 (0.0478-0.0506) 0.7999 (0.7974-0.8024) 
0.40 0.20 79 25% 0.0496 (0.0482-0.0510) 0.8066 (0.8041-0.8091) 
50% 0.0496 (0.0482-0.0510) 0.8025 (0.8000-0.8050) 
75% 0.0482 (0.0468-0.0496) 0.7955 (0.7930-0.7980) 
100% 0.0487 (0.0473-0.0501) 0.7958 (0.7933-0.7983) 
0.40 0.10 354 25% 0.0501 (0.0487-0.0515) 0.8057 (0.8032-0.8082) 
50% 0.0499 (0.0485-0.0513) 0.8014 (0.7989-0.8039) 
75% 0.0492 (0.0478-0.0506) 0.8009 (0.7984-0.8034) 
100% 0.0504 (0.0490-0.0518) 0.8020 (0.7995-0.8045) 
Note:  
1. SS = sample size, IAL = interim analysis location. 
2. Interim analysis location refers to the percent of subjects out of the original protocol-
specified sample size who have been assessed for the outcome at the interim analysis. 




Table A.28: Results from Simulations where the Minimum Allowable Sample Size is the Original 
Protocol-Specified Sample Size and where there is No Maximum Allowable Sample Size for the 








Effect (Δ) IAL 
Simulated Lower Type I 
Error (95% CI) 
Simulated Upper Type I 






0.10 0.05 25% 0.0240 (0.0230-0.0250) 0.0267 (0.0257-0.0277) 491 3511 
50% 0.0230 (0.0220-0.0240) 0.0253 (0.0243-0.0263) 474 311 
75% 0.0233 (0.0223-0.0243) 0.0262 (0.0252-0.0272) 467 144 
100% 0.0265 (0.0255-0.0275) 0.0256 (0.0246-0.0266) 432 27 
0.20 0.10 25% 0.0238 (0.0228-0.0248) 0.0259 (0.0249-0.0269) 219 4700 
50% 0.0237 (0.0227-0.0247) 0.0255 (0.0245-0.0265) 213 256 
75% 0.0227 (0.0217-0.0237) 0.0261 (0.0251-0.0271) 210 39 
100% 0.0252 (0.0242-0.0262) 0.0244 (0.0234-0.0254) 197 7 
0.20 0.05 25% 0.0238 (0.0228-0.0248) 0.0251 (0.0241-0.0261) 944 0 
50% 0.0249 (0.0239-0.0259) 0.0246 (0.0236-0.0256) 933 0 
75% 0.0244 (0.0234-0.0254) 0.0251 (0.0241-0.0261) 927 0 
100% 0.0250 (0.0240-0.0260) 0.0251 (0.0241-0.0261) 903 0 
0.30 0.15 25% 0.0244 (0.0234-0.0254) 0.0250 (0.0240-0.0260) 128 2988 
50% 0.0236 (0.0226-0.0246) 0.0258 (0.0248-0.0268) 126 273 
75% 0.0237 (0.0227-0.0247) 0.0250 (0.0240-0.0260) 125 58 
100% 0.0255 (0.0245-0.0265) 0.0252 (0.0242-0.0262) 118 8 
0.30 0.075 25% 0.0248 (0.0238-0.0258) 0.0246 (0.0236-0.0256) 556 0 
50% 0.0248 (0.0238-0.0258) 0.0247 (0.0237-0.0257) 551 0 
75% 0.0248 (0.0238-0.0258) 0.0256 (0.0246-0.0266) 548 0 
100% 0.0249 (0.0239-0.0259) 0.0243 (0.0233-0.0253) 537 0 
0.40 0.20 25% 0.0248 (0.0238-0.0258) 0.0248 (0.0238-0.0258) 84 5091 
50% 0.0249 (0.0239-0.0259) 0.0247 (0.0237-0.0257) 83 556 
75% 0.0239 (0.0229-0.0249) 0.0243 (0.0233-0.0253) 82 81 
100% 0.0243 (0.0233-0.0253) 0.0244 (0.0234-0.0254) 79 4 
0.40 0.10 25% 0.0246 (0.0236-0.0256) 0.0256 (0.0246-0.0266) 361 0 
50% 0.0248 (0.0238-0.0258) 0.0251 (0.0241-0.0261) 360 0 
75% 0.0238 (0.0228-0.0248) 0.0254 (0.0244-0.0264) 359 0 
100% 0.0251 (0.0241-0.0261) 0.0253 (0.0243-0.0263) 354 0 
Note:  
1. IAL = interim analysis location. 
2. Interim analysis location refers to the percent of subjects out of the original protocol-
specified sample size who have been assessed for the outcome at the interim analysis. 
100% refers to the situation where no sample size re-estimation is planned. 





Table A.29: Results from Simulations where the Minimum Allowable Sample Size is the Interim 
Analysis Sample Size and the Maximum Allowable Sample Size is Twice the Original Protocol-
Specified Sample Size for the HW-SSR Method for the Alternative Hypothesis Ha: pe = (1 + γ)pc 
when the Outcome is Positive (Part 1). 
Control 
Group 
Rate (  ) 
Relative 
Treatment 






Type I Error (95% CI) 
Simulated Power 
(95% CI) 
0.90 0.0556 432 25% 0.0543 (0.0529-0.0557) 0.7066 (0.7041-0.7091) 
50% 0.0554 (0.0540-0.0568) 0.7230 (0.7205-0.7255) 
75% 0.0503 (0.0489-0.0517) 0.7432 (0.7407-0.7457) 
100% 0.0510 (0.0496-0.0524) 0.8064 (0.8039-0.8089) 
0.80 0.125 197 25% 0.0544 (0.0530-0.0558) 0.7013 (0.6988-0.7038) 
50% 0.0537 (0.0523-0.0551) 0.7162 (0.7137-0.7187) 
75% 0.0473 (0.0459-0.0487) 0.7347 (0.7322-0.7372) 
100% 0.0506 (0.0492-0.0520) 0.8055 (0.8030-0.8080) 
0.80 0.0625 903 25% 0.0517 (0.0503-0.0531) 0.7666 (0.7641-0.7691) 
50% 0.0516 (0.0502-0.0530) 0.7677 (0.7652-0.7702) 
75% 0.0512 (0.0498-0.0526) 0.7683 (0.7658-0.7708) 
100% 0.0486 (0.0472-0.0500) 0.7989 (0.7964-0.8014) 
0.70 0.2143 118 25% 0.0551 (0.0537-0.0565) 0.6882 (0.6857-0.6907) 
50% 0.0534 (0.0520-0.0548) 0.7058 (0.7033-0.7083) 
75% 0.0500 (0.0486-0.0514) 0.7262 (0.7237-0.7287) 
100% 0.0502 (0.0488-0.0516) 0.7972 (0.7947-0.7997) 
0.70 0.1071 537 25% 0.0503 (0.0489-0.0517) 0.7574 (0.7549-0.7599) 
50% 0.0520 (0.0506-0.0534) 0.7614 (0.7589-0.7639) 
75% 0.0515 (0.0501-0.0529) 0.7633 (0.7608-0.7658) 
100% 0.0512 (0.0498-0.0526) 0.8014 (0.7989-0.8039) 
0.60 0.3333 79 25% 0.0567 (0.0553-0.0581) 0.6799 (0.6774-0.6824) 
50% 0.0530 (0.0516-0.0544) 0.6936 (0.6911-0.6961) 
75% 0.0479 (0.0465-0.0493) 0.7256 (0.7231-0.7281) 
100% 0.0476 (0.0462-0.0490) 0.7960 (0.7935-0.7985) 
0.60 0.1667 354 25% 0.0514 (0.0500-0.0528) 0.7513 (0.7488-0.7538) 
50% 0.0520 (0.0506-0.0534) 0.7569 (0.7544-0.7594) 
75% 0.0514 (0.0500-0.0528) 0.7557 (0.7532-0.7582) 
100% 0.0506 (0.0492-0.0520) 0.8009 (0.7984-0.8034) 
Note:  
1. SS = sample size, IAL = interim analysis location. 
2. Interim analysis location refers to the percent of subjects out of the original protocol-
specified sample size who have been assessed for the outcome at the interim analysis. 




Table A.30: Results from Simulations where the Minimum Allowable Sample Size is the Interim 
Analysis Sample Size and the Maximum Allowable Sample Size is Twice the Original Protocol-
Specified Sample Size for the HW-SSR Method for the Alternative Hypothesis Ha: pe = (1 + γ)pc 
when the Outcome is Positive (Part 2). 
Control 
Group 
Rate (  ) 
Relative 
Treatment 
Effect (γ) IAL 
Simulated Lower Type I 
Error (95% CI) 
Simulated Upper Type I 






0.90 0.0556 25% 0.0336 (0.0326-0.0346) 0.0207 (0.0197-0.0217) 438 3529 
50% 0.0328 (0.0318-0.0338) 0.0225 (0.0215-0.0235) 436 685 
75% 0.0278 (0.0268-0.0288) 0.0225 (0.0215-0.0235) 442 301 
100% 0.0252 (0.0242-0.0262) 0.0258 (0.0248-0.0268) 432 42 
0.80 0.125 25% 0.0333 (0.0323-0.0343) 0.0212 (0.0202-0.0222) 202 4786 
50% 0.0316 (0.0306-0.0326) 0.0221 (0.0211-0.0231) 201 1335 
75% 0.0266 (0.0256-0.0276) 0.0207 (0.0197-0.0217) 203 194 
100% 0.0247 (0.0237-0.0257) 0.0259 (0.0249-0.0269) 197 35 
0.80 0.0625 25% 0.0281 (0.0271-0.0291) 0.0236 (0.0226-0.0246) 910 0 
50% 0.0276 (0.0266-0.0286) 0.0240 (0.0230-0.0250) 906 0 
75% 0.0278 (0.0268-0.0288) 0.0235 (0.0225-0.0245) 905 0 
100% 0.0240 (0.0230-0.0250) 0.0247 (0.0237-0.0257) 903 0 
0.70 0.2143 25% 0.0337 (0.0327-0.0347) 0.0214 (0.0204-0.0224) 123 7753 
50% 0.0318 (0.0308-0.0328) 0.0216 (0.0206-0.0226) 123 1763 
75% 0.0272 (0.0262-0.0282) 0.0229 (0.0219-0.0239) 124 348 
100% 0.0246 (0.0236-0.0256) 0.0256 (0.0246-0.0266) 118 80 
0.70 0.1071 25% 0.0275 (0.0265-0.0285) 0.0228 (0.0218-0.0238) 544 0 
50% 0.0284 (0.0274-0.0294) 0.0237 (0.0227-0.0247) 540 0 
75% 0.0284 (0.0274-0.0294) 0.0231 (0.0221-0.0241) 539 0 
100% 0.0259 (0.0249-0.0269) 0.0254 (0.0244-0.0264) 537 0 
0.60 0.3333 25% 0.0353 (0.0343-0.0363) 0.0215 (0.0205-0.0225) 84 12542 
50% 0.0307 (0.0297-0.0317) 0.0224 (0.0214-0.0234) 84 3629 
75% 0.0266 (0.0256-0.0276) 0.0213 (0.0203-0.0223) 85 1101 
100% 0.0231 (0.0221-0.0241) 0.0245 (0.0235-0.0255) 79 196 
0.60 0.1667 25% 0.0284 (0.0274-0.0294) 0.0230 (0.0220-0.0240) 361 0 
50% 0.0290 (0.0280-0.0300) 0.0229 (0.0219-0.0239) 357 0 
75% 0.0286 (0.0276-0.0296) 0.0229 (0.0219-0.0239) 357 0 
100% 0.0248 (0.0238-0.0258) 0.0258 (0.0248-0.0268) 354 0 
Note:  
1. IAL = interim analysis location. 
2. Interim analysis location refers to the percent of subjects out of the original protocol-
specified sample size who have been assessed for the outcome at the interim analysis. 
100% refers to the situation where no sample size re-estimation is planned. 





Table A.31: Results from Simulations where the Minimum Allowable Sample Size is the Interim 
Analysis Sample Size and where there is No Maximum Allowable Sample Size for the HW-SSR 
Method for the Alternative Hypothesis Ha: pe = (1 + γ)pc when the Outcome is Positive (Part 1). 
Control 
Group 
Rate (  ) 
Relative 
Treatment 






Type I Error (95% CI) 
Simulated Power 
(95% CI) 
0.90 0.0556 432 25% 0.0554 (0.0540-0.0568) 0.7082 (0.7057-0.7107) 
50% 0.0531 (0.0517-0.0545) 0.7271 (0.7246-0.7296) 
75% 0.0513 (0.0499-0.0527) 0.7447 (0.7422-0.7472) 
100% 0.0530 (0.0516-0.0544) 0.8070 (0.8045-0.8095) 
0.80 0.125 197 25% 0.0554 (0.0540-0.0568) 0.6982 (0.6957-0.7007) 
50% 0.0530 (0.0516-0.0544) 0.7162 (0.7137-0.7187) 
75% 0.0489 (0.0475-0.0503) 0.7352 (0.7327-0.7377) 
100% 0.0498 (0.0484-0.0512) 0.8042 (0.8017-0.8067) 
0.80 0.0625 903 25% 0.0507 (0.0493-0.0521) 0.7632 (0.7607-0.7657) 
50% 0.0522 (0.0508-0.0536) 0.7660 (0.7635-0.7685) 
75% 0.0515 (0.0501-0.0529) 0.7649 (0.7624-0.7674) 
100% 0.0518 (0.0504-0.0532) 0.8007 (0.7982-0.8032) 
0.70 0.2143 118 25% 0.0560 (0.0546-0.0574) 0.6905 (0.6880-0.6930) 
50% 0.0533 (0.0519-0.0547) 0.7060 (0.7035-0.7085) 
75% 0.0478 (0.0464-0.0492) 0.7269 (0.7244-0.7294) 
100% 0.0516 (0.0502-0.0530) 0.7971 (0.7946-0.7996) 
0.70 0.1071 537 25% 0.0521 (0.0507-0.0535) 0.7596 (0.7571-0.7621) 
50% 0.0502 (0.0488-0.0516) 0.7621 (0.7596-0.7646) 
75% 0.0513 (0.0499-0.0527) 0.7612 (0.7587-0.7637) 
100% 0.0501 (0.0487-0.0515) 0.7985 (0.7960-0.8010) 
0.60 0.3333 79 25% 0.0576 (0.0562-0.0590) 0.6801 (0.6776-0.6826) 
50% 0.0512 (0.0498-0.0526) 0.6936 (0.6911-0.6961) 
75% 0.0482 (0.0468-0.0496) 0.7250 (0.7225-0.7275) 
100% 0.0487 (0.0473-0.0501) 0.7964 (0.7939-0.7989) 
0.60 0.1667 354 25% 0.0506 (0.0492-0.0520) 0.7539 (0.7514-0.7564) 
50% 0.0507 (0.0493-0.0521) 0.7564 (0.7539-0.7589) 
75% 0.0509 (0.0495-0.0523) 0.7581 (0.7556-0.7606) 
100% 0.0503 (0.0489-0.0517) 0.8010 (0.7985-0.8035) 
Note:  
1. SS = sample size, IAL = interim analysis location. 
2. Interim analysis location refers to the percent of subjects out of the original protocol-
specified sample size who have been assessed for the outcome at the interim analysis. 




Table A.32: Results from Simulations where the Minimum Allowable Sample Size is the Interim 
Analysis Sample Size and where there is No Maximum Allowable Sample Size for the HW-SSR 
Method for the Alternative Hypothesis Ha: pe = (1 + γ)pc when the Outcome is Positive (Part 2). 
Control 
Group 
Rate (  ) 
Relative 
Treatment 
Effect ( ) IAL 
Simulated Lower Type I 
Error (95% CI) 
Simulated Upper Type I 






0.90 0.0556 25% 0.0328 (0.0318-0.0338) 0.0226 (0.0216-0.0236) 442 3441 
50% 0.0309 (0.0299-0.0319) 0.0222 (0.0212-0.0232) 437 706 
75% 0.0279 (0.0269-0.0289) 0.0234 (0.0224-0.0244) 442 275 
100% 0.0272 (0.0262-0.0282) 0.0258 (0.0248-0.0268) 432 34 
0.80 0.125 25% 0.0336 (0.0326-0.0346) 0.0218 (0.0208-0.0228) 205 4860 
50% 0.0315 (0.0305-0.0325) 0.0216 (0.0206-0.0226) 201 1346 
75% 0.0274 (0.0264-0.0284) 0.0216 (0.0206-0.0226) 203 206 
100% 0.0251 (0.0241-0.0261) 0.0248 (0.0238-0.0258) 197 33 
0.80 0.0625 25% 0.0272 (0.0262-0.0282) 0.0236 (0.0226-0.0246) 909 0 
50% 0.0282 (0.0272-0.0292) 0.0239 (0.0229-0.0249) 906 0 
75% 0.0282 (0.0272-0.0292) 0.0233 (0.0223-0.0243) 905 0 
100% 0.0260 (0.0250-0.0270) 0.0258 (0.0248-0.0268) 903 0 
0.70 0.2143 25% 0.0347 (0.0337-0.0357) 0.0213 (0.0203-0.0223) 128 7811 
50% 0.0321 (0.0311-0.0331) 0.0212 (0.0202-0.0222) 123 1678 
75% 0.0266 (0.0256-0.0276) 0.0212 (0.0202-0.0222) 124 330 
100% 0.0257 (0.0247-0.0267) 0.0259 (0.0249-0.0269) 118 88 
0.70 0.1071 25% 0.0286 (0.0276-0.0296) 0.0235 (0.0225-0.0245) 544 0 
50% 0.0271 (0.0261-0.0281) 0.0231 (0.0221-0.0241) 541 0 
75% 0.0286 (0.0276-0.0296) 0.0227 (0.0217-0.0237) 539 0 
100% 0.0248 (0.0238-0.0258) 0.0253 (0.0243-0.0263) 537 0 
0.60 0.3333 25% 0.0362 (0.0352-0.0372) 0.0214 (0.0204-0.0224) 91 12425 
50% 0.0294 (0.0284-0.0304) 0.0218 (0.0208-0.0228) 85 3583 
75% 0.0272 (0.0262-0.0282) 0.0209 (0.0199-0.0219) 85 1106 
100% 0.0241 (0.0231-0.0251) 0.0246 (0.0236-0.0256) 79 211 
0.60 0.1667 25% 0.0280 (0.0270-0.0290) 0.0226 (0.0216-0.0236) 362 0 
50% 0.0283 (0.0273-0.0293) 0.0224 (0.0214-0.0234) 357 0 
75% 0.0283 (0.0273-0.0293) 0.0227 (0.0217-0.0237) 357 0 
100% 0.0254 (0.0244-0.0264) 0.0250 (0.0240-0.0260) 354 0 
Note:  
1. IAL = interim analysis location. 
2. Interim analysis location refers to the percent of subjects out of the original protocol-
specified sample size who have been assessed for the outcome at the interim analysis. 
100% refers to the situation where no sample size re-estimation is planned. 





Table A.33: Results from Simulations where the Minimum Allowable Sample Size is 10% more 
than the Interim Analysis Sample Size and the Maximum Allowable Sample Size is Twice the 
Original Protocol-Specified Sample Size for the HW-SSR Method for the Alternative Hypothesis 
Ha: pe = (1 + γ)pc when the Outcome is Positive (Part 1). 
Control 
Group 
Rate (  ) 
Relative 
Treatment 






Type I Error (95% CI) 
Simulated Power 
(95% CI) 
0.90 0.0556 432 25% 0.0557 (0.0543-0.0571) 0.7103 (0.7078-0.7128) 
50% 0.0522 (0.0508-0.0536) 0.7270 (0.7245-0.7295) 
75% 0.0501 (0.0487-0.0515) 0.7613 (0.7588-0.7638) 
100% 0.0533 (0.0519-0.0547) 0.8041 (0.8016-0.8066) 
0.80 0.125 197 25% 0.0551 (0.0537-0.0565) 0.6992 (0.6967-0.7017) 
50% 0.0523 (0.0509-0.0537) 0.7174 (0.7149-0.7199) 
75% 0.0469 (0.0455-0.0483) 0.7542 (0.7517-0.7567) 
100% 0.0516 (0.0502-0.0530) 0.8043 (0.8018-0.8068) 
0.80 0.0625 903 25% 0.0515 (0.0501-0.0529) 0.7623 (0.7598-0.7648) 
50% 0.0513 (0.0499-0.0527) 0.7678 (0.7653-0.7703) 
75% 0.0500 (0.0486-0.0514) 0.7678 (0.7653-0.7703) 
100% 0.0506 (0.0492-0.0520) 0.7992 (0.7967-0.8017) 
0.70 0.2143 118 25% 0.0564 (0.0550-0.0578) 0.6926 (0.6901-0.6951) 
50% 0.0513 (0.0499-0.0527) 0.7086 (0.7061-0.7111) 
75% 0.0476 (0.0462-0.0490) 0.7522 (0.7497-0.7547) 
100% 0.0514 (0.0500-0.0528) 0.7977 (0.7952-0.8002) 
0.70 0.1071 537 25% 0.0518 (0.0504-0.0532) 0.7592 (0.7567-0.7617) 
50% 0.0520 (0.0506-0.0534) 0.7616 (0.7591-0.7641) 
75% 0.0504 (0.0490-0.0518) 0.7634 (0.7609-0.7659) 
100% 0.0504 (0.0490-0.0518) 0.7994 (0.7969-0.8019) 
0.60 0.3333 79 25% 0.0578 (0.0564-0.0592) 0.6776 (0.6751-0.6801) 
50% 0.0532 (0.0518-0.0546) 0.6990 (0.6965-0.7015) 
75% 0.0476 (0.0462-0.0490) 0.7459 (0.7434-0.7484) 
100% 0.0481 (0.0467-0.0495) 0.7935 (0.7910-0.7960) 
0.60 0.1667 354 25% 0.0520 (0.0506-0.0534) 0.7500 (0.7475-0.7525) 
50% 0.0515 (0.0501-0.0529) 0.7553 (0.7528-0.7578) 
75% 0.0480 (0.0466-0.0494) 0.7603 (0.7578-0.7628) 
100% 0.0500 (0.0486-0.0514) 0.7997 (0.7972-0.8022) 
Note:  
1. SS = sample size, IAL = interim analysis location. 
2. Interim analysis location refers to the percent of subjects out of the original protocol-
specified sample size who have been assessed for the outcome at the interim analysis. 




Table A.34: Results from Simulations where the Minimum Allowable Sample Size is 10% more 
than the Interim Analysis Sample Size and the Maximum Allowable Sample Size is Twice the 
Original Protocol-Specified Sample Size for the HW-SSR Method for the Alternative Hypothesis 
Ha: pe = (1 + γ)pc when the Outcome is Positive (Part 2). 
Control 
Group 
Rate (  ) 
Relative 
Treatment 
Effect ( ) IAL 
Simulated Lower Type I 
Error (95% CI) 
Simulated Upper Type I 






0.90 0.0556 25% 0.0330 (0.0320-0.0340) 0.0227 (0.0217-0.0237) 439 3567 
50% 0.0297 (0.0287-0.0307) 0.0225 (0.0215-0.0235) 437 692 
75% 0.0270 (0.0260-0.0280) 0.0231 (0.0221-0.0241) 449 256 
100% 0.0270 (0.0260-0.0280) 0.0263 (0.0253-0.0273) 432 46 
0.80 0.125 25% 0.0331 (0.0321-0.0341) 0.0220 (0.0210-0.0230) 202 4850 
50% 0.0313 (0.0303-0.0323) 0.0210 (0.0200-0.0220) 201 1467 
75% 0.0256 (0.0246-0.0266) 0.0213 (0.0203-0.0223) 207 210 
100% 0.0255 (0.0245-0.0265) 0.0261 (0.0251-0.0271) 197 35 
0.80 0.0625 25% 0.0285 (0.0275-0.0295) 0.0230 (0.0220-0.0240) 909 0 
50% 0.0286 (0.0276-0.0296) 0.0228 (0.0218-0.0238) 906 0 
75% 0.0270 (0.0260-0.0280) 0.0231 (0.0221-0.0241) 907 0 
100% 0.0254 (0.0244-0.0264) 0.0253 (0.0243-0.0263) 903 0 
0.70 0.2143 25% 0.0344 (0.0334-0.0354) 0.0220 (0.0210-0.0230) 124 7623 
50% 0.0300 (0.0290-0.0310) 0.0213 (0.0203-0.0223) 123 1657 
75% 0.0270 (0.0260-0.0280) 0.0206 (0.0196-0.0216) 127 312 
100% 0.0255 (0.0245-0.0265) 0.0259 (0.0249-0.0269) 118 75 
0.70 0.1071 25% 0.0283 (0.0273-0.0293) 0.0235 (0.0225-0.0245) 544 0 
50% 0.0285 (0.0275-0.0295) 0.0236 (0.0226-0.0246) 540 0 
75% 0.0268 (0.0258-0.0278) 0.0236 (0.0226-0.0246) 541 0 
100% 0.0253 (0.0243-0.0263) 0.0251 (0.0241-0.0261) 537 0 
0.60 0.3333 25% 0.0361 (0.0351-0.0371) 0.0217 (0.0207-0.0227) 84 12458 
50% 0.0315 (0.0305-0.0325) 0.0217 (0.0207-0.0227) 84 3552 
75% 0.0257 (0.0247-0.0267) 0.0219 (0.0209-0.0229) 87 1101 
100% 0.0237 (0.0227-0.0247) 0.0244 (0.0234-0.0254) 79 232 
0.60 0.1667 25% 0.0289 (0.0279-0.0299) 0.0231 (0.0221-0.0241) 361 0 
50% 0.0281 (0.0271-0.0291) 0.0234 (0.0224-0.0244) 358 0 
75% 0.0254 (0.0244-0.0264) 0.0226 (0.0216-0.0236) 358 0 
100% 0.0249 (0.0239-0.0259) 0.0251 (0.0241-0.0261) 354 0 
Note:  
1. IAL = interim analysis location. 
2. Interim analysis location refers to the percent of subjects out of the original protocol-
specified sample size who have been assessed for the outcome at the interim analysis. 
100% refers to the situation where no sample size re-estimation is planned. 





Table A.35: Results from Simulations where the Minimum Allowable Sample Size is 10% more 
than the Interim Analysis Sample Size and where there is No Maximum Allowable Sample Size 
for the HW-SSR Method for the Alternative Hypothesis Ha: pe = (1 + γ)pc when the Outcome is 
Positive (Part 1). 
Control 
Group 
Rate (  ) 
Relative 
Treatment 






Type I Error (95% CI) 
Simulated Power 
(95% CI) 
0.90 0.0556 432 25% 0.0552 (0.0538-0.0566) 0.7101 (0.7076-0.7126) 
50% 0.0530 (0.0516-0.0544) 0.7266 (0.7241-0.7291) 
75% 0.0485 (0.0471-0.0499) 0.7600 (0.7575-0.7625) 
100% 0.0512 (0.0498-0.0526) 0.8064 (0.8039-0.8089) 
0.80 0.125 197 25% 0.0538 (0.0524-0.0552) 0.7001 (0.6976-0.7026) 
50% 0.0519 (0.0505-0.0533) 0.7180 (0.7155-0.7205) 
75% 0.0481 (0.0467-0.0495) 0.7572 (0.7547-0.7597) 
100% 0.0499 (0.0485-0.0513) 0.8041 (0.8016-0.8066) 
0.80 0.0625 903 25% 0.0516 (0.0502-0.0530) 0.7586 (0.7561-0.7611) 
50% 0.0521 (0.0507-0.0535) 0.7667 (0.7642-0.7692) 
75% 0.0504 (0.0490-0.0518) 0.7692 (0.7667-0.7717) 
100% 0.0509 (0.0495-0.0523) 0.8026 (0.8001-0.8051) 
0.70 0.2143 118 25% 0.0559 (0.0545-0.0573) 0.6910 (0.6885-0.6935) 
50% 0.0523 (0.0509-0.0537) 0.7105 (0.7080-0.7130) 
75% 0.0488 (0.0474-0.0502) 0.7524 (0.7499-0.7549) 
100% 0.0498 (0.0484-0.0512) 0.7981 (0.7956-0.8006) 
0.70 0.1071 537 25% 0.0518 (0.0504-0.0532) 0.7595 (0.7570-0.7620) 
50% 0.0512 (0.0498-0.0526) 0.7613 (0.7588-0.7638) 
75% 0.0500 (0.0486-0.0514) 0.7644 (0.7619-0.7669) 
100% 0.0505 (0.0491-0.0519) 0.7975 (0.7950-0.8000) 
0.60 0.3333 79 25% 0.0570 (0.0556-0.0584) 0.6796 (0.6771-0.6821) 
50% 0.0540 (0.0526-0.0554) 0.7000 (0.6975-0.7025) 
75% 0.0468 (0.0454-0.0482) 0.7426 (0.7401-0.7451) 
100% 0.0486 (0.0472-0.0500) 0.7979 (0.7954-0.8004) 
0.60 0.1667 354 25% 0.0519 (0.0505-0.0533) 0.7516 (0.7491-0.7541) 
50% 0.0507 (0.0493-0.0521) 0.7553 (0.7528-0.7578) 
75% 0.0492 (0.0478-0.0506) 0.7624 (0.7599-0.7649) 
100% 0.0499 (0.0485-0.0513) 0.7984 (0.7959-0.8009) 
Note:  
1. SS = sample size, IAL = interim analysis location. 
2. Interim analysis location refers to the percent of subjects out of the original protocol-
specified sample size who have been assessed for the outcome at the interim analysis. 




Table A.36: Results from Simulations where the Minimum Allowable Sample Size is 10% more 
than the Interim Analysis Sample Size and where there is No Maximum Allowable Sample Size 
for the HW-SSR Method for the Alternative Hypothesis Ha: pe = (1 + γ)pc when the Outcome is 
Positive (Part 2). 
Control 
Group 
Rate (  ) 
Relative 
Treatment 
Effect ( ) IAL 
Simulated Lower Type I 
Error (95% CI) 
Simulated Upper Type I 






0.90 0.0556 25% 0.0326 (0.0316-0.0336) 0.0226 (0.0216-0.0236) 441 3573 
50% 0.0306 (0.0296-0.0316) 0.0224 (0.0214-0.0234) 438 682 
75% 0.0259 (0.0249-0.0269) 0.0226 (0.0216-0.0236) 449 291 
100% 0.0254 (0.0244-0.0264) 0.0259 (0.0249-0.0269) 432 45 
0.80 0.125 25% 0.0325 (0.0315-0.0335) 0.0214 (0.0204-0.0224) 205 4771 
50% 0.0305 (0.0295-0.0315) 0.0214 (0.0204-0.0224) 202 1405 
75% 0.0259 (0.0249-0.0269) 0.0222 (0.0212-0.0232) 207 200 
100% 0.0253 (0.0243-0.0263) 0.0246 (0.0236-0.0256) 197 34 
0.80 0.0625 25% 0.0280 (0.0270-0.0290) 0.0236 (0.0226-0.0246) 908 0 
50% 0.0277 (0.0267-0.0287) 0.0244 (0.0234-0.0254) 907 0 
75% 0.0268 (0.0258-0.0278) 0.0236 (0.0226-0.0246) 907 0 
100% 0.0254 (0.0244-0.0264) 0.0256 (0.0246-0.0266) 903 0 
0.70 0.2143 25% 0.0343 (0.0333-0.0353) 0.0217 (0.0207-0.0227) 128 7498 
50% 0.0315 (0.0305-0.0325) 0.0208 (0.0198-0.0218) 124 1731 
75% 0.0273 (0.0263-0.0283) 0.0215 (0.0205-0.0225) 127 349 
100% 0.0249 (0.0239-0.0259) 0.0249 (0.0239-0.0259) 118 81 
0.70 0.1071 25% 0.0278 (0.0268-0.0288) 0.0240 (0.0230-0.0250) 544 0 
50% 0.0280 (0.0270-0.0290) 0.0232 (0.0222-0.0242) 540 0 
75% 0.0267 (0.0257-0.0277) 0.0233 (0.0223-0.0243) 541 0 
100% 0.0256 (0.0246-0.0266) 0.0249 (0.0239-0.0259) 537 0 
0.60 0.3333 25% 0.0358 (0.0348-0.0368) 0.0212 (0.0202-0.0222) 91 12440 
50% 0.0328 (0.0318-0.0338) 0.0213 (0.0203-0.0223) 85 3617 
75% 0.0253 (0.0243-0.0263) 0.0215 (0.0205-0.0225) 87 1013 
100% 0.0243 (0.0233-0.0253) 0.0243 (0.0233-0.0253) 79 231 
0.60 0.1667 25% 0.0292 (0.0282-0.0302) 0.0228 (0.0218-0.0238) 361 0 
50% 0.0286 (0.0276-0.0296) 0.0220 (0.0210-0.0230) 357 0 
75% 0.0257 (0.0247-0.0267) 0.0235 (0.0225-0.0245) 358 0 
100% 0.0249 (0.0239-0.0259) 0.0250 (0.0240-0.0260) 354 0 
Note:  
1. IAL = interim analysis location. 
2. Interim analysis location refers to the percent of subjects out of the original protocol-
specified sample size who have been assessed for the outcome at the interim analysis. 
100% refers to the situation where no sample size re-estimation is planned. 





Table A.37: Results from Simulations where the Minimum Allowable Sample Size is the Original 
Protocol-Specified Sample Size and the Maximum Allowable Sample Size is Twice the Original 
Protocol-Specified Sample Size for the HW-SSR Method for the Alternative Hypothesis Ha: pe = (1 
+ γ)pc when the Outcome is Positive (Part 1). 
Control 
Group 
Rate (  ) 
Relative 
Treatment 






Type I Error (95% CI) 
Simulated Power 
(95% CI) 
0.90 0.0556 432 25% 0.0505 (0.0491-0.0519) 0.8288 (0.8263-0.8313) 
50% 0.0486 (0.0472-0.0500) 0.8179 (0.8154-0.8204) 
75% 0.0500 (0.0486-0.0514) 0.8134 (0.8109-0.8159) 
100% 0.0515 (0.0501-0.0529) 0.8095 (0.8070-0.8120) 
0.80 0.125 197 25% 0.0487 (0.0473-0.0501) 0.8263 (0.8238-0.8288) 
50% 0.0484 (0.0470-0.0498) 0.8145 (0.8120-0.8170) 
75% 0.0482 (0.0468-0.0496) 0.8096 (0.8071-0.8121) 
100% 0.0500 (0.0486-0.0514) 0.8061 (0.8036-0.8086) 
0.80 0.0625 903 25% 0.0502 (0.0488-0.0516) 0.8145 (0.8120-0.8170) 
50% 0.0491 (0.0477-0.0505) 0.8054 (0.8029-0.8079) 
75% 0.0489 (0.0475-0.0503) 0.8023 (0.7998-0.8048) 
100% 0.0497 (0.0483-0.0511) 0.7989 (0.7964-0.8014) 
0.70 0.2143 118 25% 0.0503 (0.0489-0.0517) 0.8240 (0.8215-0.8265) 
50% 0.0482 (0.0468-0.0496) 0.8118 (0.8093-0.8143) 
75% 0.0477 (0.0463-0.0491) 0.8071 (0.8046-0.8096) 
100% 0.0499 (0.0485-0.0513) 0.8004 (0.7979-0.8029) 
0.70 0.1071 537 25% 0.0491 (0.0477-0.0505) 0.8118 (0.8093-0.8143) 
50% 0.0490 (0.0476-0.0504) 0.8058 (0.8033-0.8083) 
75% 0.0496 (0.0482-0.0510) 0.8014 (0.7989-0.8039) 
100% 0.0491 (0.0477-0.0505) 0.7985 (0.7960-0.8010) 
0.60 0.3333 79 25% 0.0492 (0.0478-0.0506) 0.8259 (0.8234-0.8284) 
50% 0.0482 (0.0468-0.0496) 0.8117 (0.8092-0.8142) 
75% 0.0478 (0.0464-0.0492) 0.8007 (0.7982-0.8032) 
100% 0.0499 (0.0485-0.0513) 0.7947 (0.7922-0.7972) 
0.60 0.1667 354 25% 0.0492 (0.0478-0.0506) 0.8131 (0.8106-0.8156) 
50% 0.0488 (0.0474-0.0502) 0.8089 (0.8064-0.8114) 
75% 0.0484 (0.0470-0.0498) 0.8038 (0.8013-0.8063) 
100% 0.0493 (0.0479-0.0507) 0.7996 (0.7971-0.8021) 
Note:  
1. SS = sample size, IAL = interim analysis location. 
2. Interim analysis location refers to the percent of subjects out of the original protocol-
specified sample size who have been assessed for the outcome at the interim analysis. 




Table A.38: Results from Simulations where the Minimum Allowable Sample Size is the Original 
Protocol-Specified Sample Size and the Maximum Allowable Sample Size is Twice the Original 
Protocol-Specified Sample Size for the HW-SSR Method for the Alternative Hypothesis Ha: pe = (1 
+ γ)pc when the Outcome is Positive (Part 2). 
Control 
Group 
Rate (  ) 
Relative 
Treatment 
Effect ( ) IAL 
Simulated Lower Type I 
Error (95% CI) 
Simulated Upper Type I 






0.90 0.0556 25% 0.0267 (0.0257-0.0277) 0.0237 (0.0227-0.0247) 508 3587 
50% 0.0254 (0.0244-0.0264) 0.0232 (0.0222-0.0242) 486 700 
75% 0.0259 (0.0249-0.0269) 0.0242 (0.0232-0.0252) 477 285 
100% 0.0255 (0.0245-0.0265) 0.0260 (0.0250-0.0270) 432 31 
0.80 0.125 25% 0.0264 (0.0254-0.0274) 0.0223 (0.0213-0.0233) 236 4735 
50% 0.0263 (0.0253-0.0273) 0.0221 (0.0211-0.0231) 225 1394 
75% 0.0264 (0.0254-0.0274) 0.0218 (0.0208-0.0228) 220 213 
100% 0.0248 (0.0238-0.0258) 0.0252 (0.0242-0.0262) 197 33 
0.80 0.0625 25% 0.0255 (0.0245-0.0265) 0.0247 (0.0237-0.0257) 975 0 
50% 0.0253 (0.0243-0.0263) 0.0238 (0.0228-0.0248) 953 0 
75% 0.0255 (0.0245-0.0265) 0.0233 (0.0223-0.0243) 944 0 
100% 0.0253 (0.0243-0.0263) 0.0244 (0.0234-0.0254) 903 0 
0.70 0.2143 25% 0.0268 (0.0258-0.0278) 0.0235 (0.0225-0.0245) 145 7717 
50% 0.0260 (0.0250-0.0270) 0.0223 (0.0213-0.0233) 138 1726 
75% 0.0261 (0.0251-0.0271) 0.0216 (0.0206-0.0226) 135 331 
100% 0.0246 (0.0236-0.0256) 0.0252 (0.0242-0.0262) 118 76 
0.70 0.1071 25% 0.0256 (0.0246-0.0266) 0.0235 (0.0225-0.0245) 587 0 
50% 0.0247 (0.0237-0.0257) 0.0242 (0.0232-0.0252) 571 0 
75% 0.0253 (0.0243-0.0263) 0.0244 (0.0234-0.0254) 565 0 
100% 0.0244 (0.0234-0.0254) 0.0247 (0.0237-0.0257) 537 0 
0.60 0.3333 25% 0.0256 (0.0246-0.0266) 0.0235 (0.0225-0.0245) 100 12672 
50% 0.0252 (0.0242-0.0262) 0.0230 (0.0220-0.0240) 95 3505 
75% 0.0259 (0.0249-0.0269) 0.0220 (0.0210-0.0230) 92 1079 
100% 0.0253 (0.0243-0.0263) 0.0247 (0.0237-0.0257) 79 195 
0.60 0.1667 25% 0.0266 (0.0256-0.0276) 0.0226 (0.0216-0.0236) 393 0 
50% 0.0255 (0.0245-0.0265) 0.0233 (0.0223-0.0243) 381 0 
75% 0.0250 (0.0240-0.0260) 0.0234 (0.0224-0.0244) 376 0 
100% 0.0251 (0.0241-0.0261) 0.0243 (0.0233-0.0253) 354 0 
Note:  
1. IAL = interim analysis location. 
2. Interim analysis location refers to the percent of subjects out of the original protocol-
specified sample size who have been assessed for the outcome at the interim analysis. 
100% refers to the situation where no sample size re-estimation is planned. 





Table A.39: Results from Simulations where the Minimum Allowable Sample Size is the Original 
Protocol-Specified Sample Size and where there is No Maximum Allowable Sample Size for the 




Rate (  ) 
Relative 
Treatment 






Type I Error (95% CI) 
Simulated Power 
(95% CI) 
0.90 0.0556 432 25% 0.0506 (0.0492-0.0520) 0.8287 (0.8262-0.8312) 
50% 0.0486 (0.0472-0.0500) 0.8202 (0.8177-0.8227) 
75% 0.0500 (0.0486-0.0514) 0.8126 (0.8101-0.8151) 
100% 0.0517 (0.0503-0.0531) 0.8073 (0.8048-0.8098) 
0.80 0.125 197 25% 0.0497 (0.0483-0.0511) 0.8264 (0.8239-0.8289) 
50% 0.0495 (0.0481-0.0509) 0.8159 (0.8134-0.8184) 
75% 0.0470 (0.0456-0.0484) 0.8104 (0.8079-0.8129) 
100% 0.0502 (0.0488-0.0516) 0.8049 (0.8024-0.8074) 
0.80 0.0625 903 25% 0.0496 (0.0482-0.0510) 0.8097 (0.8072-0.8122) 
50% 0.0489 (0.0475-0.0503) 0.8053 (0.8028-0.8078) 
75% 0.0485 (0.0471-0.0499) 0.8024 (0.7999-0.8049) 
100% 0.0504 (0.0490-0.0518) 0.8005 (0.7980-0.8030) 
0.70 0.2143 118 25% 0.0477 (0.0463-0.0491) 0.8235 (0.8210-0.8260) 
50% 0.0477 (0.0463-0.0491) 0.8122 (0.8097-0.8147) 
75% 0.0470 (0.0456-0.0484) 0.8025 (0.8000-0.8050) 
100% 0.0510 (0.0496-0.0524) 0.7982 (0.7957-0.8007) 
0.70 0.1071 537 25% 0.0500 (0.0486-0.0514) 0.8138 (0.8113-0.8163) 
50% 0.0494 (0.0480-0.0508) 0.8052 (0.8027-0.8077) 
75% 0.0485 (0.0471-0.0499) 0.8023 (0.7998-0.8048) 
100% 0.0498 (0.0484-0.0512) 0.7975 (0.7950-0.8000) 
0.60 0.3333 79 25% 0.0483 (0.0469-0.0497) 0.8236 (0.8211-0.8261) 
50% 0.0476 (0.0462-0.0490) 0.8104 (0.8079-0.8129) 
75% 0.0474 (0.0460-0.0488) 0.8030 (0.8005-0.8055) 
100% 0.0484 (0.0470-0.0498) 0.7967 (0.7942-0.7992) 
0.60 0.1667 354 25% 0.0490 (0.0476-0.0504) 0.8157 (0.8132-0.8182) 
50% 0.0483 (0.0469-0.0497) 0.8075 (0.8050-0.8100) 
75% 0.0491 (0.0477-0.0505) 0.8039 (0.8014-0.8064) 
100% 0.0503 (0.0489-0.0517) 0.8005 (0.7980-0.8030) 
Note:  
1. SS = sample size, IAL = interim analysis location. 
2. Interim analysis location refers to the percent of subjects out of the original protocol-
specified sample size who have been assessed for the outcome at the interim analysis. 




Table A.40: Results from Simulations where the Minimum Allowable Sample Size is the Original 
Protocol-Specified Sample Size and where there is No Maximum Allowable Sample Size for the 




Rate (  ) 
Relative 
Treatment 
Effect ( ) IAL 
Simulated Lower Type I 
Error (95% CI) 
Simulated Upper Type I 






0.90 0.0556 25% 0.0269 (0.0259-0.0279) 0.0237 (0.0227-0.0247) 509 3490 
50% 0.0260 (0.0250-0.0270) 0.0226 (0.0216-0.0236) 486 709 
75% 0.0267 (0.0257-0.0277) 0.0234 (0.0224-0.0244) 476 271 
100% 0.0252 (0.0242-0.0262) 0.0265 (0.0255-0.0275) 432 36 
0.80 0.125 25% 0.0266 (0.0256-0.0276) 0.0231 (0.0221-0.0241) 238 4832 
50% 0.0261 (0.0251-0.0271) 0.0234 (0.0224-0.0244) 225 1446 
75% 0.0254 (0.0244-0.0264) 0.0216 (0.0206-0.0226) 220 219 
100% 0.0255 (0.0245-0.0265) 0.0247 (0.0237-0.0257) 197 29 
0.80 0.0625 25% 0.0257 (0.0247-0.0267) 0.0239 (0.0229-0.0249) 975 0 
50% 0.0250 (0.0240-0.0260) 0.0239 (0.0229-0.0249) 953 0 
75% 0.0250 (0.0240-0.0260) 0.0235 (0.0225-0.0245) 944 0 
100% 0.0247 (0.0237-0.0257) 0.0257 (0.0247-0.0267) 903 0 
0.70 0.2143 25% 0.0254 (0.0244-0.0264) 0.0223 (0.0213-0.0233) 149 7761 
50% 0.0256 (0.0246-0.0266) 0.0221 (0.0211-0.0231) 139 1655 
75% 0.0261 (0.0251-0.0271) 0.0209 (0.0199-0.0219) 135 373 
100% 0.0255 (0.0245-0.0265) 0.0255 (0.0245-0.0265) 118 107 
0.70 0.1071 25% 0.0257 (0.0247-0.0267) 0.0243 (0.0233-0.0253) 587 0 
50% 0.0261 (0.0251-0.0271) 0.0234 (0.0224-0.0244) 571 0 
75% 0.0254 (0.0244-0.0264) 0.0231 (0.0221-0.0241) 565 0 
100% 0.0246 (0.0236-0.0256) 0.0252 (0.0242-0.0262) 537 0 
0.60 0.3333 25% 0.0257 (0.0247-0.0267) 0.0227 (0.0217-0.0237) 106 12412 
50% 0.0253 (0.0243-0.0263) 0.0224 (0.0214-0.0234) 96 3503 
75% 0.0265 (0.0255-0.0275) 0.0209 (0.0199-0.0219) 92 1101 
100% 0.0240 (0.0230-0.0250) 0.0243 (0.0233-0.0253) 79 202 
0.60 0.1667 25% 0.0245 (0.0235-0.0255) 0.0245 (0.0235-0.0255) 394 0 
50% 0.0248 (0.0238-0.0258) 0.0235 (0.0225-0.0245) 381 0 
75% 0.0257 (0.0247-0.0267) 0.0234 (0.0224-0.0244) 376 0 
100% 0.0247 (0.0237-0.0257) 0.0257 (0.0247-0.0267) 354 0 
Note:  
1. IAL = interim analysis location. 
2. Interim analysis location refers to the percent of subjects out of the original protocol-
specified sample size who have been assessed for the outcome at the interim analysis. 
100% refers to the situation where no sample size re-estimation is planned. 





Table A.41: Results from Simulations where the Minimum Allowable Sample Size is the Interim 
Analysis Sample Size and the Maximum Allowable Sample Size is Twice the Original Protocol-
Specified Sample Size for the HW-SSR Method for the Alternative Hypothesis Ha: pe = pc + Δ 
when the Outcome is Positive (Part 1). 
Control 
Group 










Type I Error (95% CI) 
Simulated Power 
(95% CI) 
0.90 0.05 432 25% 0.0552 (0.0538-0.0566) 0.7186 (0.7161-0.7211) 
50% 0.0539 (0.0525-0.0553) 0.7356 (0.7331-0.7381) 
75% 0.0516 (0.0502-0.0530) 0.7503 (0.7478-0.7528) 
100% 0.0526 (0.0512-0.0540) 0.8066 (0.8041-0.8091) 
0.80 0.10 197 25% 0.0553 (0.0539-0.0567) 0.7203 (0.7178-0.7228) 
50% 0.0543 (0.0529-0.0557) 0.7379 (0.7354-0.7404) 
75% 0.0496 (0.0482-0.0510) 0.7464 (0.7439-0.7489) 
100% 0.0508 (0.0494-0.0522) 0.8042 (0.8017-0.8067) 
0.80 0.05 903 25% 0.0516 (0.0502-0.0530) 0.7745 (0.7720-0.7770) 
50% 0.0521 (0.0507-0.0535) 0.7754 (0.7729-0.7779) 
75% 0.0502 (0.0488-0.0516) 0.7772 (0.7747-0.7797) 
100% 0.0502 (0.0488-0.0516) 0.7997 (0.7972-0.8022) 
0.70 0.15 118 25% 0.0539 (0.0525-0.0553) 0.7233 (0.7208-0.7258) 
50% 0.0547 (0.0533-0.0561) 0.7382 (0.7357-0.7407) 
75% 0.0513 (0.0499-0.0527) 0.7517 (0.7492-0.7542) 
100% 0.0497 (0.0483-0.0511) 0.7978 (0.7953-0.8003) 
0.70 0.075 537 25% 0.0515 (0.0501-0.0529) 0.7766 (0.7741-0.7791) 
50% 0.0507 (0.0493-0.0521) 0.7787 (0.7762-0.7812) 
75% 0.0502 (0.0488-0.0516) 0.7814 (0.7789-0.7839) 
100% 0.0504 (0.0490-0.0518) 0.7981 (0.7956-0.8006) 
0.60 0.20 79 25% 0.0533 (0.0519-0.0547) 0.7249 (0.7224-0.7274) 
50% 0.0548 (0.0534-0.0562) 0.7407 (0.7382-0.7432) 
75% 0.0513 (0.0499-0.0527) 0.7515 (0.7490-0.7540) 
100% 0.0495 (0.0481-0.0509) 0.7940 (0.7915-0.7965) 
0.60 0.10 354 25% 0.0513 (0.0499-0.0527) 0.7794 (0.7769-0.7819) 
50% 0.0505 (0.0491-0.0519) 0.7848 (0.7823-0.7873) 
75% 0.0508 (0.0494-0.0522) 0.7830 (0.7805-0.7855) 
100% 0.0499 (0.0485-0.0513) 0.7977 (0.7952-0.8002) 
Note:  
1. SS = sample size, IAL = interim analysis location. 
2. Interim analysis location refers to the percent of subjects out of the original protocol-
specified sample size who have been assessed for the outcome at the interim analysis. 




Table A.42: Results from Simulations where the Minimum Allowable Sample Size is the Interim 
Analysis Sample Size and the Maximum Allowable Sample Size is Twice the Original Protocol-
Specified Sample Size for the HW-SSR Method for the Alternative Hypothesis Ha: pe = pc + Δ 
when the Outcome is Positive (Part 2). 
Control 
Group 




Effect (Δ) IAL 
Simulated Lower Type I 
Error (95% CI) 
Simulated Upper Type I 






0.90 0.05 25% 0.0324 (0.0314-0.0334) 0.0228 (0.0218-0.0238) 429 3580 
50% 0.0309 (0.0299-0.0319) 0.0230 (0.0220-0.0240) 430 301 
75% 0.0283 (0.0273-0.0293) 0.0233 (0.0223-0.0243) 436 156 
100% 0.0271 (0.0261-0.0281) 0.0255 (0.0245-0.0265) 432 23 
0.80 0.10 25% 0.0326 (0.0316-0.0336) 0.0228 (0.0218-0.0238) 192 4903 
50% 0.0317 (0.0307-0.0327) 0.0226 (0.0216-0.0236) 194 297 
75% 0.0275 (0.0265-0.0285) 0.0221 (0.0211-0.0231) 197 49 
100% 0.0251 (0.0241-0.0261) 0.0257 (0.0247-0.0267) 197 6 
0.80 0.05 25% 0.0279 (0.0269-0.0289) 0.0237 (0.0227-0.0247) 898 0 
50% 0.0273 (0.0263-0.0283) 0.0247 (0.0237-0.0257) 901 0 
75% 0.0268 (0.0258-0.0278) 0.0234 (0.0224-0.0244) 901 0 
100% 0.0249 (0.0239-0.0259) 0.0253 (0.0243-0.0263) 903 0 
0.70 0.15 25% 0.0305 (0.0295-0.0315) 0.0235 (0.0225-0.0245) 114 3080 
50% 0.0313 (0.0303-0.0323) 0.0234 (0.0224-0.0244) 116 266 
75% 0.0275 (0.0265-0.0285) 0.0238 (0.0228-0.0248) 118 58 
100% 0.0254 (0.0244-0.0264) 0.0244 (0.0234-0.0254) 118 8 
0.70 0.075 25% 0.0269 (0.0259-0.0279) 0.0246 (0.0236-0.0256) 533 0 
50% 0.0265 (0.0255-0.0275) 0.0243 (0.0233-0.0253) 535 0 
75% 0.0264 (0.0254-0.0274) 0.0238 (0.0228-0.0248) 535 0 
100% 0.0256 (0.0246-0.0266) 0.0248 (0.0238-0.0258) 537 0 
0.60 0.20 25% 0.0301 (0.0291-0.0311) 0.0232 (0.0222-0.0242) 75 5075 
50% 0.0309 (0.0299-0.0319) 0.0239 (0.0229-0.0249) 77 594 
75% 0.0270 (0.0260-0.0280) 0.0243 (0.0233-0.0253) 78 78 
100% 0.0248 (0.0238-0.0258) 0.0247 (0.0237-0.0257) 79 6 
0.60 0.10 25% 0.0265 (0.0255-0.0275) 0.0248 (0.0238-0.0258) 349 0 
50% 0.0260 (0.0250-0.0270) 0.0246 (0.0236-0.0256) 352 0 
75% 0.0263 (0.0253-0.0273) 0.0245 (0.0235-0.0255) 352 0 
100% 0.0252 (0.0242-0.0262) 0.0247 (0.0237-0.0257) 354 0 
Note:  
1. IAL = interim analysis location. 
2. Interim analysis location refers to the percent of subjects out of the original protocol-
specified sample size who have been assessed for the outcome at the interim analysis. 
100% refers to the situation where no sample size re-estimation is planned. 





Table A.43: Results from Simulations where the Minimum Allowable Sample Size is the Interim 
Analysis Sample Size and where there is No Maximum Allowable Sample Size for the HW-SSR 
Method for the Alternative Hypothesis Ha: pe = pc + Δ when the Outcome is Positive (Part 1). 
Control 
Group 










Type I Error (95% CI) 
Simulated Power 
(95% CI) 
0.90 0.05 432 25% 0.0543 (0.0529-0.0557) 0.7186 (0.7161-0.7211) 
50% 0.0531 (0.0517-0.0545) 0.7364 (0.7339-0.7389) 
75% 0.0525 (0.0511-0.0539) 0.7480 (0.7455-0.7505) 
100% 0.0520 (0.0506-0.0534) 0.8074 (0.8049-0.8099) 
0.80 0.10 197 25% 0.0551 (0.0537-0.0565) 0.7209 (0.7184-0.7234) 
50% 0.0531 (0.0517-0.0545) 0.7369 (0.7344-0.7394) 
75% 0.0506 (0.0492-0.0520) 0.7485 (0.7460-0.7510) 
100% 0.0510 (0.0496-0.0524) 0.8053 (0.8028-0.8078) 
0.80 0.05 903 25% 0.0507 (0.0493-0.0521) 0.7748 (0.7723-0.7773) 
50% 0.0513 (0.0499-0.0527) 0.7785 (0.7760-0.7810) 
75% 0.0510 (0.0496-0.0524) 0.7802 (0.7777-0.7827) 
100% 0.0514 (0.0500-0.0528) 0.8017 (0.7992-0.8042) 
0.70 0.15 118 25% 0.0525 (0.0511-0.0539) 0.7226 (0.7201-0.7251) 
50% 0.0547 (0.0533-0.0561) 0.7400 (0.7375-0.7425) 
75% 0.0515 (0.0501-0.0529) 0.7489 (0.7464-0.7514) 
100% 0.0499 (0.0485-0.0513) 0.7950 (0.7925-0.7975) 
0.70 0.075 537 25% 0.0511 (0.0497-0.0525) 0.7763 (0.7738-0.7788) 
50% 0.0516 (0.0502-0.0530) 0.7808 (0.7783-0.7833) 
75% 0.0510 (0.0496-0.0524) 0.7819 (0.7794-0.7844) 
100% 0.0503 (0.0489-0.0517) 0.7979 (0.7954-0.8004) 
0.60 0.20 79 25% 0.0533 (0.0519-0.0547) 0.7267 (0.7242-0.7292) 
50% 0.0544 (0.0530-0.0558) 0.7421 (0.7396-0.7446) 
75% 0.0514 (0.0500-0.0528) 0.7504 (0.7479-0.7529) 
100% 0.0485 (0.0471-0.0499) 0.7945 (0.7920-0.7970) 
0.60 0.10 354 25% 0.0515 (0.0501-0.0529) 0.7776 (0.7751-0.7801) 
50% 0.0502 (0.0488-0.0516) 0.7855 (0.7830-0.7880) 
75% 0.0499 (0.0485-0.0513) 0.7858 (0.7833-0.7883) 
100% 0.0493 (0.0479-0.0507) 0.8006 (0.7981-0.8031) 
Note:  
1. SS = sample size, IAL = interim analysis location. 
2. Interim analysis location refers to the percent of subjects out of the original protocol-
specified sample size who have been assessed for the outcome at the interim analysis. 




Table A.44: Results from Simulations where the Minimum Allowable Sample Size is the Interim 
Analysis Sample Size and where there is No Maximum Allowable Sample Size for the HW-SSR 
Method for the Alternative Hypothesis Ha: pe = pc + Δ when the Outcome is Positive (Part 2). 
Control 
Group 




Effect (Δ) IAL 
Simulated Lower Type I 
Error (95% CI) 
Simulated Upper Type I 






0.90 0.05 25% 0.0317 (0.0307-0.0327) 0.0226 (0.0216-0.0236) 429 3498 
50% 0.0304 (0.0294-0.0314) 0.0227 (0.0217-0.0237) 431 296 
75% 0.0288 (0.0278-0.0298) 0.0237 (0.0227-0.0247) 436 155 
100% 0.0263 (0.0253-0.0273) 0.0257 (0.0247-0.0267) 432 31 
0.80 0.10 25% 0.0322 (0.0312-0.0332) 0.0229 (0.0219-0.0239) 193 4777 
50% 0.0312 (0.0302-0.0322) 0.0219 (0.0209-0.0229) 195 253 
75% 0.0283 (0.0273-0.0293) 0.0223 (0.0213-0.0233) 197 37 
100% 0.0255 (0.0245-0.0265) 0.0255 (0.0245-0.0265) 197 10 
0.80 0.05 25% 0.0266 (0.0256-0.0276) 0.0241 (0.0231-0.0251) 899 0 
50% 0.0271 (0.0261-0.0281) 0.0242 (0.0232-0.0252) 901 0 
75% 0.0274 (0.0264-0.0284) 0.0236 (0.0226-0.0246) 901 0 
100% 0.0256 (0.0246-0.0266) 0.0258 (0.0248-0.0268) 903 0 
0.70 0.15 25% 0.0309 (0.0299-0.0319) 0.0216 (0.0206-0.0226) 114 3035 
50% 0.0313 (0.0303-0.0323) 0.0234 (0.0224-0.0244) 116 264 
75% 0.0276 (0.0266-0.0286) 0.0239 (0.0229-0.0249) 118 58 
100% 0.0254 (0.0244-0.0264) 0.0245 (0.0235-0.0255) 118 8 
0.70 0.075 25% 0.0270 (0.0260-0.0280) 0.0241 (0.0231-0.0251) 532 0 
50% 0.0270 (0.0260-0.0280) 0.0246 (0.0236-0.0256) 534 0 
75% 0.0272 (0.0262-0.0282) 0.0237 (0.0227-0.0247) 535 0 
100% 0.0248 (0.0238-0.0258) 0.0256 (0.0246-0.0266) 537 0 
0.60 0.20 25% 0.0298 (0.0288-0.0308) 0.0235 (0.0225-0.0245) 75 5107 
50% 0.0308 (0.0298-0.0318) 0.0236 (0.0226-0.0246) 77 592 
75% 0.0267 (0.0257-0.0277) 0.0247 (0.0237-0.0257) 78 79 
100% 0.0247 (0.0237-0.0257) 0.0239 (0.0229-0.0249) 79 7 
0.60 0.10 25% 0.0268 (0.0258-0.0278) 0.0247 (0.0237-0.0257) 349 0 
50% 0.0258 (0.0248-0.0268) 0.0244 (0.0234-0.0254) 352 0 
75% 0.0257 (0.0247-0.0267) 0.0242 (0.0232-0.0252) 352 0 
100% 0.0253 (0.0243-0.0263) 0.0240 (0.0230-0.0250) 354 0 
Note:  
1. IAL = interim analysis location. 
2. Interim analysis location refers to the percent of subjects out of the original protocol-
specified sample size who have been assessed for the outcome at the interim analysis. 
100% refers to the situation where no sample size re-estimation is planned. 





Table A.45: Results from Simulations where the Minimum Allowable Sample Size is 10% more 
than the Interim Analysis Sample Size and the Maximum Allowable Sample Size is Twice the 
Original Protocol-Specified Sample Size for the HW-SSR Method for the Alternative Hypothesis 
Ha: pe = pc + Δ when the Outcome is Positive (Part 1). 
Control 
Group 










Type I Error (95% CI) 
Simulated Power 
(95% CI) 
0.90 0.05 432 25% 0.0549 (0.0535-0.0563) 0.7212 (0.7187-0.7237) 
50% 0.0519 (0.0505-0.0533) 0.7367 (0.7342-0.7392) 
75% 0.0508 (0.0494-0.0522) 0.7618 (0.7593-0.7643) 
100% 0.0517 (0.0503-0.0531) 0.8070 (0.8045-0.8095) 
0.80 0.10 197 25% 0.0558 (0.0544-0.0572) 0.7206 (0.7181-0.7231) 
50% 0.0529 (0.0515-0.0543) 0.7370 (0.7345-0.7395) 
75% 0.0499 (0.0485-0.0513) 0.7615 (0.7590-0.7640) 
100% 0.0500 (0.0486-0.0514) 0.8058 (0.8033-0.8083) 
0.80 0.05 903 25% 0.0499 (0.0485-0.0513) 0.7773 (0.7748-0.7798) 
50% 0.0509 (0.0495-0.0523) 0.7782 (0.7757-0.7807) 
75% 0.0515 (0.0501-0.0529) 0.7789 (0.7764-0.7814) 
100% 0.0501 (0.0487-0.0515) 0.8004 (0.7979-0.8029) 
0.70 0.15 118 25% 0.0536 (0.0522-0.0550) 0.7227 (0.7202-0.7252) 
50% 0.0517 (0.0503-0.0531) 0.7397 (0.7372-0.7422) 
75% 0.0494 (0.0480-0.0508) 0.7563 (0.7538-0.7588) 
100% 0.0512 (0.0498-0.0526) 0.7958 (0.7933-0.7983) 
0.70 0.075 537 25% 0.0519 (0.0505-0.0533) 0.7751 (0.7726-0.7776) 
50% 0.0514 (0.0500-0.0528) 0.7803 (0.7778-0.7828) 
75% 0.0502 (0.0488-0.0516) 0.7809 (0.7784-0.7834) 
100% 0.0511 (0.0497-0.0525) 0.7987 (0.7962-0.8012) 
0.60 0.20 79 25% 0.0531 (0.0517-0.0545) 0.7264 (0.7239-0.7289) 
50% 0.0545 (0.0531-0.0559) 0.7380 (0.7355-0.7405) 
75% 0.0506 (0.0492-0.0520) 0.7562 (0.7537-0.7587) 
100% 0.0494 (0.0480-0.0508) 0.7965 (0.7940-0.7990) 
0.60 0.10 354 25% 0.0501 (0.0487-0.0515) 0.7798 (0.7773-0.7823) 
50% 0.0509 (0.0495-0.0523) 0.7845 (0.7820-0.7870) 
75% 0.0501 (0.0487-0.0515) 0.7857 (0.7832-0.7882) 
100% 0.0496 (0.0482-0.0510) 0.8007 (0.7982-0.8032) 
Note:  
1. SS = sample size, IAL = interim analysis location. 
2. Interim analysis location refers to the percent of subjects out of the original protocol-
specified sample size who have been assessed for the outcome at the interim analysis. 




Table A.46: Results from Simulations where the Minimum Allowable Sample Size is 10% more 
than the Interim Analysis Sample Size and the Maximum Allowable Sample Size is Twice the 
Original Protocol-Specified Sample Size for the HW-SSR Method for the Alternative Hypothesis 
Ha: pe = pc + Δ when the Outcome is Positive (Part 2). 
Control 
Group 




Effect (Δ) IAL 
Simulated Lower Type I 
Error (95% CI) 
Simulated Upper Type I 






0.90 0.05 25% 0.0326 (0.0316-0.0336) 0.0224 (0.0214-0.0234) 429 3517 
50% 0.0298 (0.0288-0.0308) 0.0221 (0.0211-0.0231) 431 325 
75% 0.0275 (0.0265-0.0285) 0.0233 (0.0223-0.0243) 441 160 
100% 0.0258 (0.0248-0.0268) 0.0259 (0.0249-0.0269) 432 30 
0.80 0.10 25% 0.0325 (0.0315-0.0335) 0.0233 (0.0223-0.0243) 192 4875 
50% 0.0301 (0.0291-0.0311) 0.0227 (0.0217-0.0237) 195 280 
75% 0.0266 (0.0256-0.0276) 0.0233 (0.0223-0.0243) 199 38 
100% 0.0248 (0.0238-0.0258) 0.0253 (0.0243-0.0263) 197 11 
0.80 0.05 25% 0.0258 (0.0248-0.0268) 0.0241 (0.0231-0.0251) 899 0 
50% 0.0273 (0.0263-0.0283) 0.0237 (0.0227-0.0247) 901 0 
75% 0.0273 (0.0263-0.0283) 0.0242 (0.0232-0.0252) 902 0 
100% 0.0255 (0.0245-0.0265) 0.0246 (0.0236-0.0256) 903 0 
0.70 0.15 25% 0.0304 (0.0294-0.0314) 0.0232 (0.0222-0.0242) 114 3078 
50% 0.0289 (0.0279-0.0299) 0.0229 (0.0219-0.0239) 116 268 
75% 0.0260 (0.0250-0.0270) 0.0234 (0.0224-0.0244) 119 64 
100% 0.0254 (0.0244-0.0264) 0.0259 (0.0249-0.0269) 118 8 
0.70 0.075 25% 0.0273 (0.0263-0.0283) 0.0245 (0.0235-0.0255) 532 0 
50% 0.0266 (0.0256-0.0276) 0.0248 (0.0238-0.0258) 535 0 
75% 0.0259 (0.0249-0.0269) 0.0243 (0.0233-0.0253) 535 0 
100% 0.0253 (0.0243-0.0263) 0.0258 (0.0248-0.0268) 537 0 
0.60 0.20 25% 0.0296 (0.0286-0.0306) 0.0235 (0.0225-0.0245) 75 5088 
50% 0.0310 (0.0300-0.0320) 0.0235 (0.0225-0.0245) 77 604 
75% 0.0268 (0.0258-0.0278) 0.0238 (0.0228-0.0248) 78 92 
100% 0.0243 (0.0233-0.0253) 0.0250 (0.0240-0.0260) 79 9 
0.60 0.10 25% 0.0262 (0.0252-0.0272) 0.0239 (0.0229-0.0249) 349 0 
50% 0.0261 (0.0251-0.0271) 0.0247 (0.0237-0.0257) 352 0 
75% 0.0256 (0.0246-0.0266) 0.0245 (0.0235-0.0255) 352 0 
100% 0.0249 (0.0239-0.0259) 0.0247 (0.0237-0.0257) 354 0 
Note:  
1. IAL = interim analysis location. 
2. Interim analysis location refers to the percent of subjects out of the original protocol-
specified sample size who have been assessed for the outcome at the interim analysis. 
100% refers to the situation where no sample size re-estimation is planned. 





Table A.47: Results from Simulations where the Minimum Allowable Sample Size is 10% more 
than the Interim Analysis Sample Size and where there is No Maximum Allowable Sample Size 
for the HW-SSR Method for the Alternative Hypothesis Ha: pe = pc + Δ when the Outcome is 
Positive (Part 1). 
Control 
Group 










Type I Error (95% CI) 
Simulated Power 
(95% CI) 
0.90 0.05 432 25% 0.0542 (0.0528-0.0556) 0.7196 (0.7171-0.7221) 
50% 0.0530 (0.0516-0.0544) 0.7364 (0.7339-0.7389) 
75% 0.0511 (0.0497-0.0525) 0.7608 (0.7583-0.7633) 
100% 0.0532 (0.0518-0.0546) 0.8061 (0.8036-0.8086) 
0.80 0.10 197 25% 0.0533 (0.0519-0.0547) 0.7202 (0.7177-0.7227) 
50% 0.0532 (0.0518-0.0546) 0.7351 (0.7326-0.7376) 
75% 0.0480 (0.0466-0.0494) 0.7600 (0.7575-0.7625) 
100% 0.0503 (0.0489-0.0517) 0.8047 (0.8022-0.8072) 
0.80 0.05 903 25% 0.0505 (0.0491-0.0519) 0.7736 (0.7711-0.7761) 
50% 0.0522 (0.0508-0.0536) 0.7782 (0.7757-0.7807) 
75% 0.0497 (0.0483-0.0511) 0.7791 (0.7766-0.7816) 
100% 0.0500 (0.0486-0.0514) 0.7999 (0.7974-0.8024) 
0.70 0.15 118 25% 0.0546 (0.0532-0.0560) 0.7212 (0.7187-0.7237) 
50% 0.0540 (0.0526-0.0554) 0.7403 (0.7378-0.7428) 
75% 0.0489 (0.0475-0.0503) 0.7603 (0.7578-0.7628) 
100% 0.0502 (0.0488-0.0516) 0.7981 (0.7956-0.8006) 
0.70 0.075 537 25% 0.0510 (0.0496-0.0524) 0.7761 (0.7736-0.7786) 
50% 0.0507 (0.0493-0.0521) 0.7797 (0.7772-0.7822) 
75% 0.0503 (0.0489-0.0517) 0.7814 (0.7789-0.7839) 
100% 0.0505 (0.0491-0.0519) 0.7977 (0.7952-0.8002) 
0.60 0.20 79 25% 0.0536 (0.0522-0.0550) 0.7256 (0.7231-0.7281) 
50% 0.0542 (0.0528-0.0556) 0.7435 (0.7410-0.7460) 
75% 0.0515 (0.0501-0.0529) 0.7549 (0.7524-0.7574) 
100% 0.0474 (0.0460-0.0488) 0.7942 (0.7917-0.7967) 
0.60 0.10 354 25% 0.0496 (0.0482-0.0510) 0.7807 (0.7782-0.7832) 
50% 0.0513 (0.0499-0.0527) 0.7859 (0.7834-0.7884) 
75% 0.0500 (0.0486-0.0514) 0.7834 (0.7809-0.7859) 
100% 0.0507 (0.0493-0.0521) 0.8008 (0.7983-0.8033) 
Note:  
1. SS = sample size, IAL = interim analysis location. 
2. Interim analysis location refers to the percent of subjects out of the original protocol-
specified sample size who have been assessed for the outcome at the interim analysis. 




Table A.48: Results from Simulations where the Minimum Allowable Sample Size is 10% more 
than the Interim Analysis Sample Size and where there is No Maximum Allowable Sample Size 
for the HW-SSR Method for the Alternative Hypothesis Ha: pe = pc + Δ when the Outcome is 
Positive (Part 2). 
Control 
Group 




Effect (Δ) IAL 
Simulated Lower Type I 
Error (95% CI) 
Simulated Upper Type I 






0.90 0.05 25% 0.0314 (0.0304-0.0324) 0.0228 (0.0218-0.0238) 429 3491 
50% 0.0298 (0.0288-0.0308) 0.0232 (0.0222-0.0242) 431 315 
75% 0.0275 (0.0265-0.0285) 0.0236 (0.0226-0.0246) 441 165 
100% 0.0266 (0.0256-0.0276) 0.0267 (0.0257-0.0277) 432 33 
0.80 0.10 25% 0.0312 (0.0302-0.0322) 0.0221 (0.0211-0.0231) 192 4873 
50% 0.0301 (0.0291-0.0311) 0.0231 (0.0221-0.0241) 195 274 
75% 0.0257 (0.0247-0.0267) 0.0223 (0.0213-0.0233) 199 43 
100% 0.0247 (0.0237-0.0257) 0.0256 (0.0246-0.0266) 197 8 
0.80 0.05 25% 0.0265 (0.0255-0.0275) 0.0240 (0.0230-0.0250) 898 0 
50% 0.0277 (0.0267-0.0287) 0.0245 (0.0235-0.0255) 901 0 
75% 0.0264 (0.0254-0.0274) 0.0233 (0.0223-0.0243) 902 0 
100% 0.0252 (0.0242-0.0262) 0.0248 (0.0238-0.0258) 903 0 
0.70 0.15 25% 0.0312 (0.0302-0.0322) 0.0235 (0.0225-0.0245) 114 3000 
50% 0.0300 (0.0290-0.0310) 0.0240 (0.0230-0.0250) 116 245 
75% 0.0258 (0.0248-0.0268) 0.0231 (0.0221-0.0241) 119 52 
100% 0.0254 (0.0244-0.0264) 0.0248 (0.0238-0.0258) 118 4 
0.70 0.075 25% 0.0269 (0.0259-0.0279) 0.0241 (0.0231-0.0251) 533 0 
50% 0.0267 (0.0257-0.0277) 0.0240 (0.0230-0.0250) 535 0 
75% 0.0262 (0.0252-0.0272) 0.0241 (0.0231-0.0251) 535 0 
100% 0.0258 (0.0248-0.0268) 0.0247 (0.0237-0.0257) 537 0 
0.60 0.20 25% 0.0303 (0.0293-0.0313) 0.0233 (0.0223-0.0243) 75 5160 
50% 0.0307 (0.0297-0.0317) 0.0235 (0.0225-0.0245) 77 569 
75% 0.0274 (0.0264-0.0284) 0.0241 (0.0231-0.0251) 78 100 
100% 0.0239 (0.0229-0.0249) 0.0235 (0.0225-0.0245) 79 5 
0.60 0.10 25% 0.0256 (0.0246-0.0266) 0.0240 (0.0230-0.0250) 349 0 
50% 0.0261 (0.0251-0.0271) 0.0252 (0.0242-0.0262) 352 0 
75% 0.0261 (0.0251-0.0271) 0.0239 (0.0229-0.0249) 352 0 
100% 0.0255 (0.0245-0.0265) 0.0252 (0.0242-0.0262) 354 0 
Note:  
1. IAL = interim analysis location. 
2. Interim analysis location refers to the percent of subjects out of the original protocol-
specified sample size who have been assessed for the outcome at the interim analysis. 
100% refers to the situation where no sample size re-estimation is planned. 





Table A.49: Results from Simulations where the Minimum Allowable Sample Size is the Original 
Protocol-Specified Sample Size and the Maximum Allowable Sample Size is Twice the Original 
Protocol-Specified Sample Size for the HW-SSR Method for the Alternative Hypothesis Ha: pe = pc 
+ Δ when the Outcome is Positive (Part 1). 
Control 
Group 










Type I Error (95% CI) 
Simulated Power 
(95% CI) 
0.90 0.05 432 25% 0.0518 (0.0504-0.0532) 0.8280 (0.8255-0.8305) 
50% 0.0487 (0.0473-0.0501) 0.8177 (0.8152-0.8202) 
75% 0.0506 (0.0492-0.0520) 0.8114 (0.8089-0.8139) 
100% 0.0518 (0.0504-0.0532) 0.8068 (0.8043-0.8093) 
0.80 0.10 197 25% 0.0472 (0.0458-0.0486) 0.8207 (0.8182-0.8232) 
50% 0.0482 (0.0468-0.0496) 0.8132 (0.8107-0.8157) 
75% 0.0482 (0.0468-0.0496) 0.8082 (0.8057-0.8107) 
100% 0.0517 (0.0503-0.0531) 0.8012 (0.7987-0.8037) 
0.80 0.05 903 25% 0.0497 (0.0483-0.0511) 0.8060 (0.8035-0.8085) 
50% 0.0500 (0.0486-0.0514) 0.8026 (0.8001-0.8051) 
75% 0.0504 (0.0490-0.0518) 0.8030 (0.8005-0.8055) 
100% 0.0490 (0.0476-0.0504) 0.8010 (0.7985-0.8035) 
0.70 0.15 118 25% 0.0504 (0.0490-0.0518) 0.8110 (0.8085-0.8135) 
50% 0.0495 (0.0481-0.0509) 0.8038 (0.8013-0.8063) 
75% 0.0481 (0.0467-0.0495) 0.8044 (0.8019-0.8069) 
100% 0.0522 (0.0508-0.0536) 0.7953 (0.7928-0.7978) 
0.70 0.075 537 25% 0.0513 (0.0499-0.0527) 0.8036 (0.8011-0.8061) 
50% 0.0489 (0.0475-0.0503) 0.8037 (0.8012-0.8062) 
75% 0.0491 (0.0477-0.0505) 0.7996 (0.7971-0.8021) 
100% 0.0506 (0.0492-0.0520) 0.8002 (0.7977-0.8027) 
0.60 0.20 79 25% 0.0496 (0.0482-0.0510) 0.8055 (0.8030-0.8080) 
50% 0.0492 (0.0478-0.0506) 0.8001 (0.7976-0.8026) 
75% 0.0486 (0.0472-0.0500) 0.7974 (0.7949-0.7999) 
100% 0.0483 (0.0469-0.0497) 0.7950 (0.7925-0.7975) 
0.60 0.10 354 25% 0.0502 (0.0488-0.0516) 0.8064 (0.8039-0.8089) 
50% 0.0492 (0.0478-0.0506) 0.8015 (0.7990-0.8040) 
75% 0.0505 (0.0491-0.0519) 0.8019 (0.7994-0.8044) 
100% 0.0503 (0.0489-0.0517) 0.7984 (0.7959-0.8009) 
Note:  
1. SS = sample size, IAL = interim analysis location. 
2. Interim analysis location refers to the percent of subjects out of the original protocol-
specified sample size who have been assessed for the outcome at the interim analysis. 




Table A.50: Results from Simulations where the Minimum Allowable Sample Size is the Original 
Protocol-Specified Sample Size and the Maximum Allowable Sample Size is Twice the Original 
Protocol-Specified Sample Size for the HW-SSR Method for the Alternative Hypothesis Ha: pe = pc 
+ Δ when the Outcome is Positive (Part 2). 
Control 
Group 




Effect (Δ) IAL 
Simulated Lower Type I 
Error (95% CI) 
Simulated Upper Type I 






0.90 0.05 25% 0.0277 (0.0267-0.0287) 0.0241 (0.0231-0.0251) 491 3610 
50% 0.0253 (0.0243-0.0263) 0.0234 (0.0224-0.0244) 474 335 
75% 0.0265 (0.0255-0.0275) 0.0241 (0.0231-0.0251) 467 165 
100% 0.0259 (0.0249-0.0269) 0.0259 (0.0249-0.0269) 432 27 
0.80 0.10 25% 0.0241 (0.0231-0.0251) 0.0231 (0.0221-0.0241) 219 4770 
50% 0.0243 (0.0233-0.0253) 0.0239 (0.0229-0.0249) 213 282 
75% 0.0248 (0.0238-0.0258) 0.0234 (0.0224-0.0244) 210 44 
100% 0.0256 (0.0246-0.0266) 0.0262 (0.0252-0.0272) 197 4 
0.80 0.05 25% 0.0261 (0.0251-0.0271) 0.0236 (0.0226-0.0246) 944 0 
50% 0.0258 (0.0248-0.0268) 0.0242 (0.0232-0.0252) 933 0 
75% 0.0254 (0.0244-0.0264) 0.0250 (0.0240-0.0260) 927 0 
100% 0.0246 (0.0236-0.0256) 0.0245 (0.0235-0.0255) 903 0 
0.70 0.15 25% 0.0261 (0.0251-0.0271) 0.0243 (0.0233-0.0253) 128 2891 
50% 0.0259 (0.0249-0.0269) 0.0236 (0.0226-0.0246) 126 293 
75% 0.0247 (0.0237-0.0257) 0.0234 (0.0224-0.0244) 125 57 
100% 0.0259 (0.0249-0.0269) 0.0263 (0.0253-0.0273) 118 10 
0.70 0.075 25% 0.0263 (0.0253-0.0273) 0.0251 (0.0241-0.0261) 556 0 
50% 0.0250 (0.0240-0.0260) 0.0239 (0.0229-0.0249) 551 0 
75% 0.0252 (0.0242-0.0262) 0.0239 (0.0229-0.0249) 548 0 
100% 0.0257 (0.0247-0.0267) 0.0249 (0.0239-0.0259) 537 0 
0.60 0.20 25% 0.0254 (0.0244-0.0264) 0.0242 (0.0232-0.0252) 83 5059 
50% 0.0250 (0.0240-0.0260) 0.0242 (0.0232-0.0252) 83 623 
75% 0.0248 (0.0238-0.0258) 0.0238 (0.0228-0.0248) 82 80 
100% 0.0241 (0.0231-0.0251) 0.0242 (0.0232-0.0252) 79 5 
0.60 0.10 25% 0.0253 (0.0243-0.0263) 0.0249 (0.0239-0.0259) 361 0 
50% 0.0244 (0.0234-0.0254) 0.0247 (0.0237-0.0257) 360 0 
75% 0.0263 (0.0253-0.0273) 0.0243 (0.0233-0.0253) 359 0 
100% 0.0249 (0.0239-0.0259) 0.0254 (0.0244-0.0264) 354 0 
Note:  
1. IAL = interim analysis location. 
2. Interim analysis location refers to the percent of subjects out of the original protocol-
specified sample size who have been assessed for the outcome at the interim analysis. 
100% refers to the situation where no sample size re-estimation is planned. 





Table A.51: Results from Simulations where the Minimum Allowable Sample Size is the Original 
Protocol-Specified Sample Size and where there is No Maximum Allowable Sample Size for the 














Type I Error (95% CI) 
Simulated Power 
(95% CI) 
0.90 0.05 432 25% 0.0502 (0.0488-0.0516) 0.8246 (0.8221-0.8271) 
50% 0.0494 (0.0480-0.0508) 0.8169 (0.8144-0.8194) 
75% 0.0499 (0.0485-0.0513) 0.8121 (0.8096-0.8146) 
100% 0.0517 (0.0503-0.0531) 0.8068 (0.8043-0.8093) 
0.80 0.10 197 25% 0.0484 (0.0470-0.0498) 0.8215 (0.8190-0.8240) 
50% 0.0500 (0.0486-0.0514) 0.8127 (0.8102-0.8152) 
75% 0.0494 (0.0480-0.0508) 0.8072 (0.8047-0.8097) 
100% 0.0517 (0.0503-0.0531) 0.8032 (0.8007-0.8057) 
0.80 0.05 903 25% 0.0493 (0.0479-0.0507) 0.8065 (0.8040-0.8090) 
50% 0.0496 (0.0482-0.0510) 0.8012 (0.7987-0.8037) 
75% 0.0491 (0.0477-0.0505) 0.8007 (0.7982-0.8032) 
100% 0.0509 (0.0495-0.0523) 0.7991 (0.7966-0.8016) 
0.70 0.15 118 25% 0.0490 (0.0476-0.0504) 0.8121 (0.8096-0.8146) 
50% 0.0486 (0.0472-0.0500) 0.8034 (0.8009-0.8059) 
75% 0.0492 (0.0478-0.0506) 0.8027 (0.8002-0.8052) 
100% 0.0499 (0.0485-0.0513) 0.7972 (0.7947-0.7997) 
0.70 0.075 537 25% 0.0499 (0.0485-0.0513) 0.8034 (0.8009-0.8059) 
50% 0.0495 (0.0481-0.0509) 0.8015 (0.7990-0.8040) 
75% 0.0490 (0.0476-0.0504) 0.7990 (0.7965-0.8015) 
100% 0.0488 (0.0474-0.0502) 0.7974 (0.7949-0.7999) 
0.60 0.20 79 25% 0.0479 (0.0465-0.0493) 0.8046 (0.8021-0.8071) 
50% 0.0485 (0.0471-0.0499) 0.8011 (0.7986-0.8036) 
75% 0.0474 (0.0460-0.0488) 0.7980 (0.7955-0.8005) 
100% 0.0477 (0.0463-0.0491) 0.7963 (0.7938-0.7988) 
0.60 0.10 354 25% 0.0492 (0.0478-0.0506) 0.8040 (0.8015-0.8065) 
50% 0.0509 (0.0495-0.0523) 0.8006 (0.7981-0.8031) 
75% 0.0505 (0.0491-0.0519) 0.8019 (0.7994-0.8044) 
100% 0.0509 (0.0495-0.0523) 0.8017 (0.7992-0.8042) 
Note:  
1. SS = sample size, IAL = interim analysis location. 
2. Interim analysis location refers to the percent of subjects out of the original protocol-
specified sample size who have been assessed for the outcome at the interim analysis. 




Table A.52: Results from Simulations where the Minimum Allowable Sample Size is the Original 
Protocol-Specified Sample Size and where there is No Maximum Allowable Sample Size for the 








Effect (Δ) IAL 
Simulated Lower Type I 
Error (95% CI) 
Simulated Upper Type I 






0.90 0.05 25% 0.0260 (0.0250-0.0270) 0.0242 (0.0232-0.0252) 491 3512 
50% 0.0257 (0.0247-0.0267) 0.0237 (0.0227-0.0247) 474 342 
75% 0.0259 (0.0249-0.0269) 0.0240 (0.0230-0.0250) 467 173 
100% 0.0259 (0.0249-0.0269) 0.0257 (0.0247-0.0267) 432 21 
0.80 0.10 25% 0.0255 (0.0245-0.0265) 0.0230 (0.0220-0.0240) 219 4854 
50% 0.0263 (0.0253-0.0273) 0.0237 (0.0227-0.0247) 213 279 
75% 0.0255 (0.0245-0.0265) 0.0239 (0.0229-0.0249) 211 49 
100% 0.0264 (0.0254-0.0274) 0.0254 (0.0244-0.0264) 197 7 
0.80 0.05 25% 0.0255 (0.0245-0.0265) 0.0238 (0.0228-0.0248) 944 0 
50% 0.0254 (0.0244-0.0264) 0.0242 (0.0232-0.0252) 933 0 
75% 0.0245 (0.0235-0.0255) 0.0246 (0.0236-0.0256) 927 0 
100% 0.0254 (0.0244-0.0264) 0.0255 (0.0245-0.0265) 903 0 
0.70 0.15 25% 0.0252 (0.0242-0.0262) 0.0238 (0.0228-0.0248) 128 3036 
50% 0.0259 (0.0249-0.0269) 0.0227 (0.0217-0.0237) 126 238 
75% 0.0252 (0.0242-0.0262) 0.0240 (0.0230-0.0250) 125 74 
100% 0.0246 (0.0236-0.0256) 0.0253 (0.0243-0.0263) 118 8 
0.70 0.075 25% 0.0255 (0.0245-0.0265) 0.0244 (0.0234-0.0254) 556 0 
50% 0.0255 (0.0245-0.0265) 0.0240 (0.0230-0.0250) 551 0 
75% 0.0256 (0.0246-0.0266) 0.0235 (0.0225-0.0245) 548 0 
100% 0.0246 (0.0236-0.0256) 0.0243 (0.0233-0.0253) 537 0 
0.60 0.20 25% 0.0248 (0.0238-0.0258) 0.0231 (0.0221-0.0241) 83 5116 
50% 0.0245 (0.0235-0.0255) 0.0240 (0.0230-0.0250) 83 603 
75% 0.0242 (0.0232-0.0252) 0.0233 (0.0223-0.0243) 82 85 
100% 0.0233 (0.0223-0.0243) 0.0244 (0.0234-0.0254) 79 7 
0.60 0.10 25% 0.0247 (0.0237-0.0257) 0.0246 (0.0236-0.0256) 361 0 
50% 0.0261 (0.0251-0.0271) 0.0248 (0.0238-0.0258) 360 0 
75% 0.0261 (0.0251-0.0271) 0.0244 (0.0234-0.0254) 359 0 
100% 0.0250 (0.0240-0.0260) 0.0260 (0.0250-0.0270) 354 0 
Note:  
1. IAL = interim analysis location. 
2. Interim analysis location refers to the percent of subjects out of the original protocol-
specified sample size who have been assessed for the outcome at the interim analysis. 
100% refers to the situation where no sample size re-estimation is planned. 
3. Extreme scenarios are those that required one of the simulation rules in Section 3.3.1 to 
be used.  
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Table A.53: Mean and Standard Error Results under the Null Hypothesis Ho: pe = pc from 
Simulations and Formulas where the Minimum Allowable Sample Size is the Interim Analysis 
Sample Size and the Maximum Allowable Sample Size is Twice the Original Protocol-Specified 




(  ) 
Relative 
Treatment 
Effect ( ) IAL 
Expected 
      
Mean 
Expected 








      
SE 
Derived 
      
Mean 
Derived 
      
SE 
0.10 0.50 25% 0 0.02029 -0.00229 0.0209293 -0.002178 0.0207522 
50% 0 0.02032 -0.00228 0.0208954 -0.002252 0.0206371 
75% 0 0.02033 -0.00219 0.0204345 -0.002177 0.0204199 
100% 0 0.02041 -0.00001 0.0204173 -2.17E-13 0.0204124 
0.20 0.50 25% 0 0.04026 -0.00468 0.0416262 -0.004709 0.0414220 
50% 0 0.04024 -0.00489 0.0414614 -0.004842 0.0410631 
75% 0 0.04018 -0.00475 0.0407409 -0.004558 0.0403385 
100% 0 0.04030 -0.00003 0.0404044 -2.30E-13 0.0403034 
0.20 0.25 25% 0 0.01880 -0.00109 0.0189399 -0.001080 0.0189214 
50% 0 0.01882 -0.00115 0.0189477 -0.001079 0.0188987 
75% 0 0.01881 -0.00104 0.0189117 -0.001078 0.0188897 
100% 0 0.01882 -0.00004 0.0188083 5.23E-18 0.0188248 
0.30 0.50 25% 0 0.05980 -0.00817 0.0626455 -0.007721 0.0621332 
50% 0 0.05961 -0.00756 0.0618222 -0.007857 0.0612487 
75% 0 0.05937 -0.00717 0.0598182 -0.007140 0.0595683 
100% 0 0.05966 -0.00002 0.0597390 -1.76E-13 0.0596601 
0.30 0.25 25% 0 0.02798 -0.00198 0.0282227 -0.001791 0.0282135 
50% 0 0.02797 -0.00177 0.0281918 -0.001785 0.0281501 
75% 0 0.02797 -0.00179 0.028104 -0.001780 0.0281191 
100% 0 0.02797 0.00006 0.0279496 -2.26E-18 0.0279665 
0.40 0.50 25% 0 0.07890 -0.01174 0.0832718 -0.011487 0.0831620 
50% 0 0.07822 -0.01096 0.0813856 -0.011388 0.0809823 
75% 0 0.07760 -0.00998 0.0779625 -0.009803 0.0776715 
100% 0 0.07795 0.00015 0.0780964 -8.05E-14 0.0779484 
0.40 0.25 25% 0 0.03691 -0.00275 0.0373163 -0.002675 0.0373568 
50% 0 0.03687 -0.00260 0.0370692 -0.002656 0.0372103 
75% 0 0.03686 -0.00244 0.0372517 -0.002630 0.0371118 
100% 0 0.03682 -0.00003 0.0369663 -8.86E-18 0.0368230 
Note:  
1. IAL = interim analysis location. 
2. Interim analysis location refers to the percent of subjects out of the original protocol-
specified sample size who have been assessed for the outcome at the interim analysis. 
100% refers to the situation where no sample size re-estimation is planned. 
3. Theoretically derived refers to the results from the formulas derived in Section 3.4.1.  
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Table A.54: Mean and Standard Error Results under the Alternative Hypothesis Ha: pe = (1 - γ)pc 
from Simulations and Formulas where the Minimum Allowable Sample Size is the Interim 
Analysis Sample Size and the Maximum Allowable Sample Size is Twice the Original Protocol-




(  ) 
Relative 
Treatment 
Effect ( ) IAL 
Expected 
      
Mean 
Expected 








      
SE 
Derived 
      
Mean 
Derived 
      
SE 
0.10 0.50 25% -0.050 0.01774 -0.05223 0.0184148 -0.052178 0.0181923 
50% -0.050 0.01776 -0.05226 0.0182529 -0.052252 0.0180856 
75% -0.050 0.01777 -0.05221 0.0178973 -0.052177 0.0178503 
100% -0.050 0.01784 -0.04990 0.0178340 -0.050000 0.0178406 
0.20 0.50 25% -0.100 0.03559 -0.10471 0.0370444 -0.104709 0.0367560 
50% -0.100 0.03557 -0.10490 0.0369578 -0.104842 0.0364234 
75% -0.100 0.03551 -0.10469 0.0361374 -0.104558 0.0356504 
100% -0.100 0.03562 -0.10008 0.0355954 -0.100000 0.0356235 
0.20 0.25 25% -0.050 0.01782 -0.05111 0.0179778 -0.051080 0.0179406 
50% -0.050 0.01784 -0.05119 0.0179306 -0.051079 0.0179190 
75% -0.050 0.01783 -0.05101 0.0179019 -0.051078 0.0179103 
100% -0.050 0.01784 -0.04997 0.0178621 -0.050000 0.0178433 
0.30 0.50 25% -0.150 0.05360 -0.15784 0.0566030 -0.157721 0.0559782 
50% -0.150 0.05343 -0.15766 0.0558234 -0.157857 0.0551436 
75% -0.150 0.05322 -0.15719 0.0537499 -0.157140 0.0533760 
100% -0.150 0.05348 -0.15012 0.0534922 -0.150000 0.0534806 
0.30 0.25 25% -0.075 0.02676 -0.07682 0.0270985 -0.076791 0.0270012 
50% -0.075 0.02676 -0.07683 0.0269523 -0.076785 0.0269403 
75% -0.075 0.02676 -0.07687 0.0268991 -0.076780 0.0269098 
100% -0.075 0.02675 -0.07505 0.0267661 -0.075000 0.0267541 
0.40 0.50 25% -0.200 0.07203 -0.21170 0.0765406 -0.211487 0.0763935 
50% -0.200 0.07141 -0.21117 0.0748189 -0.211388 0.0742721 
75% -0.200 0.07084 -0.20984 0.0710299 -0.209803 0.0708377 
100% -0.200 0.07116 -0.19978 0.0712711 -0.200000 0.0711568 
0.40 0.25 25% -0.100 0.03574 -0.10257 0.0362745 -0.102675 0.0361865 
50% -0.100 0.03570 -0.10257 0.0359957 -0.102656 0.0360440 
75% -0.100 0.03569 -0.10247 0.0360548 -0.102630 0.0359455 
100% -0.100 0.03565 -0.10001 0.0355252 -0.100000 0.0356537 
Note:  
1. IAL = interim analysis location. 
2. Interim analysis location refers to the percent of subjects out of the original protocol-
specified sample size who have been assessed for the outcome at the interim analysis. 
100% refers to the situation where no sample size re-estimation is planned. 
3. Theoretically derived refers to the results from the formulas derived in Section 3.4.1.  
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Table A.55: Mean and Standard Error Results under the Null Hypothesis Ho: pe = pc from 
Simulations and Formulas where the Minimum Allowable Sample Size is the Interim Analysis 
Sample Size and where there is No Maximum Allowable Sample Size for the HW-SSR Method 




(  ) 
Relative 
Treatment 
Effect ( ) IAL 
Expected 
      
Mean 
Expected 








      
SE 
Derived 
      
Mean 
Derived 
      
SE 
0.10 0.50 25% 0 0.02024 -0.00230 0.0208969 -0.002273 0.0206603 
50% 0 0.02031 -0.00227 0.0208511 -0.002271 0.0206173 
75% 0 0.02033 -0.00219 0.0204807 -0.002182 0.0204147 
100% 0 0.02041 0.00017 0.0204730 -2.17E-13 0.0204124 
0.20 0.50 25% 0 0.04015 -0.00518 0.0416840 -0.004913 0.0412254 
50% 0 0.04022 -0.00518 0.0415269 -0.004889 0.0410163 
75% 0 0.04018 -0.00455 0.0405763 -0.004570 0.0403251 
100% 0 0.04030 -0.00005 0.0403427 -2.3E-13 0.0403034 
0.20 0.25 25% 0 0.01882 -0.00107 0.0190272 -0.001081 0.0189211 
50% 0 0.01881 -0.00108 0.0189505 -0.001079 0.0188987 
75% 0 0.01882 -0.00109 0.0188787 -0.001078 0.0188897 
100% 0 0.01882 -0.00004 0.0187975 5.23E-18 0.0188248 
0.30 0.50 25% 0 0.05950 -0.00826 0.0622008 -0.008065 0.0617995 
50% 0 0.05955 -0.00791 0.0612710 -0.007948 0.0611587 
75% 0 0.05933 -0.00689 0.0598829 -0.007164 0.0595401 
100% 0 0.05966 -0.00008 0.0594602 -1.76E-13 0.0596601 
0.30 0.25 25% 0 0.02798 -0.00184 0.0282872 -0.001792 0.0282126 
50% 0 0.02798 -0.00187 0.0282585 -0.001785 0.0281501 
75% 0 0.02798 -0.00178 0.0281165 -0.001780 0.0281191 
100% 0 0.02797 0.000020 0.0279226 -2.26E-18 0.0279665 
0.40 0.50 25% 0 0.07838 -0.01174 0.0824092 -0.011993 0.0826706 
50% 0 0.07822 -0.01165 0.0813389 -0.011531 0.0808410 
75% 0 0.07751 -0.00974 0.0778749 -0.009845 0.0776221 
100% 0 0.07795 0.000090 0.0780581 -8.05E-14 0.0779484 
0.40 0.25 25% 0 0.03690 -0.00278 0.0372998 -0.002677 0.0373547 
50% 0 0.03687 -0.00249 0.0371640 -0.002656 0.0372103 
75% 0 0.03686 -0.00275 0.0372452 -0.002630 0.0371118 
100% 0 0.03682 -0.00014 0.0369135 -8.86E-18 0.0368230 
Note:  
1. IAL = interim analysis location. 
2. Interim analysis location refers to the percent of subjects out of the original protocol-
specified sample size who have been assessed for the outcome at the interim analysis. 
100% refers to the situation where no sample size re-estimation is planned. 
3. Theoretically derived refers to the results from the formulas derived in Section 3.4.1.  
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Table A.56: Mean and Standard Error Results under the Alternative Hypothesis Ha: pe = (1 - γ)pc 
from Simulations and Formulas where the Minimum Allowable Sample Size is the Interim 
Analysis Sample Size and where there is No Maximum Allowable Sample Size for the HW-SSR 




(  ) 
Relative 
Treatment 
Effect ( ) IAL 
Expected 
      
Mean 
Expected 








      
SE 
Derived 
      
Mean 
Derived 
      
SE 
0.10 0.50 25% -0.050 0.01769 -0.05232 0.0183423 -0.052273 0.0181027 
50% -0.050 0.01776 -0.05232 0.0184140 -0.052271 0.0180647 
75% -0.050 0.01777 -0.05213 0.0179052 -0.052182 0.0178447 
100% -0.050 0.01784 -0.04991 0.0179131 -0.050000 0.0178406 
0.20 0.50 25% -0.100 0.03549 -0.10526 0.0371375 -0.104913 0.0365639 
50% -0.100 0.03555 -0.10496 0.0369132 -0.104889 0.0363745 
75% -0.100 0.03551 -0.10456 0.0359297 -0.104570 0.0356359 
100% -0.100 0.03562 -0.10006 0.0356129 -0.100000 0.0356235 
0.20 0.25 25% -0.050 0.01784 -0.05103 0.0180052 -0.051081 0.0179403 
50% -0.050 0.01783 -0.05109 0.0179445 -0.051079 0.0179190 
75% -0.050 0.01784 -0.05112 0.0178937 -0.051078 0.0179103 
100% -0.050 0.01784 -0.05004 0.0177479 -0.050000 0.0178433 
0.30 0.50 25% -0.150 0.05334 -0.15829 0.0562481 -0.158065 0.0556523 
50% -0.150 0.05338 -0.15794 0.0554602 -0.157948 0.0550505 
75% -0.150 0.05319 -0.15676 0.0535086 -0.157164 0.0533458 
100% -0.150 0.05348 -0.14994 0.0533595 -0.150000 0.0534806 
0.30 0.25 25% -0.075 0.02676 -0.07678 0.0270612 -0.076792 0.0270003 
50% -0.075 0.02677 -0.07701 0.0270436 -0.076785 0.0269403 
75% -0.075 0.02677 -0.07682 0.0269336 -0.076780 0.0269098 
100% -0.075 0.02675 -0.07495 0.0266654 -0.075000 0.0267541 
0.40 0.50 25% -0.200 0.07155 -0.21174 0.0760387 -0.211993 0.0759132 
50% -0.200 0.07141 -0.21180 0.0745368 -0.211531 0.0741271 
75% -0.200 0.07076 -0.20962 0.0710813 -0.209845 0.0707855 
100% -0.200 0.07116 -0.20019 0.0712801 -0.200000 0.0711568 
0.40 0.25 25% -0.100 0.03573 -0.10244 0.0361643 -0.102677 0.0361843 
50% -0.100 0.03570 -0.10262 0.0361120 -0.102656 0.0360439 
75% -0.100 0.03569 -0.10275 0.0361416 -0.102630 0.0359455 
100% -0.100 0.03565 -0.10015 0.0357966 -0.100000 0.0356537 
Note:  
1. IAL = interim analysis location. 
2. Interim analysis location refers to the percent of subjects out of the original protocol-
specified sample size who have been assessed for the outcome at the interim analysis. 
100% refers to the situation where no sample size re-estimation is planned. 
3. Theoretically derived refers to the results from the formulas derived in Section 3.4.1.  
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Table A.57: Mean and Standard Error Results under the Null Hypothesis Ho: pe = pc from 
Simulations and Formulas where the Minimum Allowable Sample Size is 10% more than the 
Interim Analysis Sample Size and the Maximum Allowable Sample Size is Twice the Original 
Protocol-Specified Sample Size for the HW-SSR Method for the Alternative Hypothesis Ha: pe = (1 




(  ) 
Relative 
Treatment 
Effect ( ) IAL 
Expected 
      
Mean 
Expected 








      
SE 
Derived 
      
Mean 
Derived 
      
SE 
0.10 0.50 25% 0 0.02030 -0.00221 0.0209825 -0.002178 0.0207522 
50% 0 0.02031 -0.00219 0.0208180 -0.002251 0.0206346 
75% 0 0.02024 -0.00190 0.0201083 -0.001963 0.0201101 
100% 0 0.02041 -0.00004 0.0203800 -2.17E-13 0.0204124 
0.20 0.50 25% 0 0.04026 -0.00517 0.0418110 -0.004709 0.0414220 
50% 0 0.04026 -0.00517 0.0414656 -0.004834 0.0410364 
75% 0 0.03994 -0.00393 0.0396671 -0.004038 0.0396305 
100% 0 0.04030 -0.00009 0.0401890 -2.30E-13 0.0403034 
0.20 0.25 25% 0 0.01880 -0.00106 0.0189107 -0.001080 0.0189214 
50% 0 0.01882 -0.00113 0.0189627 -0.001079 0.0188987 
75% 0 0.01882 -0.00108 0.0188795 -0.001061 0.0188533 
100% 0 0.01882 -0.00010 0.0188087 5.23E-18 0.0188248 
0.30 0.50 25% 0 0.05980 -0.00805 0.0627844 -0.007721 0.0621322 
50% 0 0.05963 -0.00808 0.0618086 -0.007813 0.0611274 
75% 0 0.05891 -0.00589 0.0586867 -0.006235 0.0584034 
100% 0 0.05966 -0.00011 0.0594505 -1.76E-13 0.0596601 
0.30 0.25 25% 0 0.02797 -0.00173 0.0282284 -0.001791 0.0282135 
50% 0 0.02798 -0.00194 0.0281782 -0.001785 0.0281501 
75% 0 0.02796 -0.00171 0.0279992 -0.001726 0.0280136 
100% 0 0.02797 -0.00007 0.0280026 -2.26E-18 0.0279665 
0.40 0.50 25% 0 0.07893 -0.01133 0.0829961 -0.011479 0.0831272 
50% 0 0.07831 -0.01185 0.0808206 -0.011216 0.0805759 
75% 0 0.07690 -0.00818 0.0759217 -0.008415 0.0760027 
100% 0 0.07795 -0.00005 0.0777279 -8.05E-14 0.0779484 
0.40 0.25 25% 0 0.03693 -0.00276 0.0374325 -0.002675 0.0373568 
50% 0 0.03688 -0.00254 0.0373378 -0.002656 0.0372102 
75% 0 0.03681 -0.00255 0.0369277 -0.002494 0.0368690 
100% 0 0.03682 0.00021 0.0368265 -8.86E-18 0.0368230 
Note:  
1. IAL = interim analysis location. 
2. Interim analysis location refers to the percent of subjects out of the original protocol-
specified sample size who have been assessed for the outcome at the interim analysis. 
100% refers to the situation where no sample size re-estimation is planned. 
3. Theoretically derived refers to the results from the formulas derived in Section 3.4.1.  
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Table A.58: Mean and Standard Error Results under the Alternative Hypothesis Ha: pe = (1 - γ)pc 
from Simulations and Formulas where the Minimum Allowable Sample Size is 10% more than the 
Interim Analysis Sample Size and the Maximum Allowable Sample Size is Twice the Original 
Protocol-Specified Sample Size for the HW-SSR Method for the Alternative Hypothesis Ha: pe = (1 




(  ) 
Relative 
Treatment 
Effect ( ) IAL 
Expected 
      
Mean 
Expected 








      
SE 
Derived 
      
Mean 
Derived 
      
SE 
0.10 0.50 25% -0.050 0.01774 -0.05227 0.0183749 -0.052178 0.0181923 
50% -0.050 0.01775 -0.05228 0.0183783 -0.052251 0.0180827 
75% -0.050 0.01769 -0.05196 0.0175023 -0.051963 0.0175211 
100% -0.050 0.01784 -0.05007 0.0178676 -0.050000 0.0178406 
0.20 0.50 25% -0.100 0.03559 -0.10507 0.0372839 -0.104709 0.0367560 
50% -0.100 0.03558 -0.10515 0.0368515 -0.104834 0.0363939 
75% -0.100 0.03530 -0.10394 0.0352067 -0.104038 0.0349091 
100% -0.100 0.03562 -0.10005 0.0355633 -0.100000 0.0356235 
0.20 0.25 25% -0.050 0.01782 -0.05107 0.0179937 -0.051080 0.0179406 
50% -0.050 0.01784 -0.05107 0.0178285 -0.051079 0.0179190 
75% -0.050 0.01783 -0.05104 0.0178908 -0.051061 0.0178724 
100% -0.050 0.01784 -0.05001 0.0178012 -0.050000 0.0178433 
0.30 0.50 25% -0.150 0.05361 -0.15812 0.0563994 -0.157721 0.0559771 
50% -0.150 0.05345 -0.15816 0.0556777 -0.157813 0.0550120 
75% -0.150 0.05281 -0.15612 0.0524462 -0.156235 0.0521741 
100% -0.150 0.05348 -0.15012 0.0531594 -0.150000 0.0534806 
0.30 0.25 25% -0.075 0.02676 -0.07682 0.0269998 -0.076791 0.0270012 
50% -0.075 0.02676 -0.07676 0.0270747 -0.076785 0.0269403 
75% -0.075 0.02674 -0.07679 0.0267781 -0.076726 0.0268010 
100% -0.075 0.02675 -0.07502 0.0266762 -0.075000 0.0267541 
0.40 0.50 25% -0.200 0.07206 -0.21160 0.0764132 -0.211479 0.0763561 
50% -0.200 0.07149 -0.21197 0.0738603 -0.211216 0.0738400 
75% -0.200 0.07020 -0.20828 0.0693492 -0.208415 0.0691441 
100% -0.200 0.07116 -0.20035 0.0711318 -0.200000 0.0711568 
0.40 0.25 25% -0.100 0.03575 -0.10265 0.0363237 -0.102675 0.0361865 
50% -0.100 0.03571 -0.10269 0.0361330 -0.102656 0.0360439 
75% -0.100 0.03564 -0.10241 0.0357047 -0.102494 0.0356978 
100% -0.100 0.03565 -0.09992 0.0356796 -0.100000 0.0356537 
Note:  
1. IAL = interim analysis location. 
2. Interim analysis location refers to the percent of subjects out of the original protocol-
specified sample size who have been assessed for the outcome at the interim analysis. 
100% refers to the situation where no sample size re-estimation is planned. 
3. Theoretically derived refers to the results from the formulas derived in Section 3.4.1.  
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Table A.59: Mean and Standard Error Results under the Null Hypothesis Ho: pe = pc from 
Simulations and Formulas where the Minimum Allowable Sample Size is 10% more than the 
Interim Analysis Sample Size and where there is No Maximum Allowable Sample Size for the 




(  ) 
Relative 
Treatment 
Effect ( ) IAL 
Expected 
      
Mean 
Expected 








      
SE 
Derived 
      
Mean 
Derived 
      
SE 
0.10 0.50 25% 0 0.02023 -0.00227 0.0208608 -0.002273 0.0206603 
50% 0 0.02033 -0.00230 0.0209122 -0.002271 0.0206147 
75% 0 0.02024 -0.00203 0.0201294 -0.001967 0.0201049 
100% 0 0.02041 0.00002 0.0204275 -2.17E-13 0.0204124 
0.20 0.50 25% 0 0.04016 -0.00497 0.0417507 -0.004913 0.0412254 
50% 0 0.04022 -0.00489 0.0412139 -0.004880 0.0409896 
75% 0 0.03994 -0.00407 0.0398446 -0.004049 0.0396170 
100% 0 0.04030 -0.00002 0.0401872 -2.30E-13 0.0403034 
0.20 0.25 25% 0 0.01880 -0.00110 0.0189763 -0.001081 0.0189211 
50% 0 0.01882 -0.00102 0.0188926 -0.001079 0.0188987 
75% 0 0.01882 -0.00112 0.0188840 -0.001061 0.0188533 
100% 0 0.01882 0.00003 0.0188231 5.23E-18 0.0188248 
0.30 0.50 25% 0 0.05948 -0.00808 0.0620839 -0.008065 0.0617985 
50% 0 0.05957 -0.00786 0.0614663 -0.007904 0.0610373 
75% 0 0.05897 -0.00601 0.0586755 -0.006259 0.0583749 
100% 0 0.05966 0.00061 0.0595527 -1.76E-13 0.0596601 
0.30 0.25 25% 0 0.02798 -0.00193 0.0282719 -0.001792 0.0282126 
50% 0 0.02799 -0.00196 0.0283156 -0.001785 0.0281501 
75% 0 0.02796 -0.00163 0.0281004 -0.001726 0.0280136 
100% 0 0.02797 -0.00004 0.0279688 -2.26E-18 0.0279665 
0.40 0.50 25% 0 0.07843 -0.01200 0.0828595 -0.011985 0.0826357 
50% 0 0.07815 -0.01124 0.0805259 -0.011358 0.0804342 
75% 0 0.07689 -0.00843 0.0761265 -0.008457 0.0759530 
100% 0 0.07795 -0.00008 0.0779601 -8.05E-14 0.0779484 
0.40 0.25 25% 0 0.03691 -0.00254 0.0373272 -0.002677 0.0373547 
50% 0 0.03689 -0.00267 0.0371883 -0.002656 0.0372102 
75% 0 0.03682 -0.00266 0.0369920 -0.002494 0.0368690 
100% 0 0.03682 0.00027 0.0367866 -8.86E-18 0.0368230 
Note:  
1. IAL = interim analysis location. 
2. Interim analysis location refers to the percent of subjects out of the original protocol-
specified sample size who have been assessed for the outcome at the interim analysis. 
100% refers to the situation where no sample size re-estimation is planned. 
3. Theoretically derived refers to the results from the formulas derived in Section 3.4.1.  
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Table A.60: Mean and Standard Error Results under the Alternative Hypothesis Ha: pe = (1 - γ)pc 
from Simulations and Formulas where the Minimum Allowable Sample Size is 10% more than the 
Interim Analysis Sample Size and where there is No Maximum Allowable Sample Size for the 




(  ) 
Relative 
Treatment 
Effect ( ) IAL 
Expected 
      
Mean 
Expected 








      
SE 
Derived 
      
Mean 
Derived 
      
SE 
0.10 0.50 25% -0.050 0.01768 -0.05235 0.0183534 -0.052273 0.0181027 
50% -0.050 0.01777 -0.05228 0.0183352 -0.052271 0.0180619 
75% -0.050 0.01769 -0.05199 0.0175725 -0.051967 0.0175154 
100% -0.050 0.01784 -0.04991 0.0178318 -0.050000 0.0178406 
0.20 0.50 25% -0.100 0.03549 -0.10502 0.0370209 -0.104913 0.0365639 
50% -0.100 0.03555 -0.10487 0.0365953 -0.104880 0.0363451 
75% -0.100 0.03531 -0.10391 0.0351678 -0.104049 0.0348945 
100% -0.100 0.03562 -0.10007 0.0356312 -0.100000 0.0356235 
0.20 0.25 25% -0.050 0.01782 -0.05106 0.0179409 -0.051081 0.0179403 
50% -0.050 0.01783 -0.05106 0.0179561 -0.051079 0.0179190 
75% -0.050 0.01784 -0.05106 0.0178626 -0.051061 0.0178724 
100% -0.050 0.01784 -0.05008 0.0178302 -0.050000 0.0178433 
0.30 0.50 25% -0.150 0.05332 -0.15808 0.0562553 -0.158065 0.0556512 
50% -0.150 0.05340 -0.15787 0.0554621 -0.157904 0.0549187 
75% -0.150 0.05286 -0.15641 0.0522746 -0.156259 0.0521436 
100% -0.150 0.05348 -0.14956 0.0535046 -0.150000 0.0534806 
0.30 0.25 25% -0.075 0.02677 -0.07685 0.0270178 -0.076792 0.0270003 
50% -0.075 0.02677 -0.07701 0.0271622 -0.076785 0.0269403 
75% -0.075 0.02674 -0.07671 0.0268384 -0.076726 0.0268010 
100% -0.075 0.02675 -0.07512 0.0267305 -0.075000 0.0267541 
0.40 0.50 25% -0.200 0.07159 -0.21229 0.0760938 -0.211985 0.0758756 
50% -0.200 0.07134 -0.21151 0.0740555 -0.211358 0.0736945 
75% -0.200 0.07019 -0.20875 0.0692505 -0.208457 0.0690915 
100% -0.200 0.07116 -0.20029 0.0710367 -0.200000 0.0711568 
0.40 0.25 25% -0.100 0.03574 -0.10241 0.0361404 -0.102677 0.0361843 
50% -0.100 0.03571 -0.10285 0.0360895 -0.102656 0.0360438 
75% -0.100 0.03565 -0.10257 0.0358611 -0.102494 0.0356978 
100% -0.100 0.03565 -0.09979 0.0356241 -0.100000 0.0356537 
Note:  
1. IAL = interim analysis location. 
2. Interim analysis location refers to the percent of subjects out of the original protocol-
specified sample size who have been assessed for the outcome at the interim analysis. 
100% refers to the situation where no sample size re-estimation is planned. 
3. Theoretically derived refers to the results from the formulas derived in Section 3.4.1.  
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Table A.61: Mean and Standard Error Results under the Null Hypothesis Ho: pe = pc from 
Simulations and Formulas where the Minimum Allowable Sample Size is the Original Protocol-
Specified Sample Size and the Maximum Allowable Sample Size is Twice the Original Protocol-
Specified Sample Size for the HW-SSR Method for the Alternative Hypothesis Ha: pe = (1 - γ)pc 




(  ) 
Relative 
Treatment 
Effect ( ) IAL 
Expected 
      
Mean 
Expected 








      
SE 
Derived 
      
Mean 
Derived 
      
SE 
0.10 0.50 25% 0 0.01907 -0.00087 0.0189203 -0.000995 0.0189906 
50% 0 0.01945 -0.00101 0.0191955 -0.001085 0.0191590 
75% 0 0.01964 -0.00116 0.0192391 -0.001106 0.0192073 
100% 0 0.02041 0.00010 0.0205076 -2.17E-13 0.0204124 
0.20 0.50 25% 0 0.03760 -0.00194 0.0376518 -0.002025 0.0374118 
50% 0 0.03832 -0.00223 0.0378166 -0.002233 0.0377281 
75% 0 0.03869 -0.00215 0.0379306 -0.002290 0.0378163 
100% 0 0.04030 -0.00017 0.0402776 -2.30E-13 0.0403034 
0.20 0.25 25% 0 0.01820 -0.00052 0.0181013 -0.000515 0.0181020 
50% 0 0.01838 -0.00050 0.0182071 -0.000523 0.0182113 
75% 0 0.01847 -0.00057 0.0182198 -0.000526 0.0182397 
100% 0 0.01882 0.00011 0.0188415 5.23E-18 0.0188248 
0.30 0.50 25% 0 0.05544 -0.00336 0.0550292 -0.003112 0.0551691 
50% 0 0.05645 -0.00321 0.0558259 -0.003499 0.0556124 
75% 0 0.05704 -0.00305 0.0556105 -0.003633 0.0557329 
100% 0 0.05966 0.00001 0.0597232 -1.76E-13 0.0596601 
0.30 0.25 25% 0 0.02696 -0.00076 0.0268909 -0.000825 0.0268091 
50% 0 0.02726 -0.00092 0.0269580 -0.000843 0.0269790 
75% 0 0.02739 -0.00080 0.0271421 -0.000850 0.0270229 
100% 0 0.02797 0.00001 0.0280131 -2.26E-18 0.0279665 
0.40 0.50 25% 0 0.07229 -0.00453 0.0716297 -0.004179 0.0718627 
50% 0 0.07364 -0.00491 0.0724578 -0.004786 0.0724279 
75% 0 0.07436 -0.00480 0.0725844 -0.005004 0.0725607 
100% 0 0.07795 0.00006 0.0779486 -8.05E-14 0.0779484 
0.40 0.25 25% 0 0.03537 -0.00113 0.0352315 -0.001178 0.0351675 
50% 0 0.03580 -0.00142 0.0355367 -0.001213 0.0354032 
75% 0 0.03598 -0.00116 0.0354865 -0.001229 0.0354639 
100% 0 0.03682 0.00001 0.0366851 -8.86E-18 0.0368230 
Note:  
1. IAL = interim analysis location. 
2. Interim analysis location refers to the percent of subjects out of the original protocol-
specified sample size who have been assessed for the outcome at the interim analysis. 
100% refers to the situation where no sample size re-estimation is planned. 
3. Theoretically derived refers to the results from the formulas derived in Section 3.4.1.  
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Table A.62: Mean and Standard Error Results under the Alternative Hypothesis Ha: pe = (1 - γ)pc 
from Simulations and Formulas where the Minimum Allowable Sample Size is the Original 
Protocol-Specified Sample Size and the Maximum Allowable Sample Size is Twice the Original 
Protocol-Specified Sample Size for the HW-SSR Method for the Alternative Hypothesis Ha: pe = (1 




(  ) 
Relative 
Treatment 
Effect ( ) IAL 
Expected 
      
Mean 
Expected 








      
SE 
Derived 
      
Mean 
Derived 
      
SE 
0.10 0.50 25% -0.050 0.01667 -0.05089 0.0165408 -0.050995 0.0165435 
50% -0.050 0.01700 -0.05106 0.0167121 -0.051085 0.0166485 
75% -0.050 0.01717 -0.05108 0.0166834 -0.051106 0.0166597 
100% -0.050 0.01784 -0.04994 0.0179335 -0.050000 0.0178406 
0.20 0.50 25% -0.100 0.03323 -0.10199 0.0331050 -0.102025 0.0329676 
50% -0.100 0.03387 -0.10234 0.0333345 -0.102233 0.0331679 
75% -0.100 0.03420 -0.10207 0.0332803 -0.102290 0.0331859 
100% -0.100 0.03562 -0.09997 0.0355929 -0.100000 0.0356235 
0.20 0.25 25% -0.050 0.01726 -0.05049 0.0171970 -0.050515 0.0171446 
50% -0.050 0.01743 -0.05044 0.0172604 -0.050523 0.0172414 
75% -0.050 0.01751 -0.05050 0.0173192 -0.050526 0.0172630 
100% -0.050 0.01784 -0.04997 0.0178296 -0.050000 0.0178433 
0.30 0.50 25% -0.150 0.04970 -0.15320 0.0493288 -0.153112 0.0493246 
50% -0.150 0.05061 -0.15348 0.0498034 -0.153499 0.0496142 
75% -0.150 0.05113 -0.15316 0.049781 -0.153633 0.0496358 
100% -0.150 0.05348 -0.15012 0.0535432 -0.150000 0.0534806 
0.30 0.25 25% -0.075 0.02579 -0.07578 0.0255819 -0.075825 0.0256293 
50% -0.075 0.02608 -0.07594 0.0257542 -0.075843 0.0257826 
75% -0.075 0.02620 -0.07583 0.0258524 -0.075850 0.0258175 
100% -0.075 0.02675 -0.07498 0.0268585 -0.075000 0.0267541 
0.40 0.50 25% -0.200 0.06599 -0.20427 0.0655624 -0.204179 0.0654608 
50% -0.200 0.06722 -0.20516 0.0662482 -0.204786 0.0658503 
75% -0.200 0.06788 -0.20484 0.0659659 -0.205004 0.0658712 
100% -0.200 0.07116 -0.19981 0.0711094 -0.200000 0.0711568 
0.40 0.25 25% -0.100 0.03425 -0.10117 0.0340049 -0.101178 0.0340329 
50% -0.100 0.03467 -0.10142 0.0342494 -0.101213 0.0342514 
75% -0.100 0.03484 -0.10102 0.0343785 -0.101229 0.0343025 
100% -0.100 0.03565 -0.10001 0.0355927 -0.100000 0.0356537 
Note:  
1. IAL = interim analysis location. 
2. Interim analysis location refers to the percent of subjects out of the original protocol-
specified sample size who have been assessed for the outcome at the interim analysis. 
100% refers to the situation where no sample size re-estimation is planned. 
3. Theoretically derived refers to the results from the formulas derived in Section 3.4.1.  
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Table A.63: Mean and Standard Error Results under the Null Hypothesis Ho: pe = pc from 
Simulations and Formulas where the Minimum Allowable Sample Size is the Original Protocol-
Specified Sample Size and where there is No Maximum Allowable Sample Size for the HW-SSR 




(  ) 
Relative 
Treatment 
Effect ( ) IAL 
Expected 
      
Mean 
Expected 








      
SE 
Derived 
      
Mean 
Derived 
      
SE 
0.10 0.50 25% 0 0.01903 -0.00098 0.0189640 -0.001091 0.0188961 
50% 0 0.01946 -0.00112 0.0192180 -0.001104 0.0191388 
75% 0 0.01963 -0.00107 0.0192059 -0.001110 0.0192020 
100% 0 0.02041 0.00015 0.0204564 -2.17E-13 0.0204124 
0.20 0.50 25% 0 0.03748 -0.00227 0.0372092 -0.002229 0.0372087 
50% 0 0.03830 -0.00238 0.0377863 -0.002279 0.0376804 
75% 0 0.03868 -0.00217 0.0380240 -0.002301 0.0378027 
100% 0 0.04030 0.00003 0.0402531 -2.30E-13 0.0403034 
0.20 0.25 25% 0 0.01821 -0.00050 0.0181403 -0.000516 0.0181017 
50% 0 0.01839 -0.00059 0.0182365 -0.000523 0.0182113 
75% 0 0.01847 -0.00051 0.0182704 -0.000526 0.0182397 
100% 0 0.01882 0.00005 0.0188908 5.23E-18 0.0188248 
0.30 0.50 25% 0 0.05517 -0.00343 0.0550721 -0.003456 0.0548219 
50% 0 0.05645 -0.00337 0.0555572 -0.003589 0.0555204 
75% 0 0.05705 -0.00330 0.0558774 -0.003656 0.0557042 
100% 0 0.05966 0.00025 0.0596496 -1.76E-13 0.0596601 
0.30 0.25 25% 0 0.02696 -0.00078 0.0268530 -0.000826 0.0268083 
50% 0 0.02726 -0.00089 0.0270372 -0.000843 0.0269790 
75% 0 0.02739 -0.00086 0.0270467 -0.000850 0.0270229 
100% 0 0.02797 0.00008 0.0278773 -2.26E-18 0.0279665 
0.40 0.50 25% 0 0.07175 -0.00417 0.0712173 -0.004685 0.0713452 
50% 0 0.07359 -0.00507 0.0721060 -0.004929 0.0722829 
75% 0 0.07438 -0.00550 0.0728900 -0.005046 0.0725106 
100% 0 0.07795 0.00003 0.0779274 -8.05E-14 0.0779484 
0.40 0.25 25% 0 0.03537 -0.00105 0.0352272 -0.001180 0.0351652 
50% 0 0.03579 -0.00104 0.0354060 -0.001213 0.0354032 
75% 0 0.03598 -0.00097 0.0355331 -0.001229 0.0354639 
100% 0 0.03682 -0.00002 0.0368758 -8.86E-18 0.0368230 
Note:  
1. IAL = interim analysis location. 
2. Interim analysis location refers to the percent of subjects out of the original protocol-
specified sample size who have been assessed for the outcome at the interim analysis. 
100% refers to the situation where no sample size re-estimation is planned. 
3. Theoretically derived refers to the results from the formulas derived in Section 3.4.1.  
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Table A.64: Mean and Standard Error Results under the Alternative Hypothesis Ha: pe = (1 - γ)pc 
from Simulations and Formulas where the Minimum Allowable Sample Size is the Original 
Protocol-Specified Sample Size and where there is No Maximum Allowable Sample Size for the 




(  ) 
Relative 
Treatment 
Effect ( ) IAL 
Expected 
      
Mean 
Expected 








      
SE 
Derived 
      
Mean 
Derived 
      
SE 
0.10 0.50 25% -0.050 0.01663 -0.05102 0.0165306 -0.051091 0.0164517 
50% -0.050 0.01701 -0.05112 0.0168099 -0.051104 0.0166273 
75% -0.050 0.01716 -0.05112 0.0166604 -0.051110 0.0166539 
100% -0.050 0.01784 -0.04996 0.0178326 -0.050000 0.0178406 
0.20 0.50 25% -0.100 0.03313 -0.10213 0.0328264 -0.102229 0.0327700 
50% -0.100 0.03385 -0.10226 0.0332238 -0.102279 0.0331179 
75% -0.100 0.03419 -0.10214 0.0334110 -0.102301 0.0331711 
100% -0.100 0.03562 -0.09999 0.0356203 -0.100000 0.0356235 
0.20 0.25 25% -0.050 0.01726 -0.05055 0.0171947 -0.050516 0.0171443 
50% -0.050 0.01743 -0.05052 0.0172382 -0.050523 0.0172414 
75% -0.050 0.01751 -0.05056 0.0173627 -0.050526 0.0172630 
100% -0.050 0.01784 -0.05006 0.0178492 -0.050000 0.0178433 
0.30 0.50 25% -0.150 0.04945 -0.15337 0.0490556 -0.153456 0.0489869 
50% -0.150 0.05060 -0.15358 0.0497210 -0.153589 0.0495187 
75% -0.150 0.05114 -0.15348 0.0497607 -0.153656 0.0496051 
100% -0.150 0.05348 -0.15009 0.0532034 -0.150000 0.0534806 
0.30 0.25 25% -0.075 0.02579 -0.07571 0.0256913 -0.075826 0.0256284 
50% -0.075 0.02608 -0.07590 0.0258257 -0.075843 0.0257826 
75% -0.075 0.02620 -0.07587 0.0258579 -0.075850 0.0258175 
100% -0.075 0.02675 -0.07494 0.0266571 -0.075000 0.0267541 
0.40 0.50 25% -0.200 0.06550 -0.20447 0.0650345 -0.204685 0.0649565 
50% -0.200 0.06718 -0.20508 0.0656946 -0.204929 0.0657011 
75% -0.200 0.06790 -0.20534 0.0661281 -0.205046 0.0658182 
100% -0.200 0.07116 -0.20021 0.0710121 -0.200000 0.0711568 
0.40 0.25 25% -0.100 0.03425 -0.10115 0.0340695 -0.101180 0.0340306 
50% -0.100 0.03465 -0.10103 0.0343322 -0.101213 0.0342514 
75% -0.100 0.03484 -0.10101 0.0341874 -0.101229 0.0343025 
100% -0.100 0.03565 -0.09998 0.0356865 -0.100000 0.0356537 
Note:  
1. IAL = interim analysis location. 
2. Interim analysis location refers to the percent of subjects out of the original protocol-
specified sample size who have been assessed for the outcome at the interim analysis. 
100% refers to the situation where no sample size re-estimation is planned. 
3. Theoretically derived refers to the results from the formulas derived in Section 3.4.1.  
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Table A.65: Mean and Standard Error Results under the Null Hypothesis Ho: pe = pc from 
Simulations and Formulas where the Minimum Allowable Sample Size is the Interim Analysis 
Sample Size and the Maximum Allowable Sample Size is Twice the Original Protocol-Specified 
Sample Size for the HW-SSR Method for the Alternative Hypothesis Ha: pe = pc – Δ when the 








Effect (Δ) IAL 
Expected 
      
Mean 
Expected 








      
SE 
Derived 
      
Mean 
Derived 
      
SE 
0.10 0.05 25% 0 0.02161 0.00331 0.0228976 0.0034980 0.0232351 
50% 0 0.02097 0.00297 0.0218149 0.0029682 0.0220353 
75% 0 0.02058 0.00232 0.0207948 0.0022525 0.0207619 
100% 0 0.02041 0.00003 0.0204521 -2.17E-13 0.0204124 
0.20 0.10 25% 0 0.04260 0.00591 0.0449040 0.0062413 0.0454315 
50% 0 0.04141 0.00514 0.0430481 0.0053554 0.0434365 
75% 0 0.04071 0.00411 0.0409447 0.0041112 0.0411652 
100% 0 0.04030 -0.00017 0.0403844 -2.30E-13 0.0403034 
0.20 0.05 25% 0 0.01898 0.00082 0.0190620 0.0008673 0.0191601 
50% 0 0.01890 0.00084 0.0190079 0.0008317 0.0190398 
75% 0 0.01887 0.00079 0.0189867 0.0008202 0.0190002 
100% 0 0.01882 0.00005 0.0188042 5.23E-18 0.0188248 
0.30 0.15 25% 0 0.06274 0.00776 0.0662061 0.008110 0.0665857 
50% 0 0.06117 0.00684 0.0637098 0.0070235 0.0641198 
75% 0 0.06024 0.00540 0.0606223 0.0054490 0.0611158 
100% 0 0.05966 -0.00025 0.0595742 -1.76E-13 0.0596601 
0.30 0.075 25% 0 0.02820 0.00091 0.0283797 0.0010506 0.0284123 
50% 0 0.02808 0.00114 0.0282215 0.0010056 0.0282545 
75% 0 0.02804 0.00093 0.0282056 0.0009916 0.0282045 
100% 0 0.02797 0.00001 0.0279911 -2.26E-18 0.0279665 
0.40 0.20 25% 0 0.08223 0.00867 0.0863827 0.0087217 0.0863542 
50% 0 0.07998 0.00772 0.0836977 0.0075944 0.0835972 
75% 0 0.07902 0.00624 0.0801575 0.0059541 0.0802976 
100% 0 0.07795 0 0.0778393 -8.05E-14 0.0779484 
0.40 0.10 25% 0 0.03714 0.00100 0.0374247 0.0009924 0.0373730 
50% 0 0.03699 0.00112 0.0372544 0.0009452 0.0371818 
75% 0 0.03695 0.00095 0.0370817 0.0009306 0.0371208 
100% 0 0.03682 -0.00021 0.0366921 -8.86E-18 0.0368230 
Note:  
1. IAL = interim analysis location. 
2. Interim analysis location refers to the percent of subjects out of the original protocol-
specified sample size who have been assessed for the outcome at the interim analysis. 
100% refers to the situation where no sample size re-estimation is planned. 
3. Theoretically derived refers to the results from the formulas derived in Section 3.4.1.  
271 
 
Table A.66: Mean and Standard Error Results under the Alternative Hypothesis Ha: pe = pc – Δ 
from Simulations and Formulas where the Minimum Allowable Sample Size is the Interim 
Analysis Sample Size and the Maximum Allowable Sample Size is Twice the Original Protocol-
Specified Sample Size for the HW-SSR Method for the Alternative Hypothesis Ha: pe = pc – Δ 








Effect (Δ) IAL 
Expected 
      
Mean 
Expected 








      
SE 
Derived 
      
Mean 
Derived 
      
SE 
0.10 0.05 25% -0.050 0.01888 -0.04673 0.0202217 -0.046502 0.0206097 
50% -0.050 0.01832 -0.04707 0.0191383 -0.047032 0.0194911 
75% -0.050 0.01799 -0.04771 0.0181414 -0.047747 0.0181745 
100% -0.050 0.01784 -0.05010 0.0178516 -0.050000 0.0178406 
0.20 0.10 25% -0.100 0.03765 -0.09380 0.0400928 -0.093759 0.0406582 
50% -0.100 0.03660 -0.09467 0.0384133 -0.094645 0.0388079 
75% -0.100 0.03599 -0.09592 0.0362011 -0.095889 0.0364629 
100% -0.100 0.03562 -0.10014 0.0356556 -0.100000 0.0356235 
0.20 0.05 25% -0.050 0.01799 -0.04919 0.0181355 -0.049133 0.0181761 
50% -0.050 0.01791 -0.04915 0.0180826 -0.049168 0.0180601 
75% -0.050 0.01789 -0.04926 0.0179896 -0.049180 0.0180217 
100% -0.050 0.01784 -0.05001 0.0178286 -0.050000 0.0178433 
0.30 0.15 25% -0.150 0.05624 -0.14218 0.0597701 -0.141890 0.0602952 
50% -0.150 0.05484 -0.14310 0.0574859 -0.142976 0.0580246 
75% -0.150 0.05400 -0.14447 0.0546072 -0.144551 0.0549349 
100% -0.150 0.05348 -0.15017 0.0535244 -0.150000 0.0534806 
0.30 0.075 25% -0.075 0.02698 -0.07408 0.0271640 -0.073949 0.0271964 
50% -0.075 0.02687 -0.07388 0.0270397 -0.073994 0.0270435 
75% -0.075 0.02682 -0.07406 0.0269329 -0.074008 0.0269950 
100% -0.075 0.02675 -0.07496 0.0268445 -0.075000 0.0267541 
0.40 0.20 25% -0.200 0.07507 -0.19136 0.0790597 -0.191278 0.0794267 
50% -0.200 0.07301 -0.19239 0.0767300 -0.192406 0.0768917 
75% -0.200 0.07213 -0.19353 0.0732180 -0.194046 0.0735180 
100% -0.200 0.07116 -0.19986 0.0710651 -0.200000 0.0711568 
0.40 0.10 25% -0.100 0.03596 -0.09892 0.0362083 -0.099008 0.0361995 
50% -0.100 0.03581 -0.09900 0.0361081 -0.099055 0.0360129 
75% -0.100 0.03577 -0.09891 0.0359293 -0.099069 0.0359535 
100% -0.100 0.03565 -0.10014 0.0356104 -0.100000 0.0356537 
Note:  
1. IAL = interim analysis location. 
2. Interim analysis location refers to the percent of subjects out of the original protocol-
specified sample size who have been assessed for the outcome at the interim analysis. 
100% refers to the situation where no sample size re-estimation is planned. 
3. Theoretically derived refers to the results from the formulas derived in Section 3.4.1.  
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Table A.67: Mean and Standard Error Results under the Null Hypothesis Ho: pe = pc from 
Simulations and Formulas where the Minimum Allowable Sample Size is the Interim Analysis 
Sample Size and where there is No Maximum Allowable Sample Size for the HW-SSR Method 








Effect (Δ) IAL 
Expected 
      
Mean 
Expected 








      
SE 
Derived 
      
Mean 
Derived 
      
SE 
0.10 0.05 25% 0 0.02159 0.00337 0.0228483 0.0034984 0.0232347 
50% 0 0.02097 0.00291 0.0217739 0.0029682 0.0220353 
75% 0 0.02057 0.00222 0.0207714 0.0022525 0.0207619 
100% 0 0.02041 0.00017 0.0204730 -2.17E-13 0.0204124 
0.20 0.10 25% 0 0.04258 0.00593 0.0447675 0.0062413 0.0454315 
50% 0 0.04141 0.00524 0.0430234 0.0053554 0.0434365 
75% 0 0.04072 0.00406 0.0408054 0.0041112 0.0411652 
100% 0 0.04030 -0.00005 0.0403427 -2.30E-13 0.0403034 
0.20 0.05 25% 0 0.01897 0.00079 0.0191105 0.0008673 0.0191601 
50% 0 0.01890 0.00089 0.0190275 0.0008317 0.0190398 
75% 0 0.01887 0.00079 0.0189507 0.0008202 0.0190002 
100% 0 0.01882 -0.00004 0.0187975 5.23E-18 0.0188248 
0.30 0.15 25% 0 0.06283 0.00752 0.0659285 0.008110 0.0665857 
50% 0 0.06120 0.00676 0.0634280 0.0070235 0.0641198 
75% 0 0.06028 0.00575 0.0609811 0.0054490 0.0611158 
100% 0 0.05966 -0.00008 0.0594602 -1.76E-13 0.0596601 
0.30 0.075 25% 0 0.02819 0.00110 0.0284659 0.0010506 0.0284123 
50% 0 0.02807 0.00099 0.0283265 0.0010056 0.0282545 
75% 0 0.02804 0.00093 0.0281385 0.0009916 0.0282045 
100% 0 0.02797 0.00002 0.0279226 -2.26E-18 0.0279665 
0.40 0.20 25% 0 0.08223 0.00880 0.0859314 0.0087217 0.0863542 
50% 0 0.07996 0.00732 0.0828428 0.0075944 0.0835972 
75% 0 0.07903 0.00613 0.0803434 0.0059541 0.0802976 
100% 0 0.07795 0.00009 0.0780581 -8.05E-14 0.0779484 
0.40 0.10 25% 0 0.03714 0.00101 0.0372461 0.0009924 0.0373730 
50% 0 0.03699 0.00104 0.0370770 0.0009452 0.0371818 
75% 0 0.03694 0.00094 0.0370943 0.0009306 0.0371208 
100% 0 0.03682 -0.00014 0.0369135 -8.86E-18 0.0368230 
Note:  
1. IAL = interim analysis location. 
2. Interim analysis location refers to the percent of subjects out of the original protocol-
specified sample size who have been assessed for the outcome at the interim analysis. 
100% refers to the situation where no sample size re-estimation is planned. 
3. Theoretically derived refers to the results from the formulas derived in Section 3.4.1.  
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Table A.68: Mean and Standard Error Results under the Alternative Hypothesis Ha: pe = pc – Δ 
from Simulations and Formulas where the Minimum Allowable Sample Size is the Interim 
Analysis Sample Size and where there is No Maximum Allowable Sample Size for the HW-SSR 








Effect (Δ) IAL 
Expected 
      
Mean 
Expected 








      
SE 
Derived 
      
Mean 
Derived 
      
SE 
0.10 0.05 25% -0.050 0.01887 -0.04666 0.0201704 -0.046502 0.0206093 
50% -0.050 0.01833 -0.04706 0.0192469 -0.047032 0.0194911 
75% -0.050 0.01798 -0.04772 0.0182313 -0.047747 0.0181745 
100% -0.050 0.01784 -0.04991 0.0179131 -0.050000 0.0178406 
0.20 0.10 25% -0.100 0.03763 -0.09409 0.0400593 -0.093759 0.0406582 
50% -0.100 0.03660 -0.09470 0.0382730 -0.094645 0.0388079 
75% -0.100 0.03599 -0.09581 0.0361843 -0.095889 0.0364629 
100% -0.100 0.03562 -0.10006 0.0356129 -0.100000 0.0356235 
0.20 0.05 25% -0.050 0.01798 -0.04921 0.0181359 -0.049133 0.0181761 
50% -0.050 0.01792 -0.04918 0.0180982 -0.049168 0.0180601 
75% -0.050 0.01789 -0.04920 0.0180701 -0.049180 0.0180217 
100% -0.050 0.01784 -0.05004 0.0177479 -0.050000 0.0178433 
0.30 0.15 25% -0.150 0.05633 -0.14230 0.0596710 -0.141890 0.0602952 
50% -0.150 0.05486 -0.14325 0.0574699 -0.142976 0.0580246 
75% -0.150 0.05403 -0.14427 0.0545793 -0.144551 0.0549349 
100% -0.150 0.05348 -0.14994 0.0533595 -0.150000 0.0534806 
0.30 0.075 25% -0.075 0.02697 -0.07396 0.0272445 -0.073949 0.0271964 
50% -0.075 0.02686 -0.07417 0.0270612 -0.073994 0.0270435 
75% -0.075 0.02683 -0.07402 0.0269563 -0.074008 0.0269950 
100% -0.075 0.02675 -0.07495 0.0266654 -0.075000 0.0267541 
0.40 0.20 25% -0.200 0.07507 -0.19142 0.0787943 -0.191278 0.0794267 
50% -0.200 0.07299 -0.19264 0.0763274 -0.192406 0.0768917 
75% -0.200 0.07214 -0.19377 0.0734734 -0.194046 0.0735180 
100% -0.200 0.07116 -0.20019 0.0712801 -0.200000 0.0711568 
0.40 0.10 25% -0.100 0.03596 -0.09902 0.0361462 -0.099008 0.0361995 
50% -0.100 0.03581 -0.09913 0.0360291 -0.099055 0.0360129 
75% -0.100 0.03577 -0.09897 0.0359820 -0.099069 0.0359535 
100% -0.100 0.03565 -0.10015 0.0357966 -0.100000 0.0356537 
Note:  
1. IAL = interim analysis location. 
2. Interim analysis location refers to the percent of subjects out of the original protocol-
specified sample size who have been assessed for the outcome at the interim analysis. 
100% refers to the situation where no sample size re-estimation is planned. 
3. Theoretically derived refers to the results from the formulas derived in Section 3.4.1.  
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Table A.69: Mean and Standard Error Results under the Null Hypothesis Ho: pe = pc from 
Simulations and Formulas where the Minimum Allowable Sample Size is 10% more than the 
Interim Analysis Sample Size and the Maximum Allowable Sample Size is Twice the Original 
Protocol-Specified Sample Size for the HW-SSR Method for the Alternative Hypothesis Ha: pe = pc 








Effect (Δ) IAL 
Expected 
      
Mean 
Expected 








      
SE 
Derived 
      
Mean 
Derived 
      
SE 
0.10 0.05 25% 0 0.02162 0.00327 0.0227860 0.0034980 0.0232351 
50% 0 0.02092 0.00273 0.0215566 0.0028209 0.0217566 
75% 0 0.02040 0.00185 0.0203283 0.0018859 0.0203185 
100% 0 0.02041 0.00009 0.0203851 -2.17E-13 0.0204124 
0.20 0.10 25% 0 0.04260 0.00603 0.0449736 0.0062413 0.0454315 
50% 0 0.04133 0.00496 0.0425965 0.0051106 0.0429560 
75% 0 0.04043 0.00337 0.0401589 0.0034451 0.0403348 
100% 0 0.04030 0.00001 0.0403382 -2.30E-13 0.0403034 
0.20 0.05 25% 0 0.01897 0.00080 0.0191102 0.0008673 0.0191601 
50% 0 0.01890 0.00083 0.0190976 0.0008317 0.0190398 
75% 0 0.01887 0.00081 0.0189542 0.0008085 0.0189737 
100% 0 0.01882 0 0.0187624 5.23E-18 0.0188248 
0.30 0.15 25% 0 0.06281 0.00785 0.0660930 0.0081100 0.0665857 
50% 0 0.06109 0.00645 0.0631733 0.0067357 0.0635225 
75% 0 0.05988 0.00473 0.0598077 0.0045855 0.0599884 
100% 0 0.05966 -0.00007 0.0598629 -1.76E-13 0.0596601 
0.30 0.075 25% 0 0.02820 0.00120 0.0284464 0.0010506 0.0284123 
50% 0 0.02808 0.00098 0.0282511 0.0010056 0.0282545 
75% 0 0.02804 0.00099 0.0282136 0.0009854 0.0281891 
100% 0 0.02797 -0.00007 0.0280006 -2.26E-18 0.0279665 
0.40 0.20 25% 0 0.08219 0.00880 0.0861275 0.0087217 0.0863542 
50% 0 0.07990 0.00739 0.0827763 0.0073149 0.0829874 
75% 0 0.07863 0.00524 0.0786560 0.0050082 0.0789988 
100% 0 0.07795 -0.00006 0.0777745 -8.05E-14 0.0779484 
0.40 0.10 25% 0 0.03714 0.00106 0.0374130 0.0009924 0.0373730 
50% 0 0.03699 0.00091 0.0371756 0.0009452 0.0371818 
75% 0 0.03694 0.00096 0.0373171 0.0009292 0.0371169 
100% 0 0.03682 -0.00009 0.0369301 -8.86E-18 0.0368230 
Note:  
1. IAL = interim analysis location. 
2. Interim analysis location refers to the percent of subjects out of the original protocol-
specified sample size who have been assessed for the outcome at the interim analysis. 
100% refers to the situation where no sample size re-estimation is planned. 
3. Theoretically derived refers to the results from the formulas derived in Section 3.4.1.  
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Table A.70: Mean and Standard Error Results under the Alternative Hypothesis Ha: pe = pc – Δ 
from Simulations and Formulas where the Minimum Allowable Sample Size is 10% more than the 
Interim Analysis Sample Size and the Maximum Allowable Sample Size is Twice the Original 
Protocol-Specified Sample Size for the HW-SSR Method for the Alternative Hypothesis Ha: pe = pc 








Effect (Δ) IAL 
Expected 
      
Mean 
Expected 








      
SE 
Derived 
      
Mean 
Derived 
      
SE 
0.10 0.05 25% -0.050 0.01889 -0.04670 0.0201433 -0.046502 0.0206097 
50% -0.050 0.01829 -0.04725 0.0190155 -0.047179 0.0191924 
75% -0.050 0.01783 -0.04810 0.0178035 -0.048114 0.0177197 
100% -0.050 0.01784 -0.04994 0.0178736 -0.050000 0.0178406 
0.20 0.10 25% -0.100 0.03765 -0.09398 0.0400132 -0.093759 0.0406582 
50% -0.100 0.03653 -0.09495 0.0378809 -0.094889 0.0382940 
75% -0.100 0.03573 -0.09662 0.0354234 -0.096555 0.0356079 
100% -0.100 0.03562 -0.10001 0.0356412 -0.100000 0.0356235 
0.20 0.05 25% -0.050 0.01798 -0.04916 0.0181084 -0.049133 0.0181761 
50% -0.050 0.01791 -0.04914 0.0180903 -0.049168 0.0180600 
75% -0.050 0.01788 -0.04924 0.0179779 -0.049192 0.0179941 
100% -0.050 0.01784 -0.04991 0.0178770 -0.050000 0.0178433 
0.30 0.15 25% -0.150 0.05630 -0.14205 0.0595931 -0.141890 0.0602952 
50% -0.150 0.05477 -0.14347 0.0569659 -0.143264 0.0573885 
75% -0.150 0.05368 -0.14521 0.0537122 -0.145415 0.0537695 
100% -0.150 0.05348 -0.15004 0.0534663 -0.150000 0.0534806 
0.30 0.075 25% -0.075 0.02698 -0.07383 0.0272100 -0.073949 0.0271964 
50% -0.075 0.02686 -0.07406 0.0270528 -0.073994 0.0270435 
75% -0.075 0.02683 -0.07398 0.0269636 -0.074015 0.0269791 
100% -0.075 0.02675 -0.07507 0.0268163 -0.075000 0.0267541 
0.40 0.20 25% -0.200 0.07503 -0.19135 0.0789990 -0.191278 0.0794267 
50% -0.200 0.07294 -0.19277 0.0759235 -0.192685 0.0762473 
75% -0.200 0.07178 -0.19473 0.0720972 -0.194992 0.0721748 
100% -0.200 0.07116 -0.19998 0.0710246 -0.200000 0.0711568 
0.40 0.10 25% -0.100 0.03596 -0.09900 0.0362234 -0.099008 0.0361995 
50% -0.100 0.03581 -0.09907 0.0360798 -0.099055 0.0360129 
75% -0.100 0.03577 -0.09906 0.0359902 -0.099071 0.0359495 
100% -0.100 0.03565 -0.10003 0.0358057 -0.100000 0.0356537 
Note:  
1. IAL = interim analysis location. 
2. Interim analysis location refers to the percent of subjects out of the original protocol-
specified sample size who have been assessed for the outcome at the interim analysis. 
100% refers to the situation where no sample size re-estimation is planned. 
3. Theoretically derived refers to the results from the formulas derived in Section 3.4.1.  
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Table A.71: Mean and Standard Error Results under the Null Hypothesis Ho: pe = pc from 
Simulations and Formulas where the Minimum Allowable Sample Size is 10% more than the 
Interim Analysis Sample Size and where there is No Maximum Allowable Sample Size for the 








Effect (Δ) IAL 
Expected 
      
Mean 
Expected 








      
SE 
Derived 
      
Mean 
Derived 
      
SE 
0.10 0.05 25% 0 0.02162 0.00339 0.0227576 0.0034984 0.0232347 
50% 0 0.02093 0.00284 0.0215615 0.0028210 0.0217566 
75% 0 0.02039 0.00193 0.0203673 0.0018859 0.0203185 
100% 0 0.02041 -0.00002 0.0202973 -2.17E-13 0.0204124 
0.20 0.10 25% 0 0.04262 0.00611 0.0450578 0.0062413 0.0454315 
50% 0 0.04133 0.00516 0.0426369 0.0051106 0.0429560 
75% 0 0.04042 0.00359 0.0402395 0.0034451 0.0403348 
100% 0 0.04030 -0.00003 0.0403200 -2.30E-13 0.0403034 
0.20 0.05 25% 0 0.01898 0.00085 0.0191343 0.0008673 0.0191601 
50% 0 0.01890 0.00077 0.0190340 0.0008317 0.0190398 
75% 0 0.01887 0.00072 0.0189963 0.0008085 0.0189737 
100% 0 0.01882 -0.00004 0.0188303 5.23E-18 0.0188248 
0.30 0.15 25% 0 0.06278 0.00762 0.0660464 0.0081100 0.0665857 
50% 0 0.06113 0.00672 0.0631116 0.0067357 0.0635225 
75% 0 0.05987 0.00471 0.0598675 0.0045855 0.0599884 
100% 0 0.05966 -0.00017 0.0594942 -1.76E-13 0.0596601 
0.30 0.075 25% 0 0.02819 0.00116 0.0284370 0.0010506 0.0284123 
50% 0 0.02808 0.00099 0.0283710 0.0010056 0.0282545 
75% 0 0.02804 0.00094 0.0281808 0.0009854 0.0281891 
100% 0 0.02797 -0.00002 0.0278917 -2.26E-18 0.0279665 
0.40 0.20 25% 0 0.08221 0.00863 0.0860843 0.0087217 0.0863542 
50% 0 0.07989 0.00719 0.0824985 0.0073149 0.0829874 
75% 0 0.07859 0.00474 0.0789242 0.0050082 0.0789988 
100% 0 0.07795 0.00024 0.0777847 -8.05E-14 0.0779484 
0.40 0.10 25% 0 0.03713 0.00097 0.0372435 0.0009924 0.0373730 
50% 0 0.03699 0.00088 0.0372050 0.0009452 0.0371818 
75% 0 0.03694 0.00102 0.0372178 0.0009292 0.0371169 
100% 0 0.03682 -0.00007 0.0368625 -8.86E-18 0.0368230 
Note:  
1. IAL = interim analysis location. 
2. Interim analysis location refers to the percent of subjects out of the original protocol-
specified sample size who have been assessed for the outcome at the interim analysis. 
100% refers to the situation where no sample size re-estimation is planned. 
3. Theoretically derived refers to the results from the formulas derived in Section 3.4.1.  
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Table A.72: Mean and Standard Error Results under the Alternative Hypothesis Ha: pe = pc – Δ 
from Simulations and Formulas where the Minimum Allowable Sample Size is 10% more than the 
Interim Analysis Sample Size and where there is No Maximum Allowable Sample Size for the 








Effect (Δ) IAL 
Expected 
      
Mean 
Expected 








      
SE 
Derived 
      
Mean 
Derived 
      
SE 
0.10 0.05 25% -0.050 0.01890 -0.04667 0.0200959 -0.046502 0.0206093 
50% -0.050 0.01829 -0.04720 0.0189217 -0.047179 0.0191924 
75% -0.050 0.01782 -0.04809 0.0177538 -0.048114 0.0177197 
100% -0.050 0.01784 -0.04999 0.0177402 -0.050000 0.0178406 
0.20 0.10 25% -0.100 0.03767 -0.09393 0.0402167 -0.093759 0.0406582 
50% -0.100 0.03653 -0.09492 0.0378962 -0.094889 0.0382940 
75% -0.100 0.03573 -0.09663 0.0353795 -0.096555 0.0356079 
100% -0.100 0.03562 -0.10011 0.0356064 -0.100000 0.0356235 
0.20 0.05 25% -0.050 0.01799 -0.04920 0.0182053 -0.049133 0.0181761 
50% -0.050 0.01791 -0.04920 0.0181236 -0.049168 0.0180600 
75% -0.050 0.01789 -0.04920 0.0180294 -0.049192 0.0179941 
100% -0.050 0.01784 -0.05011 0.0178588 -0.050000 0.0178433 
0.30 0.15 25% -0.150 0.05628 -0.14206 0.0596994 -0.141890 0.0602952 
50% -0.150 0.05480 -0.14327 0.0570445 -0.143264 0.0573885 
75% -0.150 0.05367 -0.14534 0.0534719 -0.145415 0.0537695 
100% -0.150 0.05348 -0.15006 0.0535617 -0.150000 0.0534806 
0.30 0.075 25% -0.075 0.02697 -0.07399 0.0272571 -0.073949 0.0271964 
50% -0.075 0.02686 -0.07397 0.0271137 -0.073994 0.0270435 
75% -0.075 0.02683 -0.07415 0.0269600 -0.074015 0.0269791 
100% -0.075 0.02675 -0.07504 0.0267752 -0.075000 0.0267541 
0.40 0.20 25% -0.200 0.07505 -0.19144 0.0792037 -0.191278 0.0794267 
50% -0.200 0.07293 -0.19246 0.0760692 -0.192685 0.0762473 
75% -0.200 0.07174 -0.19515 0.0718167 -0.194992 0.0721748 
100% -0.200 0.07116 -0.20011 0.0708439 -0.200000 0.0711568 
0.40 0.10 25% -0.100 0.03595 -0.09907 0.0361526 -0.099008 0.0361995 
50% -0.100 0.03581 -0.09900 0.0360527 -0.099055 0.0360129 
75% -0.100 0.03577 -0.09902 0.0360455 -0.099071 0.0359495 
100% -0.100 0.03565 -0.10028 0.0356263 -0.100000 0.0356537 
Note:  
1. IAL = interim analysis location. 
2. Interim analysis location refers to the percent of subjects out of the original protocol-
specified sample size who have been assessed for the outcome at the interim analysis. 
100% refers to the situation where no sample size re-estimation is planned. 
3. Theoretically derived refers to the results from the formulas derived in Section 3.4.1.  
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Table A.73: Mean and Standard Error Results under the Null Hypothesis Ho: pe = pc from 
Simulations and Formulas where the Minimum Allowable Sample Size is the Original Protocol-
Specified Sample Size and the Maximum Allowable Sample Size is Twice the Original Protocol-
Specified Sample Size for the HW-SSR Method for the Alternative Hypothesis Ha: pe = pc – Δ 








Effect (Δ) IAL 
Expected 
      
Mean 
Expected 








      
SE 
Derived 
      
Mean 
Derived 
      
SE 
0.10 0.05 25% 0 0.01935 0.00072 0.0192447 0.0008051 0.0192187 
50% 0 0.01959 0.00098 0.0193482 0.0009081 0.0193495 
75% 0 0.01971 0.00085 0.0193324 0.0009588 0.0193732 
100% 0 0.02041 0.00005 0.0204025 -2.17E-13 0.0204124 
0.20 0.10 25% 0 0.03851 0.00155 0.0383067 0.0013924 0.0382549 
50% 0 0.03890 0.00166 0.0384901 0.0015713 0.0384654 
75% 0 0.03911 0.00162 0.0383288 0.0016598 0.0385011 
100% 0 0.04030 -0.00010 0.0401797 -2.30E-13 0.0403034 
0.20 0.05 25% 0 0.01844 0.00038 0.0183573 0.0003199 0.0183680 
50% 0 0.01854 0.00029 0.0184829 0.0003399 0.0184239 
75% 0 0.01859 0.00032 0.0184647 0.0003497 0.0184366 
100% 0 0.01882 0.00002 0.0187653 5.23E-18 0.0188248 
0.30 0.15 25% 0 0.05747 0.00168 0.0571530 0.0016930 0.0571448 
50% 0 0.05791 0.00194 0.0571523 0.0019556 0.0573619 
75% 0 0.05810 0.00209 0.0573050 0.0020916 0.0573919 
100% 0 0.05966 0.00017 0.0596684 -1.76E-13 0.0596601 
0.30 0.075 25% 0 0.02751 0.00023 0.0274168 0.0003708 0.0274365 
50% 0 0.02763 0.00047 0.0274846 0.0003979 0.0274969 
75% 0 0.02769 0.00025 0.0274125 0.0004109 0.0275100 
100% 0 0.02797 -0.00010 0.0278811 -2.26E-18 0.0279665 
0.40 0.20 25% 0 0.07597 0.00083 0.0758088 0.0014457 0.0757519 
50% 0 0.07629 0.00244 0.0755781 0.0018152 0.0758284 
75% 0 0.07652 0.00181 0.0756771 0.0019879 0.0758094 
100% 0 0.07795 0.00019 0.0782916 -8.05E-14 0.0779484 
0.40 0.10 25% 0 0.03645 0.00026 0.0363655 0.0003009 0.0363890 
50% 0 0.03654 0.00036 0.0364464 0.0003372 0.0364260 
75% 0 0.03658 0.00059 0.0364020 0.0003538 0.0364319 
100% 0 0.03682 -0.00021 0.0368406 -8.86E-18 0.0368230 
Note:  
1. IAL = interim analysis location. 
2. Interim analysis location refers to the percent of subjects out of the original protocol-
specified sample size who have been assessed for the outcome at the interim analysis. 
100% refers to the situation where no sample size re-estimation is planned. 
3. Theoretically derived refers to the results from the formulas derived in Section 3.4.1.  
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Table A.74: Mean and Standard Error Results under the Alternative Hypothesis Ha: pe = pc – Δ 
from Simulations and Formulas where the Minimum Allowable Sample Size is the Original 
Protocol-Specified Sample Size and the Maximum Allowable Sample Size is Twice the Original 
Protocol-Specified Sample Size for the HW-SSR Method for the Alternative Hypothesis Ha: pe = pc 








Effect (Δ) IAL 
Expected 
      
Mean 
Expected 








      
SE 
Derived 
      
Mean 
Derived 
      
SE 
0.10 0.05 25% -0.050 0.01691 -0.04931 0.0167035 -0.049195 0.0167533 
50% -0.050 0.01712 -0.04900 0.0168499 -0.049092 0.0168379 
75% -0.050 0.01723 -0.04906 0.0168199 -0.049041 0.0168326 
100% -0.050 0.01784 -0.04999 0.0177906 -0.050000 0.0178406 
0.20 0.10 25% -0.100 0.03404 -0.09848 0.0337534 -0.098608 0.0337420 
50% -0.100 0.03438 -0.09831 0.0339258 -0.098429 0.0338803 
75% -0.100 0.03457 -0.09834 0.0337860 -0.098340 0.0338701 
100% -0.100 0.03562 -0.10004 0.0355021 -0.100000 0.0356235 
0.20 0.05 25% -0.050 0.01748 -0.04973 0.0173707 -0.049680 0.0174023 
50% -0.050 0.01757 -0.04972 0.0175061 -0.049660 0.0174506 
75% -0.050 0.01762 -0.04969 0.0174688 -0.049650 0.0174589 
100% -0.050 0.01784 -0.05007 0.0178334 -0.050000 0.0178433 
0.30 0.15 25% -0.150 0.05152 -0.14814 0.0513522 -0.148307 0.0511530 
50% -0.150 0.05191 -0.14796 0.0513730 -0.148044 0.0512947 
75% -0.150 0.05208 -0.14817 0.0512966 -0.147908 0.0512739 
100% -0.150 0.05348 -0.14977 0.0535996 -0.150000 0.0534806 
0.30 0.075 25% -0.075 0.02632 -0.07476 0.0262758 -0.074629 0.0262394 
50% -0.075 0.02644 -0.07450 0.0263481 -0.074602 0.0262926 
75% -0.075 0.02649 -0.07465 0.0262241 -0.074589 0.0263015 
100% -0.075 0.02675 -0.07502 0.0267407 -0.075000 0.0267541 
0.40 0.20 25% -0.200 0.06935 -0.19903 0.0691026 -0.198554 0.0691108 
50% -0.200 0.06964 -0.19771 0.0691524 -0.198185 0.0691312 
75% -0.200 0.06985 -0.19826 0.0688153 -0.198012 0.0690725 
100% -0.200 0.07116 -0.20005 0.0712487 -0.200000 0.0711568 
0.40 0.10 25% -0.100 0.03529 -0.09974 0.0353489 -0.099699 0.0352294 
50% -0.100 0.03538 -0.09957 0.0352993 -0.099663 0.0352621 
75% -0.100 0.03542 -0.09963 0.0352277 -0.099646 0.0352652 
100% -0.100 0.03565 -0.10002 0.0356357 -0.100000 0.0356537 
Note:  
1. IAL = interim analysis location. 
2. Interim analysis location refers to the percent of subjects out of the original protocol-
specified sample size who have been assessed for the outcome at the interim analysis. 
100% refers to the situation where no sample size re-estimation is planned. 
3. Theoretically derived refers to the results from the formulas derived in Section 3.4.1.  
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Table A.75: Mean and Standard Error Results under the Null Hypothesis Ho: pe = pc from 
Simulations and Formulas where the Minimum Allowable Sample Size is the Original Protocol-
Specified Sample Size and where there is No Maximum Allowable Sample Size for the HW-SSR 








Effect (Δ) IAL 
Expected 
      
Mean 
Expected 








      
SE 
Derived 
      
Mean 
Derived 
      
SE 
0.10 0.05 25% 0 0.01934 0.00083 0.0192192 0.0008055 0.0192183 
50% 0 0.01959 0.00092 0.0192433 0.0009081 0.0193495 
75% 0 0.01971 0.00095 0.0193611 0.0009588 0.0193732 
100% 0 0.02041 -0.00004 0.0203810 -2.17E-13 0.0204124 
0.20 0.10 25% 0 0.03852 0.00137 0.0381580 0.0013924 0.0382549 
50% 0 0.03891 0.00159 0.0383859 0.0015713 0.0384654 
75% 0 0.03911 0.00190 0.0384196 0.0016598 0.0385011 
100% 0 0.04030 -0.00006 0.0402311 -2.30E-13 0.0403034 
0.20 0.05 25% 0 0.01843 0.00030 0.0183045 0.0003199 0.0183680 
50% 0 0.01854 0.00029 0.0183911 0.0003399 0.0184239 
75% 0 0.01859 0.00042 0.0184223 0.0003497 0.0184366 
100% 0 0.01882 -0.00004 0.0187927 5.23E-18 0.0188248 
0.30 0.15 25% 0 0.05747 0.00133 0.0570041 0.0016930 0.0571448 
50% 0 0.05790 0.00204 0.0571731 0.0019556 0.0573619 
75% 0 0.05811 0.00208 0.0572303 0.0020916 0.0573919 
100% 0 0.05966 0.00019 0.0595818 -1.76E-13 0.0596601 
0.30 0.075 25% 0 0.02752 0.00024 0.0274362 0.0003708 0.0274365 
50% 0 0.02763 0.00034 0.0274730 0.0003979 0.0274969 
75% 0 0.02769 0.00033 0.0274868 0.0004109 0.0275100 
100% 0 0.02797 -0.00004 0.0279257 -2.26E-18 0.0279665 
0.40 0.20 25% 0 0.07595 0.00107 0.0757741 0.0014457 0.0757519 
50% 0 0.07629 0.00187 0.0757267 0.0018152 0.0758284 
75% 0 0.07653 0.00203 0.0756200 0.0019879 0.0758094 
100% 0 0.07795 -0.00028 0.0779016 -8.05E-14 0.0779484 
0.40 0.10 25% 0 0.03645 0.00022 0.0364660 0.0003009 0.0363890 
50% 0 0.03654 0.00035 0.0364913 0.0003372 0.0364260 
75% 0 0.03658 0.00035 0.0363402 0.0003538 0.0364319 
100% 0 0.03682 0.00004 0.0367684 -8.86E-18 0.036823 
Note:  
1. IAL = interim analysis location. 
2. Interim analysis location refers to the percent of subjects out of the original protocol-
specified sample size who have been assessed for the outcome at the interim analysis. 
100% refers to the situation where no sample size re-estimation is planned. 
3. Theoretically derived refers to the results from the formulas derived in Section 3.4.1.  
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Table A.76: Mean and Standard Error Results under the Alternative Hypothesis Ha: pe = pc – Δ 
from Simulations and Formulas where the Minimum Allowable Sample Size is the Original 
Protocol-Specified Sample Size and where there is No Maximum Allowable Sample Size for the 








Effect (Δ) IAL 
Expected 
      
Mean 
Expected 








      
SE 
Derived 
      
Mean 
Derived 
      
SE 
0.10 0.05 25% -0.050 0.01691 -0.04910 0.0167332 -0.049194 0.0167529 
50% -0.050 0.01712 -0.04912 0.0168176 -0.049092 0.0168379 
75% -0.050 0.01723 -0.04906 0.0168332 -0.049041 0.0168326 
100% -0.050 0.01784 -0.05004 0.0178709 -0.050000 0.0178406 
0.20 0.10 25% -0.100 0.03405 -0.09864 0.0336511 -0.098608 0.0337420 
50% -0.100 0.03439 -0.09833 0.0337541 -0.098429 0.0338803 
75% -0.100 0.03457 -0.09823 0.0337100 -0.098340 0.0338701 
100% -0.100 0.03562 -0.09983 0.0356725 -0.100000 0.0356235 
0.20 0.05 25% -0.050 0.01747 -0.04972 0.0173935 -0.049680 0.0174023 
50% -0.050 0.01757 -0.04967 0.0174328 -0.049660 0.0174506 
75% -0.050 0.01762 -0.04963 0.0174657 -0.049650 0.0174589 
100% -0.050 0.01784 -0.05004 0.0178740 -0.050000 0.0178433 
0.30 0.15 25% -0.150 0.05152 -0.14835 0.0513505 -0.148307 0.0511530 
50% -0.150 0.05191 -0.14793 0.0512221 -0.148044 0.0512947 
75% -0.150 0.05209 -0.14801 0.0511022 -0.147908 0.0512739 
100% -0.150 0.05348 -0.14979 0.0535273 -0.150000 0.0534806 
0.30 0.075 25% -0.075 0.02632 -0.07475 0.0263123 -0.074629 0.0262394 
50% -0.075 0.02644 -0.07463 0.0261886 -0.074602 0.0262926 
75% -0.075 0.02649 -0.07458 0.0262057 -0.074589 0.0263015 
100% -0.075 0.02675 -0.07505 0.0267112 -0.075000 0.0267541 
0.40 0.20 25% -0.200 0.06933 -0.19904 0.0690799 -0.198554 0.0691108 
50% -0.200 0.06964 -0.19850 0.0689830 -0.198185 0.0691312 
75% -0.200 0.06986 -0.19791 0.0690737 -0.198012 0.0690725 
100% -0.200 0.07116 -0.20028 0.0712496 -0.200000 0.0711568 
0.40 0.10 25% -0.100 0.03530 -0.09984 0.0352298 -0.099699 0.0352294 
50% -0.100 0.03538 -0.09967 0.0352781 -0.099663 0.0352621 
75% -0.100 0.03542 -0.09965 0.0352118 -0.099646 0.0352652 
100% -0.100 0.03565 -0.10009 0.0355478 -0.100000 0.0356537 
Note:  
1. IAL = interim analysis location. 
2. Interim analysis location refers to the percent of subjects out of the original protocol-
specified sample size who have been assessed for the outcome at the interim analysis. 
100% refers to the situation where no sample size re-estimation is planned. 
3. Theoretically derived refers to the results from the formulas derived in Section 3.4.1.  
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Table A.77: Mean and Standard Error Results under the Null Hypothesis Ho: pe = pc from 
Simulations and Formulas where the Minimum Allowable Sample Size is the Interim Analysis 
Sample Size and the Maximum Allowable Sample Size is Twice the Original Protocol-Specified 
Sample Size for the HW-SSR Method for the Alternative Hypothesis Ha: pe = (1 + γ)pc when the 




(  ) 
Relative 
Treatment 
Effect ( ) IAL 
Expected 
      
Mean 
Expected 








      
SE 
Derived 
      
Mean 
Derived 
      
SE 
0.90 0.0556 25% 0 0.02178 -0.00401 0.0232871 -0.004099 0.0236684 
50% 0 0.02103 -0.00348 0.0219622 -0.003436 0.0221277 
75% 0 0.02051 -0.00251 0.0205731 -0.002532 0.0206101 
100% 0 0.02041 -0.00003 0.0203922 2.17E-13 0.0204124 
0.80 0.125 25% 0 0.04324 -0.00872 0.0464831 -0.008806 0.0472064 
50% 0 0.04156 -0.00729 0.0433461 -0.007357 0.0437731 
75% 0 0.04047 -0.00539 0.0401718 -0.005324 0.0404820 
100% 0 0.04030 0.00030 0.0403012 2.30E-13 0.0403034 
0.80 0.0625 25% 0 0.01902 -0.00132 0.0193082 -0.001379 0.0193814 
50% 0 0.01892 -0.00139 0.0191733 -0.001321 0.0191820 
75% 0 0.01889 -0.00130 0.0190254 -0.001283 0.0190710 
100% 0 0.01882 -0.00004 0.0187971 2.91E-18 0.0188248 
0.70 0.2143 25% 0 0.06440 -0.01395 0.0700589 -0.014317 0.0707936 
50% 0 0.06155 -0.01186 0.0643342 -0.011893 0.0648757 
75% 0 0.05959 -0.00850 0.0595048 -0.008441 0.0594084 
100% 0 0.05966 0.00028 0.0594611 1.76E-13 0.0596601 
0.70 0.1071 25% 0 0.02830 -0.00223 0.0287896 -0.002332 0.0289455 
50% 0 0.02814 -0.00216 0.0284802 -0.002230 0.0285962 
75% 0 0.02807 -0.00219 0.0283743 -0.002140 0.0283511 
100% 0 0.02797 -0.00001 0.0280529 6.60E-18 0.0279665 
0.60 0.3333 25% 0 0.08498 -0.02027 0.0939407 -0.020504 0.0938854 
50% 0 0.08049 -0.01693 0.0843612 -0.016795 0.0846432 
75% 0 0.07730 -0.01161 0.0766735 -0.011751 0.0768748 
100% 0 0.07795 0.00011 0.0777705 8.05E-14 0.0779484 
0.60 0.1667 25% 0 0.03735 -0.00344 0.0382627 -0.003563 0.0384028 
50% 0 0.03709 -0.00341 0.0378971 -0.003400 0.0378324 
75% 0 0.03696 -0.00327 0.0373545 -0.003194 0.0373194 
100% 0 0.03682 0.00023 0.0368687 -2.63E-18 0.0368230 
Note:  
1. IAL = interim analysis location. 
2. Interim analysis location refers to the percent of subjects out of the original protocol-
specified sample size who have been assessed for the outcome at the interim analysis. 
100% refers to the situation where no sample size re-estimation is planned. 
3. Theoretically derived refers to the results from the formulas derived in Section 3.4.1.  
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Table A.78: Mean and Standard Error Results under the Alternative Hypothesis Ha: pe = (1 + γ)pc 
from Simulations and Formulas where the Minimum Allowable Sample Size is the Interim 
Analysis Sample Size and the Maximum Allowable Sample Size is Twice the Original Protocol-
Specified Sample Size for the HW-SSR Method for the Alternative Hypothesis Ha: pe = (1 + γ)pc 




(  ) 
Relative 
Treatment 
Effect ( ) IAL 
Expected 
      
Mean 
Expected 








      
SE 
Derived 
      
Mean 
Derived 
      
SE 
0.90 0.0556 25% 0.050 0.01904 0.04596 0.0205268 0.0459011 0.0210246 
50% 0.050 0.01838 0.04650 0.0192985 0.0465641 0.0195703 
75% 0.050 0.01793 0.04755 0.0180410 0.0474677 0.0180109 
100% 0.050 0.01784 0.05000 0.0178386 0.0500000 0.0178406 
0.80 0.125 25% 0.100 0.03822 0.09130 0.0416329 0.0911943 0.0423583 
50% 0.100 0.03673 0.09279 0.0385153 0.0926429 0.0390905 
75% 0.100 0.03577 0.09458 0.0355644 0.0946764 0.0357351 
100% 0.100 0.03562 0.10016 0.0357425 0.1000000 0.0356235 
0.80 0.0625 25% 0.050 0.01803 0.04875 0.0181925 0.0486209 0.0183977 
50% 0.050 0.01794 0.04863 0.0181582 0.0486794 0.0182044 
75% 0.050 0.01790 0.04876 0.0180505 0.0487170 0.0180933 
100% 0.050 0.01784 0.04994 0.0178695 0.0500000 0.0178433 
0.70 0.2143 25% 0.150 0.05773 0.13583 0.0636869 0.1356832 0.0643308 
50% 0.150 0.05518 0.13797 0.0584514 0.1381066 0.0586625 
75% 0.150 0.05342 0.14143 0.0530020 0.1415587 0.0531367 
100% 0.150 0.05348 0.15005 0.0535287 0.1500000 0.0534806 
0.70 0.1071 25% 0.075 0.02707 0.07269 0.0277542 0.0726681 0.0277307 
50% 0.075 0.02692 0.07278 0.0274098 0.0727701 0.0273896 
75% 0.075 0.02685 0.07286 0.0272446 0.0728600 0.0271426 
100% 0.075 0.02675 0.07507 0.0267064 0.0750000 0.0267541 
0.60 0.3333 25% 0.200 0.07758 0.17973 0.0861971 0.1794956 0.0866524 
50% 0.200 0.07348 0.18298 0.0776047 0.1832048 0.0777461 
75% 0.200 0.07057 0.18825 0.0698437 0.1882492 0.0699662 
100% 0.200 0.07116 0.19994 0.0709234 0.2000000 0.0711568 
0.60 0.1667 25% 0.100 0.03616 0.09665 0.0372342 0.0964367 0.0372315 
50% 0.100 0.03591 0.09681 0.0366541 0.0966001 0.0366697 
75% 0.100 0.03579 0.09667 0.0360836 0.0968064 0.036152 
100% 0.100 0.03565 0.10013 0.0357001 0.1000000 0.0356537 
Note:  
1. IAL = interim analysis location. 
2. Interim analysis location refers to the percent of subjects out of the original protocol-
specified sample size who have been assessed for the outcome at the interim analysis. 
100% refers to the situation where no sample size re-estimation is planned. 
3. Theoretically derived refers to the results from the formulas derived in Section 3.4.1.  
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Table A.79: Mean and Standard Error Results under the Null Hypothesis Ho: pe = pc from 
Simulations and Formulas where the Minimum Allowable Sample Size is the Interim Analysis 
Sample Size and where there is No Maximum Allowable Sample Size for the HW-SSR Method 




(  ) 
Relative 
Treatment 
Effect ( ) IAL 
Expected 
      
Mean 
Expected 








      
SE 
Derived 
      
Mean 
Derived 
      
SE 
0.90 0.0556 25% 0 0.02174 -0.00383 0.0232206 -0.004111 0.0236568 
50% 0 0.02100 -0.00333 0.0218389 -0.003437 0.0221267 
75% 0 0.02051 -0.00242 0.0206267 -0.002532 0.0206100 
100% 0 0.02041 -0.00013 0.0204864 2.17E-13 0.0204124 
0.80 0.125 25% 0 0.04319 -0.00880 0.0464578 -0.008872 0.0471429 
50% 0 0.04156 -0.00727 0.0433136 -0.007368 0.0437616 
75% 0 0.04047 -0.00530 0.0402127 -0.005325 0.0404796 
100% 0 0.04030 -0.00002 0.0402546 2.30E-13 0.0403034 
0.80 0.0625 25% 0 0.01903 -0.00131 0.0192673 -0.001379 0.0193814 
50% 0 0.01892 -0.00134 0.0192054 -0.001321 0.0191820 
75% 0 0.01889 -0.00140 0.0190027 -0.001283 0.0190710 
100% 0 0.01882 -0.00003 0.0188856 2.91E-18 0.0188248 
0.70 0.2143 25% 0 0.06407 -0.01436 0.0699477 -0.014556 0.0705607 
50% 0 0.06152 -0.01196 0.0645070 -0.011962 0.0648054 
75% 0 0.05956 -0.00865 0.0592264 -0.008461 0.0593842 
100% 0 0.05966 0.00015 0.0599408 1.76E-13 0.0596601 
0.70 0.1071 25% 0 0.02830 -0.00235 0.0288238 -0.002332 0.0289454 
50% 0 0.02813 -0.00215 0.0284843 -0.002230 0.0285962 
75% 0 0.02807 -0.00220 0.0283567 -0.002140 0.0283511 
100% 0 0.02797 0.00009 0.0279078 6.60E-18 0.0279665 
0.60 0.3333 25% 0 0.08412 -0.02144 0.0931111 -0.021143 0.0932499 
50% 0 0.08037 -0.01721 0.0841254 -0.017058 0.0843806 
75% 0 0.07727 -0.01201 0.0766793 -0.011862 0.0767476 
100% 0 0.07795 0.00029 0.0779391 8.05E-14 0.0779484 
0.60 0.1667 25% 0 0.03732 -0.00322 0.0381423 -0.003565 0.0384008 
50% 0 0.03708 -0.00346 0.0376439 -0.003400 0.0378324 
75% 0 0.03695 -0.00330 0.0372470 -0.003194 0.0373194 
100% 0 0.03682 0.00008 0.0367200 -2.63E-18 0.0368230 
Note:  
1. IAL = interim analysis location. 
2. Interim analysis location refers to the percent of subjects out of the original protocol-
specified sample size who have been assessed for the outcome at the interim analysis. 
100% refers to the situation where no sample size re-estimation is planned. 
3. Theoretically derived refers to the results from the formulas derived in Section 3.4.1.  
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Table A.80: Mean and Standard Error Results under the Alternative Hypothesis Ha: pe = (1 + γ)pc 
from Simulations and Formulas where the Minimum Allowable Sample Size is the Interim 
Analysis Sample Size and where there is No Maximum Allowable Sample Size for the HW-SSR 




(  ) 
Relative 
Treatment 
Effect ( ) IAL 
Expected 
      
Mean 
Expected 








      
SE 
Derived 
      
Mean 
Derived 
      
SE 
0.90 0.0556 25% 0.050 0.01900 0.04601 0.0205839 0.0458889 0.0210128 
50% 0.050 0.01836 0.04662 0.0192724 0.0465631 0.0195691 
75% 0.050 0.01792 0.04753 0.0179942 0.0474676 0.0180107 
100% 0.050 0.01784 0.04994 0.0178343 0.0500000 0.0178406 
0.80 0.125 25% 0.100 0.03818 0.09105 0.0415991 0.0911283 0.0422952 
50% 0.100 0.03673 0.09266 0.0384780 0.0926322 0.0390784 
75% 0.100 0.03577 0.09457 0.0355595 0.0946746 0.0357324 
100% 0.100 0.03562 0.09992 0.0356128 0.1000000 0.0356235 
0.80 0.0625 25% 0.050 0.01804 0.04870 0.0182991 0.0486209 0.0183977 
50% 0.050 0.01793 0.04865 0.0182457 0.0486794 0.0182044 
75% 0.050 0.01790 0.04864 0.0181101 0.0487170 0.0180933 
100% 0.050 0.01784 0.05002 0.0178489 0.0500000 0.0178433 
0.70 0.2143 25% 0.150 0.05743 0.13568 0.0634087 0.1354442 0.0641019 
50% 0.150 0.05514 0.13788 0.0580153 0.1380380 0.0585897 
75% 0.150 0.05339 0.14143 0.0528775 0.1415390 0.0531109 
100% 0.150 0.05348 0.15004 0.0536361 0.1500000 0.0534806 
0.70 0.1071 25% 0.075 0.02707 0.07283 0.0275962 0.0726681 0.0277306 
50% 0.075 0.02691 0.07284 0.0273534 0.0727701 0.0273896 
75% 0.075 0.02685 0.07274 0.0272619 0.0728600 0.0271426 
100% 0.075 0.02675 0.07502 0.0267406 0.0750000 0.0267541 
0.60 0.3333 25% 0.200 0.07679 0.17880 0.0856085 0.1788569 0.0860308 
50% 0.200 0.07337 0.18290 0.0775356 0.1829416 0.0774782 
75% 0.200 0.07054 0.18790 0.0698723 0.1881378 0.0698325 
100% 0.200 0.07116 0.20011 0.0711793 0.2000000 0.0711568 
0.60 0.1667 25% 0.100 0.03613 0.09674 0.0370509 0.0964347 0.0372294 
50% 0.100 0.03591 0.09659 0.0366516 0.0966001 0.0366697 
75% 0.100 0.03578 0.09681 0.0360484 0.0968064 0.0361520 
100% 0.100 0.03565 0.09995 0.0355317 0.1000000 0.0356537 
Note:  
1. IAL = interim analysis location. 
2. Interim analysis location refers to the percent of subjects out of the original protocol-
specified sample size who have been assessed for the outcome at the interim analysis. 
100% refers to the situation where no sample size re-estimation is planned. 
3. Theoretically derived refers to the results from the formulas derived in Section 3.4.1.  
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Table A.81: Mean and Standard Error Results under the Null Hypothesis Ho: pe = pc from 
Simulations and Formulas where the Minimum Allowable Sample Size is 10% more than the 
Interim Analysis Sample Size and the Maximum Allowable Sample Size is Twice the Original 
Protocol-Specified Sample Size for the HW-SSR Method for the Alternative Hypothesis Ha: pe = (1 




(  ) 
Relative 
Treatment 
Effect ( ) IAL 
Expected 
      
Mean 
Expected 








      
SE 
Derived 
      
Mean 
Derived 
      
SE 
0.90 0.0556 25% 0 0.02177 -0.00383 0.0234278 -0.004099 0.0236684 
50% 0 0.02096 -0.00323 0.0215451 -0.003232 0.0217744 
75% 0 0.02029 -0.00210 0.0201461 -0.002112 0.0201315 
100% 0 0.02041 -0.00008 0.0205125 2.17E-13 0.0204124 
0.80 0.125 25% 0 0.04324 -0.00848 0.0465279 -0.008806 0.0472064 
50% 0 0.04143 -0.00698 0.0426731 -0.006871 0.0429804 
75% 0 0.03999 -0.00452 0.039239 -0.004435 0.0395063 
100% 0 0.04030 0.00018 0.0403649 2.30E-13 0.0403034 
0.80 0.0625 25% 0 0.01903 -0.00147 0.0192820 -0.001379 0.0193810 
50% 0 0.01892 -0.00135 0.0192479 -0.001320 0.0191802 
75% 0 0.01886 -0.00130 0.0189218 -0.001203 0.0189313 
100% 0 0.01882 -0.00002 0.0188390 2.91E-18 0.0188248 
0.70 0.2143 25% 0 0.06427 -0.01405 0.0699287 -0.014317 0.0707936 
50% 0 0.06122 -0.01097 0.0632000 -0.011027 0.0635433 
75% 0 0.05873 -0.00681 0.0575799 -0.007046 0.0579279 
100% 0 0.05966 -0.00007 0.0597943 1.76E-13 0.0596601 
0.70 0.1071 25% 0 0.02830 -0.00225 0.0288825 -0.002332 0.0289444 
50% 0 0.02813 -0.00225 0.0285700 -0.002228 0.0285891 
75% 0 0.02801 -0.00202 0.0281030 -0.001966 0.0280670 
100% 0 0.02797 0.00014 0.0279757 6.60E-18 0.0279665 
0.60 0.3333 25% 0 0.08506 -0.02084 0.0939029 -0.020504 0.0938854 
50% 0 0.07990 -0.01579 0.0823669 -0.015440 0.0827199 
75% 0 0.07618 -0.00998 0.0746163 -0.009826 0.0749153 
100% 0 0.07795 0.00057 0.0778892 8.05E-14 0.0779484 
0.60 0.1667 25% 0 0.03737 -0.00354 0.0382227 -0.003562 0.0383988 
50% 0 0.03708 -0.00324 0.0377370 -0.003392 0.0378066 
75% 0 0.03685 -0.00287 0.0366677 -0.002868 0.0368283 
100% 0 0.03682 0.00004 0.0367524 -2.63E-18 0.0368230 
Note:  
1. IAL = interim analysis location. 
2. Interim analysis location refers to the percent of subjects out of the original protocol-
specified sample size who have been assessed for the outcome at the interim analysis. 
100% refers to the situation where no sample size re-estimation is planned. 
3. Theoretically derived refers to the results from the formulas derived in Section 3.4.1.  
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Table A.82: Mean and Standard Error Results under the Alternative Hypothesis Ha: pe = (1 + γ)pc 
from Simulations and Formulas where the Minimum Allowable Sample Size is 10% more than the 
Interim Analysis Sample Size and the Maximum Allowable Sample Size is Twice the Original 
Protocol-Specified Sample Size for the HW-SSR Method for the Alternative Hypothesis Ha: pe = (1 




(  ) 
Relative 
Treatment 
Effect ( ) IAL 
Expected 
      
Mean 
Expected 








      
SE 
Derived 
      
Mean 
Derived 
      
SE 
0.90 0.0556 25% 0.050 0.01903 0.04625 0.0207147 0.0459011 0.0210246 
50% 0.050 0.01832 0.04676 0.0189533 0.0467678 0.0191950 
75% 0.050 0.01773 0.04788 0.0175439 0.0478878 0.0175280 
100% 0.050 0.01784 0.04993 0.0179320 0.0500000 0.0178406 
0.80 0.125 25% 0.100 0.03822 0.09143 0.0417873 0.0911943 0.0423583 
50% 0.100 0.03662 0.09302 0.0379959 0.0931294 0.0382589 
75% 0.100 0.03535 0.09541 0.0345439 0.0955653 0.0347628 
100% 0.100 0.03562 0.10012 0.0357412 0.1000000 0.0356235 
0.80 0.0625 25% 0.050 0.01804 0.04864 0.0183133 0.0486209 0.0183974 
50% 0.050 0.01794 0.04877 0.0182797 0.0486799 0.0182025 
75% 0.050 0.01788 0.04875 0.0179573 0.0487966 0.0179490 
100% 0.050 0.01784 0.05002 0.0178807 0.0500000 0.0178433 
0.70 0.2143 25% 0.150 0.05761 0.13626 0.0631724 0.1356832 0.0643308 
50% 0.150 0.05488 0.13888 0.0570636 0.1389731 0.0572829 
75% 0.150 0.05265 0.14300 0.0515368 0.1429539 0.0516776 
100% 0.150 0.05348 0.15000 0.0533622 0.1500000 0.0534806 
0.70 0.1071 25% 0.075 0.02707 0.07274 0.0275524 0.0726684 0.0277295 
50% 0.075 0.02691 0.07281 0.0274319 0.0727722 0.0273821 
75% 0.075 0.02679 0.07295 0.0268661 0.0730337 0.0268516 
100% 0.075 0.02675 0.07507 0.0266327 0.0750000 0.0267541 
0.60 0.3333 25% 0.200 0.07765 0.17927 0.0860351 0.1794956 0.0866524 
50% 0.200 0.07294 0.18427 0.0753182 0.1845596 0.0757843 
75% 0.200 0.06954 0.19025 0.0679513 0.1901736 0.0680553 
100% 0.200 0.07116 0.19987 0.0713235 0.2000000 0.0711568 
0.60 0.1667 25% 0.100 0.03618 0.09636 0.0370853 0.0964375 0.0372273 
50% 0.100 0.03590 0.09668 0.0367082 0.0966084 0.0366432 
75% 0.100 0.03568 0.09692 0.0355200 0.0971318 0.0356535 
100% 0.100 0.03565 0.10001 0.0356266 0.1000000 0.0356537 
Note:  
1. IAL = interim analysis location. 
2. Interim analysis location refers to the percent of subjects out of the original protocol-
specified sample size who have been assessed for the outcome at the interim analysis. 
100% refers to the situation where no sample size re-estimation is planned. 
3. Theoretically derived refers to the results from the formulas derived in Section 3.4.1.  
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Table A.83: Mean and Standard Error Results under the Null Hypothesis Ho: pe = pc from 
Simulations and Formulas where the Minimum Allowable Sample Size is 10% more than the 
Interim Analysis Sample Size and where there is No Maximum Allowable Sample Size for the 




(  ) 
Relative 
Treatment 
Effect ( ) IAL 
Expected 
      
Mean 
Expected 








      
SE 
Derived 
      
Mean 
Derived 
      
SE 
0.90 0.0556 25% 0 0.02175 -0.00383 0.0233288 -0.004111 0.0236568 
50% 0 0.02095 -0.00326 0.0216218 -0.003233 0.0217733 
75% 0 0.02029 -0.00215 0.0201023 -0.002112 0.0201314 
100% 0 0.02041 0.00012 0.0204096 2.17E-13 0.0204124 
0.80 0.125 25% 0 0.04316 -0.00873 0.0463981 -0.008872 0.0471429 
50% 0 0.04141 -0.00670 0.0426580 -0.006881 0.0429689 
75% 0 0.03996 -0.00436 0.0392779 -0.004437 0.0395039 
100% 0 0.04030 0.00006 0.0402873 2.30E-13 0.0403034 
0.80 0.0625 25% 0 0.01903 -0.00142 0.0193117 -0.001379 0.0193810 
50% 0 0.01892 -0.00126 0.0192069 -0.001320 0.0191802 
75% 0 0.01886 -0.00120 0.0189385 -0.001203 0.0189313 
100% 0 0.01882 0.00005 0.0188324 2.91E-18 0.0188248 
0.70 0.2143 25% 0 0.06399 -0.01425 0.0697660 -0.014556 0.0705607 
50% 0 0.06117 -0.01129 0.0632120 -0.011095 0.0634724 
75% 0 0.05875 -0.00714 0.0577332 -0.007066 0.0579037 
100% 0 0.05966 0.00010 0.0595301 1.76E-13 0.0596601 
0.70 0.1071 25% 0 0.02830 -0.00207 0.0288087 -0.002332 0.0289443 
50% 0 0.02814 -0.00233 0.0284389 -0.002228 0.0285891 
75% 0 0.02800 -0.00188 0.0280852 -0.001966 0.0280670 
100% 0 0.02797 -0.00011 0.0279464 6.60E-18 0.0279665 
0.60 0.3333 25% 0 0.08426 -0.02110 0.0928081 -0.021143 0.0932499 
50% 0 0.07970 -0.01586 0.0822122 -0.015704 0.0824555 
75% 0 0.07610 -0.00939 0.0744134 -0.009938 0.0747876 
100% 0 0.07795 0.00043 0.0778252 8.05E-14 0.0779484 
0.60 0.1667 25% 0 0.03734 -0.00361 0.0382760 -0.003565 0.0383967 
50% 0 0.03709 -0.00358 0.0376337 -0.003392 0.0378066 
75% 0 0.03685 -0.00291 0.0367050 -0.002868 0.0368283 
100% 0 0.03682 -0.00011 0.0368637 -2.63E-18 0.0368230 
Note:  
1. IAL = interim analysis location. 
2. Interim analysis location refers to the percent of subjects out of the original protocol-
specified sample size who have been assessed for the outcome at the interim analysis. 
100% refers to the situation where no sample size re-estimation is planned. 
3. Theoretically derived refers to the results from the formulas derived in Section 3.4.1.  
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Table A.84: Mean and Standard Error Results under the Alternative Hypothesis Ha: pe = (1 + γ)pc 
from Simulations and Formulas where the Minimum Allowable Sample Size is 10% more than the 
Interim Analysis Sample Size and where there is No Maximum Allowable Sample Size for the 




(  ) 
Relative 
Treatment 
Effect ( ) IAL 
Expected 
      
Mean 
Expected 








      
SE 
Derived 
      
Mean 
Derived 
      
SE 
0.90 0.0556 25% 0.050 0.01901 0.04616 0.0205671 0.0458889 0.0210128 
50% 0.050 0.01831 0.04676 0.0189767 0.0467669 0.0191938 
75% 0.050 0.01774 0.04789 0.0175496 0.0478877 0.0175279 
100% 0.050 0.01784 0.05002 0.0178672 0.0500000 0.0178406 
0.80 0.125 25% 0.100 0.03815 0.09149 0.0416260 0.0911283 0.0422952 
50% 0.100 0.03660 0.09325 0.0378747 0.0931187 0.0382467 
75% 0.100 0.03532 0.09569 0.0344896 0.0955635 0.0347602 
100% 0.100 0.03562 0.09984 0.0355713 0.1000000 0.0356235 
0.80 0.0625 25% 0.050 0.01804 0.04856 0.0184242 0.0486209 0.0183974 
50% 0.050 0.01793 0.04874 0.0182575 0.0486799 0.0182025 
75% 0.050 0.01788 0.04876 0.0179256 0.0487966 0.0179490 
100% 0.050 0.01784 0.05005 0.0177835 0.0500000 0.0178433 
0.70 0.2143 25% 0.150 0.05737 0.13589 0.0632358 0.1354442 0.0641019 
50% 0.150 0.05483 0.13886 0.0568632 0.1389046 0.0572094 
75% 0.150 0.05266 0.14296 0.0515496 0.1429343 0.0516515 
100% 0.150 0.05348 0.15004 0.0535443 0.1500000 0.0534806 
0.70 0.1071 25% 0.075 0.02707 0.07284 0.0276494 0.0726683 0.0277294 
50% 0.075 0.02692 0.07276 0.0272639 0.0727722 0.0273821 
75% 0.075 0.02679 0.07298 0.0268470 0.0730337 0.0268516 
100% 0.075 0.02675 0.07491 0.0267568 0.0750000 0.0267541 
0.60 0.3333 25% 0.200 0.07691 0.17866 0.0858720 0.1788569 0.0860308 
50% 0.200 0.07275 0.18427 0.0749854 0.1842965 0.0755141 
75% 0.200 0.06947 0.18980 0.0677730 0.1900621 0.0679210 
100% 0.200 0.07116 0.20038 0.0710967 0.2000000 0.0711568 
0.60 0.1667 25% 0.100 0.03616 0.09643 0.0371168 0.0964355 0.0372252 
50% 0.100 0.03592 0.09658 0.0364885 0.0966084 0.0366432 
75% 0.100 0.03568 0.09698 0.0355544 0.0971318 0.0356535 
100% 0.100 0.03565 0.09973 0.0356356 0.1000000 0.0356537 
Note:  
1. IAL = interim analysis location. 
2. Interim analysis location refers to the percent of subjects out of the original protocol-
specified sample size who have been assessed for the outcome at the interim analysis. 
100% refers to the situation where no sample size re-estimation is planned. 
3. Theoretically derived refers to the results from the formulas derived in Section 3.4.1.  
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Table A.85: Mean and Standard Error Results under the Null Hypothesis Ho: pe = pc from 
Simulations and Formulas where the Minimum Allowable Sample Size is the Original Protocol-
Specified Sample Size and the Maximum Allowable Sample Size is Twice the Original Protocol-
Specified Sample Size for the HW-SSR Method for the Alternative Hypothesis Ha: pe = (1 + γ)pc 




(  ) 
Relative 
Treatment 
Effect ( ) IAL 
Expected 
      
Mean 
Expected 








      
SE 
Derived 
      
Mean 
Derived 
      
SE 
0.90 0.0556 25% 0 0.01912 -0.00094 0.0189886 -0.000957 0.0189890 
50% 0 0.01941 -0.00103 0.0191352 -0.001091 0.0191383 
75% 0 0.01955 -0.00114 0.0192104 -0.001153 0.0191678 
100% 0 0.02041 0.00018 0.0204214 2.17E-13 0.0204124 
0.80 0.125 25% 0 0.03754 -0.00240 0.0372662 -0.002059 0.0372525 
50% 0 0.03811 -0.00252 0.0374712 -0.002375 0.0375386 
75% 0 0.03844 -0.00269 0.0375507 -0.002517 0.0375960 
100% 0 0.04030 0.00001 0.0402615 2.30E-13 0.0403034 
0.80 0.0625 25% 0 0.01819 -0.00038 0.0180969 -0.000511 0.0180958 
50% 0 0.01836 -0.00063 0.0181371 -0.000542 0.0181888 
75% 0 0.01844 -0.00065 0.0182619 -0.000557 0.0182105 
100% 0 0.01882 -0.00005 0.0188023 2.91E-18 0.0188248 
0.70 0.2143 25% 0 0.05510 -0.00345 0.0548370 -0.003315 0.0546837 
50% 0 0.05595 -0.00405 0.0548330 -0.003933 0.0550695 
75% 0 0.05647 -0.00420 0.0550611 -0.004225 0.0551387 
100% 0 0.05966 0.00010 0.0594271 1.76E-13 0.0596601 
0.70 0.1071 25% 0 0.02689 -0.00090 0.0267116 -0.000859 0.0267452 
50% 0 0.02719 -0.00087 0.0269199 -0.000910 0.0269013 
75% 0 0.02732 -0.00091 0.0269780 -0.000934 0.0269379 
100% 0 0.02797 -0.00006 0.0279209 6.60E-18 0.0279665 
0.60 0.3333 25% 0 0.07129 -0.00423 0.0711972 -0.004620 0.0708930 
50% 0 0.07250 -0.00566 0.0713423 -0.005682 0.0713292 
75% 0 0.07326 -0.00636 0.0714201 -0.006195 0.0713596 
100% 0 0.07795 -0.00042 0.0782030 8.05E-14 0.0779484 
0.60 0.1667 25% 0 0.03519 -0.00150 0.0349179 -0.001297 0.0349780 
50% 0 0.03563 -0.00136 0.0352739 -0.001377 0.0352145 
75% 0 0.03584 -0.00140 0.0351700 -0.001414 0.0352712 
100% 0 0.03682 0.00006 0.0368014 -2.63E-18 0.0368230 
Note:  
1. IAL = interim analysis location. 
2. Interim analysis location refers to the percent of subjects out of the original protocol-
specified sample size who have been assessed for the outcome at the interim analysis. 
100% refers to the situation where no sample size re-estimation is planned. 
3. Theoretically derived refers to the results from the formulas derived in Section 3.4.1.  
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Table A.86: Mean and Standard Error Results under the Alternative Hypothesis Ha: pe = (1 + γ)pc 
from Simulations and Formulas where the Minimum Allowable Sample Size is the Original 
Protocol-Specified Sample Size and the Maximum Allowable Sample Size is Twice the Original 
Protocol-Specified Sample Size for the HW-SSR Method for the Alternative Hypothesis Ha: pe = (1 




(  ) 
Relative 
Treatment 
Effect ( ) IAL 
Expected 
      
Mean 
Expected 








      
SE 
Derived 
      
Mean 
Derived 
      
SE 
0.90 0.0556 25% 0.050 0.01671 0.04907 0.0165243 0.0490426 0.0165468 
50% 0.050 0.01697 0.04895 0.0166065 0.0489090 0.0166405 
75% 0.050 0.01709 0.04888 0.0166423 0.0488467 0.0166350 
100% 0.050 0.01784 0.05011 0.0178293 0.0500000 0.0178406 
0.80 0.125 25% 0.100 0.03318 0.09769 0.0327060 0.0979411 0.0328325 
50% 0.100 0.03369 0.09746 0.0329238 0.0976251 0.0330097 
75% 0.100 0.03398 0.09751 0.0329762 0.0974829 0.0329967 
100% 0.100 0.03562 0.10001 0.0356146 0.1000000 0.0356235 
0.80 0.0625 25% 0.050 0.01724 0.04959 0.0170804 0.0494885 0.0171398 
50% 0.050 0.01740 0.04941 0.0172531 0.0494581 0.0172206 
75% 0.050 0.01748 0.04939 0.0172685 0.0494432 0.0172353 
100% 0.050 0.01784 0.04988 0.0177813 0.0500000 0.0178433 
0.70 0.2143 25% 0.150 0.04939 0.14663 0.0489830 0.1466850 0.0488953 
50% 0.150 0.05015 0.14583 0.0489889 0.1460673 0.0491295 
75% 0.150 0.05062 0.14607 0.0490166 0.1457752 0.0490927 
100% 0.150 0.05348 0.14998 0.0534358 0.1500000 0.0534806 
0.70 0.1071 25% 0.075 0.02573 0.07411 0.0255405 0.0741414 0.0255687 
50% 0.075 0.02601 0.07409 0.0256563 0.0740904 0.0257078 
75% 0.075 0.02613 0.07411 0.0258244 0.0740657 0.0257347 
100% 0.075 0.02675 0.07504 0.0267955 0.0750000 0.0267541 
0.60 0.3333 25% 0.200 0.06508 0.19551 0.0648299 0.1953803 0.0645838 
50% 0.200 0.06618 0.19445 0.0647477 0.1943184 0.0648430 
75% 0.200 0.06687 0.19354 0.0647493 0.1938047 0.0647455 
100% 0.200 0.07116 0.19974 0.0710806 0.2000000 0.0711568 
0.60 0.1667 25% 0.100 0.03408 0.09844 0.0338733 0.0987026 0.0338488 
50% 0.100 0.03450 0.09872 0.0340374 0.0986234 0.0340666 
75% 0.100 0.03470 0.09860 0.0342133 0.0985857 0.0341124 
100% 0.100 0.03565 0.10005 0.0358260 0.1000000 0.0356537 
Note:  
1. IAL = interim analysis location. 
2. Interim analysis location refers to the percent of subjects out of the original protocol-
specified sample size who have been assessed for the outcome at the interim analysis. 
100% refers to the situation where no sample size re-estimation is planned. 
3. Theoretically derived refers to the results from the formulas derived in Section 3.4.1.  
292 
 
Table A.87: Mean and Standard Error Results under the Null Hypothesis Ho: pe = pc from 
Simulations and Formulas where the Minimum Allowable Sample Size is the Original Protocol-
Specified Sample Size and where there is No Maximum Allowable Sample Size for the HW-SSR 




(  ) 
Relative 
Treatment 
Effect ( ) IAL 
Expected 
      
Mean 
Expected 








      
SE 
Derived 
      
Mean 
Derived 
      
SE 
0.90 0.0556 25% 0 0.01912 -0.00106 0.0189833 -0.000970 0.0189765 
50% 0 0.01941 -0.00116 0.0190500 -0.001092 0.0191372 
75% 0 0.01956 -0.00128 0.0192360 -0.001153 0.0191677 
100% 0 0.02041 0.00004 0.0204279 2.17E-13 0.0204124 
0.80 0.125 25% 0 0.03745 -0.00232 0.0373284 -0.002125 0.0371840 
50% 0 0.03812 -0.00246 0.0374387 -0.002386 0.0375266 
75% 0 0.03845 -0.00258 0.0373941 -0.002519 0.0375935 
100% 0 0.04030 0.00002 0.0401480 2.30E-13 0.0403034 
0.80 0.0625 25% 0 0.01819 -0.00052 0.0180479 -0.000511 0.0180958 
50% 0 0.01836 -0.00061 0.0181729 -0.000542 0.0181888 
75% 0 0.01844 -0.00055 0.0181841 -0.000557 0.0182105 
100% 0 0.01882 0.00002 0.0188761 2.91E-18 0.0188248 
0.70 0.2143 25% 0 0.05481 -0.00368 0.0541927 -0.003554 0.0544302 
50% 0 0.05588 -0.00378 0.0546280 -0.004001 0.0549965 
75% 0 0.05648 -0.00461 0.0548851 -0.004244 0.0551142 
100% 0 0.05966 -0.00002 0.0597072 1.76E-13 0.0596601 
0.70 0.1071 25% 0 0.02689 -0.00076 0.0267875 -0.000859 0.0267451 
50% 0 0.02719 -0.00111 0.0269381 -0.000910 0.0269013 
75% 0 0.02732 -0.00096 0.0269306 -0.000934 0.0269379 
100% 0 0.02797 -0.00009 0.0278692 6.60E-18 0.0279665 
0.60 0.3333 25% 0 0.07053 -0.00556 0.0701585 -0.005258 0.0701939 
50% 0 0.07232 -0.00577 0.0708070 -0.005945 0.0710585 
75% 0 0.07323 -0.00679 0.0713104 -0.006307 0.0712313 
100% 0 0.07795 0.00026 0.0777139 8.05E-14 0.0779484 
0.60 0.1667 25% 0 0.03518 -0.00121 0.0349145 -0.001299 0.0349759 
50% 0 0.03563 -0.00121 0.0352411 -0.001377 0.0352144 
75% 0 0.03583 -0.00143 0.0353051 -0.001414 0.0352712 
100% 0 0.03682 0.00002 0.0367570 -2.63E-18 0.0368230 
Note:  
1. IAL = interim analysis location. 
2. Interim analysis location refers to the percent of subjects out of the original protocol-
specified sample size who have been assessed for the outcome at the interim analysis. 
100% refers to the situation where no sample size re-estimation is planned. 
3. Theoretically derived refers to the results from the formulas derived in Section 3.4.1.  
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Table A.88: Mean and Standard Error Results under the Alternative Hypothesis Ha: pe = (1 + γ)pc 
from Simulations and Formulas where the Minimum Allowable Sample Size is the Original 
Protocol-Specified Sample Size and where there is No Maximum Allowable Sample Size for the 




(  ) 
Relative 
Treatment 
Effect ( ) IAL 
Expected 
      
Mean 
Expected 








      
SE 
Derived 
      
Mean 
Derived 
      
SE 
0.90 0.0556 25% 0.050 0.01671 0.04898 0.0165112 0.0490305 0.0165342 
50% 0.050 0.01696 0.04891 0.0165617 0.0489081 0.0166393 
75% 0.050 0.0171 0.04882 0.0166538 0.0488466 0.0166348 
100% 0.050 0.01784 0.05007 0.0178609 0.0500000 0.0178406 
0.80 0.125 25% 0.100 0.03310 0.09785 0.0327528 0.0978751 0.0327647 
50% 0.100 0.03369 0.09759 0.0328930 0.0976144 0.0329970 
75% 0.100 0.03398 0.09750 0.0329273 0.0974811 0.0329940 
100% 0.100 0.03562 0.10014 0.0356084 0.1000000 0.0356235 
0.80 0.0625 25% 0.050 0.01724 0.04945 0.0171881 0.0494885 0.0171398 
50% 0.050 0.01740 0.04942 0.0172135 0.0494581 0.0172206 
75% 0.050 0.01748 0.04948 0.0172783 0.0494432 0.0172353 
100% 0.050 0.01784 0.05005 0.0178995 0.0500000 0.0178433 
0.70 0.2143 25% 0.150 0.04913 0.14632 0.0485178 0.1464460 0.0486479 
50% 0.150 0.05009 0.14587 0.0489573 0.1459988 0.0490537 
75% 0.150 0.05063 0.14533 0.0489431 0.1457556 0.0490664 
100% 0.150 0.05348 0.15009 0.0535888 0.1500000 0.0534806 
0.70 0.1071 25% 0.075 0.02573 0.07432 0.0256249 0.0741413 0.0255686 
50% 0.075 0.02601 0.07402 0.0257238 0.0740904 0.0257078 
75% 0.075 0.02614 0.07410 0.0257540 0.0740657 0.0257347 
100% 0.075 0.02675 0.07483 0.0266123 0.0750000 0.0267541 
0.60 0.3333 25% 0.200 0.06439 0.19480 0.0640202 0.1947416 0.0639063 
50% 0.200 0.06602 0.19419 0.0644684 0.1940553 0.0645668 
75% 0.200 0.06685 0.19350 0.0642395 0.1936933 0.0646107 
100% 0.200 0.07116 0.20019 0.0709312 0.2000000 0.0711568 
0.60 0.1667 25% 0.100 0.03406 0.09869 0.0337781 0.0987005 0.0338467 
50% 0.100 0.03449 0.09863 0.0340424 0.0986234 0.0340665 
75% 0.100 0.03470 0.09857 0.0341210 0.0985857 0.0341124 
100% 0.100 0.03565 0.09999 0.0354782 0.1000000 0.0356537 
Note:  
1. IAL = interim analysis location. 
2. Interim analysis location refers to the percent of subjects out of the original protocol-
specified sample size who have been assessed for the outcome at the interim analysis. 
100% refers to the situation where no sample size re-estimation is planned. 
3. Theoretically derived refers to the results from the formulas derived in Section 3.4.1.  
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Table A.89: Mean and Standard Error Results under the Null Hypothesis Ho: pe = pc from 
Simulations and Formulas where the Minimum Allowable Sample Size is the Interim Analysis 
Sample Size and the Maximum Allowable Sample Size is Twice the Original Protocol-Specified 
Sample Size for the HW-SSR Method for the Alternative Hypothesis Ha: pe = pc + Δ when the 








Effect (Δ) IAL 
Expected 
      
Mean 
Expected 








      
SE 
Derived 
      
Mean 
Derived 
      
SE 
0.90 0.05 25% 0 0.02161 -0.00337 0.0228653 -0.003498 0.0232351 
50% 0 0.02098 -0.00290 0.0217527 -0.002968 0.0220353 
75% 0 0.02057 -0.00223 0.0208287 -0.002253 0.0207619 
100% 0 0.02041 -0.00007 0.0204201 2.17E-13 0.0204124 
0.80 0.10 25% 0 0.04263 -0.00617 0.0449691 -0.006241 0.0454315 
50% 0 0.04141 -0.00524 0.0432614 -0.005355 0.0434365 
75% 0 0.04075 -0.00433 0.0409628 -0.004111 0.0411652 
100% 0 0.04030 0.00024 0.0404098 2.30E-13 0.0403034 
0.80 0.05 25% 0 0.01898 -0.00096 0.0191294 -0.000867 0.0191601 
50% 0 0.01890 -0.00086 0.0190722 -0.000832 0.0190398 
75% 0 0.01888 -0.00090 0.0189721 -0.000820 0.0190002 
100% 0 0.01882 0.00005 0.0188466 2.91E-18 0.0188248 
0.70 0.15 25% 0 0.06280 -0.00784 0.0661577 -0.008110 0.0665857 
50% 0 0.06119 -0.00701 0.0635328 -0.007024 0.0641198 
75% 0 0.06024 -0.00529 0.0608671 -0.005449 0.0611158 
100% 0 0.05966 0.00004 0.0596983 1.76E-13 0.0596601 
0.70 0.075 25% 0 0.02819 -0.00106 0.0284493 -0.001051 0.0284123 
50% 0 0.02808 -0.00107 0.0282768 -0.001006 0.0282545 
75% 0 0.02805 -0.00104 0.0281086 -0.000992 0.0282045 
100% 0 0.02797 0.00002 0.0280154 6.60E-18 0.0279665 
0.60 0.20 25% 0 0.08220 -0.00868 0.0861869 -0.008722 0.0863542 
50% 0 0.08001 -0.00785 0.0834429 -0.007594 0.0835972 
75% 0 0.07900 -0.00564 0.0800636 -0.005954 0.0802976 
100% 0 0.07795 0.00004 0.0780583 8.05E-14 0.0779484 
0.60 0.10 25% 0 0.03715 -0.00096 0.0374741 -0.000992 0.0373730 
50% 0 0.03698 -0.00083 0.0372607 -0.000945 0.0371818 
75% 0 0.03694 -0.00109 0.0371662 -0.000931 0.0371208 
100% 0 0.03682 -0.00020 0.0367302 -2.63E-18 0.0368230 
Note:  
1. IAL = interim analysis location. 
2. Interim analysis location refers to the percent of subjects out of the original protocol-
specified sample size who have been assessed for the outcome at the interim analysis. 
100% refers to the situation where no sample size re-estimation is planned. 
3. Theoretically derived refers to the results from the formulas derived in Section 3.4.1.  
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Table A.90: Mean and Standard Error Results under the Alternative Hypothesis Ha: pe = pc + Δ 
from Simulations and Formulas where the Minimum Allowable Sample Size is the Interim 
Analysis Sample Size and the Maximum Allowable Sample Size is Twice the Original Protocol-
Specified Sample Size for the HW-SSR Method for the Alternative Hypothesis Ha: pe = pc + Δ 








Effect (Δ) IAL 
Expected 
      
Mean 
Expected 








      
SE 
Derived 
      
Mean 
Derived 
      
SE 
0.90 0.05 25% 0.050 0.01888 0.04669 0.0202294 0.0465020 0.0206097 
50% 0.050 0.01833 0.04704 0.0191933 0.0470318 0.0194911 
75% 0.050 0.01798 0.04782 0.0181737 0.0477475 0.0181745 
100% 0.050 0.01784 0.04992 0.0178504 0.0500000 0.0178406 
0.80 0.10 25% 0.100 0.03768 0.09394 0.0401048 0.0937587 0.0406582 
50% 0.100 0.03661 0.09481 0.0383673 0.0946446 0.0388079 
75% 0.100 0.03602 0.09561 0.0363082 0.0958888 0.0364629 
100% 0.100 0.03562 0.10015 0.0357028 0.1000000 0.0356235 
0.80 0.05 25% 0.050 0.01799 0.04914 0.0181290 0.0491327 0.0181761 
50% 0.050 0.01792 0.04910 0.0181282 0.0491683 0.0180601 
75% 0.050 0.01789 0.04914 0.0180584 0.0491798 0.0180217 
100% 0.050 0.01784 0.04996 0.0178733 0.0500000 0.0178433 
0.70 0.15 25% 0.150 0.05629 0.14226 0.0596432 0.1418900 0.0602952 
50% 0.150 0.05485 0.14307 0.0573848 0.1429765 0.0580246 
75% 0.150 0.05400 0.14477 0.0546384 0.1445510 0.0549349 
100% 0.150 0.05348 0.15016 0.0535210 0.1500000 0.0534806 
0.70 0.075 25% 0.075 0.02697 0.07392 0.0271493 0.0739494 0.0271964 
50% 0.075 0.02687 0.07394 0.0271376 0.0739944 0.0270435 
75% 0.075 0.02683 0.07397 0.0269428 0.0740084 0.0269950 
100% 0.075 0.02675 0.07504 0.0267888 0.0750000 0.0267541 
0.60 0.20 25% 0.200 0.07504 0.19117 0.0789973 0.1912783 0.0794267 
50% 0.200 0.07303 0.19228 0.0767565 0.1924056 0.0768917 
75% 0.200 0.07212 0.19411 0.0732466 0.1940459 0.0735180 
100% 0.200 0.07116 0.19996 0.0711560 0.2000000 0.0711568 
0.60 0.10 25% 0.100 0.03597 0.09888 0.0362070 0.0990076 0.0361995 
50% 0.100 0.03581 0.09915 0.0359010 0.0990548 0.0360129 
75% 0.100 0.03577 0.09908 0.0359854 0.0990694 0.0359535 
100% 0.100 0.03565 0.09978 0.0356179 0.1000000 0.0356537 
Note:  
1. IAL = interim analysis location. 
2. Interim analysis location refers to the percent of subjects out of the original protocol-
specified sample size who have been assessed for the outcome at the interim analysis. 
100% refers to the situation where no sample size re-estimation is planned. 
3. Theoretically derived refers to the results from the formulas derived in Section 3.4.1.  
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Table A.91: Mean and Standard Error Results under the Null Hypothesis Ho: pe = pc from 
Simulations and Formulas where the Minimum Allowable Sample Size is the Interim Analysis 
Sample Size and where there is No Maximum Allowable Sample Size for the HW-SSR Method 








Effect (Δ) IAL 
Expected 
      
Mean 
Expected 








      
SE 
Derived 
      
Mean 
Derived 
      
SE 
0.90 0.05 25% 0 0.02160 -0.00329 0.0227839 -0.003498 0.0232347 
50% 0 0.02095 -0.00281 0.0216929 -0.002968 0.0220353 
75% 0 0.02058 -0.00232 0.0207579 -0.002253 0.0207619 
100% 0 0.02041 0.00002 0.0204261 2.17E-13 0.0204124 
0.80 0.10 25% 0 0.04258 -0.00615 0.0449250 -0.006241 0.0454315 
50% 0 0.04139 -0.00517 0.0429011 -0.005355 0.0434365 
75% 0 0.04073 -0.00408 0.0410791 -0.004111 0.0411652 
100% 0 0.04030 -0.00005 0.0403043 2.30E-13 0.0403034 
0.80 0.05 25% 0 0.01898 -0.00080 0.0191118 -0.000867 0.0191601 
50% 0 0.01890 -0.00090 0.0190713 -0.000832 0.0190398 
75% 0 0.01888 -0.00087 0.0189786 -0.000820 0.0190002 
100% 0 0.01882 -0.00005 0.0188881 2.91E-18 0.0188248 
0.70 0.15 25% 0 0.06279 -0.00797 0.0658469 -0.008110 0.0665857 
50% 0 0.06118 -0.00684 0.0635350 -0.007024 0.0641198 
75% 0 0.06025 -0.00533 0.0609100 -0.005449 0.0611158 
100% 0 0.05966 -0.00028 0.0594295 1.76E-13 0.0596601 
0.70 0.075 25% 0 0.02820 -0.00113 0.0283307 -0.001051 0.0284123 
50% 0 0.02808 -0.00102 0.0283055 -0.001006 0.0282545 
75% 0 0.02804 -0.00106 0.0281852 -0.000992 0.0282045 
100% 0 0.02797 -0.00005 0.0280127 6.60E-18 0.0279665 
0.60 0.20 25% 0 0.08226 -0.00884 0.0860017 -0.008722 0.0863542 
50% 0 0.07996 -0.00760 0.0832357 -0.007594 0.0835972 
75% 0 0.07899 -0.00538 0.0802761 -0.005954 0.0802976 
100% 0 0.07795 -0.00028 0.0778846 8.05E-14 0.0779484 
0.60 0.10 25% 0 0.03714 -0.00112 0.0374488 -0.000992 0.0373730 
50% 0 0.03698 -0.00070 0.0370811 -0.000945 0.0371818 
75% 0 0.03694 -0.00093 0.0370391 -0.000931 0.0371208 
100% 0 0.03682 -0.00010 0.0367930 -2.63E-18 0.0368230 
Note:  
1. IAL = interim analysis location. 
2. Interim analysis location refers to the percent of subjects out of the original protocol-
specified sample size who have been assessed for the outcome at the interim analysis. 
100% refers to the situation where no sample size re-estimation is planned. 
3. Theoretically derived refers to the results from the formulas derived in Section 3.4.1.  
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Table A.92: Mean and Standard Error Results under the Alternative Hypothesis Ha: pe = pc + Δ 
from Simulations and Formulas where the Minimum Allowable Sample Size is the Interim 
Analysis Sample Size and where there is No Maximum Allowable Sample Size for the HW-SSR 








Effect (Δ) IAL 
Expected 
      
Mean 
Expected 








      
SE 
Derived 
      
Mean 
Derived 
      
SE 
0.90 0.05 25% 0.050 0.01888 0.04663 0.0202411 0.0465016 0.0206093 
50% 0.050 0.01831 0.04707 0.0191349 0.0470318 0.0194911 
75% 0.050 0.01798 0.04770 0.0181400 0.0477475 0.0181745 
100% 0.050 0.01784 0.05001 0.0178577 0.0500000 0.0178406 
0.80 0.10 25% 0.100 0.03764 0.09389 0.0400777 0.0937587 0.0406582 
50% 0.100 0.03658 0.09498 0.0384034 0.0946446 0.0388079 
75% 0.100 0.03600 0.09591 0.0364265 0.0958888 0.0364629 
100% 0.100 0.03562 0.10004 0.0355438 0.1000000 0.0356235 
0.80 0.05 25% 0.050 0.01799 0.04915 0.0181863 0.0491327 0.0181761 
50% 0.050 0.01792 0.04912 0.0180589 0.0491683 0.0180601 
75% 0.050 0.01789 0.04918 0.0179613 0.0491798 0.0180217 
100% 0.050 0.01784 0.05008 0.0178431 0.0500000 0.0178433 
0.70 0.15 25% 0.150 0.05628 0.14226 0.0593855 0.1418900 0.0602952 
50% 0.150 0.05485 0.14320 0.0575087 0.1429765 0.0580246 
75% 0.150 0.05401 0.14436 0.0547908 0.1445510 0.0549349 
100% 0.150 0.05348 0.14975 0.0534040 0.1500000 0.0534806 
0.70 0.075 25% 0.075 0.02698 0.07387 0.0271604 0.0739494 0.0271964 
50% 0.075 0.02687 0.07401 0.0270039 0.0739944 0.0270435 
75% 0.075 0.02683 0.07406 0.0268917 0.0740084 0.0269950 
100% 0.075 0.02675 0.07500 0.0267856 0.0750000 0.0267541 
0.60 0.20 25% 0.200 0.07509 0.19127 0.0792776 0.1912783 0.0794267 
50% 0.200 0.07299 0.19258 0.0766467 0.1924056 0.0768917 
75% 0.200 0.07210 0.19406 0.0733417 0.1940459 0.0735180 
100% 0.200 0.07116 0.19968 0.0711598 0.2000000 0.0711568 
0.60 0.10 25% 0.100 0.03596 0.09891 0.0362094 0.0990076 0.0361995 
50% 0.100 0.03581 0.09922 0.0359071 0.0990548 0.0360129 
75% 0.100 0.03577 0.09915 0.0359276 0.0990694 0.0359535 
100% 0.100 0.03565 0.09991 0.035505 0.1000000 0.0356537 
Note:  
1. IAL = interim analysis location. 
2. Interim analysis location refers to the percent of subjects out of the original protocol-
specified sample size who have been assessed for the outcome at the interim analysis. 
100% refers to the situation where no sample size re-estimation is planned. 
3. Theoretically derived refers to the results from the formulas derived in Section 3.4.1.  
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Table A.93: Mean and Standard Error Results under the Null Hypothesis Ho: pe = pc from 
Simulations and Formulas where the Minimum Allowable Sample Size is 10% more than the 
Interim Analysis Sample Size and the Maximum Allowable Sample Size is Twice the Original 
Protocol-Specified Sample Size for the HW-SSR Method for the Alternative Hypothesis Ha: pe = pc 








Effect (Δ) IAL 
Expected 
      
Mean 
Expected 








      
SE 
Derived 
      
Mean 
Derived 
      
SE 
0.90 0.05 25% 0 0.02159 -0.00322 0.0228577 -0.003498 0.0232351 
50% 0 0.02092 -0.00270 0.0214740 -0.002821 0.0217566 
75% 0 0.02040 -0.00199 0.0203034 -0.001886 0.0203185 
100% 0 0.02041 -0.00004 0.0204225 2.17E-13 0.0204124 
0.80 0.10 25% 0 0.04263 -0.00618 0.0451443 -0.006241 0.0454315 
50% 0 0.04134 -0.00488 0.0424610 -0.005111 0.0429560 
75% 0 0.04042 -0.00317 0.0403275 -0.003445 0.0403348 
100% 0 0.04030 0.00026 0.0403589 2.30E-13 0.0403034 
0.80 0.05 25% 0 0.01897 -0.00077 0.0190510 -0.000867 0.0191601 
50% 0 0.01890 -0.00084 0.0190199 -0.000832 0.0190398 
75% 0 0.01887 -0.00094 0.0190094 -0.000808 0.0189737 
100% 0 0.01882 -0.00004 0.0187934 2.91E-18 0.0188248 
0.70 0.15 25% 0 0.06278 -0.00824 0.0658737 -0.008110 0.0665857 
50% 0 0.06110 -0.00650 0.0627795 -0.006736 0.0635225 
75% 0 0.05990 -0.00483 0.0597235 -0.004585 0.0599884 
100% 0 0.05966 0.00018 0.0597381 1.76E-13 0.0596601 
0.70 0.075 25% 0 0.02819 -0.00109 0.0284532 -0.001051 0.0284123 
50% 0 0.02808 -0.00091 0.0281986 -0.001006 0.0282545 
75% 0 0.02804 -0.00092 0.0281975 -0.000985 0.0281891 
100% 0 0.02797 0.00004 0.0280074 6.60E-18 0.0279665 
0.60 0.20 25% 0 0.08220 -0.00876 0.0860159 -0.008722 0.0863542 
50% 0 0.07995 -0.00756 0.0828932 -0.007315 0.0829874 
75% 0 0.07861 -0.00489 0.0786801 -0.005008 0.0789988 
100% 0 0.07795 0.00019 0.0780425 8.05E-14 0.0779484 
0.60 0.10 25% 0 0.03714 -0.00102 0.0372899 -0.000992 0.0373730 
50% 0 0.03699 -0.00096 0.0372655 -0.000945 0.0371818 
75% 0 0.03694 -0.00083 0.0369724 -0.000929 0.0371169 
100% 0 0.03682 0.00013 0.0367331 -2.63E-18 0.0368230 
Note:  
1. IAL = interim analysis location. 
2. Interim analysis location refers to the percent of subjects out of the original protocol-
specified sample size who have been assessed for the outcome at the interim analysis. 
100% refers to the situation where no sample size re-estimation is planned. 
3. Theoretically derived refers to the results from the formulas derived in Section 3.4.1.  
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Table A.94: Mean and Standard Error Results under the Alternative Hypothesis Ha: pe = pc + Δ 
from Simulations and Formulas where the Minimum Allowable Sample Size is 10% more than the 
Interim Analysis Sample Size and the Maximum Allowable Sample Size is Twice the Original 
Protocol-Specified Sample Size for the HW-SSR Method for the Alternative Hypothesis Ha: pe = pc 








Effect (Δ) IAL 
Expected 
      
Mean 
Expected 








      
SE 
Derived 
      
Mean 
Derived 
      
SE 
0.90 0.05 25% 0.050 0.01887 0.04670 0.0201531 0.0465020 0.0206097 
50% 0.050 0.01829 0.04723 0.0189600 0.0471791 0.0191924 
75% 0.050 0.01783 0.04803 0.0176751 0.0481141 0.0177197 
100% 0.050 0.01784 0.04996 0.0178633 0.0500000 0.0178406 
0.80 0.10 25% 0.100 0.03768 0.09393 0.0402489 0.0937587 0.0406582 
50% 0.100 0.03654 0.09502 0.0378771 0.0948894 0.0382940 
75% 0.100 0.03572 0.09671 0.0353836 0.0965549 0.0356079 
100% 0.100 0.03562 0.10028 0.0356458 0.1000000 0.0356235 
0.80 0.05 25% 0.050 0.01799 0.04925 0.0180691 0.0491327 0.0181761 
50% 0.050 0.01792 0.04918 0.0180649 0.0491683 0.0180600 
75% 0.050 0.01789 0.04910 0.0179841 0.0491915 0.0179941 
100% 0.050 0.01784 0.04996 0.0178579 0.0500000 0.0178433 
0.70 0.15 25% 0.150 0.05628 0.14189 0.0596204 0.1418900 0.0602952 
50% 0.150 0.05477 0.14341 0.0568945 0.1432643 0.0573885 
75% 0.150 0.05369 0.14503 0.0535976 0.1454145 0.0537695 
100% 0.150 0.05348 0.14986 0.0535183 0.1500000 0.0534806 
0.70 0.075 25% 0.075 0.02697 0.07389 0.0272795 0.0739494 0.0271964 
50% 0.075 0.02686 0.07411 0.0271024 0.0739944 0.0270435 
75% 0.075 0.02682 0.07399 0.0270209 0.0740146 0.0269791 
100% 0.075 0.02675 0.07499 0.0267863 0.0750000 0.0267541 
0.60 0.20 25% 0.200 0.07503 0.19118 0.0788768 0.1912783 0.0794267 
50% 0.200 0.07298 0.19214 0.0763941 0.1926851 0.0762473 
75% 0.200 0.07176 0.19502 0.0718715 0.1949918 0.0721748 
100% 0.200 0.07116 0.20011 0.0713074 0.2000000 0.0711568 
0.60 0.10 25% 0.100 0.03596 0.09908 0.0363398 0.0990076 0.0361995 
50% 0.100 0.03581 0.09916 0.0359706 0.0990548 0.0360129 
75% 0.100 0.03577 0.09917 0.0359294 0.0990708 0.0359495 
100% 0.100 0.03565 0.10015 0.0356795 0.1000000 0.0356537 
Note:  
1. IAL = interim analysis location. 
2. Interim analysis location refers to the percent of subjects out of the original protocol-
specified sample size who have been assessed for the outcome at the interim analysis. 
100% refers to the situation where no sample size re-estimation is planned. 
3. Theoretically derived refers to the results from the formulas derived in Section 3.4.1.  
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Table A.95: Mean and Standard Error Results under the Null Hypothesis Ho: pe = pc from 
Simulations and Formulas where the Minimum Allowable Sample Size is 10% more than the 
Interim Analysis Sample Size and where there is No Maximum Allowable Sample Size for the 








Effect (Δ) IAL 
Expected 
      
Mean 
Expected 








      
SE 
Derived 
      
Mean 
Derived 
      
SE 
0.90 0.05 25% 0 0.02160 -0.00325 0.0228133 -0.003498 0.0232347 
50% 0 0.02092 -0.00265 0.0216274 -0.002821 0.0217566 
75% 0 0.02039 -0.00186 0.0203401 -0.001886 0.0203185 
100% 0 0.02041 0.00009 0.0204846 2.17E-13 0.0204124 
0.80 0.10 25% 0 0.04267 -0.00608 0.0449089 -0.006241 0.0454315 
50% 0 0.04133 -0.00503 0.0425582 -0.005111 0.0429560 
75% 0 0.04044 -0.00363 0.0399970 -0.003445 0.0403348 
100% 0 0.04030 -0.00002 0.0402388 2.30E-13 0.0403034 
0.80 0.05 25% 0 0.01898 -0.00082 0.0191495 -0.000867 0.0191601 
50% 0 0.01890 -0.00081 0.0190527 -0.000832 0.0190398 
75% 0 0.01887 -0.00087 0.0189123 -0.000808 0.0189737 
100% 0 0.01882 -0.00003 0.0188422 2.91E-18 0.0188248 
0.70 0.15 25% 0 0.06279 -0.00797 0.0660935 -0.008110 0.0665857 
50% 0 0.06110 -0.00655 0.0630939 -0.006736 0.0635225 
75% 0 0.05987 -0.00454 0.0596058 -0.004585 0.0599884 
100% 0 0.05966 0.00005 0.0593469 1.76E-13 0.0596601 
0.70 0.075 25% 0 0.02819 -0.00094 0.0283554 -0.001051 0.0284123 
50% 0 0.02808 -0.00103 0.0282897 -0.001006 0.0282545 
75% 0 0.02804 -0.00090 0.0281334 -0.000985 0.0281891 
100% 0 0.02797 -0.00016 0.0280119 6.60E-18 0.0279665 
0.60 0.20 25% 0 0.08224 -0.00877 0.0858931 -0.008722 0.0863542 
50% 0 0.07988 -0.00770 0.0825300 -0.007315 0.0829874 
75% 0 0.07863 -0.00507 0.0788067 -0.005008 0.0789988 
100% 0 0.07795 -0.00019 0.0775265 8.05E-14 0.0779484 
0.60 0.10 25% 0 0.03714 -0.00116 0.0372742 -0.000992 0.0373730 
50% 0 0.03698 -0.00081 0.0372423 -0.000945 0.0371818 
75% 0 0.03695 -0.00095 0.0370874 -0.000929 0.0371169 
100% 0 0.03682 -0.00012 0.0368511 -2.63E-18 0.0368230 
Note:  
1. IAL = interim analysis location. 
2. Interim analysis location refers to the percent of subjects out of the original protocol-
specified sample size who have been assessed for the outcome at the interim analysis. 
100% refers to the situation where no sample size re-estimation is planned. 
3. Theoretically derived refers to the results from the formulas derived in Section 3.4.1.  
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Table A.96: Mean and Standard Error Results under the Alternative Hypothesis Ha: pe = pc + Δ 
from Simulations and Formulas where the Minimum Allowable Sample Size is 10% more than the 
Interim Analysis Sample Size and where there is No Maximum Allowable Sample Size for the 








Effect (Δ) IAL 
Expected 
      
Mean 
Expected 








      
SE 
Derived 
      
Mean 
Derived 
      
SE 
0.90 0.05 25% 0.050 0.01888 0.04669 0.0201782 0.0465016 0.0206093 
50% 0.050 0.01828 0.04721 0.0190097 0.0471790 0.0191924 
75% 0.050 0.01782 0.04809 0.0177355 0.0481141 0.0177197 
100% 0.050 0.01784 0.05004 0.0179018 0.0500000 0.0178406 
0.80 0.10 25% 0.100 0.03771 0.09394 0.0402022 0.0937587 0.0406582 
50% 0.100 0.03653 0.09483 0.0379900 0.0948894 0.0382940 
75% 0.100 0.03574 0.09648 0.0354442 0.0965549 0.0356079 
100% 0.100 0.03562 0.09999 0.0355429 0.1000000 0.0356235 
0.80 0.05 25% 0.050 0.01799 0.04908 0.0181551 0.0491327 0.0181761 
50% 0.050 0.01791 0.04927 0.0179961 0.0491683 0.0180600 
75% 0.050 0.01789 0.04926 0.0180153 0.0491915 0.0179941 
100% 0.050 0.01784 0.05000 0.0178813 0.0500000 0.0178433 
0.70 0.15 25% 0.150 0.05629 0.14205 0.0596647 0.1418900 0.0602952 
50% 0.150 0.05477 0.14337 0.0568761 0.1432643 0.0573885 
75% 0.150 0.05367 0.14531 0.0534979 0.1454145 0.0537695 
100% 0.150 0.05348 0.14994 0.0532591 0.1500000 0.0534806 
0.70 0.075 25% 0.075 0.02696 0.07400 0.0271596 0.0739494 0.0271964 
50% 0.075 0.02687 0.07404 0.0271117 0.0739944 0.0270435 
75% 0.075 0.02683 0.07405 0.0270554 0.0740146 0.0269791 
100% 0.075 0.02675 0.07492 0.0267963 0.0750000 0.0267541 
0.60 0.20 25% 0.200 0.07507 0.19106 0.0788039 0.1912783 0.0794267 
50% 0.200 0.07292 0.19276 0.0754810 0.1926851 0.0762473 
75% 0.200 0.07178 0.19472 0.0723270 0.1949918 0.0721748 
100% 0.200 0.07116 0.19965 0.0710764 0.2000000 0.0711568 
0.60 0.10 25% 0.100 0.03596 0.09888 0.0362145 0.0990076 0.0361995 
50% 0.100 0.03581 0.09931 0.0359675 0.0990548 0.0360129 
75% 0.100 0.03578 0.09889 0.0359313 0.0990708 0.0359495 
100% 0.100 0.03565 0.09998 0.0356614 0.1000000 0.0356537 
Note:  
1. IAL = interim analysis location. 
2. Interim analysis location refers to the percent of subjects out of the original protocol-
specified sample size who have been assessed for the outcome at the interim analysis. 
100% refers to the situation where no sample size re-estimation is planned. 
3. Theoretically derived refers to the results from the formulas derived in Section 3.4.1.  
302 
 
Table A.97: Mean and Standard Error Results under the Null Hypothesis Ho: pe = pc from 
Simulations and Formulas where the Minimum Allowable Sample Size is the Original Protocol-
Specified Sample Size and the Maximum Allowable Sample Size is Twice the Original Protocol-
Specified Sample Size for the HW-SSR Method for the Alternative Hypothesis Ha: pe = pc + Δ 








Effect (Δ) IAL 
Expected 
      
Mean 
Expected 








      
SE 
Derived 
      
Mean 
Derived 
      
SE 
0.90 0.05 25% 0 0.01933 -0.00074 0.0192141 -0.000805 0.0192187 
50% 0 0.01959 -0.00090 0.0192868 -0.000908 0.0193495 
75% 0 0.01971 -0.00086 0.0194751 -0.000959 0.0193732 
100% 0 0.02041 -0.00005 0.0203976 2.17E-13 0.0204124 
0.80 0.10 25% 0 0.03849 -0.00121 0.0380333 -0.001392 0.0382549 
50% 0 0.03889 -0.00140 0.0384094 -0.001571 0.0384654 
75% 0 0.03911 -0.00160 0.0384187 -0.001660 0.0385011 
100% 0 0.04030 -0.00028 0.0404009 2.30E-13 0.0403034 
0.80 0.05 25% 0 0.01844 -0.00037 0.0183482 -0.000320 0.0183680 
50% 0 0.01854 -0.00036 0.0184854 -0.000340 0.0184239 
75% 0 0.01858 -0.00029 0.0184928 -0.000350 0.0184366 
100% 0 0.01882 0.00004 0.0187943 2.91E-18 0.0188248 
0.70 0.15 25% 0 0.05747 -0.00183 0.0573228 -0.001693 0.0571448 
50% 0 0.05790 -0.00215 0.0574877 -0.001956 0.0573619 
75% 0 0.05811 -0.00196 0.0569735 -0.002092 0.0573919 
100% 0 0.05966 0.00003 0.0599454 1.76E-13 0.0596601 
0.70 0.075 25% 0 0.02752 -0.00048 0.0275431 -0.000371 0.0274365 
50% 0 0.02763 -0.00030 0.0275048 -0.000398 0.0274969 
75% 0 0.02769 -0.00039 0.0275548 -0.000411 0.0275100 
100% 0 0.02797 -0.00001 0.0280465 6.60E-18 0.0279665 
0.60 0.20 25% 0 0.07597 -0.00175 0.0757819 -0.001446 0.0757519 
50% 0 0.07628 -0.00237 0.0756966 -0.001815 0.0758284 
75% 0 0.07653 -0.00219 0.0758218 -0.001988 0.0758094 
100% 0 0.07795 0.00009 0.0777334 8.05E-14 0.0779484 
0.60 0.10 25% 0 0.03645 -0.00019 0.0363320 -0.000301 0.0363890 
50% 0 0.03654 -0.00031 0.0364629 -0.000337 0.0364260 
75% 0 0.03658 -0.00057 0.0364404 -0.000354 0.0364319 
100% 0 0.03682 0.00005 0.0369056 -2.63E-18 0.0368230 
Note:  
1. IAL = interim analysis location. 
2. Interim analysis location refers to the percent of subjects out of the original protocol-
specified sample size who have been assessed for the outcome at the interim analysis. 
100% refers to the situation where no sample size re-estimation is planned. 
3. Theoretically derived refers to the results from the formulas derived in Section 3.4.1.  
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Table A.98: Mean and Standard Error Results under the Alternative Hypothesis Ha: pe = pc + Δ 
from Simulations and Formulas where the Minimum Allowable Sample Size is the Original 
Protocol-Specified Sample Size and the Maximum Allowable Sample Size is Twice the Original 
Protocol-Specified Sample Size for the HW-SSR Method for the Alternative Hypothesis Ha: pe = pc 








Effect (Δ) IAL 
Expected 
      
Mean 
Expected 








      
SE 
Derived 
      
Mean 
Derived 
      
SE 
0.90 0.05 25% 0.050 0.01690 0.04929 0.0167526 0.0491949 0.0167533 
50% 0.050 0.01712 0.04901 0.0167177 0.0490919 0.0168379 
75% 0.050 0.01723 0.04903 0.0168615 0.0490412 0.0168326 
100% 0.050 0.01784 0.04994 0.0178002 0.0500000 0.0178406 
0.80 0.10 25% 0.100 0.03402 0.09865 0.0337067 0.0986076 0.0337420 
50% 0.100 0.03438 0.09853 0.0338037 0.0984287 0.0338803 
75% 0.100 0.03457 0.09830 0.0337884 0.0983402 0.0338701 
100% 0.100 0.03562 0.09972 0.0356448 0.1000000 0.0356235 
0.80 0.05 25% 0.050 0.01747 0.04968 0.0173915 0.0496801 0.0174023 
50% 0.050 0.01757 0.04970 0.0175030 0.0496601 0.0174506 
75% 0.050 0.01762 0.04966 0.0174064 0.0496503 0.0174589 
100% 0.050 0.01784 0.05006 0.0178160 0.0500000 0.0178433 
0.70 0.15 25% 0.150 0.05151 0.14817 0.0511405 0.1483070 0.0511530 
50% 0.150 0.05190 0.14792 0.0512570 0.1480444 0.0512947 
75% 0.150 0.05209 0.14814 0.0511218 0.1479084 0.0512739 
100% 0.150 0.05348 0.14986 0.0536538 0.1500000 0.0534806 
0.70 0.075 25% 0.075 0.02632 0.07456 0.0262066 0.0746292 0.0262394 
50% 0.075 0.02643 0.07465 0.0262800 0.0746021 0.0262926 
75% 0.075 0.02649 0.07451 0.0262398 0.0745891 0.0263015 
100% 0.075 0.02675 0.07496 0.0267719 0.0750000 0.0267541 
0.60 0.20 25% 0.200 0.06935 0.19855 0.0690489 0.1985543 0.0691108 
50% 0.200 0.06964 0.19786 0.0688635 0.1981848 0.0691312 
75% 0.200 0.06986 0.19807 0.0688760 0.1980121 0.0690725 
100% 0.200 0.07116 0.20030 0.0711055 0.2000000 0.0711568 
0.60 0.10 25% 0.100 0.03529 0.09995 0.0351699 0.0996991 0.0352294 
50% 0.100 0.03538 0.09964 0.0352334 0.0996628 0.0352621 
75% 0.100 0.03542 0.09958 0.0352423 0.0996462 0.0352652 
100% 0.100 0.03565 0.09994 0.0356258 0.1000000 0.0356537 
Note:  
1. IAL = interim analysis location. 
2. Interim analysis location refers to the percent of subjects out of the original protocol-
specified sample size who have been assessed for the outcome at the interim analysis. 
100% refers to the situation where no sample size re-estimation is planned. 
3. Theoretically derived refers to the results from the formulas derived in Section 3.4.1.  
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Table A.99: Mean and Standard Error Results under the Null Hypothesis Ho: pe = pc from 
Simulations and Formulas where the Minimum Allowable Sample Size is the Original Protocol-
Specified Sample Size and where there is No Maximum Allowable Sample Size for the HW-SSR 








Effect (Δ) IAL 
Expected 
      
Mean 
Expected 








      
SE 
Derived 
      
Mean 
Derived 
      
SE 
0.90 0.05 25% 0 0.01934 -0.00079 0.0191702 -0.000806 0.0192183 
50% 0 0.01960 -0.00095 0.0192643 -0.000908 0.0193495 
75% 0 0.01971 -0.00088 0.0193932 -0.000959 0.0193732 
100% 0 0.02041 -0.00003 0.0204439 2.17E-13 0.0204124 
0.80 0.10 25% 0 0.03851 -0.00149 0.0381904 -0.001392 0.0382549 
50% 0 0.03890 -0.00162 0.0384182 -0.001571 0.0384654 
75% 0 0.03910 -0.00153 0.0384521 -0.001660 0.0385011 
100% 0 0.04030 -0.00001 0.0404671 2.30E-13 0.0403034 
0.80 0.05 25% 0 0.01844 -0.00041 0.0183566 -0.000320 0.0183680 
50% 0 0.01854 -0.00038 0.0184495 -0.000340 0.0184239 
75% 0 0.01858 -0.00029 0.0184288 -0.000350 0.0184366 
100% 0 0.01882 0.00002 0.0188399 2.91E-18 0.0188248 
0.70 0.15 25% 0 0.05747 -0.00180 0.0570576 -0.001693 0.0571448 
50% 0 0.05790 -0.00211 0.0572464 -0.001956 0.0573619 
75% 0 0.05811 -0.00220 0.0573386 -0.002092 0.0573919 
100% 0 0.05966 0.00008 0.0594354 1.76E-13 0.0596601 
0.70 0.075 25% 0 0.02752 -0.00039 0.0274095 -0.000371 0.0274365 
50% 0 0.02763 -0.00051 0.0275083 -0.000398 0.0274969 
75% 0 0.02769 -0.00063 0.0274660 -0.000411 0.0275100 
100% 0 0.02797 0.00001 0.0278625 6.60E-18 0.0279665 
0.60 0.20 25% 0 0.07598 -0.00183 0.0757859 -0.001446 0.0757519 
50% 0 0.07628 -0.00171 0.0756995 -0.001815 0.0758284 
75% 0 0.07653 -0.00220 0.0753321 -0.001988 0.0758094 
100% 0 0.07795 0.00009 0.0778844 8.05E-14 0.0779484 
0.60 0.10 25% 0 0.03645 -0.00027 0.0362885 -0.000301 0.0363890 
50% 0 0.03654 -0.00029 0.0364748 -0.000337 0.0364260 
75% 0 0.03658 -0.00040 0.0364216 -0.000354 0.0364319 
100% 0 0.03682 -0.00004 0.0367956 -2.63E-18 0.0368230 
Note:  
1. IAL = interim analysis location. 
2. Interim analysis location refers to the percent of subjects out of the original protocol-
specified sample size who have been assessed for the outcome at the interim analysis. 
100% refers to the situation where no sample size re-estimation is planned. 
3. Theoretically derived refers to the results from the formulas derived in Section 3.4.1.  
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Table A.100: Mean and Standard Error Results under the Alternative Hypothesis Ha: pe = pc + Δ 
from Simulations and Formulas where the Minimum Allowable Sample Size is the Original 
Protocol-Specified Sample Size and where there is No Maximum Allowable Sample Size for the 








Effect (Δ) IAL 
Expected 
      
Mean 
Expected 








      
SE 
Derived 
      
Mean 
Derived 
      
SE 
0.90 0.05 25% 0.050 0.01691 0.04916 0.0167729 0.0491945 0.0167529 
50% 0.050 0.01713 0.04904 0.0167411 0.0490919 0.0168379 
75% 0.050 0.01723 0.04907 0.0168364 0.0490412 0.0168326 
100% 0.050 0.01784 0.04993 0.0178576 0.0500000 0.0178406 
0.80 0.10 25% 0.100 0.03404 0.09855 0.0336204 0.0986076 0.0337420 
50% 0.100 0.03439 0.09836 0.0336668 0.0984287 0.0338803 
75% 0.100 0.03456 0.09840 0.0338487 0.0983402 0.0338701 
100% 0.100 0.03562 0.10010 0.0356980 0.1000000 0.0356235 
0.80 0.05 25% 0.050 0.01748 0.04965 0.0174506 0.0496801 0.0174023 
50% 0.050 0.01757 0.04954 0.0174880 0.0496601 0.0174506 
75% 0.050 0.01762 0.04967 0.0175029 0.0496503 0.0174589 
100% 0.050 0.01784 0.04995 0.0179177 0.0500000 0.0178433 
0.70 0.15 25% 0.150 0.05152 0.14826 0.0510405 0.1483070 0.0511530 
50% 0.150 0.05191 0.14795 0.0513975 0.1480444 0.0512947 
75% 0.150 0.05209 0.14772 0.0513052 0.1479084 0.0512739 
100% 0.150 0.05348 0.15012 0.0533665 0.1500000 0.0534806 
0.70 0.075 25% 0.075 0.02632 0.07450 0.0263006 0.0746292 0.0262394 
50% 0.075 0.02643 0.07457 0.0262610 0.0746021 0.0262926 
75% 0.075 0.02649 0.07446 0.0262597 0.0745891 0.0263015 
100% 0.075 0.02675 0.07492 0.0267347 0.0750000 0.0267541 
0.60 0.20 25% 0.200 0.06936 0.19823 0.0690285 0.1985543 0.0691108 
50% 0.200 0.06963 0.19837 0.0689927 0.1981848 0.0691312 
75% 0.200 0.06986 0.19773 0.0688441 0.1980121 0.0690725 
100% 0.200 0.07116 0.20042 0.0713927 0.2000000 0.0711568 
0.60 0.10 25% 0.100 0.03530 0.09975 0.0351327 0.0996991 0.0352294 
50% 0.100 0.03538 0.09962 0.0353016 0.0996628 0.0352621 
75% 0.100 0.03542 0.09974 0.0353222 0.0996462 0.0352652 
100% 0.100 0.03565 0.10018 0.0356505 0.1000000 0.0356537 
Note:  
1. IAL = interim analysis location. 
2. Interim analysis location refers to the percent of subjects out of the original protocol-
specified sample size who have been assessed for the outcome at the interim analysis. 
100% refers to the situation where no sample size re-estimation is planned. 
3. Theoretically derived refers to the results from the formulas derived in Section 3.4.1.  
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Table A.101: Comparisons Between Simulations and mFKα Calculated Lower-Type I Error Rates 
where the Minimum Allowable Sample Size is the Interim Analysis Sample Size and the 
Maximum Allowable Sample Size is Twice the Original Protocol-Specified Sample Size for the 
Alternative Hypothesis Ha: pe = (1 - γ)pc when the Outcome is Negative. 
Control 
 Group Rate 
(  ) 
Relative 
Treatment 




Simulated Lower Type I 
Error (95% CI)* 
mFKα Calculated Lower 
Type I Error 
0.10 0.50 25% 0.0288 (0.0278-0.0298) 0.0282601 
50% 0.0297 (0.0287-0.0307) 0.0283347 
75% 0.0275 (0.0265-0.0285) 0.0272385 
100% 0.0260 (0.0250-0.0270) N/A 
0.20 0.50 25% 0.0285 (0.0275-0.0295) 0.0289649 
50% 0.0290 (0.0280-0.0300) 0.0289441 
75% 0.0288 (0.0278-0.0298) 0.0279952 
100% 0.0251 (0.0241-0.0261) N/A 
0.20 0.25 25% 0.0269 (0.0259-0.0279) 0.0267428 
50% 0.0278 (0.0268-0.0288) 0.0267597 
75% 0.0274 (0.0264-0.0284) 0.0267721 
100% 0.0250 (0.0240-0.0260) N/A 
0.30 0.50 25% 0.0299 (0.0289-0.0309) 0.0298221 
50% 0.0299 (0.0289-0.0309) 0.0296725 
75% 0.0263 (0.0253-0.0273) 0.0259751 
100% 0.0253 (0.0243-0.0263) N/A 
0.30 0.25 25% 0.0274 (0.0264-0.0284) 0.0270580 
50% 0.0268 (0.0258-0.0278) 0.0270491 
75% 0.0274 (0.0264-0.0284) 0.0270106 
100% 0.0251 (0.0241-0.0261) N/A 
0.40 0.50 25% 0.0304 (0.0294-0.0314) 0.0303175 
50% 0.0302 (0.0292-0.0312) 0.0305677 
75% 0.0292 (0.0282-0.0302) 0.0285726 
100% 0.0244 (0.0234-0.0254) N/A 
0.40 0.25 25% 0.0272 (0.0262-0.0282) 0.0274989 
50% 0.0274 (0.0264-0.0284) 0.0273855 
75% 0.0267 (0.0257-0.0277) 0.0273140 
100% 0.0258 (0.0248-0.0268) N/A 
*Results are presented from the corresponding scenarios in Chapter 3. 
Note:  
1. Interim analysis location refers to the percent of subjects out of the original protocol-
specified sample size who have been assessed for the outcome at the interim analysis. 




Table A.102: Comparisons Between Simulations and mFKα Calculated Lower-Type I Error Rates 
where the Minimum Allowable Sample Size is 10% more than the Interim Analysis Sample Size 
and the Maximum Allowable Sample Size is Twice the Original Protocol-Specified Sample Size 
for the Alternative Hypothesis Ha: pe = (1 - γ)pc when the Outcome is Negative. 
Control 
 Group Rate 
(  ) 
Relative 
Treatment 




Simulated Lower Type I 
Error (95% CI)* 
mFKα Calculated Lower 
Type I Error 
0.10 0.50 25% 0.0290 (0.0280-0.0300) 0.0282601 
50% 0.0280 (0.0270-0.0290) 0.0283210 
75% 0.0270 (0.0260-0.0280) 0.0267307 
100% 0.0256 (0.0246-0.0266) N/A 
0.20 0.50 25% 0.0299 (0.0289-0.0309) 0.0289649 
50% 0.0294 (0.0284-0.0304) 0.0289186 
75% 0.0258 (0.0248-0.0268) 0.0263268 
100% 0.0250 (0.0240-0.0260) N/A 
0.20 0.25 25% 0.0257 (0.0247-0.0267) 0.0267428 
50% 0.0278 (0.0268-0.0288) 0.0267597 
75% 0.0272 (0.0262-0.0282) 0.0265127 
100% 0.0257 (0.0247-0.0267) N/A 
0.30 0.50 25% 0.0308 (0.0298-0.0318) 0.0298219 
50% 0.0304 (0.0294-0.0314) 0.0296319 
75% 0.0272 (0.0262-0.0282) 0.0268956 
100% 0.0251 (0.0241-0.0261) N/A 
0.30 0.25 25% 0.0270 (0.0260-0.0280) 0.0270580 
50% 0.0272 (0.0262-0.0282) 0.0270491 
75% 0.0269 (0.0259-0.0279) 0.0263839 
100% 0.0249 (0.0239-0.0259) N/A 
0.40 0.50 25% 0.0289 (0.0279-0.0299) 0.0302768 
50% 0.0299 (0.0289-0.0309) 0.0294914 
75% 0.0246 (0.0236-0.0256) 0.0255490 
100% 0.0239 (0.0229-0.0249) N/A 
0.40 0.25 25% 0.0282 (0.0272-0.0292) 0.0274989 
50% 0.0277 (0.0267-0.0287) 0.0273854 
75% 0.0266 (0.0256-0.0276) 0.0265544 
100% 0.0258 (0.0248-0.0268) N/A 
*Results are presented from the corresponding scenarios in Chapter 3. 
Note:  
1. Interim analysis location refers to the percent of subjects out of the original protocol-
specified sample size who have been assessed for the outcome at the interim analysis. 




Table A.103: Comparisons Between Simulations and mFKα Calculated Lower-Type I Error Rates 
where the Minimum Allowable Sample Size is the Original Protocol-Specified Sample Size and 
the Maximum Allowable Sample Size is Twice the Original Protocol-Specified Sample Size for the 
Alternative Hypothesis Ha: pe = (1 - γ)pc when the Outcome is Negative. 
Control 
 Group Rate 
(  ) 
Relative 
Treatment 




Simulated Lower Type I 
Error (95% CI)* 
mFKα Calculated Lower 
Type I Error 
0.10 0.50 25% 0.0253 (0.0243-0.0263) 0.0260498 
50% 0.0255 (0.0245-0.0265) 0.0257954 
75% 0.0264 (0.0254-0.0274) 0.0256056 
100% 0.0259 (0.0249-0.0269) N/A 
0.20 0.50 25% 0.0265 (0.0255-0.0275) 0.0260685 
50% 0.0258 (0.0248-0.0268) 0.0257592 
75% 0.0251 (0.0241-0.0261) 0.0255385 
100% 0.0255 (0.0245-0.0265) N/A 
0.20 0.25 25% 0.0251 (0.0241-0.0261) 0.0254070 
50% 0.0253 (0.0243-0.0263) 0.0252329 
75% 0.0253 (0.0243-0.0263) 0.0251180 
100% 0.0250 (0.0240-0.0260) N/A 
0.30 0.50 25% 0.0269 (0.0259-0.0279) 0.0263040 
50% 0.0264 (0.0254-0.0274) 0.0260500 
75% 0.0247 (0.0237-0.0257) 0.0258077 
100% 0.0257 (0.0247-0.0267) N/A 
0.30 0.25 25% 0.0256 (0.0246-0.0266) 0.0254896 
50% 0.0256 (0.0246-0.0266) 0.0252917 
75% 0.0251 (0.0241-0.0261) 0.0251393 
100% 0.0256 (0.0246-0.0266) N/A 
0.40 0.50 25% 0.0253 (0.0243-0.0263) 0.0252829 
50% 0.0249 (0.0239-0.0259) 0.0249067 
75% 0.0251 (0.0241-0.0261) 0.0246592 
100% 0.0247 (0.0237-0.0257) N/A 
0.40 0.25 25% 0.0258 (0.0248-0.0268) 0.0258201 
50% 0.0260 (0.0250-0.0270) 0.0256083 
75% 0.0262 (0.0252-0.0272) 0.0254341 
100% 0.0249 (0.0239-0.0259) N/A 
*Results are presented from the corresponding scenarios in Chapter 3. 
Note:  
1. Interim analysis location refers to the percent of subjects out of the original protocol-
specified sample size who have been assessed for the outcome at the interim analysis. 




Table A.104: Comparisons Between Simulations and mFKα Calculated Lower-Type I Error Rates 
where the Minimum Allowable Sample Size is the Interim Analysis Sample Size and the 
Maximum Allowable Sample Size is Twice the Original Protocol-Specified Sample Size for the 
Alternative Hypothesis Ha: pe = pc – Δ when the Outcome is Negative. 
Control 
Group Rate 








Simulated Lower Type I 
Error (95% CI)* 
mFKα Calculated Lower 
Type I Error 
0.10 0.05 25% 0.0227 (0.0217-0.0237) 0.0224106 
50% 0.0230 (0.0220-0.0240) 0.0225264 
75% 0.0230 (0.0220-0.0240) 0.0225155 
100% 0.0260 (0.0250-0.0270) N/A 
0.20 0.10 25% 0.0230 (0.0220-0.0240) 0.0228588 
50% 0.0236 (0.0226-0.0246) 0.0228452 
75% 0.0231 (0.0221-0.0241) 0.0229209 
100% 0.0258 (0.0248-0.0268) N/A 
0.20 0.05 25% 0.0240 (0.0230-0.0250) 0.0239833 
50% 0.0234 (0.0224-0.0244) 0.0239927 
75% 0.0242 (0.0232-0.0252) 0.0240045 
100% 0.0252 (0.0242-0.0262) N/A 
0.30 0.15 25% 0.0237 (0.0227-0.0247) 0.0232084 
50% 0.0229 (0.0219-0.0239) 0.0233130 
75% 0.0232 (0.0222-0.0242) 0.0234347 
100% 0.0251 (0.0241-0.0261) N/A 
0.30 0.075 25% 0.0241 (0.0231-0.0251) 0.0242039 
50% 0.0242 (0.0232-0.0252) 0.0242224 
75% 0.0246 (0.0236-0.0256) 0.0242434 
100% 0.0247 (0.0237-0.0257) N/A 
0.40 0.20 25% 0.0239 (0.0229-0.0249) 0.0233416 
50% 0.0241 (0.0231-0.0251) 0.0237697 
75% 0.0239 (0.0229-0.0249) 0.0239754 
100% 0.0240 (0.0230-0.0250) N/A 
0.40 0.10 25% 0.0243 (0.0233-0.0253) 0.0245683 
50% 0.0244 (0.0234-0.0254) 0.0245522 
75% 0.0242 (0.0232-0.0252) 0.0245104 
100% 0.0246 (0.0236-0.0256) N/A 
*Results are presented from the corresponding scenarios in Chapter 3. 
Note:  
1. Interim analysis location refers to the percent of subjects out of the original protocol-
specified sample size who have been assessed for the outcome at the interim analysis. 




Table A.105: Comparisons Between Simulations and mFKα Calculated Lower-Type I Error Rates 
where the Minimum Allowable Sample Size is 10% more than the Interim Analysis Sample Size 
and the Maximum Allowable Sample Size is Twice the Original Protocol-Specified Sample Size 
for the Alternative Hypothesis Ha: pe = pc – Δ when the Outcome is Negative. 
Control 
Group Rate 








Simulated Lower Type I 
Error (95% CI)* 
mFKα Calculated Lower 
Type I Error 
0.10 0.05 25% 0.0231 (0.0221-0.0241) 0.0224106 
50% 0.0232 (0.0222-0.0242) 0.0225266 
75% 0.0233 (0.0223-0.0243) 0.0225281 
100% 0.0254 (0.0244-0.0264) N/A 
0.20 0.10 25% 0.0229 (0.0219-0.0239) 0.0228588 
50% 0.0224 (0.0214-0.0234) 0.0228454 
75% 0.0226 (0.0216-0.0236) 0.0229283 
100% 0.0256 (0.0246-0.0266) N/A 
0.20 0.05 25% 0.0245 (0.0235-0.0255) 0.0239833 
50% 0.0250 (0.0240-0.0260) 0.0239927 
75% 0.0247 (0.0237-0.0257) 0.0240045 
100% 0.0247 (0.0237-0.0257) N/A 
0.30 0.15 25% 0.0228 (0.0218-0.0238) 0.0232084 
50% 0.0236 (0.0226-0.0246) 0.0233130 
75% 0.0240 (0.0230-0.0250) 0.0234396 
100% 0.0262 (0.0252-0.0272) N/A 
0.30 0.075 25% 0.0244 (0.0234-0.0254) 0.0242039 
50% 0.0249 (0.0239-0.0259) 0.0242224 
75% 0.0243 (0.0233-0.0253) 0.0242434 
100% 0.0252 (0.0242-0.0262) N/A 
0.40 0.20 25% 0.0228 (0.0218-0.0238) 0.0233416 
50% 0.0235 (0.0225-0.0245) 0.0237697 
75% 0.0235 (0.0225-0.0245) 0.0239768 
100% 0.0243 (0.0233-0.0253) N/A 
0.40 0.10 25% 0.0242 (0.0232-0.0252) 0.0245683 
50% 0.0250 (0.0240-0.0260) 0.0245522 
75% 0.0246 (0.0236-0.0256) 0.0245104 
100% 0.0259 (0.0249-0.0269) N/A 
*Results are presented from the corresponding scenarios in Chapter 3. 
Note:  
1. Interim analysis location refers to the percent of subjects out of the original protocol-
specified sample size who have been assessed for the outcome at the interim analysis. 




Table A.106: Comparisons Between Simulations and mFKα Calculated Lower-Type I Error Rates 
where the Minimum Allowable Sample Size is the Original Protocol-Specified Sample Size and 
the Maximum Allowable Sample Size is Twice the Original Protocol-Specified Sample Size for the 
Alternative Hypothesis Ha: pe = pc – Δ when the Outcome is Negative. 
Control 
Group Rate 








Simulated Lower Type I 
Error (95% CI)* 
mFKα Calculated Lower 
Type I Error 
0.10 0.05 25% 0.0239 (0.0229-0.0249) 0.0235111 
50% 0.0229 (0.0219-0.0239) 0.0231014 
75% 0.0238 (0.0228-0.0248) 0.0228008 
100% 0.0258 (0.0248-0.0268) N/A 
0.20 0.10 25% 0.0239 (0.0229-0.0249) 0.0237996 
50% 0.0238 (0.0228-0.0248) 0.0233832 
75% 0.0239 (0.0229-0.0249) 0.0231944 
100% 0.0248 (0.0238-0.0258) N/A 
0.20 0.05 25% 0.0242 (0.0232-0.0252) 0.0242894 
50% 0.0249 (0.0239-0.0259) 0.0241604 
75% 0.0253 (0.0243-0.0263) 0.0240887 
100% 0.0244 (0.0234-0.0254) N/A 
0.30 0.15 25% 0.0242 (0.0232-0.0252) 0.0240653 
50% 0.0237 (0.0227-0.0247) 0.0236790 
75% 0.0241 (0.0231-0.0251) 0.0235738 
100% 0.0258 (0.0248-0.0268) N/A 
0.30 0.075 25% 0.0247 (0.0237-0.0257) 0.0244511 
50% 0.0239 (0.0229-0.0249) 0.0243509 
75% 0.0247 (0.0237-0.0257) 0.0243172 
100% 0.0249 (0.0239-0.0259) N/A 
0.40 0.20 25% 0.0250 (0.0240-0.0260) 0.0242253 
50% 0.0237 (0.0227-0.0247) 0.0241875 
75% 0.0246 (0.0236-0.0256) 0.0242067 
100% 0.0248 (0.0238-0.0258) N/A 
0.40 0.10 25% 0.0243 (0.0233-0.0253) 0.0247656 
50% 0.0245 (0.0235-0.0255) 0.0246227 
75% 0.0242 (0.0232-0.0252) 0.0245377 
100% 0.0255 (0.0245-0.0265) N/A 
*Results are presented from the corresponding scenarios in Chapter 3. 
Note:  
1. Interim analysis location refers to the percent of subjects out of the original protocol-
specified sample size who have been assessed for the outcome at the interim analysis. 




Table A.107: Comparisons Between Simulations and mFKα Calculated Upper-Type I Error Rates 
where the Minimum Allowable Sample Size is the Interim Analysis Sample Size and the 
Maximum Allowable Sample Size is Twice the Original Protocol-Specified Sample Size for the 
Alternative Hypothesis Ha: pe = (1 + γ)pc when the Outcome is a Positive Event. 
Control 
 Group Rate 
(  ) 
Relative 
Treatment 




Simulated Upper Type I 
Error (95% CI)* 
mFKα Calculated Upper 
Type I Error 
0.90 0.0555556 25% 0.0207 (0.0197-0.0217) 0.0218931 
50% 0.0225 (0.0215-0.0235) 0.0219345 
75% 0.0225 (0.0215-0.0235) 0.0219699 
100% 0.0258 (0.0248-0.0268) N/A 
0.80 0.125 25% 0.0212 (0.0202-0.0222) 0.0217563 
50% 0.0221 (0.0211-0.0231) 0.0218678 
75% 0.0207 (0.0197-0.0217) 0.0217670 
100% 0.0259 (0.0249-0.0269) N/A 
0.80 0.0625 25% 0.0236 (0.0226-0.0246) 0.0233533 
50% 0.0240 (0.0230-0.0250) 0.0233766 
75% 0.0235 (0.0225-0.0245) 0.0233777 
100% 0.0247 (0.0237-0.0257) N/A 
0.70 0.2142857 25% 0.0214 (0.0204-0.0224) 0.0216765 
50% 0.0216 (0.0206-0.0226) 0.0216482 
75% 0.0229 (0.0219-0.0239) 0.0215176 
100% 0.0256 (0.0246-0.0266) N/A 
0.70 0.1071429 25% 0.0228 (0.0218-0.0238) 0.0231551 
50% 0.0237 (0.0227-0.0247) 0.0231962 
75% 0.0231 (0.0221-0.0241) 0.0231851 
100% 0.0254 (0.0244-0.0264) N/A 
0.60 0.3333333 25% 0.0215 (0.0205-0.0225) 0.0214833 
50% 0.0224 (0.0214-0.0234) 0.0221628 
75% 0.0213 (0.0203-0.0223) 0.0211932 
100% 0.0245 (0.0235-0.0255) N/A 
0.60 0.1666667 25% 0.0230 (0.0220-0.0240) 0.0228610 
50% 0.0229 (0.0219-0.0239) 0.0229196 
75% 0.0229 (0.0219-0.0239) 0.0229265 
100% 0.0258 (0.0248-0.0268) N/A 
*Results are presented from the corresponding scenarios in Chapter 3. 
Note:  
1. Interim analysis location refers to the percent of subjects out of the original protocol-
specified sample size who have been assessed for the outcome at the interim analysis. 




Table A.108: Comparisons Between Simulations and mFKα Calculated Upper -Type I Error Rates 
where the Minimum Allowable Sample Size is 10% more than the Interim Analysis Sample Size 
and the Maximum Allowable Sample Size is Twice the Original Protocol-Specified Sample Size 
for the Alternative Hypothesis Ha: pe = (1 + γ)pc when the Outcome is Positive. 
Control 
 Group Rate 
(  ) 
Relative 
Treatment 




Simulated Upper Type I 
Error (95% CI)* 
mFKα Calculated Upper 
Type I Error 
0.90 0.0555556 25% 0.0227 (0.0217-0.0237) 0.0218931 
50% 0.0225 (0.0215-0.0235) 0.0219352 
75% 0.0231 (0.0221-0.0241) 0.0219928 
100% 0.0263 (0.0253-0.0273) N/A 
0.80 0.125 25% 0.0220 (0.0210-0.0230) 0.0217563 
50% 0.0210 (0.0200-0.0220) 0.0218690 
75% 0.0213 (0.0203-0.0223) 0.0217978 
100% 0.0261 (0.0251-0.0271) N/A 
0.80 0.0625 25% 0.0230 (0.0220-0.0240) 0.0233533 
50% 0.0228 (0.0218-0.0238) 0.0233766 
75% 0.0231 (0.0221-0.0241) 0.0233778 
100% 0.0253 (0.0243-0.0263) N/A 
0.70 0.2142857 25% 0.0220 (0.0210-0.0230) 0.0216765 
50% 0.0213 (0.0203-0.0223) 0.0216511 
75% 0.0206 (0.0196-0.0216) 0.0215566 
100% 0.0259 (0.0249-0.0269) N/A 
0.70 0.1071429 25% 0.0235 (0.0225-0.0245) 0.0231551 
50% 0.0236 (0.0226-0.0246) 0.0231962 
75% 0.0236 (0.0226-0.0246) 0.0231853 
100% 0.0251 (0.0241-0.0261) N/A 
0.60 0.3333333 25% 0.0217 (0.0207-0.0227) 0.0214833 
50% 0.0217 (0.0207-0.0227) 0.0221708 
75% 0.0219 (0.0209-0.0229) 0.0212178 
100% 0.0244 (0.0234-0.0254) N/A 
0.60 0.1666667 25% 0.0231 (0.0221-0.0241) 0.0228610 
50% 0.0234 (0.0224-0.0244) 0.0229196 
75% 0.0226 (0.0216-0.0236) 0.0229271 
100% 0.0251 (0.0241-0.0261) N/A 
*Results are presented from the corresponding scenarios in Chapter 3. 
Note:  
1. Interim analysis location refers to the percent of subjects out of the original protocol-
specified sample size who have been assessed for the outcome at the interim analysis. 




Table A.109: Comparisons Between Simulations and mFKα Calculated Upper -Type I Error Rates 
where the Minimum Allowable Sample Size is the Original Protocol-Specified Sample Size and 
the Maximum Allowable Sample Size is Twice the Original Protocol-Specified Sample Size for the 
Alternative Hypothesis Ha: pe = (1 + γ)pc when the Outcome is Positive. 
Control 
 Group Rate 
(  ) 
Relative 
Treatment 




Simulated Upper Type I 
Error (95% CI)* 
mFKα Calculated Upper 
Type I Error 
0.90 0.0555556 25% 0.0237 (0.0227-0.0247) 0.0231385 
50% 0.0232 (0.0222-0.0242) 0.0225938 
75% 0.0242 (0.0232-0.0252) 0.0223002 
100% 0.0260 (0.0250-0.0270) N/A 
0.80 0.125 25% 0.0223 (0.0213-0.0233) 0.0230356 
50% 0.0221 (0.0211-0.0231) 0.0225446 
75% 0.0218 (0.0208-0.0228) 0.0221353 
100% 0.0252 (0.0242-0.0262) N/A 
0.80 0.0625 25% 0.0247 (0.0237-0.0257) 0.0238206 
50% 0.0238 (0.0228-0.0248) 0.0236333 
75% 0.0233 (0.0223-0.0243) 0.0235089 
100% 0.0244 (0.0234-0.0254) N/A 
0.70 0.2142857 25% 0.0235 (0.0225-0.0245) 0.0230385 
50% 0.0223 (0.0213-0.0233) 0.0222824 
75% 0.0216 (0.0206-0.0226) 0.0218117 
100% 0.0252 (0.0242-0.0262) N/A 
0.70 0.1071429 25% 0.0235 (0.0225-0.0245) 0.0236607 
50% 0.0242 (0.0232-0.0252) 0.0234648 
75% 0.0244 (0.0234-0.0254) 0.0233311 
100% 0.0247 (0.0237-0.0257) N/A 
0.60 0.3333333 25% 0.0235 (0.0225-0.0245) 0.0231038 
50% 0.0230 (0.0220-0.0240) 0.0229288 
75% 0.0220 (0.0210-0.0230) 0.0216013 
100% 0.0247 (0.0237-0.0257) N/A 
0.60 0.1666667 25% 0.0226 (0.0216-0.0236) 0.0234428 
50% 0.0233 (0.0223-0.0243) 0.0231792 
75% 0.0234 (0.0224-0.0244) 0.0230451 
100% 0.0243 (0.0233-0.0253) N/A 
*Results are presented from the corresponding scenarios in Chapter 3. 
Note:  
1. Interim analysis location refers to the percent of subjects out of the original protocol-
specified sample size who have been assessed for the outcome at the interim analysis. 




Table A.110: Comparisons Between Simulations and mFKα Calculated Upper -Type I Error Rates 
where the Minimum Allowable Sample Size is the Interim Analysis Sample Size and the 
Maximum Allowable Sample Size is Twice the Original Protocol-Specified Sample Size for the 
Alternative Hypothesis Ha: pe = pc + Δ when the Outcome is Positive. 
Control 
Group Rate 








Simulated Upper Type I 
Error (95% CI)* 
mFKα Calculated Upper 
Type I Error 
0.90 0.05 25% 0.0228 (0.0218-0.0238) 0.0224106 
50% 0.0230 (0.0220-0.0240) 0.0225264 
75% 0.0233 (0.0223-0.0243) 0.0225155 
100% 0.0255 (0.0245-0.0265) N/A 
0.80 0.10 25% 0.0228 (0.0218-0.0238) 0.0228588 
50% 0.0226 (0.0216-0.0236) 0.0228452 
75% 0.0221 (0.0211-0.0231) 0.0229209 
100% 0.0257 (0.0247-0.0267) N/A 
0.80 0.05 25% 0.0237 (0.0227-0.0247) 0.0239833 
50% 0.0247 (0.0237-0.0257) 0.0239927 
75% 0.0234 (0.0224-0.0244) 0.0240045 
100% 0.0253 (0.0243-0.0263) N/A 
0.70 0.15 25% 0.0235 (0.0225-0.0245) 0.0232084 
50% 0.0234 (0.0224-0.0244) 0.0233130 
75% 0.0238 (0.0228-0.0248) 0.0234347 
100% 0.0244 (0.0234-0.0254) N/A 
0.70 0.075 25% 0.0246 (0.0236-0.0256) 0.0242039 
50% 0.0243 (0.0233-0.0253) 0.0242224 
75% 0.0238 (0.0228-0.0248) 0.0242434 
100% 0.0248 (0.0238-0.0258) N/A 
0.60 0.20 25% 0.0232 (0.0222-0.0242) 0.0233416 
50% 0.0239 (0.0229-0.0249) 0.0237697 
75% 0.0243 (0.0233-0.0253) 0.0239754 
100% 0.0247 (0.0237-0.0257) N/A 
0.60 0.10 25% 0.0248 (0.0238-0.0258) 0.0245683 
50% 0.0246 (0.0236-0.0256) 0.0245522 
75% 0.0245 (0.0235-0.0255) 0.0245104 
100% 0.0247 (0.0237-0.0257) N/A 
*Results are presented from the corresponding scenarios in Chapter 3. 
Note:  
1. Interim analysis location refers to the percent of subjects out of the original protocol-
specified sample size who have been assessed for the outcome at the interim analysis. 




Table A.111: Comparisons Between Simulations and mFKα Calculated Upper -Type I Error Rates 
where the Minimum Allowable Sample Size is 10% more than the Interim Analysis Sample Size 
and the Maximum Allowable Sample Size is Twice the Original Protocol-Specified Sample Size 
for the Alternative Hypothesis Ha: pe = pc + Δ when the Outcome is Positive. 
Control 
Group Rate 








Simulated Upper Type I 
Error (95% CI)* 
mFKα Calculated Upper 
Type I Error 
0.90 0.05 25% 0.0224 (0.0214-0.0234) 0.0224106 
50% 0.0221 (0.0211-0.0231) 0.0225266 
75% 0.0233 (0.0223-0.0243) 0.0225281 
100% 0.0259 (0.0249-0.0269) N/A 
0.80 0.10 25% 0.0233 (0.0223-0.0243) 0.0228588 
50% 0.0227 (0.0217-0.0237) 0.0228454 
75% 0.0233 (0.0223-0.0243) 0.0229283 
100% 0.0253 (0.0243-0.0263) N/A 
0.80 0.05 25% 0.0241 (0.0231-0.0251) 0.0239833 
50% 0.0237 (0.0227-0.0247) 0.0239927 
75% 0.0242 (0.0232-0.0252) 0.0240045 
100% 0.0246 (0.0236-0.0256) N/A 
0.70 0.15 25% 0.0232 (0.0222-0.0242) 0.0232084 
50% 0.0229 (0.0219-0.0239) 0.0233130 
75% 0.0234 (0.0224-0.0244) 0.0234396 
100% 0.0259 (0.0249-0.0269) N/A 
0.70 0.075 25% 0.0245 (0.0235-0.0255) 0.0242039 
50% 0.0248 (0.0238-0.0258) 0.0242224 
75% 0.0243 (0.0233-0.0253) 0.0242434 
100% 0.0258 (0.0248-0.0268) N/A 
0.60 0.20 25% 0.0235 (0.0225-0.0245) 0.0233416 
50% 0.0235 (0.0225-0.0245) 0.0237697 
75% 0.0238 (0.0228-0.0248) 0.0239768 
100% 0.0250 (0.0240-0.0260) N/A 
0.60 0.10 25% 0.0239 (0.0229-0.0249) 0.0245683 
50% 0.0247 (0.0237-0.0257) 0.0245522 
75% 0.0245 (0.0235-0.0255) 0.0245104 
100% 0.0247 (0.0237-0.0257) N/A 
*Results are presented from the corresponding scenarios in Chapter 3. 
Note:  
1. Interim analysis location refers to the percent of subjects out of the original protocol-
specified sample size who have been assessed for the outcome at the interim analysis. 




Table A.112: Comparisons Between Simulations and mFKα Calculated Upper-Type I Error Rates 
where the Minimum Allowable Sample Size is the Original Protocol-Specified Sample Size and 
the Maximum Allowable Sample Size is Twice the Original Protocol-Specified Sample Size for the 
Alternative Hypothesis Ha: pe = pc + Δ when the Outcome is Positive. 
Control 
Group Rate 








Simulated Upper Type I 
Error (95% CI)* 
mFKα Calculated Upper 
Type I Error 
0.90 0.05 25% 0.0241 (0.0231-0.0251) 0.0235111 
50% 0.0234 (0.0224-0.0244) 0.0231014 
75% 0.0241 (0.0231-0.0251) 0.0228008 
100% 0.0259 (0.0249-0.0269) N/A 
0.80 0.10 25% 0.0231 (0.0221-0.0241) 0.0237996 
50% 0.0239 (0.0229-0.0249) 0.0233832 
75% 0.0234 (0.0224-0.0244) 0.0231944 
100% 0.0262 (0.0252-0.0272) N/A 
0.80 0.05 25% 0.0236 (0.0226-0.0246) 0.0242894 
50% 0.0242 (0.0232-0.0252) 0.0241604 
75% 0.0250 (0.0240-0.0260) 0.0240887 
100% 0.0245 (0.0235-0.0255) N/A 
0.70 0.15 25% 0.0243 (0.0233-0.0253) 0.0240653 
50% 0.0236 (0.0226-0.0246) 0.023679 
75% 0.0234 (0.0224-0.0244) 0.0235738 
100% 0.0263 (0.0253-0.0273) N/A 
0.70 0.075 25% 0.0251 (0.0241-0.0261) 0.0244511 
50% 0.0239 (0.0229-0.0249) 0.0243509 
75% 0.0239 (0.0229-0.0249) 0.0243172 
100% 0.0249 (0.0239-0.0259) N/A 
0.60 0.20 25% 0.0242 (0.0232-0.0252) 0.0242253 
50% 0.0242 (0.0232-0.0252) 0.0241875 
75% 0.0238 (0.0228-0.0248) 0.0242067 
100% 0.0242 (0.0232-0.0252) N/A 
0.60 0.10 25% 0.0249 (0.0239-0.0259) 0.0247656 
50% 0.0247 (0.0237-0.0257) 0.0246227 
75% 0.0243 (0.0233-0.0253) 0.0245377 
100% 0.0254 (0.0244-0.0264) N/A 
*Results are presented from the corresponding scenarios in Chapter 3. 
Note:  
1. Interim analysis location refers to the percent of subjects out of the original protocol-
specified sample size who have been assessed for the outcome at the interim analysis. 
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